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Foreword
In this foreword to the annual report of the International Narcotics Control Board (INCB) for 2016, 
I would like to recognize the tremendous efforts that went into the thirtieth special session of the 
General Assembly, which was held in April 2016. Over the past two years, we have seen the global 
community examine in depth the successes and challenges faced in addressing the world drug prob-
lem, and INCB applauds the results of this hard work, as reflected in the outcome document of 
the thirtieth special session, entitled “Our joint commitment to effectively addressing and counter-
ing the world drug problem”.1 
INCB notes that, in the outcome document, Member States underscored the role of the three inter-
national drug control treaties as the basis for international cooperation, ensuring the availability of 
narcotic drugs and psychotropic substances for medical and scientific purposes, preventing illicit 
drug crop cultivation and production and addressing drug trafficking and abuse. Governments have 
demonstrated that they intend to fulfil their joint commitments to cooperate on demand and sup-
ply reduction as well as on preventing diversion. At the special session of the General Assembly, 
the international community reaffirmed the pivotal role of the conventions and reiterated its com-
mitment to their implementation. However, some actors will continue to talk about a need to “mod-
ernize” the treaties and their provisions; INCB is of the view that the international drug control 
system continues to provide a modern and flexible structure that can meet the world’s drug  control 
needs of today and tomorrow.
In that context, INCB calls upon all stakeholders to place science and evidence-based approaches 
at the centre of drug control discussions. INCB sees its treaty-mandated role in determining the 
extent to which implementation at the national level is within the flexibility allowed for by the con-
ventions. As we have often pointed out, the conventions provide for a certain flexibility at the 
national level, particularly with respect to determining appropriate sanctions, including non- punitive 
or non-custodial measures, for minor offences, for example for possession of drugs for personal 
use. However, flexibility has limits; it does not extend to regulating the use of drugs for non- medical 
purposes. States parties are now challenged to examine how to respond to the developments in 
some countries that are in contravention of the treaties by permitting and regulating the non- 
medical use of drugs. A special topic in chapter II of the present report explores the possible effects 
of legislation in several jurisdictions that permits the non-medical use of cannabis.
The success of future international cooperation on drug control will depend on the ability of States 
parties to recognize that the treaties emphasize, first and foremost, the health needs and human 
rights of individuals. As a treaty-monitoring body, INCB assumes that the States parties themselves 
understand that it is their treaty obligation to prevent and treat drug abuse and reduce its negative 
consequences, based on the principles and provisions of the conventions and political declarations. 
Protecting the health and welfare of humankind remains the ultimate goal of the international drug 
control system; all drug-related policies and programmes that address current challenges in a bal-
anced manner, in conformity with the treaties and with respect for human rights, will continue to 
be acknowledged and supported by INCB.
This year’s report of the Board contains a thematic chapter on women and drugs, the specific needs 
of women who use drugs and the harms they face in connection to drug use. That chapter looks 
at the epidemiology of drug use among women and the socioeconomic contexts surrounding issues 
such as drug injection. Drug-related harms to women and the resulting consequences for commu-
nities are often sorely under-studied, and gender-disaggregated data on drug use are rarely col-
lected. There are also inadequate budget allocations by Member States for the specific prevention 
and treatment of drug dependence and substance use disorders among women, who often do not 
1 General Assembly resolution S-30/1, annex.
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have access to any assistance and suffer in silence. INCB believes that this year’s thematic chapter 
can change perceptions and remind people, particularly policymakers, of the importance of pro-
tecting the rights of women who use drugs or who have committed drug-related crimes and of 
protecting the rights of their families.
In the foreword to the INCB annual report for 2015, I discussed the spirit of the conventions, with 
the hope that when Governments developed their operational approaches to addressing local drug 
control issues, they would strive for the betterment of public health and put in place practices and 
programmes that fully respect human rights. Criminal justice responses to drug use must be tem-
pered by respect for due process and acknowledgment that the conventions foresee humane and 
proportionate responses to substance abuse and drug-related crimes, including alternatives to con-
viction through education, treatment, aftercare, rehabilitation and social reintegration. In that con-
nection, the death penalty for drug-related offences should not be retained. Moreover, it is often 
the most vulnerable in society who suffer most from unjust, inappropriate or disproportionate law 
enforcement measures and criminal justice sanctions. Public safety and security are critical objec-
tives for any Government, yet the pursuit of them must not be at the expense of the inherent dig-
nity of the individual. It goes without saying that the same applies to demand reduction: there is 
no place for demand reduction interventions that violate human rights in the name of drug con-
trol. Such interventions are contrary to the spirit and letter of the drug control conventions, the 
objectives of which include the protection of public and individual health and welfare.
This year’s report, together with the annual report on precursors, provides an up-to-date analysis 
on developments in global drug control, as well as recommendations to Governments and relevant 
international and regional organizations. In the light of the discussions surrounding the thirtieth 
special session of the General Assembly, the Board’s recommendations in our 2016 publications are 
aimed at helping States take effective measures and implement comprehensive plans to tackle drug-
related challenges. In the report on precursors,2 for example, guidance and information are pro-
vided to enable States to enhance information-sharing, develop multilateral operational cooperation 
and implement measures for preventing the diversion of chemicals used in the illicit manufacture 
of drugs.
Following the thirtieth special session of the General Assembly, we are actively working towards 
the next milestone of a review in 2019 of the implementation of the Political Declaration and Plan 
of Action on International Cooperation towards an Integrated and Balanced Strategy to Counter 
the World Drug Problem. INCB looks forward, in the next three years and beyond, to being a voice 
for the practical application of evidence-based knowledge that coherently supports States in the 
protection of the health and welfare of their citizens. I hope that, through the release of these annual 
reports, greater understanding of the work and functions of INCB can be achieved. As always, 
Member States are invited to communicate directly with the Board regarding any questions they 
may have about implementation of the treaties.
 Werner Sipp
 President
 International Narcotics Control Board
2 E/INCB/2016/4.
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Explanatory notes
Data reported later than 1 November 2016 could not be taken into consideration in preparing this 
report.
The designations employed and the presentation of the material in this publication do not imply 
the expression of any opinion whatsoever on the part of the Secretariat of the United Nations con-
cerning the legal status of any country, territory, city or area or of its authorities, or concerning the 
delimitation of its frontiers or boundaries.
Countries and areas are referred to by the names that were in official use at the time the relevant 
data were collected.
References to dollars ($) are to United States dollars, unless otherwise stated.
The following abbreviations have been used in this report:
AIRCOP Airport Communication Project
APAAN alpha-phenylacetoacetonitrile
ASEAN Association of Southeast Asian Nations
CARICC Central Asian Regional Information and Coordination Centre
CARICOM Caribbean Community
CICAD Inter-American Drug Abuse Control Commission
ECOWAS Economic Community of West African States
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
Europol European Police Office
GBL gamma-butyrolactone
GHB gamma-hydroxybutyric acid
ha hectare
I2ES International Import and Export Authorization System
INCB International Narcotics Control Board 
INTERPOL International Criminal Police Organization
IONICS Project Ion Incident Communication System
LSD lysergic acid diethylamide
MDMA 3,4-methylenedioxymethamphetamine
NATO North Atlantic Treaty Organization
OAS Organization of American States
PEN Online Pre-Export Notification Online
PICS Precursors Incident Communication System
SMART global Synthetics Monitoring: Analysis, Reporting and Trends programme
THC tetrahydrocannabinol
UNAIDS Joint United Nations Programme on HIV/AIDS
WCO World Customs Organization
WHO World Health Organization
1Chapter I.
Women and drugs
1. There is growing awareness of the importance of 
appropriately incorporating a gender perspective into 
drug-related policies and programmes. The Political 
Declarations of 19983 and 20094 incorporate gender con-
siderations, and both the General Assembly5 and the 
Commission on Narcotic Drugs6 have given increasing 
attention to this aspect over the past 10 years. In addi-
tion, the General Assembly, in its resolution on the 2030 
Agenda for Sustainable Development,7 underlined the 
critical importance of gender equality and the empower-
ment of women. In the outcome document of the thirti-
eth special session of the General Assembly, entitled “Our 
joint commitment to effectively addressing and counter-
ing the world drug problem”,8 Member States are encour-
aged to address the specific needs of women in the context 
of drug policy. The Commission on Narcotic Drugs, the 
main policymaking body of the United Nations system 
for drug-related matters, has adopted a number of reso-
lutions with regard to the situation of women as it relates 
to the world drug problem. To contribute to the advance-
ment of gender-sensitive policies to address this issue, the 
Commission has highlighted the specific needs of women, 
most recently at its fifty-ninth session, held in March 
2016, when it adopted its resolution 59/5, entitled 
3 Political Declaration adopted by the General Assembly at its twen-
tieth special session, devoted to countering the world drug problem 
 together (General Assembly resolution S-20/2, annex).
4 Political Declaration and Plan of Action on International Coopera-
tion towards an Integrated and Balanced Strategy to Counter the World 
Drug Problem (see Official Records of the Economic and Social Council, 
2009, Supplement No. 8 (E/2009/28), chap. I, sect. C).
5 General Assembly resolutions 58/138, 61/143, 63/241 and 70/182.
6 Commission on Narcotic Drugs resolutions 52/1, 55/5 and 59/5.
7 General Assembly resolution 70/1.
8 General Assembly resolution S-30/1, annex.
“Mainstreaming a gender perspective in drug-related 
 policies and programmes”.
2. Recognizing the importance of gender- responsiveness, 
the International Narcotics Control Board (INCB) has 
devoted the first chapter of the present annual report to 
the topic of women and drugs. However, owing to the 
multifaceted nature of this subject, it cannot be dealt with 
in an exhaustive manner in only one chapter. Moreover, 
data on women drug users are sparse, further complicat-
ing analysis. For those reasons, the present chapter is lim-
ited to some salient aspects: drug-related harms, special 
populations, prevention and treatment, and rehabilitation 
for drug dependence. 
3. Drug-dependent women may face many difficulties: 
they can experience high levels of stigmatization; they can 
be ostracized by their family or community; they may be 
subjected to violence from partners or family members; 
and they may turn to, or be coerced into, sex work to 
support their drug use or that of their partner. In addi-
tion, they lack access to gender-sensitive treatment for 
drug dependence. The limited data available at the global 
level show that women drug users are increasing in num-
ber among youth and prison populations. Few countries 
provide adequate levels of drug-dependency treatment to 
women, and virtually all countries need to expand 
 gender-sensitive treatment if they are to achieve the high-
est attainable standard of health for women.
4. Criminal justice data indicate that an increasing 
number of women are arrested for drug-related crimes. 
The incarceration of women involved in drug-related 
offences may have a catastrophic effect on their children, 
particularly if they are the primary caregivers. Additionally, 
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female prisoners have very high levels of drug depend-
ence but rarely have access to treatment and rehabilita-
tion services. 
A. Prevalence and patterns of drug 
abuse
5. Women and girls comprise one third of people who 
use drugs globally. In 2010, the global estimated number 
of women dependent on amphetamines was 6.3 million; 
women dependent on opioids numbered 4.7 million; and 
women dependent on cocaine numbered 2.1 million. 
Women had a high prevalence of amphetamine depend-
ence (0.31 per cent) in South-East Asia and Oceania, of 
opioid dependence (0.25 per cent) in Oceania, and of 
cocaine dependence (0.22 per cent) in North America 
and Latin America. Also in 2010, an estimated 3.8 mil-
lion women injected drugs globally, corresponding to 
0.11  per cent of the world female population.9 Drug-use 
patterns among women reflect differences in opportuni-
ties to use drugs, which are a result of the influence of 
their social or cultural environment.
6. Generally, women start using drugs later than men 
do, and their use is strongly influenced by partners who 
also use drugs. However, once women start abusing 
drugs, their rate of consumption of cannabis, opioids and 
cocaine progresses more rapidly than among men, and 
they tend to develop a substance use disorder more 
quickly than men do. In the case of methamphetamines, 
women begin using them at an earlier age than men, and 
they are more likely to have a methamphetamine use dis-
order than men. Compared with men, women who use 
heroin are younger, likely to use smaller amounts and for 
a shorter time, are less likely to inject the drug and are 
more likely to be influenced by drug-using sexual part-
ners. Often, someone else, typically their partner, will 
administer a woman’s first injection of drugs.
7. Women in high-income countries have a higher level 
of drug use than women in low- and middle-income 
countries. In terms of abuse of all drugs, the gap between 
women and men is narrower among the youth popula-
tion than among the adult population. Women also con-
stitute a large proportion of those abusing prescription 
9 Harvey A. Whiteford and others, “Global burden of disease attrib-
utable to mental and substance use disorders: findings from the Global 
Burden of Disease Study 2010”, The Lancet, vol. 382, No. 9904 (2013), pp. 
1575-1586.
drugs. The Pompidou Group of the Council of Europe 
reported that the use of prescription drugs by women 
increases according to age group, peaking among women 
in their thirties. Although data are limited, both Germany 
and Serbia reported that fatal overdoses owing to pre-
scription drug abuse were more common among women 
than among men.10 Studies show that women are more 
likely to use prescription drugs, such as narcotic analge-
sics and tranquillizers (e.g., benzodiazepines), for non-
medical purposes.11 This is compounded by the greater 
vulnerability of women to depression, anxiety, trauma 
and victimization compared with men. Women report 
using drugs to cope with stressful situations in their lives, 
and there is evidence that women are significantly more 
likely than men to be prescribed narcotics and anti- 
anxiety medications.12 
8. The prevalence of illicit drug use, drug abuse by 
injection and drug dependence is consistently higher 
among women who have sex with women. Among 
transgender women, drug abuse, including by injection, 
is also common, ranging from approximately 30 per cent 
in the United States of America, to 42 per cent in Australia 
and up to 50 per cent in Portugal and Spain. However, a 
study carried out in 2004 in Pakistan found that fewer 
than 2 per cent of transgender women had injected drugs 
in the previous year.13 
B. Initiation into, reasons for and 
circumstances of drug abuse
9. Both drug abuse and drug abuse by injection typi-
cally begin in adolescence and early adulthood. Particularly 
vulnerable young people, such as those who are home-
less, may begin injecting in their early teenage years. 
Women, like men, take drugs for a variety of reasons, 
including experimentation, peer pressure, to escape or to 
10 Marilyn Clark, The Gender dimension of non-medical use of 
 prescription drugs (Strasbourg, Council of Europe, 2015).
11 L. Simoni-Wastila, G. Ritter and G. Strickler, “Gender and other 
factors associated with the nonmedical use of abusable prescription 
drugs”, Substance Use and Misuse, vol. 39, No. 1 (2004), pp. 1-23; 2007 
ESPAD Report: Substance Use Among Students in 35 European Countries 
(Stockholm, Swedish Council for Information on Alcohol and Other 
Drugs, 2009).
12 UNODC, The Non-Medical Use of Prescription Drugs: Policy 
 Direction Issues (Vienna, 2011).
13 Sarah Larney and others, “Global epidemiology of HIV among 
women and girls who use or inject drugs: current knowledge and limita-
tions of existing data”, Journal of Acquired Immune Deficiency Syndromes, 
vol. 69, supp. 2 (June 2015).
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relax. Factors such as personality or environment can lead 
to a woman progressing from drug abuse to drug abuse 
by injection. Additional factors may include being sub-
ject to physical or sexual abuse during childhood, involve-
ment in sex work and socializing with persons who abuse 
drugs by injection.
10. Some women report using substances to relieve 
stress or negative emotions or to cope with divorce, loss 
of child custody or the death of a relative. Women with 
substance use disorders have often experienced a difficult 
upbringing and conflict within the family, as well as hav-
ing had to prematurely take on adult responsibilities. They 
often have a family member who is drug-dependent, and 
many women identify relationship problems as a factor 
leading to substance use. Additionally, mood and anxiety 
disorders often predate the onset of substance abuse prob-
lems. Other reasons given by women for abusing drugs 
are to aid with dieting, to counter exhaustion, to relieve 
pain, and as self-medication for mental health 
problems.
1. Biological factors
11. Dependence on drugs is determined by a combina-
tion of biological, environmental, behavioural and social 
factors. Factors increasing the risk of dependence include 
being male, having a novelty- and sensation-seeking tem-
perament, early defiant behaviour and conduct disorders, 
poor school performance and inadequate sleep. Women 
may face unique issues when it comes to substance use, 
in part related to biological factors.
12. Dependence develops when a person’s neurons 
adapt to repeated drug exposure and only function nor-
mally in the presence of the drug. Genetic variability can 
determine to a large extent an individual’s risk of depend-
ence. Therefore, understanding the role of genetic factors 
may assist in the treatment of drug dependence. It is 
thought that genetic factors account for between 40 and 
60 per cent of a person’s vulnerability to addiction. Studies 
of twins have revealed that the likelihood of heritability 
of addictive disorders, on a scale from 0 to 1, ranges from 
0.39 for hallucinogens to 0.72 for cocaine.14 A meta- 
analysis of studies of twins conducted by Verweij and oth-
ers (2010) estimated that, among females, 59 per cent of 
problematic cannabis use could be attributed to shared 
genes, while among male twins, just 51 per cent was 
attributed to shared genes.
14 Laura Bevilacqua and David Goldman, “Genes and addictions”, 
Clinical Pharmacology and Therapeutics, vol. 85, No. 4 (2009).
13. Women may face unique issues when it comes to 
substance use, in part influenced by differences based on 
biology and distinctions related to gender norms. Research 
has determined that women’s experience of drugs and the 
ability to recover from drug use can be impacted by hor-
mones, the menstrual cycle, fertility, pregnancy, breast-
feeding and menopause. In human studies, the follicular 
phase of the menstrual cycle, in which estradiol levels are 
high and progesterone low, is associated with the great-
est responsivity to stimulants. A study investigating 
response to cocaine administration found that women in 
the luteal phase reported lower ratings of feeling high 
than women in the follicular phase or men.15 Research 
has also found different effects of monoamine oxidase A 
(MAO-A) (an enzyme that breaks down monoamine 
neuro transmitters, e.g., serotonin) genotypes on female 
psychopathology and behaviour.16 There is also evidence 
that childhood sexual abuse and intimate partner violence 
constitute unique risk factors for antisocial behaviour and 
drug use among women and can predict relapse many 
years later.17 
2. Social and environmental factors
14. Some countries have high levels of unemployment, 
drug availability and crime that result in an environment 
likely to foster problematic drug use. It has been sug-
gested that there is a reciprocal relationship between low 
socioeconomic status and drug use. Living in poverty can 
create chronic stress, which affects an individual’s mental 
health, from which drugs can provide some temporary 
reprieve. Additionally, albeit to a lesser extent, drug abuse 
may lower socioeconomic status. In the case of women, 
the impact of these factors is often exacerbated. For exam-
ple, an investigation by the United Nations Office on 
Drugs and Crime (UNODC) into the impact of drug use 
on the family unit in Afghanistan found strong links 
between drug use, unemployment and poverty.18 Over 
half of those who had been employed prior to using drugs 
had subsequently lost their jobs, and over one third of 
the children interviewed said that they had been forced 
to leave school because of drug abuse by a family mem-
ber. Communities with high levels of drug use often have 
15 Mehmet Sofuoglu and others, “Sex and menstrual cycle differences 
in the subjective effects from smoked cocaine in humans”, Experimental 
Clinical Psychopharmacology, vol. 7, No. 3 (1999), pp. 274-283.
16 J. Kim-Cohen and others, “MAOA, maltreatment, and gene- 
environment interaction predicting children’s mental health: new evi-
dence and a meta-analysis”, Molecular Psychiatry, vol. 11 (2006), pp. 903-
913.
17 Office of Research on Women’s Health, “Research summaries, FY 
2011” (Bethesda, Maryland, National Institutes of Health, 2011).
18 UNODC, Impacts of Drug Use on Users and Their Families in 
 Afghanistan (Vienna, 2014).
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poor access to social support, health care and commu-
nity organizations, making it more difficult for residents 
to receive assistance to break the cycle of drug abuse and 
poverty.
15. A large study of nearly 3,000 people who use drugs 
in India19 found that almost 10 per cent were women. 
Many of the women were illiterate, and very few had 
received any vocational training. Most were using heroin. 
The women commonly reported both physical and psy-
chological problems resulting from their drug abuse, 
including miscarriages or terminations. About half of the 
women who took part in the study engaged in sex work 
to support their drug use, increasing their risk of con-
tracting HIV, which, in turn, in the case of pregnancy or 
breastfeeding, can be transmitted to the child. Marital 
conflict was a common reason given for starting to abuse 
drugs.
C. Drug-related harm
1. HIV infection, overdose and other 
negative health consequences
16. Studies of drug abuse and its related harms often do 
not specifically consider women, in turn limiting the 
accurate assessment of how various issues affect women 
who use drugs. Furthermore, most research is undertaken 
in high-income countries, thus limiting the global under-
standing of the situation. Nevertheless, a reasonable 
amount of data on HIV among women has been gener-
ated, providing some indication of the problem, given the 
link between injecting drug use and the risk of HIV infec-
tion. HIV prevalence among female drug users can range 
vastly, from low levels in several countries to over 50 per 
cent in some others, such as Estonia and the Philippines. 
In the United Republic of Tanzania, 72 per cent of women 
who abuse heroin by injection are HIV positive, com-
pared with 45 per cent of men. In Senegal, HIV preva-
lence among women who abuse drugs by injection is 
three times higher than among men. 
17. Overall, even in generalized epidemics in sub- 
Saharan Africa, female sex workers are 12 times more 
likely to be HIV positive than the general female popu-
lation. Similarly, in other environments with medium or 
19 India, Ministry of Social Justice and Empowerment, and UNODC, 
Regional Office for South Asia, “Women and drug abuse: the problem in 
India—highlights of the report” (New Delhi, 2002).
high prevalence of HIV, or generalized HIV epidemics, 
the likelihood of HIV infection was found to be high.20 
Female prisoners also have higher rates of HIV infection 
compared with both the general population and male 
prisoners.21 
18. Women who inject drugs frequently report sharing 
needles, giving reasons such as being unaware of the risks, 
being unable to obtain needles from pharmacies and 
being afraid of being caught by police. Some women 
report that they share needles with their partner as a sign 
of love or trust. Poor injecting techniques cause vein inju-
ries with severe complications. Women injecting drugs 
face problems such as fatigue, weight loss, withdrawal 
pain, depression and suicidal tendencies; many also have 
sexually transmitted infections and hepatitis. For these 
women, access to health care is mainly hindered by the 
stigma attached to women who abuse drugs by 
injection.
19. In 2012, more than 15,000 women died from drug 
overdoses in the United States. Between 1999 and 2010, 
the number of deaths related to the use of prescription 
opioid painkillers among women in the United States 
increased by a factor of 5, while the rate for men increased 
by a factor of 3.6. A review of mortality data in the United 
Kingdom of Great Britain and Northern Ireland from 
2007 to 2008 revealed larger increases in overdoses (of 
all substances) among women than among men (17 per 
cent for women and 8 per cent for men). In particular, 
there was an 8 per cent increase in the number of deaths 
of women from heroin/morphine overdose and a 20 per 
cent increase in the number of deaths of women from 
cocaine overdose during that period.22 
2. Mental illness
20. The dual occurrence of substance use disorder and 
mental illness is difficult to diagnose and treat and is 
more common in women than men. If women who suf-
fer from this dual occurrence are not treated they will 
have poorer clinical outcomes than women with a single 
disorder. In Europe, co-morbid major depression is more 
frequent in women with substance use disorders than in 
20 Stefan Baral and others, “Burden of HIV among female sex work-
ers in low-income and middle-income countries: a systematic review and 
meta-analysis”, The Lancet, vol. 12, No. 7 (2012), pp. 538-549.
21 Kate Dolan and others, “People who inject drugs in prison: HIV 
prevalence, transmission and prevention”, International Journal of Drug 
Policy, vol. 26, Suppl. No. 1 (2015), pp. S12-S15.
22 Silvia Martins and others, “Worldwide prevalence and trends in 
unintentional drug overdose: a systematic review of the literature”, 
 American Journal of Public Health, vol. 105, No. 11 (November 2015).
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men with such disorders. Among this group of women, 
the prevalence of major depression is twice as high among 
women in the general population.23 Individuals with a 
dual diagnosis have a poorer prognosis, require more 
intense supportive care and have a higher risk of suicide 
compared with those with a single diagnosis.24 Effective 
treatments for dual diagnosis focus equally on both types 
of disorders and deliver services in a fully integrated 
manner.
21. A comparison between female prisoners with a dual 
diagnosis and those with severe mental illness alone 
found that the first group was more likely to have more 
immediate service needs once released, such as housing, 
and were more likely to reoffend. Once in prison, women 
are at risk of acquiring major depressive and anxiety dis-
orders. Furthermore, whereas psychiatric symptom prev-
alence has been noted to decline among men who have 
been convicted, this is not found to be the case among 
women who are held as pretrial detainees. 
3. Violence
22. Globally, it is estimated that one in three women 
has experienced physical or sexual violence. Rates of 
physical and sexual violence suffered by women under-
going drug treatment are very high, ranging from 40 to 
70 per cent.25 Such violence has adverse consequences on 
the mental, physical and reproductive health of women. 
About 20 per cent of women who have experienced vio-
lence will develop a psychiatric disorder, such as depres-
sion or post-traumatic stress disorder. An investigation 
by UNODC into the impact of drug use on the family 
unit in Afghanistan found that drug use increased the 
likelihood of domestic violence.26 In a review undertaken 
in 2015, the Pompidou Group of the Council of Europe 
found that women who used drugs were subjected to 
more violence than women who did not use drugs. Rates 
of violence were found to be even higher among drug-
using women who were pregnant or who engaged in sex 
work.27 
23 EMCDDA, Comorbidity of Substance Use and Mental Disorders in 
Europe (Luxembourg, Publications Office of the European Union, 2015). 
24 Stephanie Hartwell, “Triple stigma: Persons with mental illness 
and substance abuse problems in the criminal justice system”, Criminal 
Justice Policy Review, vol. 15, No. 1 (March 2004).
25 Mayumi Okuda and others, “Mental health of victims of intimate 
partner violence: results from a national epidemiologic survey”, Psychiat-
ric Services, vol. 62, No. 8 (August 2011).
26 Impacts of Drug Use on Users and Their Families in Afghanistan.
27 Thérèse Benoit and Marie Jauffret-Roustide, Improving the Man-
agement of Violence Experienced by Women Who Use Psychoactive Sub-
stances (Strasbourg, Council of Europe, 2016). Available at www.coe.int/.
4. Imprisonment
23. The proportion of women involved in drug offences 
is increasing. Over the last 30 years, the number of 
women incarcerated in the United States for drug-related 
offences increased by over 800 per cent, compared with 
a 300 per cent increase for men. Two thirds of women in 
federal prisons in the United States are incarcerated for 
non-violent drug offences. In Europe and Central Asia, 
more than 25 per cent (and up to 70 per cent in Tajikistan) 
of women prisoners have been convicted of drug-related 
offences. In Latin America, between 2006 and 2011, the 
female prison population almost doubled, with 60 to 80 
per cent incarcerated for drug-related offences.
24. Women who have little formal education or who lack 
employment opportunities are those most frequently found 
to be involved in the drug trade. Most women who are 
arrested for acting as drug couriers have no previous crimi-
nal convictions and many are foreign-born. In Argentina, 
9 out of every 10 foreign female prisoners with drug con-
victions were couriers, and the overwhelming majority 
were first-time offenders.28 These female inmates have no 
family, social or institutional ties to the country in which 
they are held and are often serving long sentences.
D. Special populations who use 
drugs
1. Female prisoners and their children
25. Although men outnumber women by a ratio of 10 
to 1 in prison populations, the number of incarcerated 
women is increasing. Over the last 15 years, the number 
of women in prison has increased by about 50 per cent.29 
In 2015, over 700,000 women and girls were held in penal 
institutions throughout the world as either pretrial detain-
ees or as convicted and sentenced prisoners.30 Prevalence 
of drug use among female prisoners is much higher than 
among male prisoners. Globally, between 30 and 60 per 
cent of women abused drugs in the month before being 
imprisoned, compared with between 10 and 50 per cent 
of men.
28 Corina Giacomello, “Women, drug offenses and penitentiary 
 systems in Latin America”, IDPC Briefing Paper (International Drug 
 Policy Consortium, 2013).
29 Roy Walmsley, “World Female Imprisonment List”, 3rd ed., World 
Prison Brief (London, Institute for Criminal Policy Research, Birkbeck, 
University of London, 2015).
30 Ibid.
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26. When women are imprisoned, family life is often 
greatly disrupted: in Latin America, a third of female pris-
oners lose their homes, and just 5 per cent of children 
remain in their own home once their mother has been 
imprisoned. A study done in Brazil revealed that most 
children continue to be cared for by their mother when 
their father is imprisoned; however, in the event of a 
mother being incarcerated, just 10 per cent of children 
remain in their father’s care. In Latin America, most 
incarcerated women are first-time offenders and, as pri-
mary caregivers to their children, their incarceration 
often means that their children either accompany them 
to prison or become homeless.
27. Owing to an insufficient number of female prison 
facilities, women are often imprisoned far from their 
homes, making it difficult to receive visits. Separation 
from their communities, homes and families has a con-
siderably detrimental impact on the mental well-being of 
female prisoners. Female prisoners have significantly 
higher levels of psychiatric conditions than male prison-
ers. Such conditions include depression, bipolar disorder, 
psychosis, post-traumatic stress disorder, anxiety, person-
ality disorder and drug dependence.
28. A large proportion of women incarcerated world-
wide are in pretrial detention. Some have been detained 
for years; often longer than the sentence they are poten-
tially facing. In Pakistan, over half of all female prison-
ers interviewed for a UNODC study were on trial, and 
one fifth of them had spent over a year awaiting trial. An 
inspection of nine prisons in the country found virtually 
no recreational facilities, educational services or health 
services for women or children, and no vocational train-
ing for women. In one prison, 60 inmates shared one 
washroom and eight of the nine prisons had unsafe 
drinking water, leading to waterborne diseases. Medical 
facilities were inadequate and lacked any mental health 
services. Most of the specialist women’s health care was 
being provided by non-governmental organizations, 
rather than the Ministry of Health or the Prison 
Department. In small towns, female prisoners had given 
birth in prison without any medical assistance.31 
29. Several South American countries have amended 
their national legislation pertaining to pretrial detention 
for pregnant women and nursing mothers. The amend-
ments allow such women to serve pretrial periods at 
home.
31 UNODC, Females Behind Bars: Situation and Needs Assessment in 
Female Prisons and Barracks (Islamabad, 2011).
30. Countries wishing to reduce the numbers of women 
incarcerated have the possibility of making use of the pro-
visions of article 3, subparagraph 4 (c), of the United 
Nations Convention against Illicit Traffic in Narcotic 
Drugs and Psychotropic Substances of 1988,32 which 
clearly provides for alternatives to incarceration, stating 
that “in appropriate cases of a minor nature, the Parties 
may provide, as alternatives to conviction or punishment, 
measures such as education, rehabilitation or social rein-
tegration, as well as, when the offender is a drug abuser, 
treatment and aftercare.” 
2. Sex workers
31. Female sex workers who abuse drugs by injection 
face major health risks, the threat of violence and social 
marginalization. Many countries have severe punish-
ments, including the death penalty, for people who engage 
in sex work. There is a high correlation between drug use 
and sex work: drug dependence may account for a wom-
an’s entry into sex work as a means to support that 
dependence; women may also engage in drug use to cope 
with the demands and nature of sex work.
32. Globally, rates of drug abuse and HIV infection and 
incidences of imprisonment are high among female sex 
workers. In Myanmar, one third of female sex workers 
interviewed for a study reported using amphetamine-type 
stimulants for occupational reasons, exacerbating the 
risks of HIV infection and other sexually transmitted 
infections. Sex workers who used drugs were three and a 
half times more likely to report having a sexually trans-
mitted infection than other sex workers.33 
33. Female sex workers use amphetamine-type stimu-
lants for increased energy and weight control. Cambodian 
sex workers interviewed for one study also stated that use 
of amphetamine-type stimulants use increased their over-
all confidence and control with clients. However, use of 
amphetamine-type stimulants is associated with risky sex-
ual behaviour and higher rates of sexually transmitted 
infection. Furthermore, chronic use of amphetamine-type 
stimulants can lead to paranoia and aggressive 
behaviour.34 
32 United Nations, Treaty Series, vol. 1582, No. 27627.
33 Katie Hail-Jares and others, “Occupational and demographic fac-
tors associated with drug use among female sex workers at the China-
Myanmar border”, Drug and Alcohol Dependence, vol. 161 (April 2016).
34 Marie-Claude Couture and others, “Correlates of amphetamine-
type stimulant use and associations with HIV-related risks among young 
women engaged in sex work in Phnom Penh, Cambodia”, Drug and 
 Alcohol Dependence, vol. 120 (January 2012).
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3. Pregnant women
34. Drug dependence is strongly correlated with 
unwanted pregnancies, poor birth outcomes and child 
abuse or neglect. Utilization of drugs during pregnancy 
may lead to premature births, newborns with a low birth-
weight and postpartum haemorrhage. Women who use 
drugs during their pregnancy are also more likely to be 
admitted to intensive care units during labour and to 
 suffer higher incidences of infant mortality.
35. Prenatal exposure to drugs can result in an array of 
emotional, psychological and physical disorders. Children 
who have been exposed to drugs while in the womb may 
suffer significant developmental problems that require 
additional care, resulting in both personal and societal 
costs. Children exposed to a drug-using environment are 
at a significantly higher risk of both physical and sexual 
abuse, as well as neglect.
36. Babies whose mothers used cannabis during preg-
nancy may exhibit neurological development problems; 
exposure to cannabis in early life may adversely affect 
brain development and behaviour. Later on, those chil-
dren are likely to demonstrate impaired attention, poor 
learning and memory skills, impulsivity and behavioural 
problems at school. They also have a higher likelihood of 
using cannabis as adults.
E. Prevention of and treatment and 
rehabilitation for drug dependence
1. Prevention of drug abuse
37. Programmes for the prevention of substance use 
disorders in special populations vary across countries. 
The primary objective of drug abuse prevention is to help 
people, particularly young people, avoid initiation into 
the use of drugs or, if they have already started using 
drugs, to avoid becoming dependent. Prevention pro-
grammes are frequently targeted at children and families 
at risk, prisoners, people living with HIV/AIDS, pregnant 
women and sex workers. As part of such programmes, 
particular regard should be paid to the stigma associated 
with drug use, especially for women. Specific interven-
tions should be developed that enable women to partici-
pate in prevention programmes. 
38. The provision of evidence-based integrated treat-
ment to pregnant women can have a positive impact 
on  child development, the emotional and behavioural 
functioning of the mother and parenting skills.
2. Barriers to accessing treatment
39. According to the World Health Organization 
(WHO), most Governments have no specific budget allo-
cation for the treatment of substance use disorders. 
Furthermore, the incorporation of drug prevention and 
treatment services into national health systems is uncom-
mon. Specialized drug treatment for pregnant women 
(available in 31 per cent of countries) and sex workers 
(available in 26 per cent of countries) is low and cover-
age is poor. However, drug treatment services for preg-
nant women exist in 61 per cent of countries in Europe, 
and 40 per cent of countries in South-East Asia have such 
services for sex workers.35 
40. Globally, women make up one third of people who 
abuse drugs but just one fifth of those who are in treat-
ment. Women encounter significant systemic, structural, 
social, cultural and personal barriers to accessing sub-
stance abuse treatment. At the structural level, the main 
obstacles include a lack of childcare services and judg-
mental attitudes to women who abuse drugs, especially 
if  they are pregnant. Often, residential treatment 
 programmes do not admit women with children.
41. Women who use drugs may not seek treatment for 
fear of losing custody of their children. Other reasons for 
low uptake of treatment by women include hostile atti-
tudes of medical staff or clinics being inundated with 
male clients, making them uninviting for female clients.
42. In many countries, women who abuse drugs face 
stigma. Therefore, women may be reluctant to disclose 
their abuse of drugs and may be hesitant to access health 
services, including drug treatment, for fear of discrimi-
nation. Women and girls who use drugs may lose the sup-
port of their family, find themselves with limited 
employment opportunities and turn to sex work, further 
exacerbating the stigma they face.
43. Pregnant women may be afraid to seek help because 
of the possible involvement of the authorities and the 
legal or social repercussions this could entail. However, 
if pregnant, drug-abusing women remain untreated, it can 
have major implications for the health of their babies. 
Some of the factors that motivate women to enter treat-
ment are pregnancy, parenthood and a partner’s entry 
35 WHO, Atlas on Substance Use (2010): Resources for the Prevention 
and Treatment of Substance Use Disorders (Geneva, 2010).
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into treatment. If a woman’s partner leaves treatment, she 
is likely to leave as well. There is much debate as to 
whether couples should enter rehabilitation together or 
separately: although many experts claim that a couple 
must separate to overcome dependency, many couples 
have successfully completed treatment together. 
Nevertheless, relationships rarely survive if only one 
 person stops using drugs.
44. In general, fewer women than men who need to 
access treatment are able to do so. This is particularly true 
in low- and middle-income countries; in Afghanistan, 
despite the high rates of opium and heroin use among 
women, women make up only 4 per cent of those in treat-
ment; in Pakistan, that figure is 13 per cent. In some 
regions of the world, such as the Middle East, women 
generally still fulfil the traditional role of taking care of 
the household while men go to work. When women step 
outside of that role by using drugs it can lead to stigma, 
which prevents women from seeking treatment for their 
drug dependence.
45. Access to drug treatment increased for women in 
the Islamic Republic of Iran when women-only drug 
treatment services were introduced. Prior to the introduc-
tion of such services, fewer than 20 per cent of women 
using drugs had accessed treatment in the previous 10 
years. Positive outcomes from the women-only clinics 
resulted in an increase in the number of such clinics in 
the country.
3. Treatment outcomes
46. Although population-based studies demonstrate no 
clear differences between men and women when it comes 
to staying in and completing treatment programmes, 
there are certain factors to consider. Two factors that sig-
nificantly aid in predicting the treatment outcome for 
women are dual diagnosis and a history of trauma. It is 
therefore important for treatment programmes to address 
those issues in order to increase their effectiveness. 
47. Although providing exclusively female treatment 
programmes is still a novel approach, such programmes 
have been positively endorsed by women. Women who 
participate in them feel that they are better understood 
and can more easily relate to other female attendants. 
Some women report that they feel unsafe or are harassed 
in mixed-gender programmes. In women-only pro-
grammes, clients report that the availability of individual 
counselling, the absence of sexual harassment and the 
provision of childcare services are important.
48. In order for treatment services to be gender-sensitive, 
they should also offer a non-punitive environment and pre-
sent a positive attitude towards women and their needs. In 
countries where the provision of drug treatment to women 
is a recent development, staff are likely to require training 
to address any biases that they may hold and to ensure 
non-judgmental treatment. Women are just as likely as 
men to remain in treatment once it is initiated, but multi-
ple factors increase the likelihood of this taking place. 
These factors include a patient-centred approach to treat-
ment, on-site childcare facilities and trauma or sexual 
abuse counselling. Treatment programmes should also pro-
vide women with skills, knowledge and support to enable 
them to change their substance use behaviour when they 
return to their family and re-enter their community. The 
rehabilitation process needs to prevent a relapse into sub-
stance use by providing women with the skills required to 
control the impulse to use drugs. The ultimate goals of the 
rehabilitation process are to assist women in regaining con-
trol of their lives, improve their personal health and allow 
them to re-establish healthy relationships with their 
 children, families and communities.
49. Many studies support the finding that treatment is 
effective for men and women alike, with minimal differ-
ences in treatment-related outcomes. However, women 
have been found to be more receptive than men to treat-
ment for methamphetamine dependence. The first type 
of treatment offered to women who use drugs should be 
voluntary, as compulsory treatment should be limited to 
exceptional cases. The use of compulsory drug detention 
centres has been criticized by a number of United Nations 
organizations.36 Among other reasons, women detained 
in such centres are particularly vulnerable to sexual 
 violence and abuse. 
F. Recommendations 
50. INCB encourages Member States to collect and 
share data, disaggregated by age, sex and other relevant 
factors, when providing information through the annual 
report questionnaire and when reporting to the 
Commission on Narcotic Drugs.
51. All Governments are encouraged to collect gender-
disaggregated data on participation in drug use preven-
tion programmes and access to treatment services, to 
allow the efficient allocation of resources. Targeted 
36 International Labour Organization and others, “Compulsory drug 
detention and rehabilitation centres”, joint statement, March 2012. 
 Available at www.unodc.org.
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interventions, based on research, can be particularly effec-
tive in meeting the specific needs of female drug users.
52. Efforts to prevent and treat drug abuse among 
women should be better funded, coordinated and based 
on evidence. In addition to Governments, stakeholders 
such as non-governmental organizations and academia 
can provide treatment and generate data for a better 
understanding of drug use by women.
53. Governments should give priority to providing eas-
ily accessible health care for drug-dependent women. 
Special groups such as drug-dependent women who are 
pregnant need the enhanced services of a specially trained 
multidisciplinary team. Prenatal care could include test-
ing for HIV and other sexually transmitted infections in 
order to improve the detection and management of those 
conditions, but such measures should not be punitive.
54. Drug treatment programmes should be able to guar-
antee personal safety and confidentiality with women-
only spaces or times. Services become more accessible 
when childcare and interventions or strategies for women 
engaged in sex work or women who have experienced 
gender-based violence are provided. In order to main-
stream gender equality, policymakers should work to 
improve the availability, accessibility, affordability and 
acceptability of services for women who use drugs.
55. Women’s right to health includes the right to be free 
from torture, non-consensual treatment and experimen-
tation. Drug treatment programmes should be held to the 
same standards of safety and efficacy as programmes for 
the treatment of other ailments. Furthermore, inhumane 
or degrading forms of treatment of drug users, such as 
compulsory drug detention centres, should be eliminated 
in favour of voluntary, residential and evidence-informed 
alternatives in the community. 
56. Governments should ensure the provision of drug 
abuse prevention services and evidence-based treatment, 
especially in communities experiencing social disintegra-
tion. Strategies should address high-risk groups, such as 
pregnant women, sex workers and prisoners. 
57. Efforts to eliminate the stigma associated with drug 
dependence, particularly among women, should be given 
high priority. Governments need to show leadership if 
discrimination is to be eliminated. Women who use 
drugs, engage in sex work or have HIV infection need 
protection and better access to services. 
58. The United Nations Rules for the Treatment of 
Women Prisoners and Non-custodial Measures for 
Women Offenders (the Bangkok Rules)37 specifically refer 
to substance abuse treatment programmes and recom-
mend the provision of gender-sensitive, trauma-informed, 
women-only substance abuse treatment programmes in 
the community. They also recommend that women’s 
access to such treatment should be improved, for crime 
prevention as well as for diversion and alternative sen-
tencing purposes. They emphasize the need to ensure 
respect for the dignity of women in prison and to avoid 
any source of physical or sexual violence. 
59. INCB encourages Governments to take into consid-
eration the specific needs and circumstances of women 
subject to arrest, detention, prosecution, trial or the 
implementation of a sentence for drug-related offences, 
including appropriate measures to bring to justice perpe-
trators of abuse of women in custody or in prison set-
tings for drug-related offences. Governments should 
draw, as appropriate, on the Bangkok Rules, the United 
Nations Standard Minimum Rules for Non-custodial 
Measures (the Tokyo Rules)38 and the United Nations 
Standard Minimum Rules for the Treatment of Prisoners 
(the Nelson Mandela Rules).39
37 General Assembly resolution 65/229, annex.
38 General Assembly resolution 45/110, annex.
39 General Assembly resolution 70/175, annex.
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Chapter II.
Functioning of the international drug control 
system
A. Promoting the consistent 
application of the international drug 
control treaties
60. During the period under review, INCB has contin-
ued to work closely with all Governments to encourage 
full ratification of the three international drug control 
conventions and their implementation into domestic 
law.
61. The objectives of the drug control framework cre-
ated by the conventions are manifold and include the fol-
lowing: regulating all licit trade in narcotic drugs and 
psychotropic substances and precursors used in their 
illicit manufacture, while preventing their diversion into 
illicit channels; ensuring adequate access to medicines 
containing controlled substances for legitimate medical 
purposes for those who need them; establishing treat-
ment, rehabilitation, after care and social reintegration 
structures to address drug use and addiction; addressing 
drug-related criminality in a proportionate manner that 
is firmly anchored in the rule of law and due process 
guarantees and that provides for the adoption of institu-
tional responses to address the commission of unlawful 
acts by individuals affected by drug use or addiction; and 
facilitating mutual legal assistance and extradition and 
combating money-laundering.
62. In order to fulfil those objectives, States must adopt 
a corpus of legal, policy and regulatory measures. In line 
with the mandate conferred upon it by the drug control 
conventions, the Board continues to engage with States 
through a sustained dialogue aimed at helping to ensure 
the comprehensive implementation of these important 
instruments, which are aimed at promoting the health 
and welfare of humanity.
Status of adherence to the international drug 
control treaties
63. The Board welcomes the international community’s 
widespread support of the international drug control con-
ventions, which is evidenced by the fact that the conven-
tions benefit from near-universal adherence. The Board 
takes note of the renewed support for the conventions as 
the cornerstone of the global legal framework governing 
drug control, as expressed in the outcome document of 
the special session of the General Assembly on the world 
drug problem held in April 2016, entitled “Our joint com-
mitment to effectively addressing and countering the 
world drug problem”. 
64. As at 1 November 2016, only 11 States had yet to 
ratify the Single Convention on Narcotic Drugs of 1961 
as amended by the 1972 Protocol:40 2 States in Africa 
(Equatorial Guinea and South Sudan), 2 States in Asia 
(State of Palestine and Timor-Leste) and 7 States in 
Oceania (Cook Islands, Kiribati, Nauru, Niue, Samoa, 
Tuvalu und Vanuatu). Chad remains the only State hav-
ing acceded to the 1961 Convention in its unamended 
state.41
65. The Convention on Psychotropic Substances of 
197142 has been ratified by 183 States parties. The 14 States 
40 United Nations, Treaty Series, vol. 976, No. 14152.
41 Ibid., vol. 520, No. 7515.
42 Ibid., vol. 1019, No. 14956.
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still not parties to it are as follows: 3 States in Africa 
(Equatorial Guinea, Liberia and South Sudan), 1 State in 
the Americas (Haiti), 2 States in Asia (State of Palestine 
and Timor-Leste) and 8 States in Oceania (Cook Islands, 
Kiribati, Nauru, Niue, Samoa, Solomon Islands, Tuvalu 
und Vanuatu).
66. The United Nations Convention against Illicit Traffic 
in Narcotic Drugs and Psychotropic Substances of 1988 
has been ratified or acceded to by a total of 189 States 
and formally confirmed by the European Union. Nine 
States have yet to become party to it: three States in Africa 
(Equatorial Guinea, Somalia and South Sudan), one State 
in Asia (State of Palestine) and five States in Oceania 
(Kiribati, Palau, Papua New Guinea, Solomon Islands and 
Tuvalu).
67. The Board calls upon all States that have not rat-
ified one or more of the international drug control con-
ventions to do so without delay, and to ensure that the 
provisions contained therein are comprehensively 
implemented within their respective national legal 
orders.
B. Ensuring the implementation of 
the provisions of the international 
drug control treaties
68. The fundamental goal of the international drug con-
trol systems is assuring the health and welfare of human-
kind. That goal is to be achieved through two, twin 
actions: ensuring the availability of internationally con-
trolled substances for medical and scientific purposes; 
and preventing the diversion of controlled substances into 
illicit channels or, in the case of precursor chemicals, for 
use in the illicit manufacture of narcotic drugs and 
 psychotropic substances.
69. To monitor compliance with the international drug 
control treaties, the Board examines action taken by 
Governments to implement the treaty provisions aimed 
at achieving the overall goals of the conventions. Over 
the years, the treaty provisions have been supplemented 
with additional control measures adopted by the Economic 
and Social Council and the Commission on Narcotic 
Drugs to enhance their effectiveness. In the present sec-
tion, the Board highlights action that needs to be taken 
to implement the international drug control system, 
describes problems encountered in that regard and 
provides specific recommendations on how to deal with 
those problems.
1. Preventing the diversion of 
controlled substances
(a) Legislative and administrative basis
70. Governments have to ensure that national legisla-
tion complies with the provisions of the international 
drug control treaties. They also have the obligation to 
amend lists of the substances controlled at the national 
level when a substance is included in a schedule of an 
international drug control treaty or transferred from one 
schedule to another. Inadequate legislation or implemen-
tation mechanisms at the national level or delays in bring-
ing lists of substances controlled at the national level into 
line with the schedules of the international drug control 
treaties will result in inadequate national controls being 
applied to substances under international control and 
may lead to the diversion of substances into illicit chan-
nels. The Board is therefore pleased to note that, as in 
previous years, Governments have continued to furnish 
information to the Board on legislative or administrative 
measures taken to ensure compliance with the provisions 
of the international drug control treaties.
71. In its decision 59/1, the Commission on Narcotic 
Drugs decided to include acetylfentanyl in Schedules I 
and IV of the 1961 Convention as amended. In its deci-
sion 59/2, the Commission decided to include MT-45 in 
Schedule I of that Convention. In accordance with arti-
cle 3, paragraph 7, of the 1961 Convention as amended, 
that decision was communicated by the Secretary-General 
to all Governments, to WHO and to the Board on 
17  May  2016, and became effective with respect to each 
party upon receipt of that notification. The Board 
acknowledges the efforts made by Governments that 
have already put those substances under control and 
urges all other Governments to amend the lists of sub-
stances controlled at the national level accordingly and 
to apply to those substances all control measures 
required under the 1961 Convention as amended.
72. The Board also wishes to draw the attention of 
Governments to the fact that five substances were placed 
under international control under the 1971 Convention by 
the Commission on Narcotic Drugs in March 2016. 
Pursuant to Commission decision 59/3, para-methoxy-
methylamphetamine (PMMA) was added to Schedule I of 
the 1971 Convention. Pursuant to Commission decisions 
59/4, 59/5 and 59/6, α-pyrrolidinovalerophenone (α-PVP), 
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para-methyl-4-methylaminorex (4,4’-DMAR) and meth-
oxetamine (MXE) were added to Schedule II of that 
Convention and, pursuant to Commission decision 59/7, 
phenazepam was added to Schedule IV. In accordance 
with article 2, paragraph 7, of the 1971 Convention, those 
decisions of the Commission were communicated by the 
Secretary-General to all Governments, to WHO and to 
the Board on 17 May 2016, and became fully effective 
with respect to each party on 13 November 2016. The 
Board acknowledges the efforts made by some 
Governments that have already put those substances 
under control and urges all other Governments to 
amend the lists of substances controlled at the national 
level accordingly and to apply to those substances all 
control measures required under the 1971 Convention.
73. In accordance with Economic and Social Council 
resolutions 1985/15, 1987/30 and 1993/38, Governments 
are required to introduce an import authorization require-
ment for zolpidem, a substance that was included in 
Schedule IV of the 1971 Convention in 2001. In response 
to the Board’s request made in its annual reports for 2012 
and 2013 and a circular letter sent in 2016, a number of 
Governments have provided the requisite information. As 
at 1 November 2016, relevant information was available 
for 129 countries and territories. Of those, 119 countries 
and territories have introduced an import authorization 
requirement, and 2 countries (Indonesia and the United 
States) require a pre-import declaration. Six countries and 
territories do not require an import authorization for 
zolpidem (Cabo Verde, Ireland, New Zealand, Singapore, 
Vanuatu and Gibraltar). Imports of zolpidem into 
Azerbaijan are prohibited, and Ethiopia does not import 
the substance. At the same time, information on the con-
trol of zolpidem remains unknown for 85 countries and 
territories. The Board therefore again invites the 
Governments of countries and territories that have not 
yet done so to supply it with information on the  control 
status of zolpidem as soon as possible.
74. With regard to precursor chemicals, the Board 
wishes to recall that alpha-phenylacetoacetonitrile 
(APAAN) and its optical isomers were added to Table I 
of the 1988 Convention in accordance with Commission 
on Narcotic Drugs decision 57/1. Governments were 
therefore required, as of 6 October 2014, to have placed 
the substance under national control. The Board notes 
that a certain number of countries have yet to implement 
at the national level the international scheduling decision 
with regard to APAAN. In order to effectively monitor 
the movement of precursor chemicals, both domestically 
and across borders, it is important that Governments have 
the appropriate legislation and national control mecha-
nisms in place to allow irregularities in licit trade 
patterns to be identified at an early stage and thereby mit-
igate the risk of diversion of precursor chemicals into 
illicit channels. Governments are thus requested to adopt 
and implement national precursor control measures, 
which are a prerequisite for the functioning of the inter-
national precursor control system.
(b) Prevention of diversion from 
international trade
Estimates and assessments of annual 
requirements for internationally controlled 
substances
75. The system of estimates and assessments of annual 
licit requirements for narcotic drugs and psychotropic 
substances is the cornerstone of the international drug 
control system. It enables exporting and importing coun-
tries alike to ensure that trade in those substances stays 
within the limits determined by the Governments of 
importing countries and that diversions of controlled sub-
stances from international trade are effectively prevented. 
For narcotic drugs, such a system is mandatory under the 
1961 Convention, and the estimates furnished by 
Governments need to be confirmed by the Board before 
becoming the basis for calculating the limits on manu-
facture and import. 
76. The system of assessments of annual requirements 
for psychotropic substances was adopted by the Economic 
and Social Council in its resolutions 1981/7, 1991/44, 
1993/38 and 1996/30 and the system of estimates of 
annual legitimate requirements for selected precursors 
was adopted by the Commission on Narcotic Drugs in 
its resolution 49/3, to help Governments to prevent 
attempts by traffickers to divert controlled substances into 
illicit channels. The assessments of annual legitimate 
requirements for psychotropic substances and estimates 
of annual legitimate requirements for selected precursors 
help Governments to identify unusual transactions. In 
many cases, the diversion of a drug has been prevented 
when the exporting country refused to authorize the 
export of the substance because the quantities of the 
 substance to be exported would have exceeded the 
 quantities required in the importing country.
77. Although not mandatory under the 1988 Convention, 
the Commission on Narcotic Drugs, in its resolution 
49/3, requested Governments to provide to the Board 
their estimated annual legitimate requirements for 
selected precursor chemicals. The availability of realistic 
and up-to-date estimates facilitates the identification of 
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suspicious requests and transactions that may, in the 
event of such transactions exceeding the legitimate 
requirements communicated by a country’s competent 
national authorities, indicate an attempt at diversion and 
can thus function as an early warning mechanism for 
authorities tasked with the authorization of proposed 
exports. It is therefore encouraging that 159 out of 189 
(84 per cent) of States parties to the 1988 Convention are 
now providing annual legitimate requirements for at least 
one of the amphetamine-type stimulant precursors listed 
in Commission on Narcotic Drugs resolution 49/3.
78. The Board regularly investigates cases involving pos-
sible non-compliance by Governments with the system of 
estimates or assessments, as such non-compliance could 
facilitate the diversion of controlled substances from licit 
international trade into illicit channels. In that connec-
tion, the Board provides information, support and guid-
ance to Governments on the working of the system for 
estimates or assessments, as necessary.
79. Governments are obliged to comply with the lim-
its on imports and exports of narcotic drugs provided for 
under articles 21 and 31 of the 1961 Convention. Article 
21 stipulates, inter alia, that the total of the quantities of 
each drug manufactured and imported by any country or 
territory in a given year shall not exceed the sum of the 
following: the quantity consumed for medical and scien-
tific purposes; the quantity used, within the limits of the 
relevant estimates, for the manufacture of other drugs, 
preparations or substances; the quantity exported; the 
quantity added to the stock for the purpose of bringing 
that stock up to the level specified in the relevant esti-
mate; and the quantity acquired within the limit of the 
relevant estimate for special purposes. Article 31 requires 
all exporting countries to limit the export of narcotic 
drugs to any country or territory so that the quantities 
imported fall within the limits of the total of the estimates 
of the importing country or territory, with the addition 
of the amounts intended for re-export.
80. As in previous years, the Board finds that the sys-
tem of imports and exports generally continues to be 
respected and works well. In 2015, a total of 18 countries 
were contacted regarding possible excess imports or 
excess exports identified with regard to international 
trade in narcotic drugs that had been effected during the 
year. As at 1 November 2016, 13 countries had responded 
and most of the cases were clarified as: (a) a result of 
errors in reporting on imports or exports; (b) drugs 
imported for re-export; (c) a result of errors in the report-
ing of the drugs or trading partner; and (d) drugs 
exported for destruction. However, four countries con-
firmed that excess exports or excess imports had actually 
occurred, and they were reminded of the need to ensure 
full compliance with the relevant treaty provisions. 
The  Board continues to pursue the matter with those 
countries that have failed to respond.
81. Pursuant to Economic and Social Council resolu-
tions 1981/7 and 1991/44, Governments are requested to 
provide to the Board assessments of annual domestic 
medical and scientific requirements for psychotropic sub-
stances listed in Schedules II, III and IV of the 1971 
Convention. The assessments received are communicated 
to all States and territories to assist the competent author-
ities of exporting countries when approving exports of 
psychotropic substances. As at 1 November 2016, the 
Governments of all countries and territories, except for 
South Sudan, for which assessments were established by 
the Board in 2011, had submitted at least one assessment 
of their annual medical requirements for psychotropic 
substances.
82. The Board recommends that Governments review 
and update the assessments of their annual medical and 
scientific requirements for psychotropic substances at 
least every three years. However, 31 Governments have 
not submitted a revision of their legitimate requirements 
for psychotropic substances for three years or more. The 
assessments valid for those countries and territories may 
therefore no longer reflect their actual medical and 
 scientific requirements for psychotropic substances.
83. When assessments are lower than the actual legit-
imate requirements, the importation of psychotropic 
substances needed for medical or scientific purposes 
may be delayed. When assessments are significantly 
higher than legitimate needs, the risk of psychotropic 
substances being diverted into illicit channels may be 
increased. The Board has repeatedly reminded countries 
that it is important that Governments estimate and 
assess correctly and realistically the initial needs of their 
country. Therefore, the Board calls upon all 
Governments to review and update their assessments 
and estimates on a regular basis and to keep it informed 
of all modifications, with a view to preventing any 
unnecessary importation and, at the same time, 
 facilitating the timely importation of psychotropic 
 substances needed for medical purposes. 
84. As in previous years, the system of assessments of 
annual requirements for psychotropic substances contin-
ues to function well and is respected by most countries 
and territories. In 2015, the authorities of 14 countries 
issued import authorizations for substances for which 
they had not established any such assessments or for 
quantities that significantly exceeded their assessments. 
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Only three countries exported psychotropic substances in 
quantities exceeding the relevant assessment.
Requirement for import and export 
authorizations
85. The universal application of the requirement for 
import and export authorizations laid down in the 1961 
and 1971 Conventions is key to preventing the diversion 
of drugs into the illicit market. Such authorizations are 
required for transactions involving any of the substances 
controlled under the 1961 Convention or listed in 
Schedules I and II of the 1971 Convention. Competent 
national authorities are required by those conventions to 
issue import authorizations for transactions involving the 
importation of such substances into their country. The 
competent national authorities of exporting countries 
must verify the authenticity of such import authorizations 
before issuing the export authorizations required to allow 
shipments containing the substances to leave their 
country.
86. The 1971 Convention does not require import and 
export authorizations for trade in the psychotropic sub-
stances listed in its Schedules III and IV. However, in view 
of the widespread diversion of those substances from licit 
international trade during the 1970s and 1980s, the 
Economic and Social Council, in its resolutions 1985/15, 
1987/30 and 1993/38, requested Governments to extend 
the system of import and export authorizations to cover 
those psychotropic substances as well.
87. Most countries and territories have already intro-
duced an import and export authorization requirement 
for psychotropic substances listed in Schedules III and IV 
of the 1971 Convention, in accordance with the above-
mentioned Economic and Social Council resolutions. In 
response to a circular letter sent in 2016, the Board also 
received additional and updated information from the 
Governments of Serbia, Turkey and Timor-Leste. By 1 
November 2016, specific information had been made 
available to the Board by 206 countries and territories, 
showing that all major importing and exporting countries 
now require import and export authorizations for all psy-
chotropic substances in Schedules III and IV of the 1971 
Convention. A table showing the import authorization 
requirements for substances in Schedules III and IV 
applied pursuant to the relevant Economic and Social 
Council resolutions by individual countries is dissemi-
nated by the Board to all Governments twice a year. That 
table is also published in the secure area of the Board’s 
website, which is accessible only to specifically authorized 
Government officials, so that the competent national 
authorities of exporting countries may be informed as 
soon as possible of changes in import authorization 
requirements in importing countries. The Board urges 
the Governments of the remaining 15 States in which 
national legislation does not yet require import and 
export authorizations for all psychotropic substances, 
regardless of whether they are States parties to the 1971 
Convention, to extend such controls to all substances in 
Schedules III and IV of the 1971 Convention as soon as 
possible and to inform the Board accordingly.
88. The 1988 Convention does not prescribe specific 
import or export authorization requirements for inter-
nationally scheduled precursor chemicals. Instead, the 
international precursor control system relies on the mon-
itoring of international trade in order to facilitate the iden-
tification of suspicious transactions and prevent diversion. 
The provision of pre-export notifications regarding ship-
ments of precursor chemicals to an importing country’s 
authorities can be made mandatory under the Convention, 
if a State party chooses to invoke article 12, subpara-
graph  10  (a), by sending a corresponding request to the 
Secretary-General (see paras. 92 and 93 below, regarding 
pre-export notifications for precursor chemicals).
International electronic import and export 
authorization system for narcotic drugs and 
psychotropic substances
89. Import and export authorizations are required for 
narcotic drugs listed in all Schedules of the 1961 
Convention and for psychotropic substances listed in 
Schedules I and II of the 1971 Convention. Furthermore, 
pursuant to the relevant Economic and Social Council 
resolutions, Governments are urged to apply an import 
and export authorization requirement to substances listed 
in Schedules III and IV as well. As part of its endeavours 
to harness technological progress for the effective and effi-
cient implementation of the import and export authori-
zation regime for licit international trade in narcotic 
drugs and psychotropic substances, the Board has spear-
headed efforts to develop an electronic tool to facilitate 
and expedite the work of competent national authorities 
and to reduce the risks of diversion of those drugs and 
substances. The International Import and Export 
Authorization System (I2ES) is an innovative, web-based 
application that was developed by the Board in coopera-
tion with UNODC and with the support of Member 
States. I2ES allows Governments to electronically gener-
ate import and export authorizations for licit imports and 
exports of narcotic drugs and psychotropic substances, to 
exchange those authorizations in real time and to instantly 
verify the legitimacy of individual transactions while 
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ensuring full compliance with the requirements of the 
international drug control conventions. I2ES significantly 
reduces the risk of drug consignments being diverted into 
illicit channels (see section F, below (paras. 338-342), for 
more details).
90. I2ES was officially launched in 2015 and competent 
national authorities from 24 countries have registered 
with the system. In March 2016, a user-group meeting to 
gather feedback on the system was held on the margins 
of the fifty-ninth session of the Commission on Narcotic 
Drugs. Over 30 experts from 21 countries participated in 
that user-group meeting. The meeting afforded govern-
ment officials of participating countries a valuable oppor-
tunity to exchange ideas on bringing about the 
implementation of I2ES and to provide feedback to INCB 
and the information technology service of UNODC that 
will guide future action and the further development of 
the system. The user group emphasized the importance 
of a high level of enrolment in and usage of I2ES by the 
competent national authorities of Governments around 
the world, and encouraged all Governments to register to 
use the system. 
91. The Board wishes to encourage all competent 
national authorities that have not yet done so to regis-
ter with and start using I2ES as soon as possible, as only 
through its widespread application will Governments be 
able to avail themselves of all the advantages that the 
tool provides. The Board stands ready to assist in that 
regard. The Board reiterates the call to Member States 
contained in Commission on Narcotic Drugs resolution 
58/10 to provide the fullest possible financial support 
to enable the secretariat of the Board to continue admin-
istering and monitoring the system.
Pre-export notifications for precursor chemicals
92. The system of rapid information exchange through 
pre-export notifications, which enables the Governments 
of importing and exporting countries to instantly verify 
the legitimacy of individual shipments of precursor chem-
icals, has proved to be the most effective tool to prevent 
the diversion of those substances from international 
trade. Article 12, subparagraph 10 (a), of the 1988 
Convention allows the Governments of importing coun-
tries to make it mandatory for exporting countries to 
inform them of any planned export of precursors to their 
territory. To date, 112 States and territories have invoked 
the provision and have formally requested pre-export 
notifications. However, there is a noteworthy number of 
Governments and regions that remain unaware of, and 
vulnerable to, precursor shipments of concern entering 
their territory. INCB therefore strongly encourages the 
remaining Governments to invoke article 12, subpara-
graph 10 (a), of the 1988 Convention as soon as 
possible.
93. Pre-Export Notification Online (PEN Online) is an 
electronic tool that has been provided by INCB free of 
charge to allow importing and exporting Governments to 
communicate securely with one another on international 
trade in precursor chemicals and to raise alerts when the 
legitimacy of a given shipment is in doubt. PEN Online 
has been in operation for more than 10 years and cur-
rently has registered users from a total of 153 countries 
and territories. Nonetheless, the Board notes that PEN 
Online is not always used to its full potential, despite a 
technical upgrade that was performed in 2015, making 
the tool even more user-friendly and intuitive (for more 
information, see the subsection entitled “New tools for 
old purposes” in section F, below (paras. 336-356)). INCB 
therefore calls upon Governments to actively and sys-
tematically use PEN Online and urges the States that 
have not yet registered to do so as soon as possible.
(c) Effectiveness of the control measures 
aimed at preventing the diversion of 
controlled substances from international 
trade 
94. The system of control measures laid down in the 
1961 Convention provides effective protection to inter-
national trade in narcotic drugs against attempts to divert 
such drugs into illicit channels. Similarly, as a result of 
the almost universal implementation of the control meas-
ures stipulated in the 1971 Convention and the relevant 
Economic and Social Council resolutions, there have been 
no identified cases involving the diversion of psychotropic 
substances from international trade into illicit channels 
in recent years. In addition, the 1988 Convention obliges 
parties to prevent the diversion of precursor chemicals 
from international trade to the manufacture of narcotic 
drugs and psychotropic substances. The Board has devel-
oped various systems to monitor compliance with that 
aspect of the 1988 Convention and has recorded limited 
cases of diversion from licit international trade. 
95. Discrepancies in Government reports on inter-
national trade in narcotic drugs and psychotropic sub-
stances are regularly investigated with the competent 
authorities of the relevant countries to ensure that no 
diversion of narcotic drugs and psychotropic substances 
from licit international trade takes place. Those investi-
gations may reveal shortcomings in the implementation 
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of control measures for narcotic drugs and psychotropic 
substances, including the failure of companies to comply 
with national drug control provisions.
96. Since May 2016, investigations regarding discrep-
ancies for 2015 related to the trade in narcotic drugs have 
been initiated with 37 countries. As at 1 November 2016, 
replies had been received from 23 countries. The responses 
indicated that the discrepancies were caused by clerical 
and technical errors in preparing the reports, reporting 
on exports or imports of preparations in Schedule III of 
the 1961 Convention without indicating it on the form, 
or inadvertent reporting of transit countries as trading 
partners. In some cases, countries confirmed the quanti-
ties reported by them, resulting in follow-up investiga-
tions with their respective trading partners being initiated. 
Reminder letters were sent to the countries that did not 
reply.
97. Similarly, with regard to international trade in psy-
chotropic substances, investigations into 264 discrepan-
cies related to 2014 data were initiated with 17 countries. 
As at 1 November 2016, 9 countries had provided replies 
relating to 179 cases involving discrepancies, leading to 
the resolution of 129 of those cases. In all cases in which 
the data provided were confirmed by the responding 
countries, follow-up actions with the counterpart coun-
tries were initiated. All responses received so far indicate 
that the discrepancies were caused by clerical or techni-
cal errors, in most cases either the failure to convert 
amounts into anhydrous base or “overlapping”, i.e. an 
export in a given year was received by the importing 
country only at the beginning of the following year. None 
of the cases investigated showed a possible diversion of 
psychotropic substances from international trade.
98. Preventing the diversion of substances frequently 
used in the illicit manufacture of narcotic drugs and psy-
chotropic substances, and cooperating to that end, is one 
of the key obligations of States parties under the 1988 
Convention. Aided by a number of monitoring systems 
developed by the Board to support the achievement of 
that aim, the number of recorded cases of diversion from 
licit international trade has decreased over the years.
99. The Board continues to be in regular contact with 
importing and exporting authorities to flag suspicious 
shipments, request clarification on the details of individ-
ual transactions with a view to supporting the expedi-
tious processing of pre-export notifications among 
competent national authorities and generally facilitate 
communication on international trade in precursors. A 
detailed analysis of recent developments and trends 
observed can be found in the Board’s dedicated report on 
the implementation of article 12 of the 1988 Convention.43 
100. The Board calls upon Governments to continue 
to monitor international trade in narcotic drugs, psy-
chotropic substances and precursors by using the INCB 
tools described in section F, below (see paras. 336-356). 
Competent national authorities are encouraged to 
request the assistance of the Board in ascertaining 
whether a suspicious individual transaction is legitimate 
or not.
(d) Prevention of diversion of precursors 
from domestic distribution channels
101. In recent years, the Board has observed a shift in 
the diversion of precursors from international to domes-
tic trade, i.e. within a country’s own national borders. 
While that shift may be an indicator of the successful 
functioning of the precursors control regime at the inter-
national level, which increasingly manages to reduce the 
opportunities for traffickers to channel chemicals away 
from licit cross-border trade into illicit drug manufacture, 
it exposes potential weaknesses in the design of domes-
tic control systems, which the 1988 Convention leaves to 
the discretion of States parties. Increased attention must 
thus be paid to setting up and implementing comprehen-
sive monitoring systems at the national level, focusing on 
domestic trade. Article 12, paragraph 8, of the 1988 
Convention provides some guidance on possible basic 
features of such a system. Several initiatives of the Board, 
including Project Prism and Project Cohesion, which 
focus on precursors used in the illicit manufacture of 
amphetamine-type stimulants and cocaine and heroin, 
respectively, also offer a platform for the exchange of 
information on best practices in tackling new challenges 
in precursor control.
2. Ensuring the availability of 
internationally controlled substances for 
medical and scientific purposes
102. In line with its mandate to ensure the availability 
of internationally controlled substances for medical and 
scientific purposes, the Board carries out various activi-
ties related to narcotic drugs and psychotropic substances. 
The Board monitors action taken by Governments, inter-
national organizations and other bodies to support the 
availability and rational use of controlled substances for 
43 E/INCB/2016/4.
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medical and scientific purposes and provides, through its 
secretariat, technical support and guidance to Governments 
in their implementation of the provisions of the inter-
national drug control treaties.
103. To supplement and increase the effectiveness of the 
action mentioned above, in 2016, the Board launched a 
project called INCB Learning (see also paras. 154-157, 
below). The project provides assistance to Member States 
in their efforts to achieve full compliance with the provi-
sions of the international drug control treaties. One of 
the objectives of the project is to ensure the appropriate 
availability of internationally controlled substances, while 
preventing their abuse and diversion into illicit 
channels. 
104. Under INCB Learning, two regional training sem-
inars for competent national authorities were conducted 
in 2016. In April, the secretariat, in collaboration with 
UNODC, implemented a training seminar in Nairobi for 
19 participants from nine countries in East Africa. In July, 
45 participants from 19 countries in South and East Asia 
attended a three-day seminar held in Bangkok. The activ-
ity was co-organized with the Office of the Narcotics 
Control Board of Thailand. Both activities were followed 
by national awareness-raising workshops for the host 
countries, which brought together participants from 
national authorities, civil society and the international 
community to discuss the importance of ensuring the 
availability of opioid analgesics and psychotropics for 
medical and scientific purposes. 
Supply of and demand for opiate raw materials
105. The Board, in fulfilment of the functions assigned 
to it under the 1961 Convention and relevant resolutions 
of the Economic and Social Council and the Commission 
on Narcotic Drugs, regularly examines issues affecting the 
supply of and the demand for opiates for licit require-
ments, and endeavours to ensure a standing balance 
between that supply and demand on the basis of data 
 provided by Governments.44
106. In order to establish the status of the supply of 
and demand for opiate raw materials, the Board analy-
ses the data on opiate raw materials and on opiates 
manu factured from those raw materials provided by 
Governments. In addition, the Board analyses 
44 The analysis excludes data on China and the Democratic People’s 
Republic of Korea, which produce opiate raw materials solely for domes-
tic use. It also excludes data on the utilization of seized opium that was 
released for licit use in the Islamic Republic of Iran and on the demand for 
opiates derived from such opium.
information on the utilization of those raw materials, 
estimated consumption for licit use and stocks at the 
global level. A detailed analysis of the current situation 
as it pertains to the supply of and demand for opiate raw 
materials is contained in the 2016 technical report of the 
Board on narcotic drugs.45
107. In 2015, the area sown with opium poppy rich in 
morphine in the main producing countries, as well as the 
actual area harvested, decreased compared with the pre-
vious year in Australia, France, Hungary and Spain, but 
increased in Turkey. In India, the only country licitly pro-
ducing opium for export, cultivation remained stable, 
with an actual area harvested of 5,422 ha in 2015. The 
total area of opium poppy rich in morphine sown in the 
main producing countries was 76 per cent of the total 
estimated area.
108. In 2015, the cultivation of opium poppy rich in 
thebaine, in terms of actual area harvested, decreased in 
Australia and Spain. France did not cultivate any opium 
poppy rich in thebaine. The total area sown in the main 
producing countries was 86 per cent of the total estimated 
area.
109. The actual area harvested for opium poppy rich in 
codeine in 2015 more than doubled in Australia and 
increased by 52 per cent in France compared with the 
previous year.
110. Recently, an increase in the cultivation of opium 
poppy rich in noscapine in some producing countries has 
been reported. The quantity of opiates under international 
control obtained from the cultivation of that particular 
variety and all other varieties of opium poppy were 
included in the analysis of the global production of and 
demand for opiate raw materials. In 2015, Hungary was 
the only country that reported the cultivation of opium 
poppy rich in noscapine.
111. The advance data for 2016 show a 15 per cent 
decrease in the total estimated area of opium poppy rich 
in morphine to be harvested in the main producing coun-
tries. In 2017, the cultivation of opium poppy rich in 
morphine is expected to increase in Hungary, India and 
Turkey and to decrease in Australia, France and Spain.
112. Australia, Hungary and Spain decreased their esti-
mate of the area to be used for the cultivation of opium 
poppy rich in thebaine, whereas France increased its esti-
mate. The estimated area for Hungary for 2016 is the 
same as for 2015. For 2017, Australia, Hungary and Spain 
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are estimating a decrease in cultivation of that variety, 
while France is planning to increase the area of 
cultivation.
113. Both Australia and France, the only countries 
among the main producers that cultivate opium poppy 
rich in codeine, are expected to decrease their cultivation 
in 2016, but Australia is projecting an increase in 2017. 
France did not provide an estimate of cultivation for that 
year.
114. The total production of morphine-rich opiate raw 
materials in the main producing countries increased to 
586 tons in morphine equivalent in 2015 and it is pro-
jected to decrease to about 566 tons in morphine equiv-
alent in 2016. Of that quantity, poppy straw will account 
for 561 tons (99 per cent) and opium will account for 5 
tons (1 per cent). For 2017, it is estimated that global pro-
duction of opiate raw materials rich in morphine will 
increase to 669 tons in morphine equivalent, mainly as a 
result of the increase in the estimates of Hungary, India, 
Spain and Turkey.
115. In 2015, the global production of opiate raw mate-
rials rich in thebaine was 216 tons in thebaine equiva-
lent. During that year, production decreased in almost all 
the main producing countries, but it is expected to 
increase to about 298 tons in thebaine equivalent in 2016 
as a result of the expected increase in France and Spain. 
Australia, France and Spain are expected to account for 
about 99 per cent of the global production of opiate raw 
materials rich in thebaine in 2016. Production of thebaine- 
rich raw materials in 2017 is expected to increase further, 
to 366 tons. Again, that will result mainly from the 
expected increase in production in France and Spain, as 
well as the increase in the thebaine obtained from the 
cultivation of opium poppy in India. As in previous years, 
the actual production of opiate raw materials in 2016 and 
2017 may differ considerably from the estimates, depend-
ing on weather and other conditions.
116. Stocks of opiate raw materials rich in morphine 
(poppy straw, concentrate of poppy straw and opium) 
amounted to about 746 tons in morphine equivalent at 
the end of 2015. Those stocks were considered to be suf-
ficient to cover 19 months of expected global demand by 
manufacturers at the 2016 level of demand.
117. Stocks of opiate raw materials rich in thebaine 
(poppy straw, concentrate of poppy straw and opium) 
decreased to about 274 tons in thebaine equivalent by the 
end of 2015. Those stocks are sufficient to cover 16 
months of expected global demand by manufacturers at 
the 2016 level of demand.
118. Global stocks of opiates based on morphine-rich 
raw materials, mainly in the form of codeine and mor-
phine, held at the end of 2015 (558 tons in morphine 
equivalent) were sufficient to cover global demand for 
those opiates for about 16 months. On the basis of data 
reported by Governments, total stocks of both opiates and 
opiate raw materials are fully sufficient to cover demand 
for medical and scientific purposes.
119. Global stocks of opiates based on thebaine-rich 
raw materials (oxycodone, thebaine and a small quantity 
of oxymorphone) increased to 241 tons in thebaine equiv-
alent at the end of 2015 and were sufficient to cover global 
demand for medical and scientific purposes for thebaine-
based opiates for about 18 months.
120. In 2015, global demand for opiate raw materials 
rich in morphine decreased to 437 tons in morphine 
equivalent because of the decrease in demand for opium 
and poppy straw. However, it is expected to increase in 
2016 and 2017.
121. Global demand by manufacturers for opiate raw 
materials rich in thebaine has been decreasing since 2012, 
probably as a result of restrictions on prescription drugs 
introduced in the United States, the main market. In 
2015, total demand continued to decrease, to 183 tons of 
thebaine equivalent, compared with 202 tons in 2014. 
Global demand for raw materials rich in thebaine is 
expected to amount to 210 tons of thebaine equivalent 
in 2016 and to reach 220 tons in 2017.
122. Codeine and hydrocodone are the most-consumed 
opiates manufactured from morphine. Global demand for 
morphine-based opiates decreased slightly, to 410 tons in 
morphine equivalent in 2015, compared with 416 tons in 
2014.
123. Demand for thebaine-based opiates is concentrated 
mainly in the United States and has increased sharply 
since the late 1990s. In 2015, the global demand for 
 thebaine-based opiates stayed at the level of the previous 
year and amounted to 151 tons.
124. The global production of opiate raw materials rich 
in morphine has exceeded the global demand for those 
raw materials since 2009. As a result, stocks have been 
increasing, albeit with fluctuations. In 2015, stocks 
increased to 746 tons in morphine equivalent and were 
sufficient to cover the expected global demand for about 
19 months. In 2016, global production of opiate raw 
materials rich in morphine is expected to exceed global 
demand again, with the result that global stocks of those 
raw materials will further increase in 2017. Stocks are 
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expected to reach 842 tons by the end of 2016, which is 
equivalent to about 21 months of expected global demand 
at the 2017 level of demand (although not all data are 
available for a complete forecast). The global supply of 
opiate raw materials rich in morphine (stocks and pro-
duction) will remain sufficient to cover global demand.
125. In 2015, global production of opiate raw materials 
rich in thebaine was again higher than demand. However 
the gap between production and demand was reduced, 
with a decrease in stocks (274 tons) at the end of 2015. 
Those stocks were equivalent to global demand for 16 
months. Production is expected to increase in 2016 and 
2017. By the end of 2016, global stocks of opiate raw 
materials rich in thebaine are likely to reach 362 tons, 
sufficient to cover global demand for about 20 months, 
and at the end of 2017 they may reach 508 tons, suffi-
cient to cover global demand for more than one year. The 
global supply of opiate raw materials rich in thebaine 
(stocks and production) will be more than sufficient to 
cover global demand in 2016 and 2017.
C. Governments’ cooperation with 
the Board
1. Provision of information by 
Governments to the Board
126. The Board is mandated to publish two reports each 
year: the annual report and the report of the Board on 
the implementation of article 12 of the 1988 Convention. 
It also publishes technical reports that provide 
Governments with an analysis of statistical information 
on the manufacture, trade, consumption, utilization and 
stocks of internationally controlled substances, and with 
an analysis of estimates and assessments of requirements 
for those substances.
127. The Board’s reports and technical publications are 
based on information that parties to the international 
drug control treaties are obligated to submit. In addition, 
pursuant to resolutions of the Economic and Social 
Council and the Commission on Narcotic Drugs, 
Governments voluntarily provide information in order to 
facilitate an accurate and comprehensive evaluation of the 
functioning of the international drug and precursor 
 control system.
128. The data and other information received from 
Governments enable the Board to monitor licit activities 
involving narcotic drugs, psychotropic substances and 
precursor chemicals and to evaluate treaty compliance 
and the overall functioning of the international drug con-
trol system. On the basis of its analysis, the Board makes 
recommendations to improve the system with a view to 
ensuring the availability of narcotic drugs and psycho-
tropic substances for medical and scientific needs, while 
at the same time preventing their diversion from licit into 
illicit channels and preventing the diversion of precursors 
to illicit drug manufacture.
2. Submission of statistical 
information
129. Governments have an obligation to furnish to the 
Board the statistical reports required by the international 
drug control conventions on an annual basis and in a 
timely manner.
130. As at 1 November 2016, the Board had received 
annual statistical reports from 149 States (both parties 
and non-parties to the 1961 Convention) and territories 
on the production, manufacture, consumption, stocks and 
seizures of narcotic drugs during 2015 (form C), or about 
70 per cent of those requested. That number was higher 
than in 2015 (139 reports pertaining to 2014), but almost 
equal to that of 2014 (145 reports pertaining to 2013). 
Seventy-nine Governments (37 per cent) had submitted 
their data on time, which was more than in the three pre-
ceding years (71 countries in 2015, 64 in 2014 and 61 in 
2013). Governments of 56 countries and 9 territories (30 
per cent) had not yet submitted their annual statistics for 
2015, but several could be expected do so in the follow-
ing months. Most of the countries that had failed to sub-
mit their reports on time were in Africa, the Caribbean, 
Asia and Oceania. Almost all countries where large 
amounts of narcotic drugs were being produced, manu-
factured, imported, exported or consumed had submitted 
their annual statistics. However, the Board was concerned 
about the quality of their data, especially the data from 
some of the major producing and manufacturing coun-
tries, as they seemed to indicate deficiencies in national 
mechanisms for regulating and monitoring internation-
ally controlled substances. INCB invites Governments to 
enhance their national mechanisms to monitor the cul-
tivation, production and manufacture of and trade in 
controlled substances. This may be achieved, in part, by 
improving and developing national data systems, train-
ing staff of the competent national authorities and 
ensuring that companies licensed to deal with inter-
nationally controlled substances fulfil the legal require-
ments associated with their licences.
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131. As at 1 November 2016, the complete set of four 
quarterly statistics of imports and exports of narcotic 
drugs for 2015 (form A) had been received from 136 
Governments (122 countries and 14 territories), i.e. about 
64 per cent of the 214 Governments requested. In addi­
tion, 34 Governments (about 16 per cent) had submitted 
at least one quarterly report. A total of 40 countries and 
4 territories (about 21 per cent) had failed to submit any 
quarterly statistics for 2015, most of them in Africa 
(22 countries and 1 territory).
132. The Board routinely investigates discrepancies in 
Government reports on international trade in narcotic 
drugs to ensure that none are diverted from licit inter­
national trade. Some of those investigations have revealed 
shortcomings in the implementation of control measures 
and infringements of national drug control provisions by 
companies. Governments have an obligation to comply 
with the limits on imports and exports of narcotic drugs 
imposed by articles 21 and 31 of the 1961 Convention. 
Under article 21, the total of the quantities of each drug 
manufactured and imported by any country or territory 
in any one year may not exceed the sum of the quanti­
ties consumed and utilized, within the limits of the rele­
vant estimates, the quantity exported, the quantity added 
to the stock for the purpose of bringing that stock up to 
the level specified in the relevant estimate, and the quan­
tity acquired within the limit of the relevant estimate for 
special purposes. Article 31 requires all exporting coun­
tries to limit the export of narcotic drugs to any country 
or territory to the total of the estimates of the importing 
country or territory, with the addition of the amounts 
intended for re­export. The secretariat routinely identifies 
cases of possible non­compliance by Governments with 
those provisions. Non­compliance could facilitate the 
diversion of narcotic drugs from licit international trade 
into illicit channels. Therefore, the Governments con­
cerned are requested to identify reasons for any cases of 
excess trade and inform INCB of the outcome of their 
investigations. They are also requested to strictly comply 
with the limits for imports and exports in the future, and 
are directed to consult the annual estimates of narcotic 
drug requirements for each country, which are published 
by INCB in its technical report on narcotic drugs and in 
the monthly updates of the list of estimates on the INCB 
website.
133. As at 1 November 2016, annual statistical reports 
for 2015 on psychotropic substances (form P) had been 
submitted to the Board in conformity with article 16 of 
the 1971 Convention by 137 States and territories, amount­
ing to 63 per cent of those required to do so. The Board 
notes that this rate of submission is almost identical to 
that for 2014. In addition, 95 Governments voluntarily 
submitted all four quarterly statistical reports on imports 
and exports of substances listed in Schedule II of the 1971 
Convention for 2015, in conformity with Economic and 
Social Council resolution 1981/7, and a further 59 
Governments submitted several quarterly reports.
134. While the majority of Governments regularly sub­
mit their mandatory and voluntary statistical reports, the 
cooperation of some has not been satisfactory. In 2016, 
only about 60 per cent of the countries that submitted 
form P related to 2015 did so before the deadline. Among 
those that failed to submit form P before the deadline of 
30 June 2016 were major manufacturing, importing and 
exporting countries such as Australia, Brazil, China, 
France, India, Japan and New Zealand. The Republic of 
Korea, a significant importer and exporter of psycho­
tropic substances, furnished form P for 2014 but failed 
to do so for the years 2011 to 2013. The Board notes that 
at the end of September 2016, three months after the 
deadline, the Republic of Korea had not yet furnished its 
reports for 2015.
135. The Board notes with concern that the number of 
countries and territories that have not furnished form P 
is again highest in Africa, Oceania and the Caribbean. A 
total of 34 countries and territories in Africa46 (60 per 
cent of those in that region) failed to furnish form P for 
2015. Likewise, 55 per cent of the countries and territo­
ries in Oceania (10 countries and 1 territory)47 and 42 
per cent (9 countries and 5 territories) of those in Latin 
America and the Caribbean48 failed to do so. In Europe, 
form P for 2015 was furnished by 84 per cent of all coun­
tries, but three countries did not furnish it for 2015 
(Greece, Luxembourg and Serbia), compared with just 
two in 2014. In South America, a total of three countries 
failed to furnish form P for 2015 (Paraguay, Suriname 
46 Angola, Benin, Cameroon, Central African Republic, Chad, Con­
go, Côte d’Ivoire, Djibouti, Equatorial Guinea (non­party to the 1971 
Convention), Eritrea, Gabon, Gambia, Guinea, Guinea­Bissau, Lesotho, 
Liberia (non­party to the 1971 Convention), Libya, Malawi, Mali, 
 Mauritania, Mozambique, Namibia, Niger, Sao Tome and Principe, 
 Senegal, Somalia, South Sudan (non­party to the 1971 Convention), 
 Swaziland, Togo, Uganda and Zambia, as well as Ascension Island, Saint 
Helena and Tristan da Cunha.
47 Fiji, Kiribati (non­party to the 1971 Convention), Nauru (non­
party to the 1971 Convention), Niue, Palau, Papua New Guinea, Samoa 
(non­party to the 1971 Convention), Solomon Islands (non­party to the 
1971 Convention), Tuvalu (non­party to the 1971 Convention) and 
 Vanuatu, as well as French Polynesia.
48 Antigua and Barbuda, Bahamas, Belize, Cuba, Dominican Repub­
lic, Grenada, Saint Kitts and Nevis, Saint Lucia and Trinidad and Tobago, 
as well as Aruba, Bermuda, British Virgin Islands, Cayman  Islands and 
Turks and Caicos Islands.
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and Uruguay). In Asia, 25 per cent of the countries and 
territories did not  furnish form P for 2015.49 
136. Difficulties encountered by Governments in sub­
mitting statistical reports to the Board may indicate defi­
ciencies in their national mechanisms for regulating and 
monitoring controlled substances. The Board therefore 
wishes to invite the Governments concerned to take steps 
to enhance, as necessary, their mechanisms for regulat­
ing licit activities involving controlled substances, includ­
ing their national systems for compiling data for the 
mandatory and voluntary statistical reports on psycho­
tropic substances, and to provide adequate training to the 
staff of their competent national authorities, in line with 
the requirements of the international drug control 
treaties.
137. The Economic and Social Council, in its resolu­
tions 1985/15 and 1987/30, requested Governments to 
provide the Board with details on trade (data broken 
down by countries of origin and destination) in sub­
stances listed in Schedules III and IV of the 1971 
Convention in their annual statistical reports on psycho­
tropic substances. For 2015, complete details on such 
trade were submitted by 105 Governments (77 per cent 
of all submissions of form P), which is about the same 
number as for 2014. The remaining 32 Governments sub­
mitted incomplete trade data, submitted forms with some 
trade data missing for 2015 or submitted blank forms.
138. The Board notes with appreciation that a number 
of countries have already submitted consumption data for 
psychotropic substances on a voluntary basis in accord­
ance with Commission on Narcotic Drugs resolution 
54/6. Thus, for 2015, a total of 59 countries and territo­
ries submitted data on the consumption of some or all 
psychotropic substances. The Board appreciates the 
cooperation of the Governments concerned and calls 
upon all Governments to report on the consumption of 
psychotropic substances on an annual basis, pursuant to 
Commission on Narcotic Drugs resolution 54/6, as such 
data are essential for an improved evaluation of the 
availability of psychotropic substances for medical and 
scientific purposes.
139. The Board notes with appreciation that reports on 
seizures of psychotropic substances were furnished by the 
Governments of India, Malaysia and Romania. 
Notifications on seizures of internationally controlled licit 
substances smuggled through the mail, including those 
49 Bhutan, Cambodia, Democratic People’s Republic of Korea, Iraq, 
Republic of Korea, Singapore, Sri Lanka, Thailand, Turkmenistan, United 
Arab Emirates and Yemen, as well as Macao, China.
ordered via the Internet, were furnished by the 
Governments of Norway and Romania, pursuant to 
Commission on Narcotic Drugs resolution 50/11. The 
Board acknowledges the interdiction efforts of the 
Governments concerned and calls on all Governments 
to regularly furnish to the Board information on sei-
zures of psychotropic substances ordered via the Internet 
and delivered through the mail, pursuant to Commission 
on Narcotic Drugs resolution 50/11. 
140. Under article 12 of the 1988 Convention, parties 
are obliged to furnish information on substances fre­
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances. That information, provided 
on form D, helps the Board to monitor and identify 
trends in trafficking in precursors and the illicit manu­
facture of drugs. It also enables INCB to offer Governments 
recommendations concerning remedial action and 
 policies, as necessary.
141. As at 1 November 2016, a total of 120 countries 
and territories had submitted form D for 2015. Seventy­
one Governments had done so by the deadline of 30 June 
2016.
142. Of the States and territories that provided data for 
2015, 81 reported seizures of scheduled substances and 
45 reported seizures of non­scheduled substances, more 
than in the previous year. As in previous years, many of 
those authorities did not provide details on the methods 
of diversion and illicit manufacture or on stopped 
 shipments. The Board urges Governments to put the 
 relevant mechanisms in place to ensure that all data are 
comprehensive and are submitted on time.
143. In accordance with Economic and Social Council 
resolution 1995/20, Governments are requested to pro­
vide information regarding their licit trade in substances 
listed in Tables I and II of the 1988 Convention on a vol­
untary and confidential basis. As at 1 November 2016, 
115 States parties had provided information on licit trade 
related to 2015.
3. Submission of estimates and 
assessments
144. Under the 1961 Convention, parties are obliged to 
provide the Board each year with estimates of their 
requirements for narcotic drugs for the following year. As 
at 1 November 2016, a total of 160 States and territories, 
75 per cent of those required, had submitted estimates of 
their requirements for narcotic drugs for 2017 for confir­
mation by the Board. As in previous years, the Board had 
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to establish estimates for those States and territories that 
had not submitted their estimates on time, in accordance 
with article 12 of the 1961 Convention.
145. As at 1 November 2016, the Governments of all 
countries except South Sudan and of all territories had sub-
mitted to the Board at least one assessment of their annual 
medical and scientific requirements for psychotropic sub-
stances. In accordance with Economic and Social Council 
resolution 1996/30, the assessments of requirements for 
South Sudan were established by the Board in 2011 to ena-
ble that country to import psychotropic substances for 
medical purposes without undue delay.
146. In line with Economic and Social Council resolu-
tions 1981/7 and 1991/44, Governments are requested to 
provide to the Board assessments of their annual medi-
cal and scientific requirements for psychotropic sub-
stances listed in Schedules II, III and IV of the 1971 
Convention. Assessments for psychotropic substances 
remain in force until Governments modify them to reflect 
changes in national requirements. To facilitate the sub-
mission of such modifications by competent national 
authorities, the Board has created a new form, entitled 
“Supplement to form B/P”. It has been translated into the 
six official languages of the United Nations and was made 
available to all Governments in October 2014. As at 
October 2016, two years after its release, almost all coun-
tries were using it. The Board recommends that 
Governments review and update the assessments of their 
annual medical and scientific requirements for psycho-
tropic substances at least once every three years.
147. Between 1 November 2015 and 1 November 2016, 
a total of 78 countries and 11 territories submitted fully 
revised assessments of their requirements for psycho-
tropic substances, and a further 42 Governments submit-
ted modifications to their assessments for one or more 
substances. As at 1 November 2016, Governments of 33 
countries and 2 territories had not submitted any revi-
sion of their legitimate requirements for psychotropic 
substances for over three years.
148. The Board wishes to emphasize the importance 
of determining estimates for narcotic drugs and assess-
ments for psychotropic substances at levels that reflect 
actual licit needs. If estimates and assessments are lower 
than the legitimate requirements, the importation or use 
of narcotic drugs or psychotropic substances needed for 
medical or scientific purposes may be delayed or 
impeded, whereas if they are significantly higher they 
might increase the risk that imported narcotic drugs 
and psychotropic substances are diverted into illicit 
channels.
149. The Board reminds all Governments that they can 
submit to the Board supplementary estimates for nar-
cotic drugs or modifications to assessments for psycho-
tropic substances at any time during the year, whenever 
they find that their country’s current estimates or assess-
ments are insufficient to cover licit needs. To adequately 
assess their country’s needs, Governments may wish to 
avail themselves of the Guide on Estimating Requirements 
for Substances under International Control, developed by 
the Board and the World Health Organization for use by 
competent national authorities and published in February 
2012. That guide is available on the Board’s website (www.
incb.org) in the six official languages of the United Nations.
150. In line with Commission on Narcotics Drugs res-
olution 49/3 entitled “Strengthening systems for the con-
trol of precursor chemicals used in the illicit manufacture 
of synthetic drugs”, Governments are requested to pro-
vide to the Board, on a voluntary basis, annual estimates 
of their legitimate requirements for imports of the follow-
ing four precursors of amphetamine-type stimulants: 
ephedrine, pseudoephedrine, 3,4-methylenedioxyphenyl-
2-propanone (3,4-MDP-2-P) and 1-phenyl-2-propanone 
(P-2-P) and, to the extent possible, preparations contain-
ing those substances present in such a way that they can 
easily be used or recovered by readily applicable means. 
Between the publication of the Board’s 2015 report on 
precursors and 1 November 2016, five Governments sub-
mitted annual estimates of their legitimate requirements 
for the first time, bringing the total number of 
Governments having submitted such estimates to 162. 
Similarly, the number of individual estimates increased 
from 810 in 2015 (published in the Board’s report on pre-
cursors for that year) to 851 in 2016. Those figures con-
firm that estimates continue to be a very important tool 
for Governments to assess the legitimacy of shipments 
and to identify any excesses in transactions.
151. The latest estimates, as submitted by countries and 
territories, are regularly updated and published on the 
Board’s website. They are also accessible to registered users 
through PEN Online and are available as an annex to the 
Board’s annual report on precursors.50 Governments are 
advised to consult the Board’s website for the most recent 
estimates. Governments can request to have those estimates 
revised at any time by contacting the INCB secretariat.
152. The Board wishes to remind all Governments that 
the total estimates of annual medical and scientific 
requirements for narcotic drugs and the assessments of 
requirements for psychotropic substances are published 
in yearly and quarterly publications and that monthly 
50 E/INCB/2016/4.
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updates are available on the Board’s website. Updated 
annual estimates of legitimate requirements for precursors 
of amphetamine-type stimulants are also available on the 
website.
153. Problems encountered by Governments in furnish-
ing adequate statistics and/or estimates and assessments 
to the Board are often an indication of deficiencies in 
their national control mechanisms and/or health-care sys-
tems. Such deficiencies may reflect problems in the imple-
mentation of treaty provisions, for instance gaps in 
national legislation, shortcomings in administrative reg-
ulations or a lack of training for staff of competent 
national authorities. The Board invites all Governments 
concerned to find the causes for such deficiencies in 
reporting statistics and/or estimates and assessments to 
the Board and to inform the Board accordingly with a 
view to resolving those problems and ensuring adequate 
and timely reporting. To assist Governments, the Board 
has developed tools and kits, as well as several sets of 
guidelines, for use by competent national authorities. 
They are available on its website free of charge and 
include training materials and the Guide on Estimating 
Requirements for Substances under International 
Control. Governments are invited to make full use of 
these tools in their efforts to comply with the inter-
national drug control treaties. The Board also wishes to 
encourage Governments to avail themselves of the 
 specific training that is provided by INCB upon request.
INCB Learning
154. In early 2016, the secretariat of the Board launched 
the first activities under a new project named INCB 
Learning to provide technical assistance to Member States 
in complying with the international conventions on nar-
cotic drugs, psychotropic substances and precursor chem-
icals. The Board has observed that many countries have 
difficulties in meeting their reporting requirements as set 
out in the international drug control treaties and related 
resolutions of the Economic and Social Council and the 
Commission on Narcotic Drugs, or fail to meet them alto-
gether. The fact that some Member States have insufficient 
capacity to comply with their reporting obligations weak-
ens the international drug control system as a whole and 
increases the risk of diversion, trafficking, abuse, and insuf-
ficient availability for medical and scientific purposes. The 
ultimate goal of the project is to ensure the appropriate 
availability of internationally controlled substances while 
preventing their abuse and diversion to illicit channels.
155. To address this problem, the Board has initiated 
INCB Learning. Its objective is to support Governments 
in the implementation of the operational recommenda-
tions on ensuring access to controlled substances for 
medical and scientific purposes contained in the outcome 
document of the special session of the General Assembly 
on the world drug problem held in 2016. Under the pro-
ject, two regional training seminars for competent 
national authorities were conducted in 2016. In April 
2016, the secretariat held a training seminar in Nairobi 
in collaboration with UNODC that was attended by 19 
participants from nine East African countries. In July 
2016, 45 participants from 19 countries attended a three-
day seminar in Bangkok for South and East Asia and the 
Pacific that had been co-organized with the Office of the 
Narcotics Control Board of Thailand.
156. Another aim of INCB Learning is to provide tar-
geted technical support to individual Member States as a 
follow-up to regional training seminars. Awareness-
raising workshops are held on issues related to the avail-
ability of narcotic drugs and psychotropic substances for 
medical and scientific purposes. E-learning modules are 
being developed so that the secretariat can reach more 
officers and staff of competent national authorities in 
need of training. Finally, the project will also promote 
and facilitate access to INCB statistics and data already 
made available as paper publications by developing free 
and open-access online tools.
157. The Board looks forward to the continued politi-
cal support of the Commission on Narcotic Drugs for its 
efforts to implement the operational recommendation, 
contained in the outcome document of the special ses-
sion of the General Assembly held in 2016, to provide 
capacity-building and training to ensure the availability 
of and access to controlled substances exclusively for 
medical and scientific purposes, while preventing their 
diversion. Continued political and financial support from 
Member States is essential to enable the Board to sustain 
its work and expand its activities to new regions,  countries 
and territories.
D. Evaluation of overall treaty 
compliance
1. Evaluation of overall treaty 
compliance in selected countries
158. In the pursuit of its treaty-mandated functions, the 
Board regularly reviews the drug control situation in 
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different countries. The areas reviewed by the Board 
include the regulatory framework in place to monitor the 
cultivation of crops for the licit production and manufac-
ture of and licit trade in controlled substances; the ade-
quacy of national drug control legislation and policy; 
measures to combat drug trafficking and diversion; the 
provision of prevention, treatment, rehabilitation, after-
care measures and social reintegration; the availability of 
narcotic drugs and psychotropic substances for rational 
medical use; and cooperation with the Board in the form 
of timely and accurate reporting, responses to Board 
requests for additional information and acceptance of 
Board country missions.
159. The Board engages in an ongoing dialogue with 
Governments that is aimed at working with them to iden-
tify good practices and areas in which the implementation 
of their international legal obligations can be strengthened 
and to suggest remedial measures, as necessary.
160. In 2016, the Board reviewed the drug control sit-
uation in Australia, Colombia, Denmark, Mauritania, 
Spain and the United States. It also reviewed the meas-
ures taken by the Governments of those countries to 
implement the international drug control treaties.
(a) Australia
161. The Government of Australia is committed to tak-
ing an integrated approach to ensure that controlled sub-
stances are handled effectively and that their diversion 
from licit distribution channels is countered through 
effective control measures.
162. The Board notes that the Narcotic Drugs Act 1967 
was amended by the Australian Parliament in February 
2016 to permit the legal cultivation of cannabis for the 
manufacture of medical cannabis products. That amend-
ment was scheduled to enter into force on 30 October 
2016. Under the Narcotic Drugs Amendment Bill 2016, 
the establishment of licensing and permit schemes for the 
cultivation and production of cannabis and cannabis resin 
for medical and scientific purposes is permitted. The 
Board notes the adoption of an amendment to the 
Therapeutic Goods Act 1989 to allow the use of canna-
bis for certain medical conditions, including terminal 
cancer and multiple sclerosis, and for children affected by 
intractable forms of epilepsy.
163. Reflecting concerns about abuse and diversion, the 
1961 Convention establishes an additional set of control 
measures, set forth in its articles 23 and 28, which should 
be implemented in order for programmes involving the 
use of cannabis for medical purposes to be in compliance 
with the Convention, to which Australia is a State party.
164. The Board notes that the Office of Drug Control 
has been established within the Department of Health of 
the Government of Australia as the single agency respon-
sible for the licensing of cannabis grown for medical pur-
poses, as stipulated in article 23 of the 1961 Convention. 
The Medical Cannabis Section within that Office will be 
responsible for monitoring compliance and for develop-
ing a monitoring regime for cultivators to prevent diver-
sion of cannabis to any use other than that for which a 
licence is granted. The Board also notes the Government’s 
efforts to ensure full compliance with the provisions of 
the 1961 Convention and to limit the amount of canna-
bis plant cultivated for medical cannabis products, to the 
quantity necessary to meet domestic demand.
165. The Board also notes that, with respect to the pre-
scription of medical cannabis products, the Department 
of Health, in close cooperation with state and territorial 
authorities, is developing guidelines to ensure uniform 
application across the entire country. Prescription of 
medical cannabis products will be possible only by medi-
cal doctors who have been authorized to do so by the 
Therapeutic Goods Administration of the Department of 
Health.
166. The Board has continued to monitor developments 
in Australia with respect to the expansion of jurisdictions 
within the country in which the licit cultivation of opium 
poppy is authorized by the Government and has contin-
ued to work with the Australian authorities to ensure that 
the control measures set out in the 1961 Convention with 
respect to opium cultivation are met. The Board also 
reminds the Government of Australia of the need to 
maintain a balance between the global supply of opium 
poppy and demand for it, so as to prevent diversion into 
illicit channels.
167. The Board commends the Government of Australia 
for providing it with updates on the results and analysis 
of surveys and data collected on the drug abuse situation. 
The Board notes that national drug strategy household 
surveys were conducted in 2010 and 2013 and that the 
fieldwork for the 2016 survey is expected to be completed 
by the end of 2016. The Board would appreciate receiv-
ing the latest results of the survey and the information 
on prevalence of use and public attitudes towards illicit 
drug use that is anticipated to be released in late 2017. 
The Board looks forward to continuing close cooperation 
with the Government of Australia on that and other 
 matters of drug control.
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(b) Colombia
168. In December 2015, the Government of Colombia 
enacted Decree No. 2467, which permits the cultivation 
and establishment of a licit market for cannabis for medi-
cal purposes. The decree provides for the establishment 
of a legal and regulatory framework for the cultivation, 
production, sale, transportation, distribution and delivery 
of cannabis for medical purposes. As it has done with all 
other countries choosing to establish legal and regulatory 
frameworks to allow the use of cannabis for medical pur-
poses, the Board has emphasized to the Government of 
Colombia the importance of adhering to the legal obliga-
tions set out in articles 23 and 28 of the 1961 Convention, 
which set out the conditions needing to be met for the 
establishment of a medical cannabis programme. Those 
obligations include the need to establish a national can-
nabis agency to control and supervise the cultivation of 
cannabis crops, designate the areas in which cultivation 
is permitted and provide licences to cultivators. The 
Government has designated the Health Ministry as the 
competent authority in charge of the application of the 
legislative amendment. It granted the Ministry a coordi-
nating role in the production, manufacture, import and 
export of and establishment of a licit market for canna-
bis for medical purposes and made it responsible for 
authorizing the use of cannabis for medical purposes.
169. While the Colombian legal and regulatory frame-
work satisfies most of the conditions for the establish-
ment of medical cannabis schemes under the 1961 
Convention, the Board notes with concern that cultiva-
tion by private individuals for personal use is authorized 
by the Government of Colombia. As it has done before, 
the Board wishes to remind all States that such cultiva-
tion does not meet the minimum control requirement set 
out in the Convention, owing to the heightened risk of 
diversion it represents. The Board therefore invites the 
Government of Colombia to take measures to prohibit 
that form of cultivation. 
170. The Board welcomes the signature of the ceasefire 
agreement between the Government of Colombia and the 
leadership of the Revolutionary Armed Forces of 
Colombia in June 2016. The peace agreement, signed in 
August 2016, was expected to mark the end of a conflict 
that had spanned more than five decades. Among the pil-
lars of the peace agreement was a chapter entitled 
“Solution to the illicit drug problem”, which was aimed 
at strengthening measures against drug trafficking, while 
enhancing border control, law enforcement and inter-
national cooperation. A referendum on the peace agree-
ment was held on 2 October 2016, in which it was rejected 
by Colombian voters.
171. The Board looks forward to continuing its dialogue 
with the Government of Colombia in order to assist it in 
whatever manner it can in strengthening the implemen-
tation of the international drug control treaties.
(c) Denmark
172. Over the reporting period, the Board has contin-
ued its dialogue with the Government of Denmark on 
several issues related to drug control, including the ques-
tion of “drug consumption rooms”. In order to fully 
appraise the situation with respect to treaty compliance, 
the Board requested the Government to provide it with 
more detailed information as to the applicable legal 
framework and the operation of such premises. The 
Board received an English translation of the legislation 
on “drug consumption rooms” in April 2016, which was 
accompanied by explanatory notes.
173. On the basis of the information provided, the 
Board notes that, in June 2012, the Parliament adopted 
an amendment to the Danish Law on Psychoactive 
Substances that provides the legal basis for the opening 
of “drug consumption rooms” in Denmark, and in 2014 
the Parliament adopted a law on “drug consumption 
rooms”. Additional amendments to the legislative frame-
work of the operation of such rooms followed and are 
contained in the Consolidated Act on Controlled 
Substances, which entered into force in July 2016.
174. As it has done with other countries that have 
allowed the operation of “drug consumption rooms”, the 
Board reiterates that the ultimate objective of such 
measures is to reduce the adverse consequences of drug 
abuse without condoning or encouraging drug 
 trafficking. Accordingly, any such facility must provide, 
or refer patients to, treatment, rehabilitation and social 
reintegration measures.
175. The Board notes from the information provided by 
the Government that the substances consumed in the 
“drug consumption rooms” are acquired by users prior to 
entering the facilities. The Board expresses its reservations 
about those practices. 
176. In March 2016, the Government of Denmark 
informed the Board that it had commissioned an inde-
pendent evaluation of the implementation of the new pol-
icy on “drug consumption rooms”, the results of which 
had led to some adjustments being made to the 2014 law. 
The Board has requested information on the findings of 
that evaluation, which was conducted in 2015.
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177. The Board appreciates the continued cooperation 
it has received from the Government of Denmark and 
the detailed information that the Government has pro-
vided regarding Danish drug control policy. The Board 
looks forward to continuing its ongoing dialogue with the 
Government on issues related to drug control. 
(d) Mauritania
178. Mauritania has established certain institutional 
mechanisms to address the problems associated with 
illicit drug use and it has participated in efforts to enhance 
regional cooperation to combat drug trafficking and 
organized crime. In January 2016, according to the 
Council of Ministers, a draft decree on the creation of a 
special fund to counter drug trafficking was published. 
The fund would be financed by the sale of confiscated 
assets from drug-related crimes. Under the draft decree, 
the capacity of the authorities involved in countering drug 
trafficking would be increased through the provision of 
earmarked financial support.
179. The Government of Mauritania has developed a 
National Strategy on Drug Control. The Strategy provides 
for specific actions by the Directorate General of National 
Security, including the reactivation of the Central Office 
for Combating Illicit Drug Traffic, the creation of special 
drug enforcement units, the provision of increased 
resources to border control authorities, and the provision 
of equipment and capacity-building. The Government has 
also reported improvements to the institutional frame-
work, including the creation of 45 adequately equipped 
entry points; the provision of scanner equipment for con-
tainer control at the Nouakchott Port; the provision of 
training to customs officers; and the creation of the posts 
of special judge and associate prosecutor to address drug 
trafficking. 
180. The country continues to face numerous challenges 
in its drug control efforts. In particular, the lack of 
resources allocated to the competent national authorities 
limits their ability to effectively carry out their regulatory 
functions. Further capacity-building initiatives may also 
be required to support the efforts of national law enforce-
ment authorities. Additional areas of concern include 
poor coordination among drug control stakeholders and 
limited statistical and epidemiological data.
181. The Board continues to be concerned about the 
drug control situation in Mauritania. It is difficult to eval-
uate the situation, in view of the scarcity of relevant infor-
mation related to drug control available from official and 
open sources. In particular, the Board is concerned about 
the lack of cooperation by the Government of Mauritania 
with regard to the provision of information to the Board 
on the drug control situation in the country and the 
country’s compliance with its reporting obligations under 
the international drug control treaties, as well as the 
Board’s efforts to secure a mission to the country. The 
Board has also noted several deficiencies in the legisla-
tive and institutional drug control frameworks, including 
inadequate mechanisms for coordination among 
Government agencies in the field of drug control.
182. From the limited information available from offi-
cial sources, including seizure data, the Board notes with 
concern that Mauritania continues to be targeted by inter-
national drug trafficking syndicates as a transit country 
for drugs, including cannabis and cocaine, destined for 
Europe. There have also been reports of drug trafficking 
groups involving both Mauritanian and foreign nationals 
operating within the country.
183. Within the scope of its mandate, the Board reiter-
ates its readiness to assist the Government of Mauritania 
in fulfilling its obligations under the international drug 
control conventions, in particular through the provision 
of statistical data to the Board, and encourages the 
Government to maintain an ongoing dialogue with it in 
order to identify existing challenges and means of 
addressing them.
(e) Spain
184. The Board continues to pursue a constructive dia-
logue with the Government of Spain on drug-related 
developments in the country. During the special session 
of the General Assembly on the world drug problem held 
in April 2016, Spain expressed its commitment to the 
international drug control conventions and related inter-
national human rights instruments. The Government par-
ticularly underscored the importance of the proportionality 
of sanctions for drug-related offences and of alternative 
development programmes for farmers.
185. The Government of Spain has taken several legis-
lative measures related to drug control during the period 
under review. Spanish drug control policy continues to 
be guided by the National Drug Strategy for the period 
2009-2016, most recently implemented by means of an 
action plan for the period 2013-2016.
186. The legal regime governing the Spanish Council on 
Drug Dependence and other Addictions was established 
by royal decree in December 2015. In November 2015, 
the Centralized Body for the Prevention of 
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Money-Laundering was created. In addition, asset recov-
ery procedures led to confiscated assets linked to drug-
related offences being used to fund various drug control 
initiatives, including those related to supply reduction at 
the national and international levels. 
187. Under the Spanish legislative framework, cannabis 
remains a controlled substance pursuant to Narcotic 
Drugs Control Act No. 17/1967, and possession, con-
sumption and cultivation of cannabis are liable to crimi-
nal sanctions under the Citizen Security Law. However, 
the Board notes with concern the continued proliferation 
of “cannabis consumption clubs” in several autonomous 
communities in Spain. According to the last communica-
tion sent to the Board by the Government of Spain on 
that topic, associations that operate primarily within the 
territory of an autonomous community are required to 
register with the associations registry of that community. 
According to information provided previously, the 
Autonomous Community of the Basque Country was the 
only one maintaining a registry of “cannabis consump-
tion clubs”. The Government has not supported any ini-
tiative to regulate or authorize such clubs. The clubs have 
been developing using the regulatory framework of arti-
cle 22 of the Constitution of Spain and Act No. 1/2002 
of 22 March 2002, which deals with freedom of associa-
tion. Associations that pursue aims or use methods clas-
sified as criminal are illegal. Hence, the General 
Prosecutor’s Office is coordinating the investigation into 
the alleged distribution of cannabis. 
188. The Board reiterates its position that the estab-
lishment of “cannabis consumption clubs” is not con-
sistent with article 4, paragraph (c), of the 1961 
Convention, pursuant to which States parties are obliged 
to limit exclusively to medical and scientific purposes 
the production, manufacture, export, import and distri-
bution of, trade in and use and possession of drugs, or 
with article 3, subparagraph 1 (a), of the 1988 
Convention, which requires States to adopt such meas-
ures as may be necessary to establish as criminal offences 
under its domestic law the production, manufacture, 
extraction, preparation, offering, offering for sale, 
 distribution, sale, delivery on any terms whatsoever, 
brokerage, dispatch, dispatch in transit, transport, 
importation or exportation of any narcotic drug  contrary 
to the provisions of the 1961 Convention.
189. The Board has actively engaged the Spanish author-
ities in an ongoing dialogue on the matter. The Board 
notes the various measures undertaken and planned by 
the Government of Spain to stem the spread of “cannabis 
consumption clubs” in certain autonomous communities, 
including through the refusal to authorize their 
registration on the official registry of associations and the 
referral of such requests to prosecutorial authorities. One 
of the measures taken by the Government is the establish-
ment of the Special Drug Prosecutor’s Office. Another 
measure is the referral to the Constitutional Court to 
decide on the constitutionality of laws issued by the auton-
omous communities that led to the development of those 
structures. Finally, administrative instruction No. 2/2013 
was issued with the aim of coordinating the investigative 
criteria in the General Prosecutor’s Office and of estab-
lishing common guidelines on the exercise of penal action. 
190. The Board encourages the Government of Spain to 
continue to take all practical actions to control cannabis 
in accordance with the requirements of international drug 
control treaties, bearing in mind that cannabis is subject 
to special control measures owing to its scheduling in 
Schedules I and IV of the 1961 Convention.
191. Although the prevalence rate of new psychoactive 
substances is low and the use of such substances is con-
sidered by the National Drugs Observatory as a minor 
phenomenon in Spain, there is evidence to suggest that 
small groups of high-risk drug users who used to inject 
heroin have switched to injecting new psychoactive 
substances.
192. Spain has informed the Board that it has achieved 
a significant reduction in rates of cocaine consumption 
over the past 10 years. The country has also witnessed a 
decline in heroin use prevalence since 2013, reversing an 
earlier trend toward increased abuse of the drug, which 
had contributed to rising rates of HIV infection. The 
Government has reported that one of the major chal-
lenges it continues to face is the high lifetime prevalence 
rate of cannabis use, reported to be over 30 per cent, 
although surveys in Spain show a decreasing or stable 
prevalence rate of cannabis use over the past decade. 
Despite that development, an increase in acute medical 
emergencies related to cannabis abuse has been reported 
to the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA).
193. Spain has over 500 accredited drug treatment and 
rehabilitation centres. In addition, prisons are also 
equipped with drug treatment and rehabilitation units, 
offer syringe distribution services and ensure the  provision 
of opioid substitution therapy.
194. Several important challenges remain, including 
those related to Spain’s continued status as a major entry 
and transit point for drugs trafficked into Europe: Spain 
reported seizing almost 16 tons of cannabis herb, over 380 
kg of cannabis resin and over 21 tons of cocaine in 2015.
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195. The Board notes that drug trafficking continues to 
pose a significant challenge to the Government’s efforts 
to address the drug problem. Clandestine laboratories 
continue to be dismantled in Spain, with large seizures 
being made. The Board encourages the Government of 
Spain to pursue its drug control efforts, in particular 
those that are aimed at combating illicit cannabis culti-
vation and trafficking in the country, and stands ready to 
assist in whatever manner it can.
(f ) United States of America
196. During the period under review, the Board has 
maintained an active dialogue with the Government of 
the United States on drug-related developments in the 
country. Among the principal issues on which discussions 
have centred is the control of cannabis in various 
 jurisdictions in the country.
197. Under federal legislation, namely the Controlled 
Substances Act, cannabis is classified as a substance hav-
ing no currently accepted medical use in the United 
States, a lack of accepted safety for use under medical 
supervision and a high potential for abuse; however, the 
legal regime applicable to cannabis in several states is an 
area of great concern for the Board.
198. In its discussions with the Government of the 
United States, the Board has continued to reiterate that 
the legislative and administrative measures taken by sev-
eral states in the country to legalize and regulate the sale 
of cannabis for non-medical purposes cannot be recon-
ciled with the legal obligation contained in article 4, par-
agraph (c), of the 1961 Convention to limit exclusively to 
medical and scientific purposes the production, manufac-
ture, export, import and distribution of, trade in and use 
and possession of drugs.
199. Accordingly, the Board notes with concern the 
results of several ballot initiatives held at the state level 
in November 2016 on the legalization of cannabis for 
non-medical purposes.
200. The Board also remains concerned that many of the 
legal and regulatory frameworks of the states that permit 
the use of cannabis for medical purposes do not fully com-
ply with articles 23 and 28 of the 1961 Convention, which 
set out the conditions needing to be met for the establish-
ment of a medical cannabis programme. Accordingly, the 
Board reiterates its call to Governments of all countries, 
including in the United States, in which medical canna-
bis schemes are in place, or in which the establishment 
of such programmes is being considered, to ensure the 
full implementation, within the entirety of their  territory, 
of the provisions of the 1961 Convention applicable to 
the use of cannabis for medical purposes.
201. The Board notes, with great concern, the large-
scale opioid, prescription drug and heroin abuse problem 
that continues to affect the United States, claiming tens 
of thousands of victims each year, as expounded upon in 
chapter III of the present report. The Board welcomes the 
adoption by the Drug Enforcement Administration of a 
comprehensive action plan to address opioid addiction 
and the allocation by the Government of $27.6 billion for 
the 2016 fiscal year to support the implementation of the 
2015 National Drug Control Strategy.
(g) Uruguay 
202. The Board notes the continued implementation 
by the Government of Uruguay of measures aimed at 
creating a regulated market for the non-medical use of 
cannabis. While this policy has not yet been fully imple-
mented, the Board wishes to reiterate its position that 
such legislation is contrary to the provisions of the 
international drug control conventions, particularly to 
the measures set out in article 4, paragraph (c), of the 
1961 Convention as amended, according to which States 
parties are obliged to “limit exclusively to medical and 
scientific purposes the production, manufacture, export, 
import, distribution of, trade in, use and possession of 
drugs”. Additionally, according to article 3, subparagraph 
(1) (a), of the 1988 Convention, each State party is obliged 
to adopt such measures as may be necessary to establish 
as criminal offences under its domestic law the produc-
tion, manufacture, extraction, preparation, offering, offer-
ing for sale, distribution, sale, delivery on any terms 
whatsoever, brokerage, dispatch, dispatch in transit, trans-
port, importation or exportation of any narcotic drug 
contrary to the provisions of the 1961 Convention.
203. The Board will continue its dialogue with the 
Government of Uruguay with the aim of promoting the 
country’s compliance with the three international drug 
control conventions.
2. Country missions
204. Every year, as part of its mandate as a treaty- 
monitoring body, the Board undertakes a number of 
 missions to countries it selects. The objective of the missions 
is to assist States in meeting the international legal obliga-
tions incumbent upon them by virtue of their status as States 
parties to the international drug control conventions.
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205. During a mission, in order to gain a comprehen-
sive overview of the drug control situation in the coun-
try being visited, the Board holds meetings with major 
stakeholders in the drug control field, including govern-
ment officials and representatives from regulatory author-
ities, treatment and rehabilitation providers and civil 
society groups. 
206. Following the discussions held, the Board member 
leading the mission presents his or her findings to the 
Board, based upon which the Board adopts a series of 
confidential recommendations that are conveyed to the 
Government for its consideration and action. 
207. The recommendations transmitted to the Government 
contain proposed actions to improve compliance with the 
international drug control framework in various fields 
related to drug control, including: national drug policy; 
inter-agency cooperation; the regulation of licit production 
of and trade in narcotic drugs and psychotropic substances 
subject to international control under the drug control con-
ventions; the prevention of drug use and the treatment and 
rehabilitation of drug users; access to controlled substances 
for rational medical use; law enforcement; measures to 
address illicit drug production, manufacture and  trafficking; 
and precursor chemical control.
208. During the period under review, the Board under-
took missions to Afghanistan, Argentina, Bolivia 
(Plurinational State of), Canada, China, Israel, Myanmar, 
Oman, Senegal, South Africa, the State of Palestine, 
Uruguay and Viet Nam.
209. Additional missions have been accepted, in princi-
ple, by the Governments of Colombia, Egypt, Iraq, 
Jamaica, Kuwait and Uzbekistan but have not yet been 
carried out. The Board has also contacted the Governments 
of the Democratic Republic of the Congo, Papua New 
Guinea and Qatar, but has not yet received confirmation 
of the acceptance of a mission by those Governments.
(a) Afghanistan
210. A high-level INCB mission, led by the President of 
the Board, was carried out to Afghanistan in May 2016. 
The purpose of the mission was to continue the consul-
tations with the Government of Afghanistan that the 
Board had initiated in May 2000. At that time, INCB con-
cluded that the situation in the country, if left unattended, 
would seriously endanger the aims of the 1961 Convention, 
and it decided to invoke article 14 of that Convention 
with a view to promoting cooperative action at the inter-
national level.
211. The mission held high-level discussions with the 
Chief Executive of Afghanistan and Government repre-
sentatives, including ministers and members of the 
Parliamentary Commission on Counter Narcotics, about 
the current drug control situation, future prospects, the 
actions and initiatives of the Government and the need 
for cooperation from the international community.
212. The Board noted the adoption by the Government 
of a new National Drug Action Plan (2015-2019) in 
October 2015, the main objectives of which are to reduce 
opium poppy cultivation and opiate manufacture and 
trafficking, reduce illicit demand for drugs and increase 
the provision of treatment for users. 
213. More information on recent developments in 
Afghanistan is contained in section E, subsection 2, enti-
tled “Consultation with the Government of Afghanistan 
pursuant to article 14 of the 1961 Convention as amended 
by the 1972 Protocol”, and in chapter III of the present 
report.
(b) Argentina
214. In June 2016, an INCB mission was carried out to 
Argentina. The objective of the mission was to review 
drug control developments and progress in the imple-
mentation of the international drug control conventions 
since the Board’s previous mission to the country, in 2006. 
215. In recent years, Argentina has been a transit coun-
try for Andean-produced cocaine, with instances of 
domestic cocaine manufacture. The Board has noted that, 
in his inaugural speech, the President of the Republic had 
listed countering the drug problem as one of the three 
central priorities of the Government. During the mission, 
information was given to the Board about the reorgani-
zation of the various agencies dealing with drug control, 
in order to increase the efficiency and effectiveness of 
their work. 
216. The Board noted improvements in the oversight of 
the licit import, export and manufacturing of narcotic 
drugs and psychotropic substances and in access to opi-
oid analgesics in Argentina. Information was also pro-
vided about the efforts made by the Government in the 
area of prevention and treatment of drug abuse to develop 
a comprehensive and integrated strategy involving health, 
education and social affairs authorities and other govern-
ment agencies to ensure a comprehensive approach to the 
issue. Following the mission, those initiatives were 
reflected in a national plan on drug control that was 
launched in August 2016 by the President of the Republic.
ChaPTER II. FuNCTIONINg OF ThE INTERNaTIONal dRug CONTROl sysTEm  31
(c) Bolivia (Plurinational State of)
217. INCB undertook a treaty compliance monitoring 
visit to the Plurinational State of Bolivia from 17 to 20 
October 2016. The purpose of the mission was to discuss 
with the Government of the country its compliance with 
the three international drug control treaties, in particu-
lar the 1961 Convention as amended, in view of the coun-
try’s reaccession to that Convention in 2013 with a 
reservation with respect to coca leaf.
218. Under the reservation, and since February 2013, 
the chewing of coca leaf and the consumption and use of 
the coca leaf in its natural state for “cultural and medic-
inal purposes” are permitted in the territory of the 
Plurinational State of Bolivia.
219. During the mission, the INCB delegation held 
consultations with the Minister of the Interior, the 
Minister of Rural Development and Land, the Deputy 
Minister for Social Welfare and Controlled Substances 
and the Deputy Minister for Coca and Comprehensive 
Development. 
220. Discussions were also held on the implementation 
of the reservation expressed by the Plurinational State of 
Bolivia upon reaccession and the steps taken by the 
Government to ensure compliance with the requirements 
of the 1961 Convention. Such requirements include the 
need to ensure a licensing system, monitor the harvest 
and prevent diversion. The INCB delegation was informed 
about progress in the control of coca cultivation, the 
reduction of illicit cultivation in recent years and  measures 
taken against trafficking.
221. Consultations were held with representatives of the 
law enforcement agency responsible for the fight against 
drug trafficking, as well as with representatives of the joint 
task force of the army responsible for the eradication of 
illicit cultivation of coca bush. In addition, the delegation 
met representatives of the Regional Association of Coca 
Producers (ADEPCOCA) in the market of Villa Fatima in 
La Paz.
(d) Canada
222. The Board undertook a mission to Canada in 
October 2016. The primary objective of the mission was 
to discuss legislative measures currently being developed 
relating to the legalization and regulation of the non-
medical use of cannabis. The last mission of the Board to 
Canada took place in 2013.
223. Canada is party to all three international drug con-
trol treaties. The Government has initiated a process that 
has as its goal the legalization and regulation of access to 
cannabis for non-medical use. The Board notes that the 
legalization of the use of cannabis for non-medical pur-
poses is inconsistent with the provisions of the 1961 and 
1988 Conventions because the Conventions oblige States 
parties to limit the use of narcotic drugs exclusively to 
medical and scientific purposes. That limitation, expressed 
in article 4, paragraph (c), of the 1961 Convention, is 
binding on all parties; regulating the use of drugs outside 
medical and scientific purposes is not allowed under the 
Convention. The limitation of the use of drugs to medi-
cal and scientific purposes is a fundamental principle that 
lies at the heart of the international drug control frame-
work, to which no exception is possible and which gives 
no room for flexibility. The Board urges the Government 
to pursue its stated objectives — namely the promotion 
of health, the protection of young people and the decrim-
inalization of minor, non-violent offences — within the 
existing drug control system of the Conventions.
224. In its discussions with the Government, the dele-
gation of the Board was informed about and noted with 
concern the increasing number of overdoses and deaths 
caused by opioids, including fentanyl, which the 
Government described at being at crisis levels. The Board 
commends the Government of Canada for the action 
taken so far and for its commitment and resolve to 
addressing this important matter, and it encourages the 
authorities to take further measures in that regard.
(e) China
225. A mission of the Board was carried out to China 
in October 2015. During the mission, the INCB delega-
tion held consultations with senior officials from the 
Ministries of Security, Health, Foreign Affairs and Justice, 
as well as the General Administration of Customs. The 
delegation also had the opportunity to visit the Beijing 
Narcotics Control Volunteers Organization, a non- 
governmental organization. 
226. The delegation discussed matters of common inter-
est relating to international drug control policy, includ-
ing the outcome of the special session of the General 
Assembly on the world drug problem held in 2016, the 
latest changes in the legal drug control framework in 
China, the reporting obligations incumbent upon States 
parties to the international drug control treaties, the issue 
of new psychoactive substances, the availability of sched-
uled substances for medical purposes, and treatment and 
rehabilitation in China.
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227. The Board expresses its appreciation to the 
Government of China for the country’s active participa-
tion in various INCB initiatives, and its wish to continue 
that cooperation in the future. INCB recognizes the sub-
stantial efforts made by the Government of China with 
regard to the strict control of scheduled substances and 
the progress it has achieved in that regard.
(f ) Israel
228. A mission of the Board was carried out to Israel 
in July 2016. As Israel is party to the three international 
drug control conventions, the INCB delegation reviewed 
implementation of those conventions, including legisla-
tive and other developments relating to drug control since 
the last mission of the Board to Israel, which was carried 
out in 2009. 
229. Consultations were held with senior officials from 
the Ministry of Health, the Ministry of Justice and the 
Ministry of Economy and Industry. The delegation also 
heard directly from a recipient of a treatment and 
 rehabilitation care programme in a prison.
230. The Board noted that, since its last mission in 2009, 
the Israeli Anti-Drug Authority had continued to play a 
crucial role as an independent, interdisciplinary author-
ity, coordinating the country’s drug control policy in line 
with its international obligations.
231. During the mission, the Government demon-
strated its commitment to addressing drug addiction in 
Israel. The Board noted that Israel had implemented effec-
tive treatment and rehabilitation services, in particular 
harm reduction services, which were tailor-made for 
recipients.
232. Representatives of the Israeli Medical Cannabis 
Agency provided a comprehensive briefing for the INCB 
delegation, during which it outlined the legislative frame-
work establishing the agency and set out its mandate and 
responsibilities. The Agency demonstrated its commit-
ment to ensuring compliance with the international drug 
control treaties, in particular the requirements set forth 
in the 1961 Convention.
(g) Myanmar
233. A mission of the Board was carried out to Myanmar 
in June 2016 to review the compliance of the Government 
with its obligations under the three international drug 
control treaties and to monitor progress made in 
implementing the recommendations made by the Board 
following its previous mission to the country, in 2010. 
234. Since the Board’s mission in 2010, progress has 
been made in the country’s review of drug control legis-
lation, the assessment of its drug use situation and its 
level of international cooperation. The Board welcomes 
the adoption by the Government of a health-based 
approach to the treatment of drug addiction and the con-
duct of the country’s first national drug use survey, 
the  preliminary results of which were expected to be 
available in early 2017.
235. The Board notes that significant challenges remain 
to be addressed. In particular, the illicit cultivation of 
opium poppy and production of opium have remained 
significant over the past few years and the implementa-
tion of sustainable alternative development programmes 
has continued to be difficult. In addition, the Board reit-
erates its call to the Government to increase its efforts to 
reduce the trafficking in and illicit manufacture of 
amphetamine-type stimulants in the country, which have 
remained a major concern. More awareness and resources 
are also required to address the existing problem of inad-
equate availability of controlled substances for medical 
purposes in the country.
(h) Oman
236. A mission of the Board was carried out to Oman 
in April 2016. The objective of the mission was to review 
the Government’s compliance with the provisions of the 
international drug control treaties and its cooperation 
with the Board. During the mission, the INCB delegation 
was provided with information on relevant drug control 
legislation, including the legislative measures against 
money-laundering that are currently in force.
237. The delegation noted the commitment and strong 
political will of the Government to continue to strengthen 
its efforts with regard to drug abuse prevention and the 
treatment and rehabilitation of individuals with problems 
associated with drug use.
238. A wide range of prevention and awareness pro-
grammes are being carried out in Oman and facilities for 
the treatment and rehabilitation of drug addicts have 
been established. The Board noted that Oman, in collabo-
ration with WHO, was in the process of establishing 
 opioid substitution therapy services.
239. The Board welcomed the high-level cooperation 
between Oman and its neighbouring countries within the 
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Gulf Cooperation Council framework, and encouraged 
the authorities to continue fostering that cooperation to 
jointly combat drug-related crime in the region.
(i) Senegal
240. In October 2016, the Board undertook a mission 
to Senegal. The objective of the mission was to discuss 
progress made in the implementation of the three drug 
control conventions, to which Senegal is party, since the 
Board’s last mission to the country in 2000.
241. During the mission, meetings were held with the 
Ministries of Foreign Affairs, Justice, Finance, Health, 
Defence, the Interior and Public Security and Social 
Action, as well as with customs and law enforcement 
authorities. While in the country, the INCB delegation 
also visited a treatment facility and met with representa-
tives of two non-governmental organizations working in 
the field of prevention.
242. The INCB delegation was briefed, inter alia, on the 
development of a new strategic action plan on drug con-
trol that was being finalized under the coordination of the 
Inter-ministerial Committee on Drugs (CILD). The action 
plan sets out new policies and initiatives in the field of 
drug control, including in the fields of demand reduction, 
including prevention, treatment and rehabilitation, supply 
reduction and improved inter-institutional coordination.
243. The Board welcomes the measures taken by the 
Government of Senegal to develop a balanced and 
 evidence-based approach to drug control policy by involv-
ing all relevant institutional stakeholders and by working 
closely with civil society and community-based groups.
(j) South Africa
244. In October 2016, an INCB mission was undertaken 
to South Africa in order to hold consultations with 
Government stakeholders on questions related to South 
African drug policy and the compliance of the country 
with the three drug control conventions, to which it is a 
party.
245. Meetings were held with representatives of the 
Department of Social Development, the Central Drug 
Authority, the Department Home Affairs, the Department 
of Basic Education, the Department of Higher Education 
and Training, the Medicines Control Council, the National 
Youth Development Agency, the Department of Justice 
and Constitutional Services, the Department of Sport and 
Recreation, the Department of Science and Technology, 
the Department of Correctional Services, the South 
African Police Service and the South African Revenue 
Service. In addition, the INCB delegation had the oppor-
tunity to visit a drug treatment facility in the Pretoria area.
246. The Board notes the efforts being made by the 
Government of South Africa to strengthen its drug con-
trol efforts, in particular through the adoption of meas-
ures aimed at streamlining inter-agency and international 
cooperation, including through the establishment of a 
transnational organized crime section within the 
Department of International Relations and Cooperation.
(k) State of Palestine 
247. INCB conducted its first mission to the State of 
Palestine in July 2016. The objective of the mission was 
to obtain information on the Government’s drug control 
policy and related legislation and to discuss issues related 
to trends in trafficking and abuse of narcotic drugs, psy-
chotropic substances and precursors in the country, as 
well as the availability of substances under international 
control for medical purposes.
248. The Board recognized the efforts of the Government 
to comply with international best practices in drug con-
trol despite the State of Palestine not yet being party to 
the international drug control conventions.
249. The Board noted that drug trafficking and abuse, 
particularly of new psychoactive substances, are increas-
ing at alarming rates. Addressing them will require strong 
commitment and the consistent application of awareness 
and education campaigns.
250. The Board also noted that a national survey, to be 
conducted in the State of Palestine with the involvement 
of WHO, was planned. The survey would focus on pat-
terns of drug use and drugs of abuse and would assist in 
providing a coordinated effort to address the serious 
emerging challenges in the country.
(l) Uruguay
251. In November 2015, INCB carried out a mission to 
Uruguay. The objective of the mission was to discuss the 
legislation on the non-medical use of cannabis and its 
implementation in Uruguay. During the mission, the INCB 
delegation held consultations with senior officials from the 
Ministries of the Interior, Health and Foreign Affairs, as 
well as with the Attorney General. Meetings were also held 
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with officials from the newly established Institute for the 
Regulation and Control of Cannabis and the Scientific 
Advisory Committee. The INCB delegation also had the 
opportunity to visit drug abuse treatment facilities. 
252. During the mission, the implementation of Law 
No. 19.172, permitting the non-medical use of cannabis, 
was discussed with the national authorities of Uruguay. 
The discussions were focused on the inconsistency of that 
law with the provisions of the 1961 Convention. The 
Board expressed its intention to continue to monitor the 
situation and the compliance of the Government of 
Uruguay with the international drug control treaties. To 
that end it requested the Government to keep it informed 
of all relevant developments in that area and to be pro-
vided with information on the public health consequences 
of the implementation of Law No. 19.172. More informa-
tion regarding developments in Uruguay are contained in 
chapters II and III of the present report (see paras. 202-
203 and 509-566).
(m) Viet Nam
253. In April 2016, the Board carried out a mission to 
Viet Nam. The objective of the mission was to discuss the 
implementation by the country of the three international 
drug control conventions in general and, in particular, 
the high prevalence rates of illicit drug use and addiction, 
the discontinuation of compulsory treatment for drug 
dependency, the administration of opioid substitution 
therapy, the availability of controlled substances for 
rational medical use, the reform of criminal justice 
responses to drug-related crime and the control measures 
applicable to precursor chemicals.
254. During the mission, the INCB delegation held 
high-level talks with senior officials from the Government 
of Viet Nam, including the Deputy Prime Minister, who 
is also the Chair of the National Committee for AIDS, 
Drugs and Prostitution Prevention and Control, and sen-
ior government officials from the Ministries of Foreign 
Affairs, Public Security, Health, Justice, Labour, Invalids 
and Social Affairs, Industry and Trade, and Information 
and Communication. The delegation also visited a drug 
treatment centre and held consultations with representa-
tives of civil society groups.
255. The delegation noted that significant resources had 
been invested by the Government to address drug use 
and addiction and that a fundamental, ongoing policy 
shift was being made towards the provision of voluntary 
drug abuse treatment services under a health-centred 
approach. During the mission, discussions were held on 
ways to ensure adequate access to controlled substances 
for rational medical use, to strengthen institutional 
capacity and to improve precursor control.
3. Evaluation of the implementation by 
Governments of recommendations made 
by the Board following its country 
missions 
256. In order to follow up on the implementation by 
Governments of the Board’s post-mission recommenda-
tions, the Board undertakes an annual review of drug 
control developments three to four years after it has 
undertaken a mission. In order to follow up on the imple-
mentation of its recommendations, the Board communi-
cates with the Governments concerned in order to solicit 
information detailing the legislative and policy measures 
that they have adopted to address the aspects of their 
drug control systems that the Board had raised, in view 
of its findings following those missions.
257. In 2016, the Board invited the Governments of 
countries that had received INCB missions in 2013, 
namely Haiti, Kenya, the Lao People’s Democratic 
Republic, Malaysia, Panama and Singapore, to submit 
detailed information on legislative, regulatory and policy 
action taken pursuant to the Board’s recommendations 
resulting from the missions to those countries.
258. The Board wishes to express its appreciation to the 
Governments of Kenya, Malaysia, Panama and Singapore 
for the information received. Their cooperation has 
assisted the Board in its review of treaty implementation 
by those States and has contributed to the important dia-
logue that the Board maintains with States parties to the 
international drug control conventions through the active 
exchange of information. 
259. The Board renews its call to the Governments of 
Haiti and the Lao People’s Democratic Republic to pro-
vide the information requested, which has yet to be 
received, in order for its review of the drug control situ-
ations in those countries to be comprehensive and duly 
informed. Once received, the information provided by 
those countries will be reviewed by the Board for 
 inclusion in its annual report for 2017.
(a) Kenya
260. Following its 2013 mission to Kenya, the Board 
notes that the Government of Kenya has taken a number 
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of measures to implement its recommendations in a 
 number of areas. 
261. In order to streamline its drug control efforts, the 
Government of Kenya has developed the National Strategy 
for Prevention, Control and Mitigation of Alcohol and 
Drug Abuse, which contains specific, time-bound objec-
tives in order to address all aspects of alcohol, drug and 
substance abuse in Kenya. 
262. The Board also welcomes the adoption of the 
Strategic Plan for the period 2015-2019, which sets out 
measurable goals on alcohol and drug demand and sup-
ply reduction, and establishes guidelines for the opera-
tion of the National Authority for the Campaign against 
Alcohol and Drug Abuse. The Plan is the result of an 
assessment of challenges and good practices identified 
through periodic and ongoing reviews of the previous 
strategic plan. The Board wishes to commend the 
Government of Kenya for its efforts to ensure the inclu-
sion and participation of key stakeholders in the preven-
tion and control of drug abuse at the strategic and 
operational levels, and the important coordination role 
given to the National Authority for the collation of data 
on drug control and the streamlining of reporting to the 
Board.
263. The Board also welcomes the establishment of a 
National Drug Observatory, which is intended to serve 
as a repository for all drug-related data, and the develop-
ment of capacity-building activities to improve compli-
ance with reporting obligations and build consensus on 
data-collection tools. Furthermore, the Government is 
currently reviewing existing drug control legislation to 
address emerging trends in drug trafficking and precur-
sors control. The Board notes that the Pharmacy and 
Poisons Board has established annual legitimate require-
ments for precursor chemicals in an effort to counter the 
trafficking in and diversion of such substances. 
264. The Board noted with appreciation the procure-
ment by the Government of additional forensic testing 
equipment, as well as the establishment of the National 
Technical Committee on Drug Trafficking and Abuse to 
coordinate policy measures to address drug trafficking 
and abuse in Kenya. 
265. The Government has also been actively working on 
strengthening controls at border crossings through the 
establishment of anti-drug units and border liaison offices, 
as well as the Border Control and Operations Coordination 
Committee. In addition, Kenya has taken steps to 
strengthen the monitoring of international cargo termi-
nals by providing the equipment needed to detect illicit 
drugs and providing capacity-building in the field of con-
tainer control. The Government continues to actively use 
PEN Online for all exports of internationally controlled 
precursor chemicals, including those contained in 
 pharmaceutical preparations.
266. The Board notes positive developments with 
respect to the development of addiction treatment meas-
ures in the country and is aware that the Government is 
taking steps to increase access to treatment services 
through the establishment of additional drug treatment 
facilities. The Board would like to encourage the 
Government of Kenya to continue to pursue the estab-
lishment of comprehensive treatment, rehabilitation and 
social reintegration services, to be offered to those affected 
by drug abuse.
267. The Board encourages the Government to take fur-
ther steps to facilitate the availability of controlled nar-
cotic drugs and psychotropic substances for rational 
medical uses, given the current scarcity of those sub-
stances, which are not available in amounts that reflect 
actual medical needs.
(b) Malaysia
268. According to the information provided by the 
Government of Malaysia, the Board has been able to 
ascertain that Malaysia has acted upon several recom-
mendations issued following the INCB mission to the 
country in 2013. In particular, the Government is com-
mitted to implementing its national drug control strategy, 
has taken considerable measures and initiatives in the 
fight against cross-border and international drug traffick-
ing and has increased law enforcement capacity at vari-
ous entry points, especially at Kuala Lumpur International 
Airport. The Government has also strengthened control 
of licit activities related to narcotic drugs, psychotropic 
substances and precursor chemicals through increased 
collaboration between various drug law enforcement 
agencies, including through the Integrated Substance 
Control Management System (SPIKE). The Board wel-
comes those measures and encourages the Government 
to continue to implement its national drug control 
strategy.
269. The Board notes that the Government of Malaysia 
has continued to strengthen its demand reduction efforts, 
for example through the development of facilities for the 
treatment of drug abuse and through community-based 
prevention programmes. According to the information 
provided to the Board by the Government of Malaysia, 
the Ministry of Health was reviewing the National 
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Guideline and Policy for Methadone Treatment 
Programme and taking additional measures to prevent 
the diversion of methadone dispensed by clinics for 
patients to use off site. In the light of continued chal-
lenges related to rates of drug abuse reported to the 
Board by the Government of Malaysia, the Board encour-
ages the Government to continue its efforts in the area 
of demand reduction. In particular, the Board encour-
ages the Government to conduct a nationwide assess-
ment of the drug abuse situation in order to inform the 
development of evidence-based demand reduction 
activities.
270. The Board notes that the availability of narcotic 
drugs and psychotropic substances for legitimate medical 
purposes to meet medical needs in Malaysia remains low 
and encourages the Government to take additional meas-
ures to foster greater access to those medicines. 
271. The Board also notes the continued imposition by 
Malaysia of capital punishment for drug-related crimes. 
As it has done in the context of other States that con-
tinue to apply the death penalty for that category of 
offence, the Board calls upon the Government of 
Malaysia to commute death sentences that have already 
been handed down and to consider the abolition of the 
death penalty for drug-related offences.
(c) Panama
272. The Board notes the action taken by the Government 
of Panama to implement its recommendations following 
its 2013 mission to the country, including several legisla-
tive and policy measures to strengthen the country’s 
implementation of its legal obligations under the three 
international drug control conventions.
273. The Board notes the continued implementation by 
the Government of Panama of the National Drug Strategy 
for the period 2012-2017. The Strategy covers demand 
reduction, supply reduction, control measures and inter-
national cooperation. It was developed with the partici-
pation of all relevant stakeholders and includes a 
framework for monitoring and evaluation. As one of the 
Strategy’s pillars, an operational and financial manage-
ment system has been established to ensure the availabil-
ity of the resources needed to achieve the strategic 
objectives and agreed targets set out in the Strategy. 
According to the information provided by the authorities, 
the Ministry of the Interior is responsible for implement-
ing the Strategy, with funds drawn from several financial 
sources, including from the auction of confiscated drug-
related assets.
274. The Board welcomes measures to improve the 
availability of opioid analgesics for medical use in the 
country through a legislative amendment that covers 
issues ranging from import to dispensing. In May 2016, 
Panama passed Act No. 14, which repealed Law No. 23 
of 16 February 1954 and established a legal framework 
for the control of the importation, exportation, gathering, 
production, purchase, stocking, sale, distribution and use 
of narcotic drugs and psychotropic substances. This leg-
islation provides for changes in the institutional frame-
work through the creation of the Department of 
Controlled Substances, which will be part of the National 
Directorate of Pharmaceutical Products and Drugs. It also 
contains provisions on licensing and a regime of sanc-
tions in cases of non-compliance. The Board would like 
to encourage Panama to continue to make progress in 
ensuring the availability and rational prescribing of 
 narcotic drugs and psychotropic substances for medical 
purposes. The Board encourages the authorities to con-
tinue to identify and address obstacles in that area, par-
ticularly those obstacles relating to capacity-building and 
the training of health-care professionals, as required. 
275. The Board notes the Government’s plan to create 
an observatory on drugs. In June 2015, Panama con-
ducted a second national household survey, the data from 
which were being processed and analysed at the time of 
writing. The Board invites the Government of Panama to 
inform it of the results of the survey once they are avail-
able. The Government has reported the results of the pre-
vious two surveys conducted among secondary school 
students about their consumption of controlled sub-
stances, which described the extent of licit and illicit drug 
use in urban agglomerations of 30,000 or more inhabit-
ants aged 12-65 years. A new national survey is planned 
for 2017, which will extend the sample group to small 
cities and rural areas, according to the information 
 provided by the Government. 
276. The Government has reported a wide array of 
measures with respect to drug-related criminality, includ-
ing the expansion of a specialized prosecution service to 
combat organized crime and the adoption of measures to 
combat money-laundering, including through the launch 
of a public awareness campaign and legislative amend-
ments. Law No. 23 of 27 April 2015 provides, inter alia, 
for additional measures against money-laundering. Law 
No. 34 of 8 May 2015 criminalizes customs fraud offences 
and includes them as a predicate offence of money- 
laundering. Panama also reported the creation of special 
prosecutors for drug-related crimes. The authorities 
explained that they planned to create an inter-agency 
regional security centre as a platform for international 
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intelligence exchange. They confirmed that 59 tons of 
controlled substances had been seized in 2015.
277. With respect to the control of precursor chemicals, 
the country has regulations in place for the control of 
chemical substances subject to control pursuant to article 
12 of the 1988 Convention and has an up-to-date register 
of legal and natural persons whose activities involve chemi-
cal substances, as well as a licensing system for manu-
facturers and distributors of those substances. Panama has 
also established a competent authority responsible for 
coordinating control activities with respect to controlled 
chemical substances and has mechanisms for the timely 
issuance of and response to pre-export notifications.
278. The Board acknowledges the allocation by the 
Government of additional law enforcement resources to 
monitor the increased number of containers transiting 
through the Panama canal following its expansion in 
2016. Additional port control units have been created, as 
well as a specialized joint container control unit, which 
now comprises representatives from various institutions. 
279. The Board welcomes the developments mentioned 
above and encourages the Government to continue its 
efforts in the area of drug control, in particular by pro-
viding adequate support to supply and demand reduction 
programmes and to additional measures against drug 
trafficking and abuse in the country.
(d) Singapore
280. The Board notes the progress made by Singapore 
in strengthening its drug control framework since the 
INCB mission to the country in 2013. In particular, the 
Government has improved the availability of drug treat-
ment programmes by expanding facilities for the treat-
ment and rehabilitation of drug addicts and establishing 
the Drug Counselling and Engagement Programme to 
increase the range of rehabilitation interventions and 
counselling services available for young people who use 
drugs. The Government has also launched several public 
awareness campaigns about the dangers of drug abuse. 
281. The Board encourages the Government of Singapore 
to continue its efforts to improve the collection and analy-
sis of prevalence data by conducting additional studies to 
inform the adoption of drug prevention and treatment 
measures and to expand drug abuse prevention 
 programmes and facilities, as needed. 
282. The Board notes that Singapore continues to apply 
the death penalty for drug-related offences. The Board calls 
upon the Government of Singapore to commute death sen-
tences that have already been handed down and to consider 
the abolition of the death penalty for drug-related offences.
E. Action taken by the Board to 
ensure the implementation of the 
international drug control treaties
1. Action taken by the Board pursuant 
to article 14 of the Single Convention 
on Narcotic Drugs of 1961 as amended 
by the 1972 Protocol and article 19 of 
the Convention on Psychotropic 
Substances of 1971 
283. Article 14 of the 1961 Convention as amended by 
the 1972 Protocol, article 19 of the 1971 Convention and 
article 22 of the 1988 Convention contain measures that 
INCB may take to ensure the execution of the provisions 
of those Conventions. Such measures, which consist of 
increasingly severe steps, are considered when the Board 
has reason to believe that the aims of the Conventions 
are being seriously endangered by the failure of a State 
party to implement their provisions.
284. Over the years, INCB has decided to invoke arti-
cle 14 of the 1961 Convention and/or article 19 of the 
1971 Convention with respect to a limited number of 
States. The Board’s objective has been to encourage ongo-
ing dialogue with those States to bring about compliance 
with the Conventions when all other means have failed. 
285. The names of the States concerned are not publicly 
disclosed until INCB decides to bring the situation to the 
attention of the parties, the Economic and Social Council 
and the Commission on Narcotic Drugs. Following inten-
sive dialogue with the Board, pursuant to the above- 
mentioned articles, most of the States concerned have 
taken remedial measures, resulting in a decision by the 
Board to terminate the action taken under those articles 
with regard to those States.
286. Afghanistan is currently the only State for which 
action is being taken pursuant to article 14 of the 1961 
Convention. The Board first invoked article 14, subpara-
graph 1 (a), of the 1961 Convention in 2000 to encour-
age dialogue with the authorities of Afghanistan to 
promote compliance with the Convention. In 2001, the 
Board invoked article 14, subparagraph 1 (d), of that 
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Convention, in order to bring about cooperative action 
at the international level to assist the Government of 
Afghanistan in ensuring compliance with the Convention. 
2. Consultation with the Government 
of Afghanistan pursuant to article 14 of 
the 1961 Single Convention on Narcotic 
Drugs as amended by the 1972 Protocol
287. During the current reporting period, the Board’s 
consultations with the Government of Afghanistan have 
continued. Following several years of preparation, a high-
level INCB mission visited Afghanistan from 8 to 10 May 
2016. The mission was led by the President of the Board, 
accompanied by the Secretary of the Board and a mem-
ber of the INCB secretariat. The purpose of the mission 
was to continue consultations with the Government of 
Afghanistan under article 14 of the 1961 Convention, 
with a view to strengthening the implementation of the 
drug control conventions in Afghanistan, including by 
continuing to seek cooperative international action and 
through the provision of technical assistance from 
 members of the international community.
288. The mission was received by the Chief Executive 
of Afghanistan, the Minister of Counter Narcotics, the 
Minister of Public Health and the Minister of Agriculture, 
Irrigation and Livestock. The President of the Board also 
held consultations with the National Security Adviser to 
the President of Afghanistan and with the Special Envoy 
of the President for the Commonwealth of Independent 
States and Senior Adviser to the First Vice-President of 
Afghanistan. In addition, consultations were held with the 
Chair and members of the Parliamentary Commission on 
Counter Narcotics, the Deputy Special Representative of 
the Secretary-General for Afghanistan, and representa-
tives of international organizations and the international 
community. The President of the Board also visited a drug 
treatment and rehabilitation centre. Discussions focused 
on the drug control situation, future prospects, the actions 
and initiatives of the Government of Afghanistan and 
cooperation with and assistance from the international 
community. The Board reiterates that article 14, sub-
paragraphs 1 (a) and (b), of the 1961 Convention will 
continue to remain invoked with respect to Afghanistan.
289. The Board has repeatedly expressed concern about 
the overall situation in Afghanistan and has cautioned 
that the deteriorating security situation may continue to 
have a serious impact on the drug control situation in the 
country, the effects of which are felt far beyond its 
borders. The Board stresses the need for the Government 
of Afghanistan to show tangible results of its drug con-
trol efforts and of the level of aid it has received in recent 
years in order to restore confidence in the Government’s 
ability to absorb assistance and implement its commit-
ments on improving the drug control situation. The 
Board also stresses that the drug problem remains inex-
tricably linked to the deeper problems faced in 
Afghanistan; it requires sustained prioritization by both 
the Government and the international community. In 
that context, the Board commends the Government of 
Afghanistan for the well-structured and promising 
National Drug Action Plan 2015-2019, approved by the 
President of Afghanistan in October 2015. The Board reit-
erates that it stands ready to continue to support the 
Government of Afghanistan in its efforts to implement 
the international drug control conventions. The Board 
will continue to take every opportunity to rally inter-
national support for Afghanistan, including in the form 
of technical assistance and capacity-building initiatives. 
Cooperation with the Board 
290. Consultations between the Board and the 
Government of Afghanistan pursuant to article 14 of the 
1961 Convention continued in 2016: the President of the 
Board held a meeting with the delegation of Afghanistan, 
which was headed by the Minister of Counter-Narcotics, 
on the margins of the fifty-ninth session of the Commission 
on Narcotic Drugs, which was held in Vienna from 14 to 
22 March 2016. The Minister updated the President on 
the current drug control situation in Afghanistan, high-
lighting challenges that the Government was likely to face 
in addressing the drug problem in the coming years and 
underlining the importance of a balanced approach to 
addressing the drug problem. The President of the Board, 
while noting the difficulties in addressing the drug prob-
lem, recalled the outcomes of the special session of the 
General Assembly on the world drug problem held in 
2016 and reiterated the obligation of Afghanistan to 
implement the provisions of the 1961 Convention and 
ensure that progress was achieved in working towards 
effective drug control policy and action.
291. The Secretary of the Board held meetings with the 
Permanent Mission of Afghanistan in Vienna on a num-
ber of occasions during the year to follow up on the 
Government’s implementation of the international drug 
control treaties. The meetings focused on issues of concern 
to the Board relating to Afghanistan, particularly with 
regard to continuing difficulties in the prevention and 
reduction of illicit opium poppy cultivation, the worrying 
trend of illicit cannabis plant cultivation and the increased 
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levels of drug abuse, as well as the need to address demand 
reduction matters, in particular drug abuse prevention, 
treatment and rehabilitation, and trafficking.
292. The Board notes that the Government’s treaty- 
mandated reporting has improved, with statistical data on 
narcotic drugs, psychotropic substances and precursors 
being regularly submitted to the Board, as required under 
the international drug control treaties. Afghanistan has 
been increasingly involved in various programmes and 
projects that are aimed at preventing the diversion of pre-
cursor chemical substances from licit sources into illicit 
channels. A recent example of cooperation to assist the 
Government of Afghanistan was the workshop on the use 
of customs data, profiling and information systems held in 
Vienna in August 2016. The workshop, organized by the 
INCB secretariat in cooperation with UNODC, focused on 
improving border risk management in Afghanistan and 
neighbouring countries, with a view to preventing the flow 
of precursor chemicals into heroin laboratories in 
Afghanistan. The workshop provided an opportunity to 
discuss the practical implementation of the provisions of 
the drug control treaties with the authorities of Afghanistan.
293. The National Drug Action Plan 2015-2019 was 
approved by the President of Afghanistan on 15 October 
2015. The Plan contains measures to reduce the illicit culti-
vation, production and smuggling of drugs though alterna-
tive development, to strengthen regional cooperation, to 
combat money-laundering and to confiscate property 
obtained as a result of illegal activity. Furthermore, the Plan 
contains measures to reduce drug demand while increasing 
capacity for drug abuse treatment. The Plan encompasses 
different dimensions of drug control efforts, taking into con-
sideration the characteristics of each province and district 
in which poppy is cultivated. The Board will continue to 
closely monitor the drug control situation in Afghanistan 
and the measures taken and progress made by the 
Government of Afghanistan in addressing the drug  problem, 
with the assistance of the international community.
Cooperation with the international community 
294. The reporting period saw continued activity under 
the regional programme for Afghanistan and neighbour-
ing countries, led by UNODC, with a focus on building 
capacity in the collection and analysis of data on drugs, 
cross-border controls and control of precursor chemicals. 
In November 2015, the sixth senior officials meeting for 
the Tripartite Initiative involving Afghanistan, Kyrgyzstan 
and Tajikistan was hosted by the Counter-Narcotics Police 
of Afghanistan. The goal of the meeting was to identify 
mechanisms to strengthen cooperation in counter- 
narcotics and border management among the partners of 
the Tripartite Initiative and to amend the road map of 
action for 2016-2017.
295. The Afghanistan Opium Survey 2015, published in 
December 2015 by UNODC, contained an overview of 
benchmarks and indicators on cultivation and produc-
tion. According to the report, the total area under opium 
poppy cultivation had decreased by 19 per cent in 2015, 
to an estimated 183,000 ha, as compared with 224,000 ha 
in 2014, representing the first decrease in cultivation area 
since 2009. 
296. However, according to the executive summary of 
the Afghanistan Opium Survey 2016, published in October 
2016 by UNODC, the total area under opium poppy cul-
tivation increased by 10 per cent in 2016, to an estimated 
201,000 ha. In addition, potential opium production in 
2016 amounted to 4,800 tons, representing an increase of 
43 per cent from the 2015 level of 3,300 tons. The 
Government had aimed at eradicating between 9,000 and 
10,000 ha of opium poppy in 2016 (see also paras. 673-
678 of the present report). 
297. In December 2015, the Ministry of Counter 
Narcotics released the Afghanistan Drug Report 2015. The 
substantial reductions in opium poppy cultivation and 
production that were seen in 2015, alongside incremen-
tal increases in drug seizures, were highlighted in the 
report. According to the report, between 1.9 million and 
2.4 million adults in the country are estimated to use 
drugs, equivalent to 12.6 per cent of the adult population. 
In the report, the limited treatment capacity in Afghanistan 
was also highlighted. The country has only 123 centres; 
together they have the capacity to treat 10.7 per cent of 
opium and heroin users. In order to increase treatment 
capacity, the Ministry of Public Health, in coordination 
with the Ministry of Counter Narcotics, opened the coun-
try’s first drug treatment and rehabilitation centre in 
Kabul in December 2015.
298. Also in December 2015, a high-level meeting of 
partners for Afghanistan and neighbouring countries was 
held in Vienna. It was chaired jointly by the Minister of 
Counter Narcotics of Afghanistan, the Executive Director 
of UNODC and the Special Representative for Afghanistan 
and Head of the United Nations Assistance Mission in 
Afghanistan and was attended by 122 delegations from 
28 countries and 7 international organizations. The high-
level meeting continued exchanges to build regional 
cooperation, combat transnational organized crime and 
drug trafficking and support the implementation of the 
Sustainable Development Goals in West Asia.
40  INCB REPORT 2016
299. In May 2016, the fourth ministerial meeting of the 
Tripartite Initiative involving Afghanistan, Kyrgyzstan and 
Tajikistan was held in Kyrgyzstan. The goal of the meeting 
was to improve cooperation in counter-narcotics and border 
management in drug control among the three countries.
300. At the North Atlantic Treaty Organization (NATO) 
summit held in Warsaw from 7 to 9 July 2016, NATO 
determined the nature and extent of the assistance that it 
would continue to provide to Afghanistan. NATO coun-
tries pledged to commit military resources beyond 2016 
and to continue to make national financial contributions 
to the Afghan National Defence and Security Forces until 
the end of 2020.
301. On 29 July 2016, Afghanistan became the 164th 
member of the World Trade Organization, following 
almost 12 years of negotiations on its accession terms.
302. The Brussels Conference on Afghanistan was held 
in October 2016. In advance of the Conference, the Board 
released a statement in which it expressed its concern 
about the deteriorating drug control situation in 
Afghanistan and called upon members of the inter-
national community to reaffirm their commitment to 
supporting the Government of Afghanistan in its devel-
opment efforts, including by acknowledging the impor-
tance of drug control as a cross-cutting issue that should 
be put at the top of the development agenda for the coun-
try. The Brussels Conference was co-hosted by the 
Government of Afghanistan and the European Union. 
The aim of the Conference was to continue providing a 
platform for the Government of Afghanistan to set out 
its vision for reform and for the international community 
to provide assistance, including financial assistance, to the 
Government. The Afghanistan National Peace and 
Development Framework for the period 2017-2021 was 
adopted at the Conference. The Framework sets out steps 
towards achieving economic development and a substan-
tial increase in the welfare of the Afghan people, with the 
goal of putting an end to corruption, criminality and 
 violence and establishing the rule of law. 
Conclusions 
303. The Board takes note of the commitment of the 
Government of Afghanistan to tackle money-laundering, 
as reflected in the National Drug Action Plan 2015-2019, 
and urges the Government of Afghanistan to take deter-
mined steps to counter money-laundering and to give effect 
to its legal framework for identifying, tracing and seizing 
illicit assets derived from drug trafficking, as well as to the 
recommendations of relevant international bodies. 
304. The Board notes with concern the deteriorating 
safety and security situation in Afghanistan and its impact 
on the authorities’ ability to monitor and control the illicit 
supply of drugs originating in the country. At the same 
time, the Board has observed that the willingness of the 
international community to continue providing aid to 
Afghanistan appears to have been declining, in particu-
lar in the area of drug control. The Board acknowledges 
that the success of drug control efforts in Afghanistan is 
intrinsically linked to broader developmental and crimi-
nal justice challenges being adequately addressed but cau-
tions that action against drugs cannot be removed from 
the equation if sustainable development is to be achieved. 
In that context, the Board calls upon partner 
Governments and the international community to sus-
tain their support for the counter-narcotics efforts of 
Afghanistan, in the spirit of their common and shared 
responsibility to respond to the world drug problem and 
in order to ensure that the potential vacuum left by the 
withdrawal of international support from the country is 
not filled by criminal or terrorist elements.
305. The deteriorating drug control situation in 
Afghanistan and the region remains of grave concern. 
That situation seriously endangers the aims of the inter-
national drug control treaties and its repercussions are 
felt internationally. The Board calls upon the Government 
of Afghanistan and the international community, includ-
ing through relevant United Nations entities and pro-
grammes, to continue their cooperation to achieve the 
goals set out in various documents adopted by the inter-
national community. Bearing in mind the overarching 
objective of the National Drug Control Strategy of 
Afghanistan, the Government of Afghanistan, with assis-
tance from the international community, including, in 
particular, UNODC, should translate its commitment 
into specific actions and ensure that substantial, sustain-
able, measurable and demonstrable progress is achieved 
in countering drug trafficking, promoting alternative 
development and reducing drug demand; in other words, 
bringing about the effective implementation of the inter-
national drug control treaties in the country.
F. Special topics 
1. State responses to drug-related 
offences
306. As the Board has reiterated on several occasions, 
the fundamental principles underpinning the three 
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international drug control treaties, as well as the Political 
Declaration adopted by the General Assembly at its twen-
tieth special session, devoted to countering the world 
drug problem together, and the Political Declaration and 
Plan of Action on International Cooperation towards an 
Integrated and Balanced Strategy to Counter the World 
Drug Problem, are the principle of a balanced approach, 
the principle of proportionality and respect for human 
rights.
307. In many States, policies to address drug-related 
offences, including possession for personal use, have con-
tinued to be rooted primarily in punitive criminal justice 
responses, which include prosecution and incarceration and 
as part of which alternative measures such as  treatment, 
rehabili tation and social integration remain underutilized.
308. While drug trafficking and the diversion of drugs 
into illicit channels may require the use of interdiction 
efforts, criminal prosecution and the imposition of crimi-
nal sanctions, in some States, approaches to dealing with 
criminal behaviour committed by persons affected by drug 
use and addiction have become more differentiated in 
recent years. This is a result of an evolution in those States 
that have come to recognize drug use and dependency as 
a public health concern requiring responses that are 
health-centred and less reliant on punitive sanctions.
309. The Board welcomes that development as entirely 
consistent with what is foreseen in the international drug 
control framework. Prevention of drug abuse, especially 
among young people, must be the primary objective of 
drug control policy, and a comprehensive drug demand 
reduction strategy that includes the reduction of the 
adverse health and social consequences associated with 
drug abuse is of paramount importance.
Proportionality and alternatives to conviction or 
punishment
310. Disproportionate responses to drug-related offences 
undermine both the aims of the conventions and the rule 
of law. Accordingly, the international drug control trea-
ties require proportionate responses by States to drug-
related offences and to the treatment of offenders.
311. States have an obligation under the drug control 
conventions to establish certain behaviours as punishable 
offences and to ensure that serious offences are liable to 
adequate punishment, including by imprisonment; how-
ever, that obligation is subject to the constitutional prin-
ciples of the State and to the principle of proportionality. 
In addition, pursuant to article 36, subparagraph 1 (b), of 
the 1961 Convention, article 22, subparagraph 1  (b), of 
the 1971 Convention and article 3, subparagraphs 4  (b) 
and (c), of the 1988 Convention, States are not obliged to 
adopt punitive responses for minor drug-related offences, 
including possession of small quantities of drugs for 
 personal use, committed by people who abuse drugs.
312. In such cases, the three conventions provide the 
possibility for alternatives to conviction or punishment 
through treatment, education, aftercare, rehabilitation 
and social reintegration. They allow States to focus the 
most severe penalties on more serious forms of crime, 
such as trafficking and money-laundering, giving States a 
certain discretion in the legislative and policy choices 
they make in implementing their obligations under the 
three conventions. There is no obligation stemming from 
the conventions to incarcerate drug users who commit 
minor offences.
313. The Board notes that the discretion to adopt crimi-
nal justice policies that include alternatives to conviction 
or punishment for minor offences that is provided for 
under the conventions remains underutilized.
314. Where States have provided legal penalties for 
more serious categories of drug-related offences, includ-
ing trafficking, the principle of proportionality must also 
continue to act as a guiding principle.
315. Although the determination of sanctions applica-
ble to drug-related offences remains the prerogative of 
States parties to the conventions, the Board has contin-
ued to encourage States that retain capital punishment 
for that category of offence to commute death sentences 
that have already been handed down and to consider the 
abolition of the death penalty for drug-related offences, 
in view of the relevant international conventions and 
 protocols and resolutions of the General Assembly, the 
Economic and Social Council and other United Nations 
bodies on the application of the death penalty.
Extrajudicial treatment of suspected drug-
related criminality
316. The Board has noted with great concern recent 
reports in some countries of the targeting of individuals 
suspected of involvement in drug-related activity, including 
drug use, who have been subjected to violent acts of reprisal 
and murder at the hands of law enforcement personnel and 
members of the civilian population. In some instances, 
those acts have been committed with the expressed or tacit 
approval, or even encouragement, of political forces and, in 
many cases, have gone unpunished.
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317. The extrajudicial targeting of persons suspected of 
illicit drug-related activity is not only a breach of the 
three international drug control conventions, it also con-
stitutes a serious breach of human rights, including due 
process norms as contained in the Universal Declaration 
of Human Rights and the International Covenant on Civil 
and Political Rights, and is an affront to the most basic 
standards of human dignity.
318. The Board wishes to reiterate, in the strongest 
possible terms, its categorical and unequivocal condem-
nation of those acts, wherever and whenever they may 
occur, and calls upon all Governments concerned to put 
an immediate stop to such actions and to publicly com-
mit to and undertake investigations into any person sus-
pected of having committed, participated in, aided and 
abetted, encouraged, counselled or incited any such 
extrajudicial actions, in full observance of due legal 
 process and the rule of law, and their prosecution and 
sanction, as warranted.
2. Regulation of the use of cannabis 
for non-medical purposes
319. The Board notes the adoption or consideration by 
some States of measures affecting the legal control meas-
ures applicable to cannabis in order to allow the use of 
cannabis for non-medical purposes and the creation of a 
regulated market for the distribution and sale of  cannabis 
products for non-medical use.
320. The Board wishes to reiterate that the 1961 
Convention establishes, in its article 4 (“General obliga-
tions”), that the parties to the Convention are to take 
such legislative and administrative measures as may be 
necessary to give effect to and carry out the provisions 
of the Convention within their own territories and to 
limit exclusively to medical and scientific purposes the 
production, manufacture, export, import, distribution 
of, trade in and use and possession of drugs. As the 
Board has repeatedly emphasized, the limitation of the 
use of controlled substances to medical and scientific pur-
poses is a fundamental principle that lies at the heart of 
the international legal framework for drug control and 
allows no exception.
321. The central role of the international drug control 
conventions was most recently reaffirmed by the States 
participating in the special session of the General 
Assembly on the world drug problem held in April 2016.
322. In examining measures taken by States with the 
aim of permitting and regulating the non-medical use of 
cannabis, the Board has maintained a dialogue with the 
States concerned in which it has reaffirmed the incom-
patibility of such measures with the legal obligations 
incumbent upon States parties to the 1961 Convention, 
with a view to promoting compliance.
323. The Board wishes to remind all States that, in rec-
ognition of the public health risks associated with its 
abuse, cannabis has been subjected to the highest levels 
of control under the international drug control treaties 
through its inclusion in Schedules I and IV of the 1961 
Convention. Schedule IV contains noxious substances 
that are particularly liable to abuse. Furthermore, dron-
abinol (delta-9 tetrahydrocannabinol), the major active 
ingredient of cannabis, and other tetrahydrocannabinol 
(THC) isomers are classified as psychotropic substances 
under Schedules II and I, respectively, of the 1971 
Convention.
324. While it is difficult to predict the effects of the 
 legislative measures making cannabis available for non-
medical use, it is certain that the abuse of cannabis poten-
tially carries serious health consequences, as acknowledged 
by WHO. In recent years, States have reported a marked 
increase in the THC content of cannabis seized and an 
associated rise in health-related adverse reactions, evi-
denced by increases in hospital emergency room admis-
sions. There have also been reported cases of children 
having ingested food products containing cannabis. 
Moreover, the rates of abuse may increase, especially 
among young people, because the legalization measures 
may affect perceptions of harm in that fewer people may 
perceive cannabis as being harmful, highlighting the need 
for enhanced prevention measures.
325. One of the central arguments advanced by propo-
nents of the legalization of the use of cannabis for non-
medical purposes is that the creation of a regulated licit 
market for cannabis intended for non-medical use would 
contribute to reducing drug trafficking by criminal net-
works. That argument fails to take into account the spill-
over effect that legalization may have in neighbouring 
jurisdictions where the use of cannabis for non-medical 
purposes remains illegal. Countries where legislative 
measures to permit and regulate the non-medical use of 
cannabis have been adopted or are being considered 
should also be aware of the risk that they will be targeted 
by criminal networks seeking to use them as transit coun-
tries for trafficking to other jurisdictions where the non-
medical use of  cannabis is not permitted.
326. In some States, the legalization of the use of can-
nabis for non-medical purposes has been justified by its 
proponents on the basis of the argument that the 
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criminalization of cannabis possession has led to the tar-
geting of drug users belonging to minority groups and to 
their disproportionate representation in the criminal jus-
tice and prison systems. While the 1961 Convention does 
require States parties to adopt measures to ensure that 
possession of drugs is a punishable offence when commit-
ted intentionally, the conventions do not require the impo-
sition of punishment or imprisonment for drug users and 
provide instead for the possibility for each State to impose 
treatment and rehabilitation measures either as an alter-
native to conviction or punishment or in addition thereto. 
The Board encourages States affected by high rates of 
arrest and incarceration for minor drug-related offences 
committed by drug users to consider availing themselves 
of the possibility provided by the international drug con-
trol conventions to adopt non-punitive responses rather 
than permitting the use of cannabis for non-medical 
purposes, which may prove to be counterproductive.
3. Importance of accurate and timely 
reporting
327. The effectiveness and efficiency of the international 
drug control system as established by the three inter-
national drug conventions depends on the accurate and 
timely reporting to the Board by Member States. 
Regrettably, many Governments fail to provide the Board 
with timely and adequate estimates and assessments and 
reliable statistical returns. Those sometimes include 
Governments of major manufacturing, importing and 
exporting countries; their lack of response has a signifi-
cant impact on the ability of the Board to accurately mon-
itor the world situation. Some Governments continue to 
experience difficulties in collecting the required informa-
tion from their national and subnational stakeholders 
because of legislative or administrative shortcomings.
328. Focusing first on narcotic drugs, the Board urges 
parties to provide accurate estimates and statistics on the 
stocks held by manufacturers and wholesalers. Information 
on stocks allows the balance between the supply of opiate 
raw materials and demand for opiates and the levels of 
accumulation to be monitored, as high levels may increase 
the risk of diversion. The Board urges Governments to 
ensure that their competent national authorities periodi-
cally obtain reliable information from private and 
 State-owned manufacturers and wholesalers.
329. Also relevant to narcotic drugs, many countries 
have been providing estimates to INCB that are much 
higher than the reported consumption. While strongly 
encouraging countries with inadequate and very 
inadequate levels of consumption of controlled sub-
stances for medical and scientific purposes to ensure 
that consumption matches actual needs, the Board 
requests parties to provide estimates that realistically 
reflect their expected consumption. The Board encour-
ages competent national authorities to refer to the Guide 
on Estimating Requirements for Substances under 
International Control, developed by INCB and WHO,51 
when calculating their estimates, and reminds 
Governments that supplementary estimates may be sent 
to the Board at any time during the year.
330. Turning to psychotropic substances and the obli-
gations set forth in the 1971 Convention, Governments 
are encouraged to fully implement Commission on 
Narcotic Drugs resolutions 53/4 and 54/6, and therefore 
to report data on the consumption of psychotropic sub-
stances (for medical and scientific purposes). The Board 
stresses the importance of providing appropriate assess-
ments for psychotropic substances, as this would ensure 
their availability for the treatment of a large variety of 
medical conditions, including mental health conditions, 
and would improve access to them worldwide, while 
reducing the risk of diversion for illicit use. The reported 
assessments for all countries are published by INCB on a 
monthly basis and amendments may be sent to the Board 
at any time.
331. The estimates of annual legitimate requirements for 
the import of selected precursors of amphetamine-type 
stimulants are requested, on a voluntary basis, pursuant 
to Commission on Narcotic Drugs resolution 49/3, in 
order to provide the authorities of exporting countries 
with an indication of the needs of importing countries. 
Additionally, pursuant to article 12, paragraph 12, of the 
1988 Convention, Governments are obliged to report 
annually to the Board information on seizures of sub-
stances listed in Tables I and II of the Convention and of 
substances not included in Tables I or II; as well as infor-
mation on methods of diversion and illicit manufacture, 
stopped shipments and thefts involving those substances. 
Although the submission rate of data for 2015 was the 
highest in five years, the Board notes that not all States 
parties to the 1988 Convention provide such information 
in an accurate and timely manner. A considerable num-
ber of the submissions often do not include important 
details such as methods of diversion or information on 
stopped shipments or the illicit manufacture of sub-
stances, or are submitted to the Board with significant 
delays. This hampers the ability of the Board to identify 
and thoroughly assess worldwide trends in trafficking in 
precursors and in the illicit manufacture of drugs.
51 Vienna, 2012.
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332. A further issue related to reporting on precursors 
is the provision of information on the licit trade in and 
use of substances in Tables I and II of the 1988 Convention, 
in accordance with Economic and Social Council resolu-
tion 1995/20. In contrast to narcotic drugs and psycho-
tropic substances, that information is submitted by 
Governments on a voluntary basis and enables the Board 
to assist Governments in preventing diversions by iden-
tifying unusual trade patterns and suspicious illicit 
activities. 
333. The Board wishes to remind Governments of 
their obligations to provide the information requested 
pursuant to article 12, paragraph 12, of the 1988 
Convention and relevant resolutions to the Board in an 
accurate and timely manner.
334. Competent national authorities play a key role in 
consolidating the information received from pharmaceu-
tical companies, importers and exporters to ensure that 
reliable data are provided to the Board in a timely man-
ner. The importance of the work of competent national 
authorities cannot be overstated: they are at the front line 
of their countries’ efforts to facilitate licit trade and to 
prevent the diversion of controlled substances into illicit 
channels. They are also responsible for estimating their 
country’s requirements for narcotic drugs and psycho-
tropic substances in order to ensure that the medical 
needs of their populations, in terms of access to such 
drugs and substances, are met, while at the same time 
preventing misuse.
335. Reporting obligations can be best fulfilled if 
Governments provide for the training of staff. The Board 
also encourages all Governments to take the necessary 
steps to maintain the knowledge base of the staff of 
competent national authorities at times of staff 
turnover.
4. New tools for old purposes: 
using modern technology to monitor 
international trade in scheduled 
substances
336. Ever since the creation of the international drug 
control system, monitoring international trade in sched-
uled substances has been one of the main pillars of the 
three drug control conventions. The ultimate purpose of 
monitoring the movement of scheduled substances at the 
global level has not changed: to strike a balance between 
ensuring the availability of narcotic drugs and psycho-
tropic substances for medical and scientific purposes and 
curbing illicit drug manufacture and trafficking, includ-
ing by preventing the diversion from licit trade into illicit 
channels of precursors used in their manufacture. The 
idea of supporting competent national authorities in their 
efforts to effectively exchange information in that regard 
is thus not new. However, the rapid advancement of mod-
ern technology, especially information and communica-
tions technology, today offers unprecedented opportunities 
for more effective, direct and immediate communication 
among Governments on drug control matters.
337. To assist drug control authorities in that regard and 
to harness the potential of modern technology for drug 
control purposes, INCB has developed several electronic 
tools to facilitate the monitoring of the movement of nar-
cotic drugs, psychotropic substances and precursors, 
offering new tools for old purposes.52
(a) International Import and Export 
Authorization System (I2ES)
338. A well-functioning import and export authoriza-
tion system is instrumental in monitoring the inter-
national trade in controlled substances and preventing 
their diversion. The International Import and Export 
Authorization System (I2ES), a new tool developed by the 
Board in cooperation with UNODC and with the sup-
port of Member States, was launched in March 2015 to 
facilitate the effective implementation of import and 
export authorization systems for licit international trade 
in narcotic drugs and psychotropic substances.
339. I2ES is a web-based application that allows import-
ing and exporting countries to upload and exchange 
import and export authorizations in a secure environ-
ment and to generate and transmit those authorizations 
electronically, including with the help of a download and 
print function. I2ES is designed to complement, but not 
replace, existing national electronic drug control systems, 
and also provides countries without pre-existing elec-
tronic systems a viable tool to manage import and export 
authorization processes online.
340. Another key feature of I2ES is that it automatically 
checks the quantity of a narcotic drug or psychotropic 
substance to be imported and/or exported against the lat-
est estimate or assessment of the importing country’s 
requirements, and automatically displays warning 
52 Enquiries about the tools, including registration requests, can be 
sent to i2es@incb.org for I2ES (narcotic drugs and psychotropic sub-
stances); pen@incb.org for PEN Online (precursors); pics@incb.org for 
PICS (precursor incidents); and nps@incb.org or ionics@incb.org for 
Project Ion and IONICS (new psychoactive substances).
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messages when it finds excess imports or exports. I2ES 
also guides the competent national authority through the 
steps required in such an eventuality. Furthermore, the 
system has an online endorsement function: after verify-
ing that an arriving shipment matches the quantity 
authorized for export, the authorities of the importing 
country can endorse it by confirming receipt to the 
authorities of the exporting country as required by the 
1961 Convention and the 1971 Convention, or alert them 
in real time if there is a discrepancy.
341. All of those features are designed to help 
Governments meet their obligations under the inter-
national drug control conventions. They are provided at 
zero cost to Governments and are fully compatible with 
any pre-existing national systems, to which I2ES can be 
linked. During a user group meeting on I2ES held in 
March 2016, initial feedback from competent national 
authorities using the system indicated that it had facili-
tated the real-time sharing of information between 
authorities and had expedited the authorization process.
342. As at 1 November 2016, the following 26 countries 
had registered for the system and had started using it: 
Afghanistan, Algeria, Australia, Bangladesh, Brazil, 
Canada, Chile, China, Colombia, Estonia, Germany, 
Hungary, India, Indonesia, Jordan, Malaysia, Peru, Poland, 
Portugal, Saint Lucia, Singapore, Spain, Switzerland, 
Thailand, Turkey and Zambia. To realize its full poten-
tial, the Commission on Narcotic Drugs, in its resolution 
58/10, again urged Member States to promote and facil-
itate the fullest possible use of I2ES. The Board therefore 
encourages all Member States that have not yet done so 
to register for the system and to start using it.
(b) Pre-Export Notification Online (PEN 
Online)
343. In March 2006, the Board officially launched PEN 
Online to help importing and exporting Governments to 
securely communicate international trade in precursor 
chemicals, to verify the legitimacy of individual transac-
tions and to identify suspicious shipments. Over time, the 
system has developed to become the backbone of precur-
sor control at the international level and is the only tool 
of its kind globally.
344. In the 10 years since its launch, over 200,000 pre-
export notifications have been sent by a total of 153 coun-
tries and territories, resulting in the prevention of 
numerous diversions of scheduled chemicals into illicit 
channels. In the last five years, the number of pre-export 
notifications sent through PEN Online has more than 
tripled and provides further evidence that the system is 
now a firmly established pillar of the international mech-
anism for monitoring licit global trade in drug 
precursors.
345. Nevertheless, PEN Online is not always used to its 
full potential. For example, some countries register with 
the system but do not actively use it. Also, a number of 
Governments have not invoked article 12, subpara-
graph  10 (a), of the 1988 Convention, allowing them to 
be informed of all planned exports of precursors to their 
territories, and therefore may remain unaware of, and 
vulnerable to, shipments of concern destined for their 
countries.
346. INCB strongly encourages all the remaining 
Governments to invoke article 12, subparagraph 10 (a), 
of the 1988 Convention and to register for and actively 
use PEN Online.
(c) Precursors Incident Communication 
System (PICS)
347. Complementing PEN Online, the Precursors 
Incident Communication System (PICS), launched in 
2012, provides a secure online platform for sharing infor-
mation in real time on chemical-related incidents with a 
potentially illicit dimension, such as seizures, shipments 
stopped in transit, diversion attempts or the dismantling 
of illicit laboratories. To provide the most comprehensive 
and up-to-date information possible to its users, PICS 
allows the communication of incidents involving not only 
internationally scheduled precursors, but also non- 
scheduled chemicals that countries have identified as hav-
ing been used in illicit drug manufacture. Like all INCB 
electronic tools, PICS is provided to Governments free of 
charge. It is currently available in four languages: English, 
French, Russian and Spanish.
348. PICS is intended as an operational communica-
tions platform rather than as a tool for reporting. It com-
plements the aggregated seizure data received annually 
from Governments through form D with real-time infor-
mation on individual seizures and other incidents as and 
when they happen. The usefulness of PICS depends to a 
large extent on the timeliness of the information provided 
so that it can facilitate immediate follow-up and cooper-
ation to identify those responsible for the diversion of 
and trafficking in precursors.
349. The system was primarily designed to connect and 
enable direct exchanges between the competent national 
authorities responsible for the control of precursors, in 
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particular law enforcement, customs or regulatory author-
ities that have relevant operational information to share 
on incidents they encounter in their daily work. By offer-
ing information of operational value in a secure environ-
ment, PICS has provided leads for national authorities to 
initiate backtracking investigations.
350. The Board is pleased to note that, on several occa-
sions, the timely communication of details of precursor 
incidents has led to further seizures or prevented diver-
sion attempts. In a recent case, a single incident commu-
nicated through PICS led to the detection of a diversion 
scheme of potentially global dimensions, in which an 
internationally non-scheduled substance was used to 
 conceal smuggled acetic anhydride. The case now spans 
across three regions on two continents.
351. The user base of PICS has continually grown since 
2012. As at 1 November 2016, PICS had nearly 450 reg-
istered users from 214 agencies in 100 countries, who had 
shared information about close to 1,700 incidents involv-
ing more than 90 countries (see figure below). To date, 
about one third of all incidents communicated through 
PICS contains immediately actionable information for 
investigators, such as on methods of concealment, con-
tainer numbers, company details or shipping documents.
Figure. Number of users of the Precursors 
Incident Communication System and number of 
incidents communicated, 2012-2016
352. To maximize the value and quality of data shared 
through the system, the Board encourages registration by 
several authorities from the same country if they have 
complementary responsibilities, and the communication 
of incidents as close as possible to the date they took  place.
(d) Project Ion Incident Communication 
System (IONICS)
353. In December 2014, under its operational initiative 
on new psychoactive substances known as Project Ion, 
the Board launched its own incident communication 
 system, the Project Ion Incident Communication System 
(IONICS). Its structure is similar to that of PICS. IONICS 
is dedicated to the exchange at the operational level of 
information on incidents involving new psychoactive sub-
stances. While by definition new psychoactive substances 
have not yet been placed under international control, 
there is growing concern about their reaching consumer 
markets. IONICS was created with a view to addressing 
that concern.
354. In the two years since its creation, 200 users from 
79 countries have registered for IONICS and communi-
cated some 800 incidents involving 155 new psychoactive 
substances. In 2016, a series of local incidents communi-
cated through the system revealed the existence of an 
organized criminal group with links in Europe and Asia 
engaged in the distribution of large amounts of a  synthetic 
cathinone.
Way forward
355. As with most online electronic systems set up to 
respond to real-life challenges, the effectiveness of the 
INCB online tools depends to a large extent on a num-
ber of common factors, such as their coverage, i.e. the 
number of registered countries and users contributing 
information; the quality and timeliness of the data shared; 
and the availability of sustained support, including finan-
cial support, to enable the continued operation and main-
tenance of the tools over time.
356. The Board wishes to express its appreciation to 
all Governments that have provided financial support 
and technical input for the development of all INCB 
electronic tools. Further funding is, however, required 
to enable the INCB secretariat to administer them in 
line with its mandate and to provide reliable, responsive 
and tailored user support to competent national author-
ities. The Board therefore invites all Governments to 
continue providing both political and financial support 
to sustain the range of new tools made available to them 
by INCB, so that it can improve them and develop new 
ones as the need arises.
500 1800
1600
1400
1200
1000
800
600
400
200
0
450
400
350
300
0
50
100
150
200
204
2012 2013 2014 2015 2016
285
325
399
448
250
Incidents Users
N
um
be
r o
f P
IC
S 
us
er
s
N
um
be
r o
f i
nc
id
en
ts
47
Chapter III.
Analysis of the world situation
Highlights
• although drug abuse and treatment data for africa remain limited, there are indications that africa is a growing 
market for all types of drugs of abuse.
• seizures of cocaine in Panama registered an increase of 32 per cent in 2015.
• In 2014, 87 per cent of the cocaine entering the united states was reportedly trafficked through Central america 
and mexico and about 13 per cent through the Caribbean.
• The growing number of accidental overdose deaths caused by fentanyl-laced drugs represented a major drug-
related challenge in Canada and the united states in 2016; in the united states, drug-related overdose deaths 
almost doubled between 2013 and 2014.
• On 8 November 2016 in the united states, voters in the states of California, maine, massachusetts and Nevada 
approved ballot measures that would legalize and regulate the use of cannabis for non-medical purposes. In 
 addition, voters in the states of arkansas, Florida and North dakota approved ballot measures that would allow 
cannabis use for medical purposes.
• Coca bush, opium poppy and cannabis plants continue to be illicitly cultivated in south america. Illicit cultivation 
of coca bush almost doubled in Colombia during the period 2015-2016.
• a peace agreement between the government of Colombia and the Revolutionary armed Forces of Colombia is 
expected to have a positive effect on, inter alia, the drug control situation in the country.
• East and south-East asia continue to face the challenges of sustained illicit opium poppy cultivation and a  further 
expansion of the manufacture of, trafficking in and abuse of methamphetamine.
• south asia continues to be affected by all aspects of the drug problem. Opiates and amphetamine-type  stimulants 
are the main substances of concern in the region.
• The critical security situation in afghanistan continues to severely impact drug control efforts in the country, with 
serious implications for the region and beyond.
• seizures of “captagon” tablets (containing amphetamine) continue to be on the rise, especially in the middle East 
and gulf subregions.
• There is no indication of a slowdown, at the global level, in the development of new psychoactive substances; 
in the European union, 100 new psychoactive substances were reported for the first time in 2015 through the 
European union early warning system.
• despite diversification of heroin trafficking routes, including through the Islamic Republic of Iran, the Caucasus 
countries and then across the Black sea, the traditional Balkan route remains the main corridor for heroin  trafficking 
into Europe.
• The abuse, trafficking and illicit manufacture of methamphetamine remain a major challenge in Oceania.
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A. Africa 
1. Major developments 
357. Africa is perceived mainly as a transit region for 
drug trafficking, but it is increasingly becoming a con-
sumer and a destination market for all types of drugs of 
abuse. That trend could, in part, be attributed to regional 
drug trafficking that has caused a supply-driven increase 
in the availability of different drugs. 
358. Illicit production of, trafficking in and abuse of 
cannabis have remained major challenges throughout 
many parts of Africa, with an estimated annual preva-
lence of cannabis use of 7.6 per cent, twice the global 
average of 3.8 per cent. Africa also remains a major pro-
duction and consumption region for cannabis herb and 
accounted for 14 per cent of cannabis herb seizures 
worldwide. Increased cannabis resin seizures were also 
reported by Morocco for 2015. While cannabis remains 
the primary drug of abuse in Africa, and the drug for 
which most drug users seek treatment, heroin abuse is 
also reportedly growing in some countries in the region, 
mainly in East Africa. 
359. Afghan opiates are increasingly being trafficked to 
East and West Africa, either for local consumption or 
onward shipment. The modus operandi used depends on 
various factors, such as proximity to other markets and 
the level of law enforcement capabilities in the country 
concerned. Maritime trafficking in opiates across the 
Indian Ocean through East Africa seems to be on the rise 
and is reportedly associated with an increase in container 
trade in East Africa. 
360. Increased involvement of nationals of countries in 
Africa has been reported in drug trafficking incidents 
worldwide. For example, the involvement of well- 
organized networks from West Africa has become more 
apparent in the trafficking in heroin, usually originating 
in Afghanistan, along the southern route. That route goes 
through either the Islamic Republic of Iran or Pakistan 
and across the Indian Ocean, the target markets being 
located in Africa, Asia and Europe.
361. Heroin trafficking is not limited only to East Africa. 
The southern route is gaining importance for the traffick-
ing of opiates from Afghanistan, which may have an 
adverse impact on other subregions in Africa and, in par-
ticular, on countries that lie along the route. There are 
indications that some of the heroin bound for North 
Africa is trafficked along the Balkan route, by land or by 
air. West Africa has reportedly seen an increase in the 
use of both air and sea to traffic heroin. According to 
UNODC, 11 per cent of global opiate users live in Africa, 
and more than half of them in West and Central Africa. 
362. West Africa, a subregion that has suffered from vio-
lent conflicts and political instability, has been increasingly 
affected by operations by well-organized criminal groups 
that involve not only drug trafficking from South America 
to Europe but also local consumption and manufacture of 
synthetic drugs destined mainly for markets in Asia. The 
yearly value of cocaine transiting West Africa is estimated 
to be $1.25 billion. Besides the trafficking of cocaine, 
 heroin trafficking is also occurring in the subregion. 
2. Regional cooperation
363. In November 2015, the West Africa Coast Initiative 
organized the third programme advisory committee 
meeting in Bissau. The meeting was attended by high-
level representatives of the Initiative’s implementing coun-
tries, the Economic Community of West African States 
(ECOWAS), the International Criminal Police 
Organization (INTERPOL), UNODC and other United 
Nations entities. During the meeting, future operational 
and strategic priorities for the implementation of the 
Initiative were agreed, and the need for deeper subre-
gional coordination, as well as enhanced cooperation 
between the transnational crime units established under 
the Initiative and other national law enforcement  agencies, 
was emphasized. 
364. In January 2016, INTERPOL carried out a 10-day 
operation named “Adwenpa”, in West Africa, in order to 
strengthen border controls between Abidjan, Côte 
d’Ivoire, and Lagos, Nigeria. The operation was the final 
activity undertaken under the two-year INTERPOL 
Capacity-Building Programme to Strengthen Border 
Management in West Africa. The operation, involving 
Benin, Côte d’Ivoire, Ghana, Nigeria and Togo, resulted 
in major seizures of drugs and other smuggled goods. 
Reportedly, nearly 900 kg of drugs were seized, including 
cocaine, cannabis, methamphetamine and khat.
365. The 23rd INTERPOL African Regional Conference, 
on the theme “Enhancing law enforcement cooperation 
in Africa: a regional response to organized crime”, was 
held in Brazzaville in February 2016. The Conference, 
which was attended by senior law enforcement officials 
from 34 African countries, as well as four observers from 
Asia, Europe and international organizations, focused on 
transnational crime-related issues, including drug 
 trafficking. Participants discussed strategies to combat 
evolving crime threats. 
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366. INCB organized a regional training seminar, held 
in Kenya in April 2016, for competent national authori-
ties in East Africa responsible for monitoring the licit 
international trade in controlled substances. The seminar 
was attended by participants from Burundi, the Comoros, 
Ethiopia, Kenya, Madagascar, Rwanda, Seychelles, Uganda 
and the United Republic of Tanzania, as well as observ-
ers from the African Union Commission and WHO. 
During the seminar, participants strengthened their 
knowledge of the international drug control framework, 
the technical reporting required of their Governments 
under the three international drug control conventions, 
and the availability and use of electronic tools developed 
by INCB, such as I2ES and PEN Online, both designed 
to facilitate the international trade in controlled  substances 
and prevent the diversion of such substances. 
367. Access to and availability of narcotic drugs and 
psychotropic substances for medical and scientific pur-
poses remain limited in Africa. In April 2016, INCB con-
ducted a national awareness-raising workshop for the 
authorities of Kenya. The workshop was attended by 
health-care professionals, representatives of different 
authorities and of civil society, and representatives of the 
African Union Commission, WHO, UNODC and the 
international community. Participants discussed the 
importance of ensuring adequate access to and availabil-
ity of medicines for the treatment of pain, palliative care 
and the treatment of mental health conditions. 
368. On 30 and 31 May 2016, under the auspices of 
UNODC, representatives of Mauritania, the United 
Nations Office for West Africa and the Sahel and ECOWAS 
and its member States met in Dakar to discuss the finali-
zation of a new regional programme for West Africa for 
the period 2016-2020. It was agreed that the following 
areas would be included in the programme: (a) strength-
ening criminal justice systems; (b) preventing and coun-
tering transnational organized crime and trafficking; (c) 
preventing and countering terrorism; (d) preventing and 
countering corruption; and (e) improving drug prevention 
and drug dependence treatment and care.
369. In August 2016, UNODC launched a regional pro-
gramme entitled “Promoting the rule of law and human 
security in East Africa (2016-2021)”. The regional pro-
gramme will address transnational organized crime and 
trafficking and corruption, as well as terrorism preven-
tion, crime prevention and criminal justice, prevention of 
drug abuse, treatment and care of those affected by drug 
use disorders, and HIV and AIDS prevention and care. 
370. The Twenty-sixth Meeting of Heads of National 
Drug Law Enforcement Agencies, Africa, was held in 
Addis Ababa from 19 to 23 September 2016. Discussions 
focused on the drug control situation in the region, and 
regional and subregional cooperation in countering drug 
trafficking. During a series of working groups, participants 
considered the following topics: (a) effective national and 
regional strategies in addressing drug trafficking by sea; 
(b) challenges in addressing new psychoactive substances, 
amphetamine-type stimulants and the diversion of precur-
sors and pre-precursors and the non-medical use and mis-
use of pharmaceuticals containing narcotic drugs and 
psychotropic substances; (c) best practices in promoting 
measures to ensure the availability and accessibility of 
internationally controlled drugs for medical and scientific 
purposes; and (d) practical measures tailored to the spe-
cific needs of children and youth to prevent and treat drug 
abuse among them and to address their involvement in 
drug-related crime, including cultivation and trafficking. 
INCB participated in the working group on best practices 
in promoting measures to ensure the availability and 
accessibility of internationally controlled drugs for medi-
cal and scientific purposes, giving a presentation on lev-
els of consumption of and obstacles to access to opioid 
analgesics in Africa and measures to be adopted by 
Governments in the region to address them.
3. National legislation, policy and 
action 
371. The Government of Algeria promulgated a decree, 
dated 9 July 2015, in which plants, psychotropic sub-
stances, narcotic drugs and precursors are classified into 
four schedules according to their dangerousness and 
medical use. 
372. The Parliament of Cameroon adopted Law No. 
2016/007 of 12 July 2016 relating to the Penal Code, 
amending the country’s Penal Code, which, inter alia, 
foresees criminal sanctions for various offences including 
the sale of counterfeit, expired or unauthorized medi-
cines, trafficking in narcotic drugs, driving any vehicle 
under the influence of drugs and causing harm to any 
person by furnishing medical treatment or administering 
any drug or other substance. The punishments vary 
depending on the offence committed. 
373. In June 2016, the Mauritius Revenue Authority 
launched the Stop Drug Platform, which enables the pub-
lic to provide and share relevant information on drug traf-
ficking and consumption through its website or a 
dedicated telephone number. The Platform acts as a tool 
to enlist the participation of the community to assist the 
Authority in countering drug trafficking. The information 
shared through the platform will remain confidential.
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374. On 24 and 25 June 2016, the Central Drug 
Authority of South Africa initiated consultations with 
rele vant national authorities, academia and civil society 
to develop a new national drug master plan for the period 
2017-2022. The new plan will build on the outcomes of 
the special session of the General Assembly on the world 
drug problem held in 2016 and will link the drug  control 
agenda to the Sustainable Development Goals.
375. The Food and Drug Authority of the United 
Republic of Tanzania issued a decision to cease the use 
of bulk packs (hospital packs) of 500 and 1,000 tablets or 
capsules in the private sector, with effect from 1 January 
2017. The decision reflects the challenges that were being 
faced, including inadvertent contamination of tablets or 
capsules packed in such containers owing to repeated 
opening and closure, counterfeiting of products by replac-
ing tablets and capsules, change of labels after the expiry 
date of products, and lack of patient information leaflets 
to guide patients during administration.
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs 
376. Illicit cultivation of, trafficking in and abuse of can-
nabis continue to present persistent challenges to author-
ities in Africa. While cannabis herb is produced 
throughout the continent, the illicit production of canna-
bis resin remains limited to a few countries in North 
Africa. Africa is still one of the main regions for canna-
bis herb production and consumption and accounted for 
14 per cent of the reported cannabis herb seizures 
worldwide.
377. Cannabis resin continues to be produced in North 
Africa. Following a decline in reported seizures of can-
nabis resin in Morocco during the period 2012-2014, sei-
zures in 2015 increased to some 235 tons. Seizures of 
cannabis resin declined in several other countries in the 
subregion. In the past, significant seizures of cannabis 
resin were reported by the Government of Algeria. 
However, since 2013, there has been a drop of almost 40 
per cent in the quantities of the substance seized, from 
211 tons in 2013 to 127 tons in 2015. Most cannabis resin 
seized in Algeria was reportedly seized in a province in 
the north-western part of the country, on the border with 
Morocco. It is estimated that up to 80 per cent of the sub-
stance is bound for foreign markets, while about 20 per 
cent is destined for local consumption. According to the 
authorities in Algeria, the typical wholesale price of 
cannabis resin trafficked through the country ranges from 
90,000 to 200,000 Algerian dinars per kilogram (approx-
imately $827 to $1,837),53 depending on the quality of the 
substance. The amount of cannabis resin seized in Egypt 
also declined, from 54 tons in 2014 to 33.5 tons in 2015.
378. In 2015, the authorities in Egypt resumed eradica-
tion campaigns targeting cannabis plant and opium poppy 
cultivation sites in the Sinai peninsula, eradicating 321 ha 
of cannabis plants and 225 ha of opium poppy during 
that year. In addition, the authorities seized 360 tons of 
cannabis herb in 2015. 
379. In May 2016, the authorities of Mali seized a record 
amount of 2.7 tons of cannabis herb and made several 
arrests. Reportedly, the substance was found in a vehicle 
en route from Ghana. Seizures of cannabis herb were also 
reported by Zambia (17 tons), Madagascar (8 tons), 
Mozambique (5 tons), Côte d’Ivoire (4 tons) and Mauritius 
(43 kg).
380. During an INTERPOL-led operation targeting 
criminal networks involved in trafficking in persons, 
drugs and arms across East and Southern Africa, nearly 
70 acres of cannabis plants were reportedly destroyed in 
Swaziland, 2.2 tons of cannabis were seized and 37 acres 
of cannabis plants were destroyed in Malawi, and 1 ton 
of cannabis concealed in a truck in Zimbabwe was seized.
381. There are indications that Africa is regaining 
importance as a transit region for cocaine. For years, West 
Africa has been associated with the trafficking by sea in 
cocaine from South America destined for Europe. The 
yearly value of cocaine transiting West Africa is estimated 
at $1.25 billion. However, West Africa is also increasingly 
witnessing local manufacture of synthetic drugs destined 
mainly for Asia. That trend is particularly notable in 
Guinea and Nigeria. Beyond the trafficking of cocaine, 
West Africa has reportedly seen an increase in the use of 
both air and sea to traffic heroin. Cocaine trafficking has 
also been a concern in North Africa, as evidenced by sei-
zures reported by countries in that subregion, including 
Algeria (over 88 kg) and Morocco (over 120 kg). 
382. The increase in drug trafficking through the inter-
national airport in Lagos, Nigeria, was reportedly associ-
ated with a steady growth in passenger air travel. 
According to the summary report on the Nigerian avia-
tion sector published by the National Bureau of Statistics 
of Nigeria on 1 May 2016, the total number of passen-
gers who travelled through Nigerian airports in the third 
quarter of 2015 was almost 4 million people, an 8.5 per 
53 Estimated on 8 September 2016.
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cent increase relative to the second quarter of the same 
year. More than 30 persons were arrested at Lagos air-
port between January and March 2016 for drug-related 
offences. 
383. There has also been an increased involvement by 
nationals of countries in Africa, in particular West Africa, 
in incidents related to global drug trafficking. Their 
involvement has been particularly visible in heroin 
 trafficking along the southern route. 
384. Trafficking of opiates originating in Afghanistan 
along the southern route, involving Africa as a transit or 
consumption region, is becoming more visible, with neg-
ative effects evident in the countries that lie along the 
route. Although both West and East Africa have report-
edly seen persistent use of air couriers to traffic heroin, 
trafficking in opiates through ports in East Africa, includ-
ing in Mombasa, Kenya, and Dar es Salaam, United 
Republic of Tanzania, is still the preferred method. 
Maritime trafficking is reportedly associated with the 
increase in container trade in East Africa. In 2015, author-
ities in the United Republic of Tanzania reported seizing 
a total of 50 kg of heroin. Madagascar reported seizing 
1 kg of heroin destined for Seychelles. 
385. Seizures of heroin in North Africa are limited. In 
2015, Egypt reported a decline of nearly 16 per cent in 
seizures of heroin, from 613 kg in 2014 to 516 kg in 2015. 
Authorities in Algeria and Morocco reported seizing 
moderate quantities of heroin in 2015: 2.6 kg and 4.5 kg, 
respectively.
(b) Psychotropic substances 
386. Countries in Africa have not been spared from 
illicit manufacture of and trafficking in psychotropic 
substances. 
387. Evidence is provided by the fact that illicit meth-
amphetamine laboratories continue to be dismantled in 
Nigeria. In March 2016, authorities in the country 
reported a seizure of 1.5 kg of methamphetamine and 
several chemicals, including acetic acid, acetone, benzal-
dehyde, hydrochloric acid and toluene, from one such 
site. The illicit laboratory was located in an abandoned 
factory in an industrial area of the Delta State of Nigeria, 
pointing towards a shift in the location of clandestine lab-
oratories from in and around Lagos to more remote areas. 
Additionally, 266 kg of methamphetamine, bound for 
South Africa, were seized by authorities at the seaport in 
Lagos. 
(c) Precursors
388. The collection, submission and analysis of 
precursors- related data by the national authorities remain 
serious challenges in many countries in Africa. Information 
on seizures of substances listed in Tables I and II of the 
1988 Convention and seizures of internationally non-
scheduled substances, as well as information on methods 
of diversion and illicit manufacture, stopped shipments 
and thefts involving those substances, which should be 
provided annually by Governments to the Board, remain 
limited and insufficient owing to a poor response rate. 
389. Fourteen countries in Africa have registered with 
PICS. According to information provided through the 
system, the following countries in Africa have been iden-
tified as having been involved in incidents reported 
between November 2015 and November 2016: Cameroon, 
Ethiopia, Kenya, Mozambique, Namibia, Nigeria, South 
Africa, United Republic of Tanzania and Zambia. Those 
incidents indicate that Africa continues to be affected by 
the diversion of precursor chemicals, notably ephedrine 
and pseudoephedrine, used in the illicit manufacture of 
amphetamine-type stimulants. Most of those incidents 
involved seizures of ephedrine (totalling over 400 kg) 
reported by Nigeria and destined to South Africa. The 
majority of the seizures reported took place at the airport 
in Lagos or at a seaport; in some cases, methampheta-
mine (totalling over 350 kg) was also found together with 
ephedrine, using the same modus operandi. In South 
Africa, over 300 kg of ephedrine were reported to have 
been seized at different locations, including at an airport, 
a land border and a seaport. In 2015, Côte d’Ivoire seized 
over 277 kg of ephedrine. 
390. Recent seizures outside Africa point to the grow-
ing significance of East Africa as a transit area for pre-
cursor chemicals. For example, in January 2016, authorities 
in Pakistan seized 21.7 tons of a misdeclared shipment of 
acetic anhydride, a Table I precursor used in the illicit 
manufacture of heroin. The investigation confirmed that 
the substance had transited the United Republic of 
Tanzania en route to Pakistan. Attempts to use East 
Africa, predominantly the United Republic of Tanzania, 
as a diversion point for heroin and amphetamine-type 
stimulant precursors were also reported in 2016.
391. Only Algeria, Benin, Côte d’Ivoire, Egypt, Ethiopia, 
Ghana, Kenya, Libya, Madagascar, Nigeria, South Africa, 
the Sudan, Togo, Uganda, the United Republic of Tanzania 
and Zimbabwe have invoked article 12, paragraph 10 (a), 
of the 1988 Convention, to be informed of chemical ship-
ments prior to their departure from the exporting coun-
try. Shipments to other countries in the region that have 
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not yet invoked article 12, paragraph 10 (a), are therefore 
at risk of being diverted into illicit channels. 
392. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the 2016 report of the Board on the implementation 
of article 12 of the 1988 Convention.54 
(d) Substances not under international 
control
393. Information about the emergence of new psycho-
active substances, the extent of their use and seizures of 
them in Africa remains limited, in particular with regard 
to synthetic new psychoactive substances, making it dif-
ficult to assess their impact in the region. During the 
reporting period, only one incident in Africa was reported 
through the INCB Project Ion Incident Communication 
System (IONICS), a secure online platform for enhanced 
communication of information on new psychoactive sub-
stances. That incident involved a shipment of 5 kg of khat 
(Catha edulis), a plant-based substance with psychoactive 
properties, that originated in South Africa, transited 
through Singapore and was destined for Hong Kong, 
China. 
394. In 2015, Mauritius reported the first emergence of 
new psychoactive substances and identified 11 kinds of 
synthetic cannabinoids. They included 1-naphtalenyl - 
(1-pentyl-1H-indazol-3-yl)-methanone, 5F-AKB48, 
5F-PB-22, AB-FUBINACA, APINACA, FUB-PB-22, 
JWH-073, JWH-210, MAM-2201, MDMB-CHMICA and 
QUCHIC.
395. The abuse of tramadol, a synthetic opioid analge-
sic that is not subject to international control, continues 
to be a matter of concern for countries in Africa, in par-
ticular in North and West Africa. However, seizures of 
tramadol in Egypt continued to decline, from 145 mil-
lion tablets in 2014 to 90 million tablets in 2015, follow-
ing the bringing of tramadol under national control in 
2013. In 2015, the Control Unit at the port of Cotonu, 
Benin, seized over 40 million pills of counterfeit trama-
dol. Increased misuse of tramadol was reportedly observed 
in the Sahel region and seems to have increased in Libya, 
which is considered a major source of tramadol trafficked 
to Egypt.
54 E/INCB/2016/4.
5. Abuse and treatment
396. Owing to a paucity of detailed and reliable infor-
mation related to abuse and treatment provided from the 
region, assessing the extent of drug abuse and accurately 
estimating the number of people in treatment in Africa 
remain challenging. 
397. According to the information available, cannabis 
remains the primary drug for which drug users seek treat-
ment. This could, however, be a result of limited treat-
ment options for users of other drugs in many parts of 
Africa. The estimated annual prevalence rate of cannabis 
use in Africa is 7.6 per cent, twice the global average 
(3.8  per cent), with the estimated number of cannabis 
users in the continent as follows: 6.6 million in East 
Africa, 5.7 million in North Africa, 4.6 million in 
Southern Africa and over 30 million in West and Central 
Africa. The estimated annual prevalence rate of cannabis 
use in those subregions is 4.2 per cent, 4.4 per cent, 
5.1 per cent and 12.4 per cent, respectively.
398. Although the information on cocaine abuse in 
Africa is very limited, the annual prevalence of cocaine 
use in Africa, based on data provided by very few African 
countries, is estimated at 0.4 per cent, comparable with 
the global estimate of 0.38 per cent. 
399. Data on the annual prevalence of opiate use in Africa 
are, for many countries, more than 10 years old. According 
to the latest available information, however, the annual 
prevalence rate of opiate use in Africa was estimated at 0.31 
per cent (almost 2 million users), which is comparable with 
the global estimate of 0.37 per cent. Within Africa, the esti-
mates range from 0.15 per cent in East Africa, 0.25 per cent 
in North Africa and 0.34 per cent in Southern Africa to 
0.43 per cent in West and Central Africa. Nonetheless, the 
abuse of opiates continues to be a significant problem in 
some countries, such as Kenya, Mauritius, Nigeria, Seychelles 
and South Africa. Owing to increased heroin trafficking to 
and through the region, as evidenced by large maritime sei-
zures of the substance near its coastal areas, increases in the 
use of heroin and in drug abuse by injection have been 
reported in Kenya, Mauritius, Seychelles and the United 
Republic of Tanzania. 
400. According to the 2016 edition of the Guidelines on 
Use of Antiretroviral Drugs for Treating and Preventing 
HIV Infection in Kenya, published by the Ministry of 
Health of Kenya, the prevalence of HIV among people 
who inject drugs is up to four times that among the gen-
eral population. People who inject drugs reportedly have 
limited access to HIV prevention, care and treatment 
 services in the country. 
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401. In Senegal, the Centre for the Integrated 
Management of Addiction in Dakar has estimated the 
number of intravenous drug users in the greater Dakar 
area at just over 1,300, representing approximately 12 per 
cent of all drug users in the city. The Centre remains the 
only drug treatment centre in West Africa providing inte-
grated outreach, health care, treatment, rehabilitation, 
vocational training and social reintegration services to 
individuals suffering from drug abuse and addiction. The 
centre offers methadone substitution treatment as well as 
outpatient medical care, and dispatches mobile teams to 
establish contact with drug users and provide them with 
kits containing sterile syringes, condoms and basic medi-
cal supplies to prevent the transmission of blood-borne 
diseases such as HIV/AIDS and hepatitis C.
402. According to the Mauritius Revenue Authority, 
cannabis, heroin, sedatives, tranquillizers and buprenor-
phine are the types of drugs that are mostly abused in 
the country. In addition, synthetic cannabinoids were 
reported as being the preferred drug of choice. For exam-
ple, according to Health Statistics Report: 2015, published 
by the Health Statistics Unit of the Ministry of Health 
and Quality of Life of Mauritius, 177 persons were treated 
at the Brown Sequard Psychiatric Hospital in 2015 for 
mental and behavioural disorders as a result of multiple 
drug use and use of psychoactive substances, and 17 per-
sons were treated for mental and behavioural disorders 
that resulted from use of opioids or cannabinoids.
403. The Government of Mozambique reported an 
increase in the number of prevention programmes that 
were aimed in particular at young people and prison 
inmates. In 2015, health units in Mozambique reportedly 
assisted a total of 7,038 patients with psychiatric disor-
ders related to drug use. Fifty per cent of those cases were 
in Maputo. Mozambique has observed that most drug 
users report consuming multiple substances and Cannabis 
sativa, while only a small percentage report using cocaine 
or heroin. Those reported to be most affected by drug use 
are aged between 26 and 30 years; that group accounts 
for 23 per cent of the total number of drug users. Ten 
per cent of registered drug users are under 20 years old.
404. As part of the implementation of its National Drug 
Strategy and Plan of Action, Algeria opened 39 treatment 
centres (out of the 53 planned) to provide drug treatment 
and rehabilitation facilities across the country. 
405. In 2015, the General Secretariat of Mental Health 
and Addiction Treatment of the Ministry of Health of 
Egypt, in cooperation with UNODC, conducted an opi-
oid substitution therapy feasibility study. According to the 
study, about 100,000 people in the country were 
dependent on opioids. It was estimated that, of those, 
about 50 per cent were dependent on tramadol and the 
other half on heroin. The study estimated that 50,000 peo-
ple were in need of opioid substitution therapy in Egypt. 
The feasibility study also focused on criteria for selecting 
opioid substitution therapy pilot sites and the substance 
to be used (methadone or buprenorphine/buprenorphine- 
naloxone). The study recommended that opioid substitu-
tion therapy be piloted in two hospitals in Cairo, with the 
target of 200 persons treated under the pilot 
programme. 
B. Americas
Central America and the Caribbean
1. Major developments
406. The region of Central America and the Caribbean 
continues to be a major trans-shipment area for illicit 
drugs trafficked from the producing countries in the 
Andean region, notably Colombia, to final destination 
markets in the United States and, to a lesser extent, 
Canada and Europe. A total of 153 countries reported 
cocaine seizures between 2009 and 2014, and most of the 
illicit movement of cocaine was from South America to 
North America and Europe. In Central America and the 
Caribbean, the cocaine market has recently shifted to 
areas that had not previously been affected by drug abuse 
or trafficking.
407. The United States reported that, in 2014, 87 per 
cent of the cocaine entering the country had been traf-
ficked through Central America and Mexico, and about 
13 per cent through the Caribbean, primarily via the 
Dominican Republic and Puerto Rico. The Dominican 
Republic and Costa Rica were the countries most fre-
quently identified by European countries as the origin of 
cocaine shipments destined for Europe.
408. Cocaine trafficking is reported to have had an envi-
ronmental impact and has been linked to deforestation 
in Central America, specifically in Guatemala, Honduras 
and Nicaragua.55 Deforestation is reported to have inten-
sified in areas affected by drug trafficking, mainly through 
the building of clandestine roads and landing strips; the 
use of bribes, property fraud or force to pressure 
55 Kendra McSweeney and others, “Drug policy as conservation pol-
icy: narco-deforestation”, Science, vol. 343, No. 6170 (2014), pp. 489-490.
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indigenous peoples and other rural inhabitants to leave 
their land; and the acquisition of public land to establish 
agricultural estates associated with drug trafficking (so-
called “narco-estates”). The latter activity involves illegally 
acquiring areas of forest in remote areas and converting 
them to agricultural land, thereby allowing criminal 
groups to gain control of territory in border regions and 
providing an activity that allows money to be 
laundered. 
409. The extent of the increase in criminal activities 
related to drug trafficking in Central American countries 
was confirmed by the release of the so-called “Panama 
papers”. The revelations contained in those leaked finan-
cial documents led to various operations, including the 
discovery, in an operation conducted by the Colombian 
National Police and the Drug Enforcement Administration 
of the United States in May 2016, of an international 
criminal ring laundering the proceeds of drug trafficking. 
Such operations have brought to light the international 
networks existing in Central America and the Caribbean 
and the actual methods used to launder the proceeds of 
criminal activities, particularly drug trafficking. According 
to the Drug Enforcement Administration, the network 
detected in the above-mentioned operation had adopted 
money-laundering practices such as bulk cash smuggling 
and false commercial invoicing to launder the proceeds 
of drug trafficking.
410. Data published by UNODC in 2016 indicate that 
rates of intentional homicide continue to be consistently 
high in Central America and the Caribbean, although 
homicide rates have decreased in Central America over 
the past few years. In some countries in the region, some 
of those homicides continue to be associated with drug-
related criminal activities. According to national data, in 
Honduras, the decreasing trend in the homicide rate con-
tinued in 2015, with about 57 homicides per 100,000 
inhabitants, compared with about 68 homicides in 2014, 
while in El Salvador, a decreasing trend has been reversed 
since 2013, when it reached a low of about 39 homicides 
per 100,000 inhabitants, increasing to 103 homicides per 
100,000 in 2015. The increase may be explained by the 
end of the truce among the youth gangs known as “maras”.
2. Regional cooperation
411. In June 2016, the Regional Commission on 
Marijuana established by the secretariat of the Caribbean 
Community (CARICOM) held, in Saint Vincent and the 
Grenadines, its first regional consultation on cannabis to 
explore the implications of the legalization of the use of 
cannabis in the region. The Commission, which operates 
under the leadership of the CARICOM Assistant 
Secretary-General of the Directorate for Human and 
Social Development, is mandated to analyse the eco-
nomic, health and legal aspects related to the use of can-
nabis in the region, to determine whether there should 
be a change in the classification of cannabis to make it 
more accessible for all types of usage, be it medical or 
non-medical. In that context, the Board notes that the 
1961 Convention limits the use of cannabis to medical 
and scientific purposes, as a fundamental principle that 
lies at the heart of the international drug control legal 
framework and that cannot be derogated from. All par-
ties to the Convention have the obligation to carry out 
the provisions of the Convention within their own ter-
ritory. The Board encourages States to adopt non- 
punitive responses for minor drug-related offences 
committed by drug users, instead of arrest and 
 incarceration, as an alternative provided by the inter-
national drug control conventions.
412. The Regional Security System, a regional organiza-
tion for the defence and security of the Eastern Caribbean 
area, continues to play a significant role in countering 
drug trafficking in the subregion. In October 2015, the 
first drug prosecutor’s course, for police prosecutors, 
was  held at the headquarters of the Regional Security 
System, in Barbados. The course was delivered by experts 
from Dominica, with participants from Antigua and 
Barbuda, Barbados, Grenada, Saint Kitts and Nevis, and 
Saint Vincent and the Grenadines. In June 2016, the 
Regional Security System’s new Fusion Centre was opened 
in Barbados. The Centre, funded by the Government 
of  the United Kingdom, hosts regional and inter-
national law enforcement experts for information-sharing 
and  the  exchange of experiences in the area of 
counter-narcotics.
413. The Training and Certification Programme for 
Prevention, Treatment and Rehabilitation of Drug Abuse 
and Violence of the Organization of American States 
(OAS) continues to provide training for drug prevention 
and treatment service providers in Central America and 
the Caribbean. Among other training activities, the 
Programme supported the certification of 47 Belizeans in 
April 2016, in cooperation with the Belize National Drug 
Abuse Control Council and the University of the West 
Indies.
414. The Governments of Central America and the 
Caribbean, in cooperation with UNODC, continued to 
undertake initiatives to counter organized crime and drug 
trafficking and to promote effective drug demand reduc-
tion actions. Such initiatives include the Container 
Control Programme, the Airport Communication Project, 
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the Central American Network of Prosecutors against 
Organized Crime, and the drug demand reduction- 
oriented Strengthening Families Programme.
3. National legislation, policy and 
action
415. Following the amendment of the Dangerous Drugs 
Act in 2015,56 Jamaica issued interim regulations for the 
Cannabis Licensing Authority in May 2016. The regula-
tions include provisions on applications and requirements 
for licences for the cultivation, processing, transporting 
and retail sale of cannabis, as well as licences for research 
and development. The Board notes that the recent regu-
latory developments in Jamaica are not in accordance 
with the 1961 Convention, which limits the use of 
 cannabis to medical and scientific purposes.
416. Barbados has approved a new national anti-drug 
plan for the period 2015-2020, developed by the National 
Council on Substance Abuse. The plan will coordinate all 
drug-related strategies of the stakeholders in the country, 
such as governmental, corporate and non-governmental 
actors. The Government will prioritize the improvement 
of the legislative framework in five strategic areas: demand 
reduction, supply reduction, control measures, strength-
ening of institutions and international cooperation.
417. In 2015, Dominica established a fully vetted 
counter- narcotic unit known as the “Strike Force”, which 
is expected to become fully operational in 2016, pending 
specialized training and the receipt of specialized 
equipment.
418. The Government of El Salvador launched the “El 
Salvador seguro” initiative in 2015. The comprehensive 
initiative comprises five pillars of action and 124 specific 
actions to address violence and crime, including drug 
trafficking, and to ensure access to justice and the provi-
sion of assistance and protection to victims. The initia-
tive is implemented by the Executive, the National 
Assembly, the judiciary, the Office of the Attorney-
General and other local government bodies, with the sup-
port of religious communities, the private sector, civil 
society and the international community. Implementation 
of the initiative is overseen and monitored by the National 
Council for Citizen Security and Coexistence.
419. In May 2016, Panama enacted Act No. 14 on the 
use of controlled substances, specifically narcotic drugs 
and psychotropic substances scheduled under the 1961 
56 See E/INCB/2015/1, paras. 141-143.
Convention and the 1971 Convention, for medical and 
scientific purposes. Under its chapter III, the Act creates 
the Department of Controlled Substances under the 
National Directorate of Pharmaceutical Products and 
Drugs. The Department will be in charge of approving 
licences for the handling of controlled substances, among 
other functions. The Act establishes the conditions and 
requirements for the issuance of licences to pharma-
ceutical establishments, as well as the prohibitions and 
sanctions related to failure to implement its provisions.
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
420. For several years, Panama has had the largest vol-
umes of seizures of cocaine in Central America and the 
Caribbean. Seizures of cocaine in Panama in 2015 
increased by about 32 per cent compared with 2014, and 
were 14 per cent higher than in 2013, reversing the 14 per 
cent decrease that occurred from 2013 to 2014. The recent 
increase may be related to the significant increase in the 
illicit cultivation of coca bush observed in Colombia in 
2015.
421. A 2015 study of the situation of women deprived 
of their liberty in Panama found that 65 per cent of the 
female prison population had been convicted of drug-
related offences,57 and that 22 per cent of them were 
 foreign nationals.
422. Cocaine is trafficked into the Caribbean from 
Colombia, transiting through Guyana, Trinidad and 
Tobago and Venezuela (Bolivarian Republic of), among 
other countries. The shipments are transported north-
wards through the islands by travellers and couriers or 
using small fishing boats, cruise ships and sailing vessels, 
among other means, and may involve the clandestine 
transfer from one ship to another at sea or the use of 
commercial airlines and freight shipping containers.
423. Even with the limited resources available to con-
tain the trafficking of cocaine, the Eastern Caribbean 
islands have a relatively high interdiction rate. However, 
trafficking persists despite such efforts, as the subregion 
struggles with low conviction rates and weak criminal 
 justice institutions.
57 UNODC, “Diagnóstico de la situación de las mujeres privadas de 
libertad en Panamá: desde un enfoque de género y derechos”. Available 
from www.unodc.org.
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424. UNODC reported that the Caribbean accounted 
for 13 per cent of global seizures of cannabis herb in 2014, 
and that that amount has been on the increase, with 
Jamaica being an important source country for cannabis 
entering the international trafficking chain. Trafficking in 
firearms, largely between Jamaica and Haiti, is also linked 
to drug trafficking. According to official estimates, 15,000 
ha were under cannabis plant cultivation in Jamaica in 
2015. The use of herbicides is prohibited by law; eradica-
tion must therefore be conducted manually. In 2015, a 
total of 725 ha of cannabis plants were eradicated.
425. According to the Organised Crime, Narcotics and 
Firearms Bureau of Trinidad and Tobago, a shift in the 
demand for cannabis herb has been observed, resulting 
in a lower demand for cannabis herb produced locally or 
on other Caribbean islands and an increased demand for 
South American cannabis herb. Seizures of cannabis herb 
in the country in 2015 were 62.5 per cent lower than in 
2013.
426. With regard to the proceeds of drug-related crimi-
nal activity in the region, the Board has noted the efforts 
of the Caribbean Financial Action Task Force, which, in 
June 2016, issued a publication entitled Anti-Money-
Laundering and Counter-Terrorist Financing: Trinidad and 
Tobago — Mutual Evaluation Report. The publication iden-
tified money-laundering connected to drug trafficking as a 
high threat area and highlighted it as a priority for action. 
427. Seizures of cannabis in Panama have been increas-
ing since 2013, while seizures of heroin in the country 
have been decreasing over the same period. In Costa Rica, 
seizures of cannabis herb increased considerably from 
2011 to 2014 (by about 660 per cent, reaching 12 tons in 
2014). In 2015, seizures decreased to 6.4 tons. 
428. Guatemala is the only country in the region to 
report illicit cultivation of opium poppy. The net area 
under poppy cultivation after eradication was estimated 
to have increased from 220 ha in 2012 to 310 ha in 2013 
and 640 ha in 2014, according to estimates by the United 
States State Department as cited by UNODC, and the 
global potential production of oven-dry opium in that 
country was estimated to be 4 tons in 2012, 6 tons in 
2013 and 14 tons in 2014. At the same time, the area of 
eradicated opium poppy decreased by 53 per cent in 2014, 
falling from 2,568 ha in 2013 to 1,197 ha in 2014. Seizures 
of heroin in Guatemala decreased by 38 per cent from 
2014 to 2015, from around 134 kg to around 83 kg. That 
decline in seizures occurred in parallel with the reported 
decline in the area under cultivation and in opium pro-
duction that took place in 2015, a reversal of the increases 
of the preceding years. According to preliminary 
estimates, that decrease was linked to (a) increased opium 
production in Mexico, (b) a disruption of the main opi-
ate trafficking networks operating in Guatemala, and (c) 
sharply falling opium prices within Guatemala (a 77 per 
cent decrease), which led farmers to turn to corn, 
 potatoes  and other licit crops in 2015.
(b) Psychotropic substances
429. Guatemala is the only country in Central America 
and the Caribbean to report dismantling clandestine lab-
oratories manufacturing amphetamine-type stimulants in 
recent years (eight laboratories in 2013, and nine labora-
tories in 2014, of which four manufactured amphetamine 
and five manufactured methamphetamine). While the 
region is thus relatively less affected by the manufacture 
and trafficking of amphetamine-type stimulants, in the 
past five years some countries have regularly reported sei-
zures of “ecstasy”-type substances, as well as lysergic acid 
diethylamide (LSD). 
430. In Costa Rica, the price of a tablet of 3,4-methyl-
enedioxymethamphetamine (MDMA, commonly known 
as “ecstasy”) sold on the streets remained stable from 
2010 to 2015, varying between $20 and $30, while the 
amounts seized have fluctuated considerably. That fluctu-
ation is due to single seizures of relatively large quanti-
ties that occurred in specific years (12,342 “doses” in 2013 
and 19,183 “doses” in 2011).
(c) Precursors
431. The Costa Rican Drug Institute’s special unit for 
controlling and regulating chemical precursors monitors 
and responds to related illegal activities. By law, import-
ers and businesses dealing with chemical precursors are 
to register in an online tracking system through which 
they have to submit monthly reports. The system moni-
tors the movement of chemical precursors and issues 
alerts to relevant authorities about specific cases that 
require further investigation. As at August 2015, approx-
imately 3,000 businesses, including 150 importers of 
chemical precursors, were registered in the system and 
were submitting regular reports. 
432. The manufacture of amphetamine-type stimulants 
continues to pose a serious challenge for Guatemala, as 
evidenced by the amount of chemical precursors seized. 
In 2015, the UNODC-World Customs Organization 
Global Container Control Programme reported the sei-
zure of 25 tons of chemical precursors in maritime ports 
in the country.
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433. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the report of the Board for 2016 on the implementa-
tion of article 12 of the 1988 Convention.
(d) Substances not under international 
control
434. The use of new psychoactive substances continues 
to be reported by countries in the Central America and 
the Caribbean region. The use of those substances may 
have serious health consequences, as their effects on the 
human body are not fully understood or known. In addi-
tion, the trafficking of those substances creates additional 
challenges for regulatory and law enforcement authorities. 
During the reporting period, no incident was reported by 
countries in Central America and the Caribbean through 
the Board’s Project Ion or its incident communication tool 
(IONICS). In that connection, the Board encourages 
countries that have not yet done so to join Project Ion and 
to register with and actively use IONICS. 
5. Abuse and treatment
435. UNODC reported in 2016 that the annual preva-
lence of use of cannabis was 2.9 per cent in Central 
America and 2.5 per cent in the Caribbean. Those rates 
are below the average in North America (12.1 per cent), 
South America (3.2 per cent) and Western and Central 
Europe (6.7 per cent). A similar pattern is observed with 
the prevalence of the use of cocaine, as both Central 
America and the Caribbean have an annual prevalence 
rate of 0.6 per cent, which is relatively low compared with 
North America (1.6 per cent) and South America (1.5 per 
cent). These are interesting patterns because countries in 
Central America and the Caribbean are confronted with 
considerable volumes of cannabis and cocaine that are 
trafficked through their territories, and, in the case of 
cannabis, being produced in the region. Thus, more com-
prehensive national household drug use surveys might be 
needed to ascertain reliable estimates of the prevalence 
rate of cannabis use in the Caribbean region.
436. According to the Report on Drug Use in the 
Americas 2015 published by the Inter-American Drug 
Abuse Control Commission (CICAD) of OAS, Belize is 
the country in Central America reporting the highest 
annual prevalence rate of cannabis herb use (15.8 per 
cent) among secondary school students. Honduras is the 
country reporting the lowest such rate (about 1 per cent), 
which may be due to the fact that the figures being 
reported are based on a 2005 survey. The same CICAD 
report states that Belize also reports the highest annual 
prevalence rate of inhalant use among secondary school 
students in Central America (5.5 per cent), and that the 
Caribbean subregion has particularly high rates of inhal-
ant use for the same group, with annual prevalence rates 
of over 8 per cent in Barbados, Grenada, Saint Kitts and 
Nevis, Saint Vincent and the Grenadines and Saint Lucia.
437. Cannabis was the primary drug of abuse for peo-
ple receiving drug treatment in El Salvador in 2015, fol-
lowed by tranquillizers and sedatives and then by cocaine. 
Authorities report that this is part of a recent trend of an 
increasing number of persons in treatment for abuse of 
cannabis, and a decreasing trend in the number of  persons 
in treatment for the abuse of cocaine.
438. According to the 2016 document A Report on 
Students’ Drug Use in 13 Caribbean Countries published 
by CICAD/OAS, cannabis herb continues to be the most 
widely used drug reported by students enrolled in sec-
ond, fourth and sixth forms in secondary school (corre-
sponding approximately to ages 13, 15 and 17 years), 
while alcohol is the main overall substance of abuse. 
Students also reported a very high perception of availa-
bility of cannabis herb (between 4 and 5 of every 10 stu-
dents), meaning that they can easily access the drug in 
their countries.
439. Trinidad and Tobago reported an increase in the 
number of persons receiving drug treatment for cocaine 
abuse, while the number of persons receiving drug treat-
ment for cannabis abuse has remained stable.
440. The annual prevalence of the use of opioids (opi-
ates and prescription opiates) in Central America and the 
Caribbean is 0.2 per cent and 0.4 per cent, respectively, 
and 0.07 per cent and 0.28 per cent, respectively, for use 
of opiates only, as reported by UNODC in 2016. Those 
rates are all below the regional average for the Americas 
and are also below global averages. 
441. The CICAD/OAS Report on Drug Use in the 
Americas 2015 shows a trend of an increased number of 
countries in the Americas reporting the existence of her-
oin users. The Dominican Republic has reported the pres-
ence of heroin users in its treatment centres, as well as 
heroin use by individuals belonging to “marginal 
populations”.
442. The annual prevalence of the use of amphetamines 
and prescription stimulants in Central America and the 
Caribbean is 0.9 per cent and 0.8 per cent, respectively, 
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which is close to the global averages. The annual preva-
lence of the use of “ecstasy” in Central America and the 
Caribbean is 0.11 per cent and 0.19 per cent, 
respectively.
443. The Report on Drug Use in the Americas 2015 states 
that lifetime prevalence of use of MDMA (“ecstasy”) 
among eighth grade students is 2.8 per cent in Panama, 
2.7 per cent in Antigua and Barbuda, and 2.5 per cent in 
Saint Lucia. Panama reported past-year prevalence among 
secondary school students of about 1 per cent, while 
Costa Rica reported 0.4 per cent. In Panama, unlike most 
other countries in the region, the past-year prevalence 
rates for males and females are similar, with the rate for 
females being slightly higher.
444. The Board recommends that countries in the 
region that have not done so should produce or update 
prevalence studies according to internationally recog-
nized parameters and use the results to inform the devel-
opment and adoption of targeted drug demand reduction 
policies and programmes.
North America
1. Major developments
445. In April 2016, Pennsylvania became the twenty-
fourth state in the United States to legislate to permit and 
regulate, at the state level, cannabis use for medical pur-
poses; it was followed by Ohio in June 2016. On 8 
November 2016, the states of Arkansas, Florida and 
North Dakota voted in favour of authorizing the use of 
cannabis for medical purposes. In addition, voters in the 
states of California, Maine, Massachusetts and Nevada 
approved ballot measures that would legalize and  regulate 
the use of cannabis for non-medical purposes.
446. Prescription opioid and heroin abuse continues to 
be a matter of great concern in the United States. 
According to the National Institute on Drug Abuse, in 
2014, over 47,000 drug overdose deaths occurred in the 
country, among which there were more than 18,000 
deaths from prescription opioid pain reliever overdose 
and over 10,000 deaths from heroin-related overdose. The 
Institute noted that the 2014 data demonstrated that the 
opioid overdose epidemic reflected both a 15-year 
increase in overdose deaths involving prescription opioid 
pain relievers and a recent surge in illicit opioid overdose 
deaths, driven largely by heroin overdose. 
447. A number of legislative, policy and law enforce-
ment actions have been taken by the Government of 
Canada and by provincial governments to tackle the rise 
in overdoses and the increased presence of fentanyl-
laced drugs, including raising awareness, working with 
prescribers and providers to give them appropriate tools 
and addressing issues of access to opioids and 
treatment. 
448. Following its election in October 2015, the 
Government of Canada confirmed its intention to legal-
ize and regulate the use of cannabis for non-medical pur-
poses through new legislation to be introduced in early 
2017. For that purpose, a nine-member Task Force on 
Marijuana Legalization and Regulation was established, 
and the Task Force was to present its final report, con-
taining advice on the design of a new legislative and reg-
ulatory framework, to the Cabinet in November 2016. 
Cannabis continues to be a schedule II drug under the 
Canadian Controlled Drugs and Substances Act; there-
fore, the growing, possessing, distributing and selling of 
cannabis remain illegal.
2. Regional cooperation
449. Regional cooperation between the three countries 
in the North American region remained extensive and is 
generally considered effective. At a high-level political 
summit held in Ottawa in June 2016, the three States, 
inter alia, sought to strengthen actions against the rising 
death toll from opioids such as heroin and fentanyl and 
violence associated with opium poppy cultivation and 
trafficking in Mexico. At the operational level, coopera-
tion among those States includes joint law enforcement 
operations, intelligence-sharing and border control 
 initiatives, including land and maritime activities. 
3. National legislation, policy and 
action
450. In response to the ongoing crisis of opioid abuse, 
dependence and overdose in the United States, the Food 
and Drug Administration released the Opioids Action 
Plan in February 2016. The plan includes expanding the 
use of advisory committees, strengthening requirements 
for drug companies to generate post-market data on the 
long-term impact of using opioids, updating risk evalua-
tion and mitigation strategy programmes, and expanding 
access to abuse-deterrent formulations to discourage 
abuse. As part of the action plan, class-wide safety label-
ling changes for immediate-release opioid pain medica-
tions have been announced. The labels will need to 
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include information on the serious risks of misuse, 
 addiction, overdose and death. 
451. The President of the United States requested $27.6 
billion for the fiscal year 2016 to support efforts under 
the 2015 National Drug Control Strategy to reduce drug 
use and its effects in the country. Most of that amount 
was allocated to prevention and treatment efforts. In 
March 2016, the President requested from Congress an 
additional $1.1 billion to bolster efforts to address the 
prescription opioid and heroin crisis in the country. The 
announced actions represent further steps to expand 
access to treatment, prevent opioid overdose deaths, 
invest in community policing to address heroin abuse, 
and increase community prevention strategies. 
452. Opioid overdose and heroin-related deaths have 
been the focus of state of the state addresses in a num-
ber of states of the United States, including Maine, 
Massachusetts, New Hampshire and Vermont, in which 
state Governors called for the strengthening of efforts to 
address illicit drug use and limit opioid prescriptions. As 
at March 2016, 49 states had established prescription drug 
monitoring programmes and 14 states had enacted legis-
lation requiring physicians to receive training on the 
proper prescription of opioids. 
453. On 22 July 2016, the Comprehensive Addiction 
and Recovery Act came into force. The Act addresses the 
opioid crisis by, inter alia, authorizing the United States 
Department of Justice to award grants to state, local and 
tribal governments to provide opioid abuse services, 
directs the Department of Veteran Affairs to expand its 
opioid safety initiative, focuses on helping communities 
develop treatment and overdose programmes and 
addresses exemptions from criminal and civil liability for 
those administering an opioid overdose reversal drug or 
who contact emergency services in response to an 
overdose. 
454. Mexico reported that, in 2015, nearly 13,500 per-
sons had been brought into formal contact with the police 
and/or the criminal justice system in connection with 
drug-related offences. Mexico continues its transition 
from the traditional inquisitorial criminal justice system 
to an accusatorial system. The changes to the Mexican 
criminal justice system are expected to increase transpar-
ency, strengthen efforts to protect human rights and civil 
liberties and reduce corruption in criminal cases. 
455. One of the main challenges in Canada has been 
the rise of drug overdoses, partly owing to the increased 
presence of fentanyl. In response, the British Columbia 
provincial health officer declared a public health 
emergency in the province in April 2016. That was the 
first time that the provincial health officer had served 
notice under the Public Health Act to exercise emergency 
powers, and British Columbia became the first province 
to take that kind of action in response to drug overdoses. 
The declaring of a public health emergency allows for 
improved collection and analysis of information and data 
about overdoses to facilitate the formulation of  appropriate 
responses and target prevention activities. 
456. Illicitly produced fentanyl is also present across the 
United States. In March 2015, the United States Drug 
Enforcement Administration issued a nationwide alert on 
fentanyl as a threat to health and public safety, and, in 
June 2016, it issued an alert to all law enforcement agen-
cies nationwide, warning of the safety precautions to be 
taken when handling fentanyl and the possibly fatal 
 consequences of undertaking field testing improperly. 
457. In March 2016, the Government of Canada revised 
the listing for naloxone on the Prescription Drug List to 
allow for emergency use for cases of opioid overdose out-
side hospital settings, thus enabling provincial govern-
ments to allow the drug to be dispensed without a 
prescription. Naloxone was subsequently reclassified as a 
schedule II drug in British Columbia, Alberta and 
Ontario, making it available without a prescription. The 
college of pharmacists of the three provinces issued guid-
ance for pharmacy professionals on dispensing or selling 
naloxone take-home kits. Other provinces, including 
Manitoba, Nova Scotia, Quebec and Saskatchewan have 
established take-home naloxone programmes permitting 
health-care providers to dispense naloxone, and encour-
aged accessibility to and use of naloxone by first respond-
ers, including paramedics, firefighters, law enforcement 
officers and others. Following those developments, mat-
ters related to appropriate training, the role of pharma-
cies and of first responders, the formulation of naloxone 
for use in kits and the payment for and coverage by insur-
ance of naloxone started to be addressed across the 
country. 
458. While naloxone is a drug administered by injec-
tion, in July 2016, as an emergency public health meas-
ure in response to the opioid crisis, the Minister of Health 
of Canada signed an interim order authorizing the sale 
of Narcan, a naloxone nasal spray, in Canada for use in 
the emergency treatment of known or suspected opioid 
overdoses. The nasal spray should be available without a 
prescription. 
459. In the United States, the Drug Enforcement 
Administration approved Narcan nasal spray (the first 
nasal spray version of naloxone hydrochloride approved 
60  INCB REPORT 2016
by the Administration) in November 2015. In response, 
the National Institute on Drug Abuse dedicated a section 
of its website to resources about this opioid overdose 
reversal drug, including information about dosage, pre-
cautions, side effects and links to pharmacies that offer 
it. The Administration has also been reviewing options, 
including making naloxone available over the counter, to 
make the drug more accessible for treating opioid over-
dose in the country. As at May 2016, 39 states allow pre-
scribers to dispense a naloxone prescription to third 
parties, such as a family member of drug users. 
460. The Canadian Agency for Drugs and Technologies 
in Health has been requested to conduct a comparison of 
the safety and effectiveness of methadone and buprenor-
phine (i.e., Suboxone), in order to enhance opioid depend-
ency treatment options. In order to prescribe methadone 
for the treatment of opioid dependence, physicians must 
be exempted under section 56 of the Controlled Drugs 
and Substances Act. However, a number of provinces have 
been exploring options to allow the prescription of 
Suboxone without being required to hold such an exemp-
tion, as required for methadone. 
461. In response to the rise in drug overdoses, fentanyl 
and related deaths, the government of Ontario launched 
the “Patch4Patch” programme (Bill 33). People with a 
prescription for fentanyl would be given new patches con-
taining the drug only when they turned in their old used 
patches. The bill received royal assent in December 2015. 
462. In January 2016, Canada approved a second super-
vised “drug injection site” in the city of Vancouver, fol-
lowing a two-year process to grant an exemption from 
the Controlled Drugs and Substances Act. The facility is 
housed in the existing HIV/AIDS treatment clinic in 
Vancouver and, as such, it is the first supervised “drug 
injection site” in North America integrated into an exist-
ing health-care facility. In March 2016, a four-year exten-
sion was issued to the supervised “drug injection site” 
(called “Insite”), granting it permission to continue its 
operation until 2020. The Minister of Health of Canada 
has stated that a number of additional applications for 
exemptions to operate “injection sites” had been received 
and were undergoing a review process by Health Canada. 
Public consultations have also been taking place in major 
cities of other provinces, including Alberta, Ontario and 
Quebec. 
463. In January 2016, the Ministry of Health of Mexico 
published early results on the impact of the new national 
strategy to increase access to controlled substances for 
pain treatment and palliative care. The new strategy is 
aimed at facilitating the dispensing, prescribing and 
administering of pharmaceutical preparations containing 
opiates. According to the results published, the range of 
different prescriptions increased from 24 to 8,000 from 
June 2015 to January 2016. Following the introduction of 
an electronic platform to facilitate their issuance, the 
number of registered prescribers increased from 232 to 
1,706 during that period. Furthermore, the results state 
that public and private health centres, as well as pharma-
cies, have a guaranteed supply of morphine and other 
opioids. 
464. According to information furnished by the 
Government of Mexico to INCB, in November 2016, fol-
lowing a claim to declare the unconstitutionality of cer-
tain articles of the General Health Law regarding cannabis 
and THC, the Supreme Court of Mexico decided to 
authorize four plaintiffs to possess and cultivate cannabis 
for non-medical personal consumption (case No. 
237/2014). The Court centred its decision on respect for 
their individual personality and freedom. The decision of 
the Supreme Court applies only to the four plaintiffs and 
does not legalize the non-medical use of cannabis in 
Mexico.
465. On 11 June 2015, in R. v. Smith, the Supreme Court 
of Canada expanded the definition of “medical mari-
juana” under the country’s medical cannabis programme 
by striking the words “dried herb” from the definition of 
medical cannabis, effectively allowing other forms of can-
nabis to be consumed for medical purposes. Following 
the judgment, medical cannabis patients legally author-
ized to possess the drug for medical purposes were 
allowed to possess cannabis products extracted from the 
active medicinal compounds in the cannabis plant. 
Therefore, those who obtain dried cannabis pursuant to 
the authorization can choose to administer it using an 
oral or topical treatment and are not limited to dried herb 
consumed through smoking. 
466. In February 2016, Canada’s medical cannabis legal 
framework, the Marihuana for Medical Purposes 
Regulations, was declared unconstitutional by the Federal 
Court of Canada (Allard v. Canada). While under the 
previous regulatory framework, patients had been author-
ized to grow their own cannabis, the Marihuana for 
Medical Purposes Regulations introduced a system of 
licensed producers. In its decision, the Federal Court 
allowed those authorized to grow their own supply under 
the previous legal framework to continue doing so. 
Following the Federal Court ruling, the new Access to 
Cannabis for Medical Purposes Regulations came into 
force on 24 August 2016. Accordingly, those who have 
been authorized by their health-care practitioner to access 
cannabis for medical purposes will continue to have the 
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option of purchasing safe, quality-controlled cannabis 
from one of the producers licensed by Health Canada. 
They will also be able to produce a limited amount of 
cannabis for their own medical purposes or designate 
someone to produce it for them. The new regulations also 
incorporate provisions to allow for the production and 
possession of cannabis in forms other than dried, further 
to the June 2015 Supreme Court of Canada decision in 
R. v. Smith. 
467. In April 2016, in the United States, the Drug 
Enforcement Administration approved clinical trials of 
smoked cannabis for the treatment of post-traumatic 
stress disorder in American military veterans, under the 
umbrella of the Multidisciplinary Association for 
Psychedelic Studies, funded by the State of Colorado. 
468. The Board continues to remind all governments in 
jurisdictions that have established medical cannabis pro-
grammes, or that are considering doing so, that the 1961 
Convention as amended sets out specific requirements 
for the establishment, administration and monitoring of 
such programmes.58 The Board encourages Governments 
in the region to take action to ensure that their medical 
cannabis programmes fully implement the measures set 
out in that Convention, particularly in articles 23 and 28, 
in order to prevent the diversion of cannabis intended to 
be used for medical purposes into illicit channels. 
469. With regard to the use of cannabis for scientific 
research purposes, the University of Mississippi has been 
the only entity authorized by the Drug Enforcement 
Administration to produce cannabis to supply research-
ers in the United States. On 11 August 2016, a policy 
change was announced designed to foster research by 
expanding the number of cannabis manufacturers regis-
tered with the Drug Enforcement Administration to be 
allowed to grow and distribute cannabis for research pur-
poses authorized by the Food and Drug Administration. 
470. On 21 March 2016, the Supreme Court of the United 
States denied a motion for leave to file a bill of complaint 
submitted to the Court by the States of Nebraska and 
Oklahoma against the State of Colorado. Arguing that can-
nabis from Colorado was being diverted to their territory, 
the plaintiff states sought a declaratory judgment against 
the State of Colorado to the effect that the amendments to 
its legislation permitting the legalization and regulation of 
the use of cannabis for non-medical purposes were pre-
empted by the federal Controlled Substances Act, which 
classifies cannabis as a schedule I substance. 
58 Those requirements were highlighted in the annual report of the 
Board for 2014 (paras. 218-227).
471. Following a scientific and medical evaluation con-
ducted by the United States Food and Drug Administration 
in consultation with the National Institute on Drug 
Abuse, the Drug Enforcement Administration announced 
on 11 August 2016 that cannabis did not meet the crite-
ria for currently accepted medical use in treatment in the 
United States, that there was a lack of accepted safety for 
its use under medical supervision and that cannabis had 
a high potential for abuse. On that basis, the Drug 
Enforcement Administration denied two petitions to 
reschedule cannabis, which thus continues to be prohib-
ited at the federal level as a substance in schedule I of the 
Controlled Substances Act. At the state level, as at May 
2016, the use of the substance for non-medical purposes 
has been legalized in four states, namely, Alaska, Colorado, 
Oregon and Washington. 
472. Between May and September 2016, the Oregon 
Liquor Control Commission approved 246 recreational 
cannabis licences, while the state’s final rules on retail 
sales are to be developed and reported to legislative bod-
ies by 1 January 2017. The Marijuana Enforcement 
Division in Colorado issued guidelines applicable to the 
sale of recreational cannabis, setting sale limits. According 
to the guidelines, edibles must be stamped to indicate the 
presence of THC and cannot include the word “candy”, 
in order to reduce the risk of accidental ingestion of can-
nabis products by children. The guidelines were to be 
applicable as at 1 October 2016. As at 1 July 2016, the 
number of licensed retail cannabis businesses in Colorado 
totalled 435 stores, 572 cultivations, 193 manufacturers 
and 15 testing facilities. 
473. In May 2016, Health Canada published a notice in 
the national gazette on its intent to return the regulatory 
oversight of diacetylmorphine to the Narcotic Control 
Regulations as had been done prior to the changes intro-
duced in 2013. That change would allow doctors to use 
diacetylmorphine-assisted treatment to support patients 
with opioid dependence who had not responded to other 
treatment options and allowed for the consideration of 
applications for the sale of diacetylmorphine for purposes 
of emergency treatment under the programme. 
4. Cultivation, production, 
manufacture and trafficking 
(a) Narcotic drugs
474. According to the World Drug Report 2016, the 
United States accounted for 15 per cent of cocaine sei-
zures worldwide in the period 2009-2014 and was second 
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only to Colombia. The largest cocaine seizures in North 
America over the period 2009-2014 were reported by the 
United States, accounting for 90 per cent of the seizures 
in North America, followed by Mexico, which accounted 
for 8 per cent. 
475. Canada continued to be supplied predominantly 
by heroin originating in Afghanistan, trafficked through 
Pakistan and along the southern route, while the United 
States was supplied predominantly by heroin produced in 
Colombia and Mexico. 
476. According to the 2016 National Heroin Threat 
Assessment Summary, law enforcement agencies in cities 
across the United States reported seizing larger than usual 
quantities of heroin. Data of the National Seizure System 
showed an 80 per cent increase in heroin seizures in the 
past five years, increasing from more than 3.7 tons in 
2011 to up to 6.8 tons in 2015. Rising heroin seizures 
in the United States seem to reflect the growing  availability 
of heroin and are in line with reports of increasing 
 heroin  use and the rapidly growing number of heroin-
related deaths (rising from 3,036 such deaths in 2010 to 
10,574 in 2014). 
477. The Government of Mexico reported eradicating 
up to 26,000 ha of opium poppy in 2015, compared with 
the eradication of over 21,000 ha in 2014 and 14,622 ha 
in 2013. According to the first joint Government of 
Mexico/UNODC opium poppy survey conducted in the 
country, over the period July 2014-June 2015, the 
Government estimated, on the basis of satellite images 
and aerial photographs, that illicit cultivation of opium 
poppy in the country covered between 21,500 ha and 
28,100 ha. 
478. In June 2016, the Government of Canada prohib-
ited domestic commercial cultivation of opium poppy. 
Following the decision, no licensed dealer shall cultivate, 
propagate or harvest opium poppy other than for 
 scientific purposes.
479. Cannabis continues to be the most widely illicitly 
cultivated, produced, trafficked and consumed drug in 
North America, as well as worldwide, with an estimated 
182.5 million users globally in 2014. In North America, 
cannabis herb is produced mainly in Mexico and the 
United States, for consumption in the subregion, while 
hydroponic cultivation of cannabis plants seems to be 
concentrated in Canada and the United States. Under the 
Domestic Cannabis Eradication/Suppression Program, 
the United States Drug Enforcement Administration was 
responsible for the eradication of almost 4 million can-
nabis plants cultivated outdoors and over 320,000 indoor 
plants in 2015. The seized assets were valued at almost 
$30 million. The Government of Mexico reported having 
eradicated over 5,700 ha of cannabis in 2013, according 
to the most recent data available. 
480. Seizures of fentanyl, as well as counterfeit hydro-
codone or oxycodone tablets containing fentanyl, have 
been increasing in the United States. Consumption of the 
tablets, marked to mimic the authentic narcotic prescrip-
tion medications, has led to multiple overdoses and 
deaths. According to the National Forensic Laboratory 
Information System, over 13,000 forensic exhibits of fen-
tanyl were tested by laboratories in the United States in 
2015, representing an increase of 65 per cent from 2014, 
and about eight times as many fentanyl exhibits as in 
2006. 
(b) Psychotropic substances
481. Customs officials in the region of North America 
reported total seizures of almost 32 tons of psychotropic 
substances in 2014. 
482. In 2014, methamphetamine dominated the North 
American markets for amphetamine-type stimulants. 
Compared with other subregions, North America consist-
ently reported the largest number of methamphetamine 
seizures each year between 2009 and 2014. According to 
information provided in the World Customs Organization 
Illicit Trade Report 2014, the United States accounted for 
64 per cent of the total number of seizures of metham-
phetamine by customs officials. Mexico increased its 
 seizures by 1.3 per cent in 2014. Road vehicles remained 
the most frequent method of transport for trafficking 
methamphetamine in that year.
483. In 2014, Mexico was the main country of depar-
ture for seizures of methamphetamine made by customs 
officials in the United States and, to a lesser extent Canada 
and China, and was an important departure country for 
trafficking to Japan. 
484. The number of seizures of amphetamine in 2014 
significantly decreased in comparison with 2013, while 
the number of seizures of MDMA (“ecstasy”) in the 
United States almost doubled from 2013 to 2014. 
485. In the United States in 2014, there were over 9,300 
incidents involving clandestine methamphetamine labo-
ratories and dump sites. The highest numbers of those 
incidents took place in the states of Indiana and Missouri, 
with 1,471 and 1,034 incidents, respectively. 
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(c) Precursor chemicals
486. Mexico reported an increase of almost 38 per cent 
in the number of clandestine laboratories dismantled in 
2015. Precursor chemicals seem to have been used predom-
inantly for the manufacture of methamphetamine, using 
1-phenyl-2-propanone (P-2-P)-based methods. However, in 
contrast to previous years, when the starting materials were 
mostly esters and other derivatives of phenylacetic acid, a 
new method, using benzaldehyde and nitroethane, has 
become increasingly common in that country. 
487. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the report of the Board for 2016 on the implementa-
tion of article 12 of the 1988 Convention. 
(d) Substances not under international 
control
488. New psychoactive substances are a significant area 
of concern for the United States. According to the 
National Forensic Laboratory Information System, the 
number of reports of substances identified as synthetic 
cannabinoids by federal, state and local forensic labora-
tories increased from 23 in 2009 to 37,500 in 2014. The 
number of reports on substances identified as synthetic 
cathinones increased from 29 reports in 2009 to 14,070 
reports in 2014. Over the past several years, the Drug 
Enforcement Administration has identified hundreds of 
designer drugs from at least eight different drug classes. 
489. The global market for synthetic new psychoactive 
substances continues to be dominated by synthetic can-
nabinoids, with 32 tons seized. North America (specifi-
cally, the United States with 26.5 tons seized) accounted 
for the largest quantities seized worldwide in 2014. 
490. Canada has seen an increased presence of W-18 
(4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-piperidinylidene]-
benzenesulfonamide), including a number of seizures in 
clandestine laboratories reported by law enforcement 
agencies in the provinces of Alberta, British Columbia 
and Quebec. Recently, W-18 was found in samples seized 
by law enforcement authorities and in a number of cases 
of fatal overdose. These included counterfeit tablets made 
to appear to be prescription oxycodone but whose only 
active ingredient was W-18. In British Columbia, seized 
W-18 was intended for use in the manufacture of coun-
terfeit heroin. In May 2016, W-18, its salts, derivatives, 
isomers and analogues and salts of derivatives, isomers 
and analogues were added to schedule I of the Controlled 
Drug and Substances Act of Canada, making it illegal to 
produce, possess, import, export or traffic them. 
491. There has been an increase in the frequency of the 
sale of counterfeit pharmaceuticals in the illicit market in 
Canada and the United States, especially with regard to 
counterfeit “OxyContin” tablets (oxycodone hydrochlo-
ride), “Xanax” tablets (alprazolam) and “Norco” tablets 
(hydrocodone bitartrate). Novel synthetic opioids used in 
these products were fentanyl and fentanyl analogues, as 
well as W-18, U-47700, AH-792159 and MT-45.60 
492. According to the World Customs Organization 
Illicit Trade Report 2014, while an increasing trend has 
been observed in other regions, the number of tramadol 
seizures by customs officials in the United States sharply 
decreased in 2014, by approximately 30 per cent in com-
parison to 2013. Seizures of gamma-butyrolactone (GBL) 
have increased significantly, with the United States record-
ing the highest number of seizures worldwide in 2014, 
while seizures of khat (Catha edulis) seem to have 
decreased in the country. 
493. Between February 2014 and July 2016, over 55 tons 
of kratom (Mitragyna speciosa) material were encoun-
tered by law enforcement authorities in the United States. 
5. Abuse and treatment
494. The significant rise of fentanyl abuse has been one 
of the main issues in Canada, where the number of deaths 
markedly increased in a number of provinces. During the 
six-year period 2009-2014, there were at least 655 deaths 
in which it was determined that fentanyl was the cause 
or a contributing cause of death. According to the data 
published by the Coroners Service of British Columbia, 
there were 308 apparent drug overdose deaths from 
January to May 2016, representing a 75 per cent increase 
over the number of deaths occurring during the same 
period in 2015. In Alberta in 2015, there were 274 over-
dose deaths in which fentanyl was detected, which was 
significantly higher than in previous years, and 69 fentanyl- 
related deaths over the first three months of 2016. In com-
parison, in the United States, deaths associated with 
synthetic opioids such as fentanyl and its analogues 
increased by 79 per cent from 2013 to 2014. 
59 The Commission on Narcotic Drugs, in its decision 58/3, placed 
AH-7921 in Schedule I of the 1961 Convention as amended.
60 The Commission on Narcotic Drugs, in its decision 59/2, placed 
MT-45 in Schedule I of the 1961 Convention as amended.
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495. Furthermore, opioids, including heroin and pre-
scription painkillers such as oxycodone, killed more than 
28,000 people in the United States in 2014, and the rate 
of overdose has increased significantly since 2000, accord-
ing to the Centers for Disease Control and Prevention. 
The number of people reporting current heroin use in the 
United States nearly tripled from 2007 to 2014. In com-
parison, the prevalence of past-year cocaine use among 
the general population fell by 32 per cent between 2006 
and 2014, and cocaine-related deaths decreased by 34 per 
cent between 2006 and 2013. 
496. Life expectancy at birth for the white, non- Hispanic 
population in the United States declined slightly from 
2013 to 2014, representing a rare drop for a major demo-
graphic group, according to new data from the Centers 
for Disease Control and Prevention. That unusual decrease 
is consistent with other research showing that upward 
trends in suicides and drug poisoning were persistent and 
large enough to drive up all-cause midlife mortality and 
morbidity for that demographic group.
497. Prescriptions of opioid pain relievers in the United 
States have quadrupled since 1999. In response to a parallel 
increase in overdoses, the Centers for Disease Control and 
Prevention issued guidelines for primary care clinicians on 
prescribing opioids for chronic pain. During the annual 
National Prescription Drug Take-Back Day, the Drug 
Enforcement Administration collected a total of approxi-
mately 447 tons of drugs in all 50 states. The states with the 
largest amount of collected prescription drugs were Texas, 
California, Wisconsin, Illinois and Massachusetts. 
498. According to recent data from the Centers for 
Disease Control and Prevention, there was an all-time 
record level of 19,659 deaths associated with hepatitis C 
in the United States in 2014. The data also point to a new 
wave of infections among people who inject drugs, cases 
of which have doubled since 2010. 
499. The prevalence of past-year use of ketamine among 
twelfth grade students (approximately the ages of 17-18 
years) was 1.5 per cent in 2014 in the United States. Canada 
reported the past-year use of ketamine among young peo-
ple aged 15 and 16 years in 2010-2011 to be 1.1 per cent. 
500. In Canada, cannabis is the most common illicitly 
used substance, followed by cocaine, hallucinogens and 
“ecstasy”. Cannabis also continues to be the most widely 
used drug in the United States and Mexico. 
501. The results of the 2015 Monitoring the Future sur-
vey of high-school students, college students and adults 
showed a decreasing trend among high-school students 
in the United States in the use of a number of substances, 
including prescription opioid pain relievers and synthetic 
cannabinoids, and a slight decrease in the use of “ecstasy”, 
inhalants and LSD. 
502. In Mexico, the prevalence of cannabis abuse among 
students was reported to be 11.6 per cent in urban areas 
and 5.2 per cent in rural areas in 2014. While these con-
sumption data are lower than in the United States and 
Canada for 2014, the reported abuse of cocaine among 
high-school students in Mexico was similar to the levels 
reported in the United States. 
503. In the United States, recent data from the states 
that have legalized the use of cannabis for non-medical 
purposes show an increase in cannabis use. The World 
Drug Report 2016 also states that there was an increase 
in adverse public health and public safety indicators, 
including cannabis-related emergency room visits, hospi-
talizations, traffic accidents and related deaths. Cannabis-
related arrests, court cases and criminal justice system 
referrals for treatment have declined.
504. There have been a number of recently published 
reports on cannabis use among young people in the 
United States, and specifically in the State of Colorado 
following legalization. However, the data and their analy-
sis in the various reports are varied. The 2015 Monitoring 
the Future survey of college students and adults states 
that in 2015, the national prevalence of past-month can-
nabis/hashish use for eighth grade students, tenth grade 
students and twelfth grade students (young people aged 
approximately 12 to 17 years old) was 6.5 per cent, 14.8 
per cent and 21.3 per cent, respectively. According to the 
2015 National Survey on Drug Use and Health, 7 per cent 
of adolescents aged 12 to 17 were past-month users of 
cannabis in the United States in 2015. 
505. The Rocky Mountain High Intensity Drug 
Trafficking Area report on the impact of legalization of 
cannabis in Colorado, published in January 2016, states 
that past-month cannabis use among young people aged 
12 to 17 years in Colorado increased by 20 per cent in 
the two-year period 2013-2014 since Colorado legalized 
the use of cannabis for non-medical purposes, and was 
74 per cent higher than the national average (which 
amounted to 7.22 per cent in that period).
506. In comparison, the executive summary of the 2015 
Healthy Kids Colorado Survey found that the rate of cur-
rent cannabis use among high-school students was 
21.2 per cent in 2015 (an increase from 19.7 per cent in 
2013). The state average of current cannabis use among 
high-school students in 2015 does not significantly differ 
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from the national average, which, according to this report, 
was 21.7 per cent. 
507. A recent study compared the incidence of  paediatric 
cannabis exposures at children’s hospitals and regional 
poison centres in Colorado before and after the use of 
cannabis for non-medical purposes became legalized in 
the state. The study concluded that, two years after legal-
ization, cases of paediatric exposure to cannabis in 
Colorado had increased, going from 9 cases in 2009 to 
47 cases in 2015 at regional poison centres, and from 
1  case in 2009 to 16 cases in 2015 at children’s hospitals 
in the state. The main source of exposure was identified 
as ingestion of edible products.61 
508. Given the discrepancies among the results of analy-
sis published in the various reports on cannabis use, it 
continues to be of critical importance for Governments 
to undertake reliable monitoring at all levels, to under-
stand trends in use and the risks of health effects associ-
ated with cannabis and to enable the measuring of the 
impact of various policies in the countries of the North 
American region.
South America
1. Major developments
509. In South America, discussions on reviewing drug 
policies have continued, particularly regarding the legal-
ization and regulation of cannabis for medical and non-
medical purposes, while the region has continued to be 
affected by large-scale illicit crop cultivation and drug 
trafficking. Legislative amendments have been adopted by 
several countries in the region; their compliance with the 
international drug conventions remains to be 
ascertained.
510. In Colombia, a peace agreement between the 
Government and the Revolutionary Armed Forces of 
Colombia was signed on 26 September 2016. A national 
referendum was held on 2 October 2016, in which 
Colombian voters rejected the agreement. A revised 
agreement was signed in November 2016. One of the pil-
lars of the peace agreement is the chapter on the illicit 
drug problem. The Board stands ready to support the 
authorities, within the sphere of its mandate, regarding 
61 G.S. Wang and others, “Unintentional pediatric exposures to mari-
juana in Colorado, 2009-2015”, JAMA Pediatrics, vol. 170, No. 9 (2016).
the implementation of the international drug control 
treaties.
511. States have developed regional mechanisms for 
ensuring coherent legal and institutional capacity- building 
on matters of law enforcement and border control. 
However, porous borders, illicit drug production, traffick-
ing in drugs and links to other forms of criminality, cou-
pled with widespread corruption and a lack of capacity 
of the criminal justice systems to bring perpetrators to 
justice, have contributed to the internationalization of the 
drug trafficking threat in the region. 
512. During the reporting period, cocaine abuse preva-
lence rose sharply in the region.
2. Regional cooperation 
513. International cooperation continues to be strength-
ened, including through regional initiatives and increased 
cooperation between countries in the region. OAS has 
developed regional mechanisms to allow its member 
States to cooperate at the policy and operational levels in 
drug control matters. Cooperation within OAS is focused 
on the decentralization of drug policies, the establishment 
of a strong institutional framework, the maintenance of 
a dialogue on alternatives to incarceration for drug-
related offences and the social reintegration of drug 
offenders. 
514. Transnational organized crime and drug traffick-
ing remained the focus of concern and cooperation at the 
regional level, including in the tri-border area between 
Argentina, Brazil and Paraguay, and within the Andean 
Community. For instance, in the framework of the joint 
committee on drugs between Colombia and Peru, a bilat-
eral meeting was held in Bogotá in May 2016 on the 
theme “Strategies for drug control: natural or synthetic 
drugs, emerging drugs, precursors and chemical prod-
ucts”. In July 2016, the first coordination workshop for 
the third Andean epidemiological study on drug use 
among university students was held in Quito. The study 
will estimate the magnitude of drug consumption and its 
main risk and protection factors. In June 2016, the 
Government of the Plurinational State of Bolivia 
announced a joint initiative with Brazil and Peru to  create 
a police intelligence centre to combat drug trafficking 
between the three countries. 
515. A 6.5-million-euro European Union project to 
counter the illicit demand for drugs is being implemented 
in Bolivia (Plurinational State of), Colombia, Ecuador 
and Peru.
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516. The Airport Communication Project (AIRCOP) of 
UNODC organized the first specialized training session 
for law enforcement officials on sharing methods to 
 counter drug trafficking and to identify passengers’ risk 
profiles and forged documentation. The training session 
was held in Buenos Aires from 25 January to 5 February 
2016. In Brazil, the Federal Police Department is imple-
menting the International Programme for Police 
Cooperation in Airports, which focuses on international 
cooperation to counter drug trafficking at airports. 
517. In March 2016, discussions on an agreement on 
political dialogue and cooperation between the European 
Union and the Andean Community were held. The agree-
ment would focus on the prevention of drug abuse 
through information campaigns on the harmful effects of 
drugs, as well as on tackling the illicit cultivation of drug 
crops, the production and processing of and trafficking 
in drugs and the diversion of precursor chemicals.
518. In April 2016, the Council of the European Union 
approved the Agreement on Strategic Cooperation 
between the European Police Office (Europol) and Brazil. 
The Agreement is aimed at supporting and strengthening 
cooperation between the competent authorities of Brazil 
and the States members of the European Union in order 
to prevent and combat serious crimes. 
519. In May 2016, representatives from Bolivia 
(Plurinational State of) and Peru attended the fifth meet-
ing of the Joint Commission on Cooperation in Alternative 
Development and Countering Drug Trafficking and 
Abuse. The two countries signed agreements on opera-
tional strategies for police cooperation.
520. In June 2016, Bolivia (Plurinational State of) and 
Brazil held the ninth meeting of the Joint Commission 
on Drugs and Related Crimes. Joint actions were agreed, 
including on information exchange, professional training 
and monitoring of coca bush cultivation. The Plurinational 
State of Bolivia has established official contact points with 
Brazil and Peru in order to exchange information on drug 
control matters through secure channels. 
521. The Cooperation Programme between Latin 
America, the Caribbean and the European Union on 
Drugs Policies (COPOLAD) held its first annual confer-
ence, on the theme “From evidence to practice: challenges 
in the field of drugs policies”, in The Hague on 14 and 15 
June 2016. Participants shared their experiences regard-
ing information exchange, coordination and cooperation 
between competent authorities responsible for policies on 
drugs in the European Union and the Community of 
Latin American and Caribbean States.
3. National legislation, policy and 
action
522. In June 2016, a ceasefire agreement was reached 
between the Government of Colombia and the 
Revolutionary Armed Forces of Colombia. On 
26 September 2016, the two parties signed a peace agree-
ment to end 52 years of an armed conflict that has 
7.2  million registered victims. One of the pillars of the 
agreement related to drug matters and related crime, in 
particular alternative development, drug demand reduc-
tion, drug precursor control, asset forfeiture and combat-
ing organized crime, money-laundering and corruption. 
The agreement was rejected in the referendum held on 
2  October 2016. A revised agreement was signed in 
November 2016. INCB wishes to continue its positive and 
fruitful dialogue with the authorities in Colombia. The 
Board remains at the disposal of the authorities in the 
implementation of the agreement, within the sphere of its 
mandate, regarding the implementation of the inter-
national drug control treaties. 
523. In December 2015, the Government of Argentina 
recognized the serious drug control challenges it faces 
and outlined a new approach to tackling the drug prob-
lem that is aimed at integrating and coordinating efforts 
at the national and international levels, focusing on 
human rights and greater access to public health services 
and drug abuse prevention programmes. On 21 January 
2016, Argentina adopted decree No. 228/2016, which 
establishes a national human security cabinet, responsi-
ble for applying and coordinating national drug control 
policy. The decree is aimed, inter alia, at strengthening 
the protection of national airspace through ordering the 
expansion of radar coverage, commencing with at-risk 
border regions, and providing for the interception and 
destruction of aircraft suspected of being used to traffic 
drugs. In March 2016, the Government informed the 
Board that it was in the process of reactivating provincial 
and municipal networks and institutions, such as the pro-
vincial and municipal drug control councils, with a view, 
inter alia, to conducting national drug abuse surveys. On 
30 August 2016, the Government launched a comprehen-
sive national plan to address the drug control problem in 
the country. Furthermore, Argentina issued decree 
No.  360/2016 establishing the National Anti-Money-
Laundering Coordination Programme.
524. In the Plurinational State of Bolivia, new legisla-
tive measures were being reviewed to replace law No. 
1008 of 19 July 1988; once adopted, draft law No. 41/2016 
on coca leaf would delineate the zones where licit coca 
bush cultivation would be permitted, with respect to the 
country’s reservation to the 1961 Convention, and 
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establish cultivation limits for each zone. Draft law No. 
213/2016 on controlled substances and sanctions for 
drug-related offences would provide for the introduction 
of tools such as wiretapping and payment of informants, 
as well as for a revised list of controlled precursor chem-
icals, and would authorize the interception and destruc-
tion of unidentified aircraft suspected of being used to 
traffic drugs. A draft law on asset confiscation would per-
mit the seizure, confiscation and forfeiture of assets 
related to drug crimes and illicit enrichment; those assets 
could then be used for financing counter-narcotic 
activities. 
525. The Government of the Plurinational State of 
Bolivia was reported to be developing a new strategic 
framework for the period 2016-2020, in which a series of 
interventions were envisaged to contribute to achieving 
the country’s priority objectives with regard to criminal 
justice and countering activities related to drugs, crime, 
corruption and terrorism. The strategy is structured 
around four pillars, namely, supply reduction, demand 
reduction, control of surplus coca bush cultivation, and 
international shared responsibility.
526. In 2016, the European Union pledged 60 million 
euros over four years to support the implementation of 
the national strategy to combat trafficking in drugs in the 
Plurinational State of Bolivia, including through the 
reduction of excess coca bush cultivation. The programme 
includes European Union support to the national 
Government’s counter-narcotics efforts and a contribu-
tion to the technical capacity-building of national police 
forces provided by their European counterparts. 
527. On 7 December 2015, Chile adopted decree No. 84, 
which permits the manufacture of medicines derived 
from cannabis. The decree also established the Institute 
of Public Health as the agency responsible for the con-
trol of the use of cannabis for the manufacture of phar-
maceutical products for human consumption. The first 
crop of cannabis for such purpose was harvested in 
March 2016. In July 2016, the parliament considered a 
bill to decriminalize consumption and cultivation of 
 cannabis for personal, medical and non-medical use. 
528. In December 2015, the Government of Colombia 
enacted decree No. 2467, which permits the cultivation 
of and establishment of a licit market for cannabis for 
medical and scientific purposes. Personal cultivation for 
medical consumption of up to 20 cannabis plants is 
exempted from the requirement to have a licence. That 
exemption may lead to the diversion of cannabis to the 
illicit market. The legal regime introduced by decree 
No.  2467 does not decriminalize the cultivation, 
possession and purchase of cannabis for non-medical use. 
The Ministry of Health was designated as the competent 
national agency responsible for the application of the leg-
islative amendment, while the National Narcotics Board 
is the body responsible for licensing. The Ministry of 
Health also bears responsibility for authorizing the use of 
cannabis for medical and scientific purposes, while the 
Ministry of Agriculture and Rural Development, along 
with the National Drug Council and the Ministry of 
Health, monitors the areas where cultivation takes place. 
The Ministry of Health issued decision No. 1816/2016 
of  12 May 2016 on the granting of licences for the 
 production and manufacture of cannabis derivatives. 
529. In March 2016, the Government of Ecuador issued 
executive decree No. 951/2016, which contains new pro-
visions regarding the country’s institutional framework 
for drug control and new sanctions for possession and 
consumption of narcotic drugs and psychotropic sub-
stances. The Inter-institutional Committee is named in 
the decree as the entity responsible for centralizing infor-
mation relating to public policies on harm reduction. The 
decree establishes another institution, the Technical 
Secretariat on Drugs, which will replace the National 
Narcotic and Psychotropic Substances Control Board in 
terms of responsibility for drug policy and the regula-
tion and monitoring of licit cultivation, production, sale, 
distribution, recycling, import and export of controlled 
substances. The administrative restructuring also named 
the National Health Authority as the competent national 
regulatory and monitoring authority. It is also empow-
ered to establish new thresholds for the possession of 
narcotic drugs and psychotropic substances for personal 
use.
530. In Ecuador, the law on the prevention, detection 
and eradication of money-laundering and the financing 
of crime was approved in July 2016. Law No. 47/16 sets 
out the forms of participation in money-laundering and 
the procedure for recovering confiscated assets that are 
the proceeds of crime.
531. In September 2015, the Penal Code of Peru was 
amended to strengthen regulations and punishment 
related to the diversion of precursors. The criminal 
offence of chemical diversion includes, as an aggravating 
circumstance, when the agent committing the offence is 
a registered user of controlled chemical substances.
532. In January 2016, Peru implemented law 
No.  30339/2015, on monitoring and protecting the 
national airspace, which enabled unauthorized civilian 
flights entering Peruvian airspace to be forced down. The 
stated purpose of the adoption of the law was the 
68  INCB REPORT 2016
Government’s constitutional mandate to defend national 
sovereignty and protect the population from the grave 
threat posed to its security by drug trafficking. The 
Government also reviewed the regulations governing nar-
cotic drugs, psychotropic substances and other controlled 
substances subject to health regulation through supreme 
decree No. 023-2001-SA and is preparing a draft amend-
ment to allow new psychotropic substances subject to 
national control to be added to the list of controlled 
 substances. In June 2016, the Congress of Peru approved 
legislative decree No. 1241, which accords responsibility 
for conducting investigations and studies on, inter alia, 
the use of chemical substances in illicit drug production, 
drug trafficking routes and the conversion factors from 
coca leaf into cocaine hydrochloride to the Executive 
Anti-Drug Directorate of the National Police of Peru.
533. The Caribbean Financial Action Task Force has 
continued to evaluate countries in the subregion. In 
November 2015, a report on Suriname was released that 
contained information on the challenges faced by the 
country in addressing money-laundering. In June 2016, 
the Task Force acknowledged that significant progress 
had been made by Suriname in improving its regime to 
counter money-laundering and the financing of terrorism 
and noted that the country had established the legal and 
regulatory frameworks to meet its commitments in its 
agreed action plan regarding the strategic deficiencies that 
had been identified. 
534. On 20 December 2013, Uruguay passed law 
No.  19.172 establishing a legal framework applicable to 
the control and regulation by the State of the use of can-
nabis for non-medical and non-scientific purposes. 
Uruguay has created three legal channels for private indi-
viduals to obtain cannabis for non-medical use: home 
cultivation, social clubs and registered retail pharmacies. 
In March 2016, the Government of Uruguay opened a 
 registry for pharmacists wishing to sell cannabis. Each 
registered user may purchase up to 40 grams of cannabis 
(with a concentration of up to 15 per cent THC) per 
 person, per month, in registered pharmacies. In addition 
to selling through pharmacies, the law allows each house-
hold to register to grow up to six cannabis plants. The 
Institute for Regulation and Control of Cannabis, the 
entity charged with monitoring and regulating the pro-
duction and sale of cannabis in Uruguay, signed an agree-
ment with the Association of Pharmacies that establishes 
the conditions for the sale of cannabis. Statements from 
police officials in Uruguay indicate that cannabis 
 trafficking has remained unchanged and that organized 
criminal groups may have benefited in the period 
 leading  up to the establishment of the retail pharmacy 
system. In September 2016, two years after the enactment 
of  the  law,  critical parts of the distribution system were 
still pending. 
535. Once again, the Board wishes to draw the atten-
tion of all Governments that measures permitting the 
non-medical use of cannabis are contrary to the provi-
sions of the international drug control conventions, 
specifically article 4, paragraph (c), and article 36 of the 
1961 Convention as amended by the 1972 Protocol, and 
article 3, paragraph 1 (a), of the 1988 Convention. 
INCB also reiterates that the limitation of the use of 
controlled substances to medical and scientific pur-
poses is a fundamental principle that lies at the heart 
of the legal framework for international drug control, 
and admits no exception.
536. Similarly, the Board wishes to draw the attention 
of all Governments to its previously conveyed position 
that personal cultivation of cannabis for medical 
 purposes is inconsistent with the 1961 Convention as 
amended, as it heightens, inter alia, the risk of  diversion. 
All medical cannabis programmes must be developed 
and implemented under the full authority of the State 
concerned, in accordance with the requirements laid 
down in articles 23 and 28 of that Convention. 
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs 
537. Seizures of cannabis in the region raise serious 
concerns about the trends in illicit cannabis plant 
 cultivation and about the trends in cannabis production, 
consumption and trafficking in the region. During the 
reporting period, information on various seizures of can-
nabis herb in countries in South America was provided. 
In Uruguay, reported seizures of cannabis herb accounted 
for 1,457 tons, according to the most recent survey, which 
took place in 2014. Cannabis herb seizures of 510 tons, 
247 tons, 206 tons and 26 tons were reported by Paraguay, 
Colombia, Argentina and the Bolivarian Republic of 
Venezuela, respectively. 
538. During the period 2009-2014, Colombia and 
Paraguay were identified as major source countries of the 
cannabis herb found in illicit drug markets. In Paraguay, 
the estimated area under illicit cannabis plant cultivation 
was 2,783 ha, with each hectare estimated to be capable 
of producing 3,000 kg of cannabis. The Government of 
Paraguay reported the eradication of over 12.1 million 
cannabis plants in 2015. 
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539. South America remained virtually the sole supplier 
of cocaine to drug abuse markets around the world. Thus, 
South America continued to account for the majority of 
global cocaine seizures. The global area under coca bush 
cultivation increased in 2014 as a result of a sharp increase 
in Colombia, while, according to UNODC, the 
Plurinational State of Bolivia reduced the area devoted to 
illicit coca bush cultivation. 
540. The total area dedicated to coca bush cultivation has 
been increasing since 2014 in Colombia, from 69,000 ha 
in that year to 96,000 ha in 2015, which was a 39 per cent 
increase and twice the area cultivated in 2013. It is reported 
that the expectations surrounding negotiations on the 
peace process may have contributed to raising farmers’ 
hopes about the benefits of prospective alternative devel-
opment programmes and acted as motivators for further 
illicit cultivation, which, combined with the cessation of 
eradication by spraying of glyphosate by the authorities in 
2015, accounted for the almost doubling of coca bush cul-
tivation in the country. According to UNODC, during the 
period 2001-2014, an annual average of 22,400 ha was 
deforested for coca bush cultivation in Colombia. UNODC 
further reported that satellite images had revealed clusters 
of persistent coca bush cultivation in national parks in all 
three coca-producing countries (Bolivia (Plurinational 
State of), Colombia and Peru). The most affected protected 
areas were the Sierra de la Macarena, Tinigua and Los 
Picachos national parks in Colombia. 
541. Alternative development programmes in Colombia 
and Peru have been shown to weaken the population’s 
ties with armed groups and drug trafficking, as well as to 
restore security and respect for the rule of law. In July 
2016, the Government of Colombia and the Revolutionary 
Armed Forces of Colombia were reported to have 
launched a pilot crop substitution programme in the 
Province of Antioquia, in the north-west of the country. 
542. Peru combines eradication of coca bush and inter-
diction activities with alternative development strategies. 
In San Martín Province in Peru, alternative development 
initiatives have included the replacement of coca bush cul-
tivation with agroforestry that includes the production of 
palm oil, cocoa and coffee. That has enabled the reforest-
ing of 7.5 per cent of former coca bush fields and the plant-
ing of alternative crops covering 650 ha. The latter activity 
involved 350 local families. An additional 687 families were 
involved in 1,315 ha of agroforestry that included coffee 
and cocoa production activities producing “fair trade” and 
organic products. According to the National Drug 
Commission of Peru, 58,000 ha of alternative crops (cof-
fee, cocoa and pineapple) are cultivated every year. The 
Commission built 1,200 miles of rural roads to improve 
access to regional and national markets and, since 2011, 
has helped 70,000 farmers to obtain land titles. 
543. As at 31 December 2015, the area under coca cul-
tivation in Peru was estimated at 40,300 ha, 6 per cent 
less than in 2014 (42,900 ha), confirming the downward 
trend observed since 2011 (when it reached 62,500 ha).
544. In South America, opium poppy is illicitly cultivated 
to a far lesser extent than cannabis and coca bush. In 2015, 
Colombia seized 393 kg of heroin and 25 kg of morphine, 
which was destined for markets in Europe and the United 
States, representing an increase in heroin  seizures and a 
decrease in morphine seizures over the previous year.
545. Trafficking in the region is reported to be facilitated 
by weak justice systems and the lack of effective action 
against corruption and organized crime. Diversification of 
the means of transport used by drug trafficking organiza-
tions operating in South America to minimize the risk of 
detection was reported by various Governments; they 
included trafficking by sea, by air and through the postal 
services, and the use of human couriers. 
546. In the Plurinational State of Bolivia, cocaine seizures 
decreased, from 22.3 tons in 2014 to 21.2 tons in 2015, the 
lowest levels recorded since 2007. Colombia continued to 
be the country with the largest amount of cocaine seized 
annually worldwide. Consistent with the sharp increase in 
coca bush cultivation and potential cocaine production in 
2014 and 2015, seizures of cocaine increased from 209 tons 
in 2014 to 252 tons in 2015. The Government of Colombia 
announced in April 2016 that it would reintroduce the use 
of the herbicide glyphosate, to be sprayed manually, by 
eradication crews, rather than from aircraft.
547. Although the illicit manufacture of cocaine occurs 
mainly (in descending order) in Colombia, Peru and the 
Plurinational State of Bolivia, clandestine laboratories for 
the processing of coca leaf derivatives were also found 
outside those countries, with Argentina, Brazil, Chile and 
Ecuador reporting the detection of such clandestine lab-
oratories. In 2015, laboratories for the illicit manufacture 
of cocaine hydrochloride were reportedly dismantled in 
the Plurinational State of Bolivia (73 laboratories) and 
Colombia (3,850 laboratories).
(b) Psychotropic substances 
548. According to information provided by 
Governments, seizures of amphetamine-type stimulants 
took place in Colombia, Paraguay and Uruguay in 2015. 
Colombia alone seized 121,579 units of “ecstasy” in 2015. 
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549. Information about the non-medical use of phar-
maceuticals and the use of prescription drugs without a 
medical prescription continues to be limited. The Board 
would like to encourage States to enhance their efforts to 
put in place and render fully operational information sys-
tems that allow for the compilation, in a systematic man-
ner, of information on the matter, with a view to 
facilitating the monitoring and assessing of the extent of 
the problem and the functioning of the drug control 
 conventions in that regard. 
(c) Precursors 
550. In 2015, as in previous years, Governments in the 
region continued to report seizures of chemicals under 
international control. The majority of the seizures were 
of substances listed in Table II of the 1988 Convention 
and an increasing number of seizures of non-controlled 
precursor substances was also reported. The largest vari-
ety of substances seized worldwide was in South America, 
owing to the extensive list of substances placed under 
national control by countries in the region.
551. In December 2015, through supreme decree 
No.  348-2105-EF, Peru listed formic acid and n-propyl 
acetate as nationally controlled chemical substances used 
in illicit drug manufacture. 
552. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the report of the Board for 2016 on the implementa-
tion of article 12 of the 1988 Convention.
(d) Substances not under international 
control
553. New psychoactive substances were reported as a 
growing concern in Argentina, Brazil, Chile, Colombia, 
Ecuador and Uruguay. Most of the reported new psycho-
active substances were phenethylamines, synthetic can-
nabinoids, synthetic cathinones, piperazines and 
plant-based substances. 
5. Abuse and treatment
554. The abuse of coca paste is concentrated in South 
America, and the annual prevalence of cocaine abuse con-
tinues to increase, although cannabis remains the most 
widely used controlled substance in the region, 
according to a report published by CICAD. The 
Commission also noted that the annual prevalence rates 
of abuse of cocaine among secondary school students 
were higher in South America than in North America, 
Central America and the Caribbean, with major differ-
ences in the levels of abuse in the analysed countries. 
According to the World Drug Report 2016, the estimated 
annual prevalence rate of cannabis use in South America 
as a whole is 3.2 per cent, based on 2014 figures. The 
annual prevalence of cocaine abuse stands at 1.5 per cent, 
amphetamines and prescription stimulants at 0.9 per cent, 
opioids are estimated at 0.3 per cent and “ecstasy” at 
slightly below 0.2 per cent. 
555. The annual prevalence of cannabis use in the gen-
eral population presented an overall upward trend. 
Annual prevalence rates in Peru rose only minimally 
from 1998 to 2010. In Argentina annual prevalence dou-
bled from 2004 to 2011. Chile saw a similar increase from 
1994 to 2012. Uruguay saw a sixfold increase from 2001 
to 2011, the largest reported. The Government of Uruguay 
confirmed that the annual prevalence of cannabis herb 
abuse remained high (9.3 per cent of the adult 
population).
556. The 2015 report of CICAD showed that the rates 
of cannabis abuse among secondary school students dif-
fered significantly from country to country. For example, 
Ecuador, Peru and Venezuela (Bolivarian Republic of) 
each reported annual prevalence rates of use of less than 
3 per cent, whereas the rate reported for Chile was 28 
per cent. Cannabis use among secondary school students 
increased in all South American countries, except in Peru, 
where there was a minor decline from 2005 to 2012. 
Perceptions of the risks associated with the occasional use 
of cannabis also vary significantly from country to 
country. 
557. The prevalence of past-year use of cocaine in 
South America is similar to that in North America, 
although the majority of cocaine use in North America 
is in salt form, whereas in South America the use of 
cocaine in other forms (base form) appears to be much 
more widespread. Moreover, some of the substances con-
sumed in base form in South America are siphoned off 
from intermediate stages of the cocaine-processing chain, 
when they may still contain high levels of impurities and 
are thus usually considered to be much more toxic and 
have less potential to fetch high prices. The rate of preva-
lence of cocaine use in the general population in Argentina 
increased from 2004 to 2011. The rates in Chile, 
Colombia  and Peru have remained stable, with only 
minor upward and downward movements over the 
years  Uruguay  saw   a  shift from 0.2 per cent to 
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1.9  per  cent  between 2001 and 2011, the largest change 
in South America.
558. Average rates of cocaine abuse among secondary 
school students were higher in South America in com-
parison with North America, Central America and the 
Caribbean. The past-year prevalence rate of cocaine use 
for secondary school students in the region was higher 
in Argentina, Chile and Colombia, followed by Brazil and 
Uruguay. The lowest prevalence rates were found in 
Suriname and Venezuela (Bolivarian Republic of). The 
use of cocaine among secondary school students has 
remained stable in Brazil, Chile and Uruguay, but with a 
minor upward trend. The situation in Peru is similar, but 
showing the reverse trend. Argentina saw a more signifi-
cant increase in annual prevalence from 2001 to 2011. 
Guyana, on the basis of studies conducted in 2007 and 
2013, saw a decreasing trend.
559. The trends in the abuse of coca paste among the 
general population do not show a clear pattern over time. 
Argentina, Bolivia (Plurinational State of) and Chile are 
the countries with the highest prevalence of past-year use 
of cocaine base paste, with rates that range from 0.8 per 
cent to 2.2 per cent. Abuse of cocaine base paste in the 
past 12 months in the general population ranges from 
0.04 per cent to 0.47 per cent, with Chile, Peru and 
Uruguay having the highest rates of abuse. Data for the 
abuse among the general population is similarly scarce, 
but minor trends can be identified. Argentina, Colombia, 
Peru and Uruguay all show relatively stable numbers. 
Chile is the only country to have experienced a down-
ward trend from 1994 to 2012, from almost 1 per cent to 
0.4 per cent.
560. Concerning the trends for the abuse of coca paste 
among secondary school students in those countries of 
South America that have relevant data, a constant charac-
teristic is stability. The annual prevalence rates for secon-
dary school students have been recorded to a limited 
extent only, with just four countries having provided 
enough information to establish trends. Argentina saw an 
increase in the annual prevalence of coca paste use from 
0.5 per cent in 2001 to 1.5 per cent in 2005, then a drop 
to around 1 per cent in 2009, at which level it remained 
until 2011, the last year for which data were available. 
Peru saw relatively stable annual prevalence rates between 
2005 (0.8 per cent) and 2013 (around 1 per cent). In 
Uruguay the annual prevalence rate of use of coca paste 
base among this population group fluctuated between 0.7 
per cent in 2003 and a peak of 1.1 per cent in 2007, then 
fell between 2007 and 2014 to 0.5 per cent. The annual 
prevalence numbers in Chile remained relatively stable 
between 2001 and 2013 at around 2.3 per cent. 
561. Concerning the annual prevalence rates of “crack” 
cocaine abuse in the general population, the lowest preva-
lence rates were reported by Argentina, Brazil, Chile and 
Paraguay. Regarding “crack” cocaine abuse among sec-
ondary school students, the lowest annual prevalence 
rates (less than 0.5 per cent), were found in Argentina, 
Brazil, Ecuador, Suriname and Venezuela (Bolivarian 
Republic of). 
562. Concern over rising levels of abuse of synthetic 
drugs among young people in South America also con-
tinued to grow in 2015. High annual prevalence rates of 
abuse of amphetamine-type stimulants among young 
people were reported in the region. According to the 
 latest information provided by Chile for 2015, 2.6 per cent 
of 15-16 year olds had used “ecstasy” in the past 12 
months. Figures provided by Argentina for 2014 indicated 
that the annual prevalence rate for the use of “ecstasy” 
for the same age group was 1.6 per cent.
563. According to CICAD, the past-year prevalence of 
the use without a medical prescription of tranquillizers 
(excluding opioids and analgesics) among secondary 
school students in several countries of the region, namely 
Bolivia (Plurinational State of), Chile, Paraguay and 
Suriname, was higher than 6 per cent. The past-year 
preva lence in Argentina, Colombia, Ecuador, Guyana and 
Peru was less than 3 per cent. 
564. The appearance of plant-based psychoactive sub-
stances on the drug market in South America raises con-
cerns. In the past, they were destined solely and exclusively 
for the religious rites of the indigenous peoples of the 
Americas. However, data from the most recent surveys 
show that young people from other backgrounds were 
abusing such substances. Those most frequently reported 
were Salvia divinorum and khat. Specifically in Colombia, 
hallucinogenic mushrooms, ayahuasca and cacao saba-
nero, the psychoactive component of which is the alka-
loid scopolamine, were reported. The use of those 
plant-based substances in Colombia was reported to be 
higher than the use of other drugs.62 Drug treatment in 
South America is mainly concerned with the abuse of 
cocaine, which accounts for nearly half of all individuals 
enrolled in drug treatment programmes in the region. 
According to a national study on patients receiving treat-
ment in Argentina in 2010, including for  alcohol- and 
tobacco-related addictions, 38 per cent had requested 
treatment for cocaine addiction. 
62 “Other drugs” in this case refers to LSD, “ecstasy”, ketamine, 
 methamphetamine and 4-bromo-2,5-dimethoxyphenethylamine (2C-B).
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565. According to the Joint United Nations Programme 
on HIV/AIDS (UNAIDS), more than 2 million people are 
living with HIV in Latin America and the Caribbean, 
with 100,000 new infections in 2015. In Brazil, the need 
was identified to scale up voluntary HIV testing and 
counselling, including among people who use drugs and 
are at risk of HIV infection. In response, UNODC, in 
cooperation with the Ministry of Health, has supported 
strategic prevention projects with 38 non-governmental 
organizations under the initiative Viva Melhor Sabendo 
(“Live better knowing it”) to develop HIV prevention, 
treatment and care among people who regularly use 
cocaine and “crack” cocaine. Also in Brazil, UNODC, 
jointly with the municipal AIDS programme, supported 
the programme De Braços Abertos (“Open arms”), which, 
as at December 2015, had reached over 1,300 people who 
use “crack” cocaine, of whom nearly 10 per cent are liv-
ing with HIV. The programme has provided them with 
job opportunities, housing and improved access to health 
services. 
566. In Argentina, over 60 health and social care  service 
providers and representatives of civil society organiza-
tions were trained in addressing the HIV risks and vul-
nerability of people who use drugs, improving awareness 
among health service providers and supporting the crea-
tion of low-threshold community-based HIV services for 
people who use drugs.
C. Asia
East and South-East Asia
1. Major developments
567. Illicit opiate production and trafficking continue to 
be a major concern for the region, as illicit cultivation of 
opium poppy continues to increase. In 2015, the total area 
under illicit cultivation of opium poppy remained high 
in Myanmar for the third consecutive year, amounting to 
an estimated 55,500 ha. A much smaller, although signifi-
cant amount, of illicit opium poppy cultivation was 
reported in the Lao People’s Democratic Republic. The 
proportion of opiates originating in those countries that 
have been seized by neighbouring countries during the 
past few years has continued to increase. Driven by the 
lucrative profits in the largest market within the region, 
the two-way trafficking in opium and precursor chemi-
cals between China and Myanmar continues. 
568. Further growth in the manufacture of, trafficking 
in and misuse of amphetamine-type stimulants, in par-
ticular methamphetamine, has become one of the biggest 
obstacles to the region’s supply and demand reduction 
efforts. A large amount of methamphetamine continues 
to be seized by most countries in East and South-East 
Asia. An increasing number of source countries, more 
diversified trafficking routes and greater connectivity 
within the region have increased the need for effective 
joint-border collaboration. Further increases in the abuse 
of methamphetamine have become increasingly problem-
atic, as relevant treatment capacities and facilities are still 
lacking in most countries. 
569. The markets for new psychoactive substances con-
tinue to expand, fuelling a major public health concern 
in the region. The recent trend of mixing new psycho-
active substances with amphetamine-type stimulants such 
as MDMA pose serious challenges to health-care provid-
ers and drug control authorities. Measures taken by 
crimi nal organizations to circumvent existing controls are 
likely to persist, as existing legislation in most countries 
is, at present, ill-suited to addressing the emergence and 
growing diversity of new psychoactive substances.
2. Regional cooperation
570. The level of cooperation in the region has been 
extensive. Ministers attending the 4th Association of 
Southeast Asian Nations (ASEAN) Ministerial Meeting 
on Drug Matters, held in Langkawi, Malaysia, on 29 
October 2015, welcomed the institutionalization of the 
Meeting as a body under the ASEAN Political-Security 
Community and endorsed the ASEAN position state-
ment, in which the commitment of ASEAN to a zero- 
tolerance approach to drugs in realizing its aspiration of 
a drug-free ASEAN region, the importance of a compre-
hensive and balanced approach towards drug control, and 
support for the international drug control conventions 
were reaffirmed. 
571. Jointly organized by UNODC, under the global 
Synthetics Monitoring: Analysis, Reporting and Trends 
(SMART) programme and the National Narcotics Control 
Commission of China, the seventh regional SMART 
workshop included discussions on the production of, 
misuse of and trafficking trends in non-controlled sub-
stances (synthetic drugs and ketamine). New trends, 
including trafficking facilitated by the Internet, were also 
discussed. 
572. The Thirty-ninth Meeting of Heads of National 
Drug Law Enforcement Agencies, Asia and the Pacific, 
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held in Bangkok from 19 to 22 October 2015, enabled 
law enforcement officers to exchange views on the chal-
lenges brought forth by faster regional integration on 
drug control. Measures to facilitate regional cooperation 
in law enforcement, border management and joint 
 operations were discussed. 
573. The twenty-first Asia-Pacific Operational Drug 
Law Enforcement Conference, held in Tokyo in February 
2016 and organized by the National Policy Agency of 
Japan, brought together officials from within the region 
and, for the first time, Africa, Europe and the Americas, 
as drug-related matters become increasingly intertwined 
across regions.
574. In July 2016, competent national authorities from 
South and East Asia and the Pacific attended an INCB 
training workshop. Experts from 19 Governments 
received training on the technical reporting requirements 
of the three international drug control conventions and 
on the use and application of new INCB tools, including 
I2ES and PEN Online. During the workshop, major 
obstacles to the availability of narcotic drugs and psycho-
tropic substances for medical and scientific purposes were 
considered, and the implementation of recommendations 
made to Governments to facilitate access to and the avail-
ability of those drugs and substances were highlighted. 
575. Senior officials from the six countries in the 
Greater Mekong subregion (Cambodia, China, Lao 
People’s Democratic Republic, Myanmar, Thailand and 
Viet Nam) met in May 2016 and agreed to coordinate 
and integrate their drug control efforts through the adop-
tion of an action plan. Participating countries restated 
the urgent need to involve neighbouring countries and 
called for a balanced approach to the implementation of 
the action plan, which incorporated law enforcement, 
criminal justice, alternative development and health 
responses. 
576. As part of the region’s endeavour to transition 
towards a community-based treatment approach, senior 
representatives of nine countries (Cambodia, China, 
Indonesia, Lao People’s Democratic Republic, Malaysia, 
Myanmar, Philippines, Thailand and Viet Nam) attended 
the Third Regional Consultation on Compulsory Centres 
for Drug Users, which was held in Manila from 21 to 23 
September 2015. A road map to accelerate the move 
towards evidence-based prevention, treatment and sup-
port services for people who abuse drugs was drafted. The 
representatives adopted recommendations on the transi-
tion to voluntary community-based treatment services for 
people who abuse drugs, clustered around the following 
three pillars of action: (a) the development of national 
transition plans; (b) the review of national policies that 
restrict voluntary access to community-based treatment 
programmes; and (c) the building of capacity to provide 
voluntary services, including treatment. 
3. National legislation, policy and 
action
577. In the Philippines, a manual to guide the establish-
ment of community-based treatment and care services 
for  persons who abuse drugs was launched in 
September   2015, signifying a first step in efforts to 
 establish community-based tertiary prevention facilities. 
578. Reports of acts of violence and murder in the 
Philippines committed against individuals suspected of 
involvement in the illicit drug trade or of drug abuse, 
which may have been encouraged or condoned by mem-
bers of the Government since July 2016, came to the 
Board’s attention. The Board issued a statement calling 
on the Government of the Philippines to issue an imme-
diate and unequivocal condemnation and denunciation 
of extrajudicial actions against individuals suspected of 
involvement in the illicit drug trade or of drug abuse, to 
put an immediate stop to such actions, and to ensure that 
the perpetrators of such acts are brought to justice in full 
observance of due process and the rule of law. The Board 
wishes to bring once again to the attention of all 
Governments that extrajudicial action, purportedly 
taken in pursuit of drug control objectives, is funda-
mentally contrary to the provisions and objectives of the 
three international drug control conventions, under 
which all actions must be undertaken within the due 
process of law. 
579. A number of countries in East and South-East 
Asia continue to apply the death penalty for drug-
related offences; the Board wishes to draw the attention 
of all Governments to its statements issued in March 
2014 and in August 2016 on the subject and to reite rate 
its call to all States that retain the death penalty for 
drug-related offences to commute death sentences that 
have already been handed down and to consider the 
abolition of the death penalty for drug-related offences. 
580. Amendments and changes to national legislation 
to strengthen the scope of control over new psychoactive 
substances continued in 2015, as the region dealt with the 
continued emergence of such substances. In Hong Kong, 
China, the definition of synthetic cannabinoids under the 
Dangerous Drugs Ordinance (cap. 134) was amended in 
November 2015 to enlarge its scope. Meanwhile, NBOMe 
compounds were added to the first schedule of the 
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Ordinance, following the decision of the Commission on 
Narcotic Drugs to include 25B-NBOMe (2C-B-NBOMe) 
in Schedule I of the 1971 Convention. 
581. Following the scheduling of 116 new psychoactive 
substances in October 2015 in China,63 the Central 
Narcotics Board of Singapore listed 20 new psychoactive 
substances and one tryptamine generic group in the first 
schedule of the Misuse of Drugs Act in May 2016. They 
had previously been listed in the fifth schedule of that 
Act. Two new substances, MT-45 and para-methyl-
4-methylaminorex (4,4’-DMAR), were also listed in the 
first schedule, following the decision of the Commission 
on Narcotic Drugs to include MT-45 in Schedule I of the 
Single Convention on Narcotic Drugs of 1961 as amended 
by the 1972 Protocol and 4,4’-DMAR in Schedule II of 
the 1971 Convention. As a pre-emptive measure to restrict 
the circulation of new psychoactive substances, four new 
substances (methyl 2-[[1-(cyclohexylmethyl)indole-3-car-
bonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA), 
THJ-018, NM-2201 and 5F-NNE1) were listed in the fifth 
schedule of the Misuse of Drugs Act.
582. Some modifications were made to the criminal 
law of China in order to strengthen the legal basis for its 
precursor control and prevent the illicit manufacture of 
and trafficking in precursor chemicals. Specifically, the 
ninth amendment to the country’s criminal law became 
effective in November 2015, whereby article 350 was 
amended to include both the crime of illegal precursor 
chemicals manufacture and the crime of illegal precursor 
chemicals trafficking. That means that a higher prescribed 
penalty will be applied for committing those crimes. 
583. The Government of the Lao People’s Democratic 
Republic completed drafting the “National Drug Control 
Master Plan for 2016-2020” in November 2015; similar 
national plans were adopted in Myanmar, the Philippines 
and Thailand in 2014. The Plan provides an overarching 
framework for the Government’s efforts in drug control 
and highlights nine elements as guiding principles: 
expanding evidence-based policymaking; promoting 
 integrated alternative development; reducing the harm 
associated with drug use; preventing drug use; using law 
enforcement strategically; effectively decriminalizing 
drug use; regulating precursors and strengthening foren-
sic laboratories; strengthening cooperation; and develop-
ing capacity. A greater emphasis is now placed on 
coordinating and integrating the work of all relevant 
stakeholders in the country for more targeted interven-
tion and greater efficiency.
63 E/INCB/2015/1, para. 502.
584. In Japan, the Act on the Suspension of Execution 
of a Part of a Sentence for Persons who Committed the 
Crime of the Use of Drugs, became effective on 18 June 
2016. The Act was introduced to ensure a rehabilitation 
period as an alternative to incarceration for persons con-
victed of using drugs. Under the Act, when a person is 
sentenced to imprisonment with or without labour for 
not more than three years for the use of drugs, there is 
an option to suspend the execution of part of the 
 sentence.  The period of such suspension is between one 
and five years, during which the drug offender is on 
 probation and is given rehabilitation services, including 
undertaking community service.
585. In 2015, authorities in China distributed the 
Work Plan on Community-Based Drug Treatment and 
Rehabilitation (2016-2020). The Plan outlines the support 
and assistance to be provided to local governments to 
integrate persons who abuse drugs after treatment and 
rehabilitation, with a focus on increasing their employa-
bility and implementing social insurance policies. 
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
586. Illicit cultivation of opium poppy continued to be 
concentrated in the Lao People’s Democratic Republic 
and Myanmar, particularly in the Shan State in Myanmar, 
and has displayed no sign of weakening. The total area 
under illicit opium poppy cultivation in Myanmar was 
estimated at 55,500 ha in 2015: one fifth of the total global 
illicit opium poppy cultivation took place in Myanmar, 
and the country remained the second-largest opium- 
producing country in the world. After reaching a low of 
fewer than 25,000 ha in 2006, illicit opium poppy 
 cultivation increased and then stabilized at the current 
level in 2013. Meanwhile, a smaller yet significant amount 
of illicit  cultivation (5,700 ha) was recorded in the Lao 
People’s Democratic Republic. With a combined esti-
mated 800 tons of opium production in 2015, those two 
countries continued to be the main suppliers within the 
region and major suppliers within Oceania and South 
Asia. Continuation of the increasing trend, however, has 
put them at risk of reversing the positive gains made over 
the last decade.
587. Regional seizure data over the past few years 
point to an increase in the trafficking of opiates from the 
Lao People’s Democratic Republic and Myanmar. That 
increase is reflected in both the total amount of heroin 
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seized and the share of seized heroin originating in the 
region. Heroin and morphine seizures in East and South-
East Asia more than doubled between 2008 and 2014, 
from 5.7 tons to 13 tons. Accounting for more than 
30  per cent of the seized opiates in South-East Asia and 
Oceania in 2008, opiates originating in or departing from 
Afghanistan and Pakistan constituted only 10 per cent of 
opiates seized in the region in 2014. The trend was per-
haps even more noticeable when focusing on China, 
where the proportion of seizures of heroin originating in 
Afghanistan fell from 30 per cent in 2010 to less than 10 
per cent in 2014 and 2015: most heroin seized originated 
in the Lao People’s Democratic Republic, Myanmar and 
Viet Nam. 
588. As the largest heroin market and chemical- 
producing country in the region, China continued to be 
affected by the trafficking of heroin into its territory and 
to be the origin of precursor chemicals being smuggled 
to neighbouring countries. The majority of heroin manu-
factured in Myanmar is trafficked by land across the 
 border to Yunnan Province in China, and a significant 
amount of precursor chemicals (mostly acetic anhydride) 
has been smuggled from China into Myanmar for opiate 
production. Such two-way trafficking continued in 2015, 
with about 8.8 tons of heroin (mostly originating in the 
Lao People’s Democratic Republic and Myanmar) seized 
in China, and 260 litres of acetic anhydride coming from 
China seized in Myanmar. Slight decreases in the amount 
of heroin seized were reported by Myanmar and Singapore, 
as well as by Hong Kong, China, for 2015. 
589. Illicit cultivation of cannabis plant continued in 
some countries in East and South-East Asia. Recent erad-
ication of illicitly cultivated outdoor cannabis herb was 
reported by the following countries: Indonesia (122 ha), 
Philippines (28 ha), Myanmar (15 ha) and Viet Nam 
(2 ha). The latest seizure data suggest that a considerable 
amount of trafficking continues to occur within the 
region. In 2015, about 29 tons of cannabis herb were 
seized in Indonesia. A total of 8.7 tons of cannabis herb 
were seized in China in 2015, much more than in previ-
ous years: the yearly average between 2010 and 2014 was 
about 3.7 tons. Cambodia and Singapore also reported 
slight increases in the amount of cannabis seized com-
pared with the previous year. At about 100 kg in 2015, 
the amount of cannabis herb seized remained steady in 
Japan compared with the previous year. 
590. The amount of cocaine trafficked among countries 
in East and South-East Asia has been rather insignificant 
for a long time. As drug markets across regions become 
more connected and diverse, however, a greater amount 
of cocaine has been seized within the region, implying its 
rising popularity. The total amount of cocaine seized in 
Asia rose from an average of 0.45 tons per year during 
the period 1998-2008, to 1.5 tons per year during the 
period 2009-2014. East and South-East Asia accounted 
for more than half of that increase. Significant seizures 
were reported by some countries in 2015. For instance, 
in Hong Kong, China, around 200 kg of cocaine were 
seized. Authorities in Viet Nam seized 31 kg of cocaine 
in a container inspection in May 2015, the largest cocaine 
seizure in the country’s history. 
(b) Psychotropic substances
591. The region continues to see growth in trafficking 
in amphetamine-type stimulants, especially methamphet-
amine. The trend is evident in the amount of metham-
phetamine seized, which almost quadrupled in the region 
between 2009 and 2014. Worryingly, that upward trend 
continued in 2015: close to 36.6 tons of methampheta-
mine were seized in China during that year, an increase 
of 35 per cent compared with 2014. A significant rise in 
the amount of methamphetamine seized was also noted 
in Myanmar, where close to 2.3 tons were seized in 2015, 
which was much more than in the previous year. Similarly, 
the amount of methamphetamine seized by authorities in 
Indonesia in 2015 (4.4 tons) was four times higher than 
that seized in 2014 (1.1 tons). 
592. Diversification in the source of methamphetamine, 
since 2009, was also noticed by law enforcement officers 
in the Republic of Korea. African countries, including 
Ghana, Kenya, Mali and South Africa, have been identi-
fied as likely source countries of methamphetamine enter-
ing the country. For example, about 4 kg of crystalline 
methamphetamine were trafficked into the Republic of 
Korea from Kenya during the period 2012-2013, and 4 kg 
of methamphetamine were identified as coming from 
Mali in both 2011 and 2013.
593. The large-scale manufacture of and trafficking in 
crystalline methamphetamine, which has a higher purity 
than methamphetamine pills, continue to pose significant 
threats to countries in the region. For instance, contin-
ued growth in the manufacture of crystalline metham-
phetamine was observed in China in 2015, despite years 
of efforts to dismantle the large number of clandestine 
laboratories manufacturing the substance. Close to 500 
cases of illicit manufacturing were uncovered in China in 
2015, an increase of 17.2 per cent over the year before. 
Indications of significant manufacture of crystalline 
methamphetamine in Myanmar have also been noticed 
by the country’s authorities.
76  INCB REPORT 2016
594. The growing popularity of crystalline methamphet-
amine across the region is particularly visible when focus-
ing on countries where methamphetamine pills have been 
identified as the most commonly abused drug. For 
instance, seizures of crystalline methamphetamine 
 continued to be reported by Thailand in 2015. Spurred 
on by higher profit margins, the growing availability of 
crystalline methamphetamine has also been reported in 
the Lao People’s Democratic Republic, particularly in 
Vientiane, in major tourist destinations and in the 
 southern provinces. 
595. UNODC estimated that a total of approximately 
244 million methamphetamine tablets were seized within 
the region in 2014. In July 2015, the largest single seizure 
of methamphetamine pills was reported in Myanmar, 
where close to 26.7 million methamphetamine pills were 
seized. According to the authorities in Thailand, most 
methamphetamine pills being trafficked into the country 
were manufactured in Myanmar, despite a slight reduc-
tion in total seizures in 2015. The amount of metham-
phetamine pills seized outside the Mekong region, for 
instance in Singapore (142 tablets), was insignificant in 
comparison.
596. East and South-East Asia have reported an 
increasing number of varieties of and substitutes for 
“ecstasy” during recent years, a likely result of tightened 
control over the major precursors used in the manufac-
ture of the substance. Seizures of “ecstasy” containing 
 little or no MDMA, but mainly a blend of non-controlled 
substances, have been reported throughout the region (in 
Brunei Darussalam; Hong Kong, China (including new 
psychoactive substances); Indonesia (including new psy-
choactive substances); Macao, China; Malaysia; Republic 
of Korea; Singapore (including new psychoactive sub-
stances); and Thailand). In 2015, about 3,000 tablets and 
2,000 tablets of “ecstasy”-type substances were seized in 
the Philippines and Indonesia, respectively. In the same 
year, China also reported seizures of close to 200 kg of 
“ecstasy”-type substances. 
(c) Precursors
597. As opium poppy cultivation and demand for 
amphetamine-type stimulants continue to grow, illicit 
manufacture and trafficking of precursor chemicals into 
the region persist. Significant quantities of the chemicals 
required for the manufacture of heroin (acetic anhydride) 
and amphetamine-type stimulants (ephedrine and 
pseudo ephedrine) have been trafficked from China and 
India to various countries, as frequently noted by law 
enforcement within the region. In Cambodia in 2014, 
authorities seized significant amounts of ephedrine and 
other precursor chemicals. In China in 2015, more than 
500 cases of illicit manufacture of drug precursors were 
uncovered and close to 1,600 tons of precursors were 
seized. 
598. The presence of sizeable chemical manufacture 
within the region has heightened the risk of diversion of 
precursor chemicals from licit channels to illicit manu-
facture and trafficking. According to authorities in China, 
an industry chain involved in the illicit manufacture of 
and trafficking in precursor chemicals has been formed 
in different parts of the country over recent years. In addi-
tion, the replacement of precursor chemicals under inter-
national control with non-scheduled ones since 2012, 
namely the replacement of ephedrine compound prepa-
ration and Ephedra plant with 2-bromopropiophenone, 
also presents significant challenges to effective precursor 
control.
599. As closer economic integration and more com-
plex supply chains connecting China, India and the 
ASEAN region develop, organized criminal groups seek-
ing to divert precursor chemicals into illicit channels 
might exploit the opportunities associated with that 
increased interconnectedness. The timely exchange of 
real-time intelligence between chemical companies and 
law enforcement authorities, and the sharing of informa-
tion among all authorities concerned, is of great relevance 
to curbing the illicit manufacture of and trafficking in 
precursor chemicals in the region. 
600. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the report of the Board for 2016 on the implementa-
tion of article 12 of the 1988 Convention. 
(d) Substances not under international 
control
601. The global trend of ketamine seizures has been 
dominated by the trafficking in the substance in coun-
tries in East and South-East Asia since 2012. The total 
amount of ketamine seized within the region increased 
from 6 tons in 2012 to more than 12 tons in 2014, 
accounting for almost all of the ketamine seized world-
wide. In particular, the amount of ketamine seized in 
China more than quadrupled, from 4.7 tons in 2012 to 
19.6 tons in 2015. Recent intelligence in Hong Kong, 
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China, revealed that ketamine is being smuggled in small 
quantities in order to evade detection and minimize 
financial loss upon interdiction. Additionally, indications 
that it is being manufactured and misused in the region 
have also raised concern. Having dismantled about 100 
ketamine laboratories per year during the recent past, 
close to 200 cases of ketamine manufacture were uncov-
ered in China in 2015, an increase of 12.4 per cent over 
2014. The first clandestine ketamine laboratory in 
Malaysia was dismantled in August 2016. At the same 
time, 269 kg of liquid and crystallized ketamine were 
seized. According to the World Drug Report 2016, there 
are expert perceptions of increases in the non-medical 
use of ketamine in East and South-East Asia. 
602. Sometimes sold under the street names given to 
amphetamine-type stimulants, new psychoactive sub-
stances continue to be manufactured and trafficked within 
the region. In Singapore, the amount of new psycho active 
substances seized has increased considerably, from 470 
tablets in 2014 to over 3,000 tablets in 2015. Considered 
one of the major manufacturing countries of new 
 psychoactive substances, a number of new synthetic 
 cannabinoids, cathinones, phenylethylamines and 
 piperazines were identified by China, following tighter 
control and the scheduling of 116 new psychoactive sub-
stances since October 2015. Authorities also reported the 
recent expansion of the manufacture of and trafficking in 
new psychoactive substances from the Yangtze River 
Delta to other parts of the country. Significant increases 
in the amount of synthetic cathinones seized were 
reported by Hong Kong, China, in 2015, alongside a surge 
in the number of newly identified substances belonging 
to that family of substances worldwide. 
603. The region continued to report on the trafficking 
in and presence of plant-based psychoactive materials 
belonging to the khat (Catha edulis) group and kratom 
(Mitragyna speciosa) group, the former of which originates 
in plants native to East Africa and the Arabian Peninsula. 
Two seizures, amounting to 4.4 tons of khat coming from 
East Africa, were reported by Viet Nam in mid-2016. In 
2014, the presence of three plant-based psychoactive 
materials belonging to the khat group were reported by 
China and Indonesia. Meanwhile, the presence of three 
plant-based psychoactive materials belonging to the 
kratom group were reported by Indonesia and Thailand. 
5. Abuse and treatment
604. Although the global trend of abuse of amphetamine- 
type stimulants remained stable, increases have been 
reported in East and South-East Asia. That is evident in 
terms of the number of countries reporting them as both 
the most commonly abused drugs and the primary drugs 
of concern among new users. Caution must be exercised 
in interpreting the data, however, as recent, reliable data 
on the prevalence of drug use among the general popu-
lation within the region remain scarce, and the continu-
ous emergence of new psychoactive substances sold under 
the street names of amphetamine-type stimulants further 
complicates the picture. The Board encourages countries 
in the region to further strengthen their work in drug 
abuse data collection and analysis. 
605. Annual prevalence of the use of amphetamines 
and prescription stimulants in East and South-East Asia 
in 2014 (0.57 per cent) is lower than the global average 
(0.8 per cent). In 2014, slightly more than 9 million peo-
ple were estimated to be abusing amphetamines and pre-
scription stimulants within the region, accounting for 
about a quarter of the global population of people abus-
ing amphetamines and prescription stimulants 
(35 million).
606. Dominance of the two main forms of methamphet-
amine (crystalline methamphetamine and methampheta-
mine pills) varied slightly across the region. As the 
primary drug of concern outside the Mekong area, crys-
talline methamphetamine was most commonly abused in 
Brunei Darussalam, Indonesia, Japan, the Philippines and 
the Republic of Korea. Methamphetamine tablets were 
most commonly abused in Cambodia, the Lao People’s 
Democratic Republic and Thailand. 
607. Increases in the rates of abuse of methampheta-
mine have been identified in the region, despite it not 
being the most widely abused drug in some countries. 
According to the World Drug Report 2016, Cambodia, 
China, Malaysia and Viet Nam saw increases in the preva-
lence of abuse of both crystalline methamphetamine and 
methamphetamine tablets in 2014. Myanmar and the 
Philippines also saw increases in the abuse of crystalline 
methamphetamine and methamphetamine pills. In 
Singapore, methamphetamine overtook heroin as the 
most commonly abused drug in 2015. At the same time, 
amphetamine-type stimulants accounted for the main 
drug used by over 70 per cent of newly registered drug 
users in China. 
608. In 2014, people receiving treatment for metham-
phetamine abuse in Brunei Darussalam, Cambodia, the 
Philippines, Singapore and Thailand made up the major-
ity of people treated for drug abuse in those countries. 
Given the difficulties of treating methamphetamine addic-
tion, the increase in its use has been straining the 
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limited treatment facilities in some countries, such as the 
Lao People’s Democratic Republic. 
609. The trend of injecting amphetamine-type stimu-
lants has been reported by some countries in East and 
South-East Asia. In Cambodia, methamphetamine, in the 
form of either crystalline methamphetamine or metham-
phetamine pills, was abused by most persons who inject 
drugs. In Thailand, a study conducted among 650 self-
reported HIV-positive persons who abuse drugs by injec-
tion showed that daily methamphetamine use was 
associated with syringe sharing.
610. Annual prevalence of the use of opiates in East 
and South-East Asia in 2014 (0.21 per cent) is lower than 
the global average (0.37 per cent). In 2014, more than 3.3 
million people were estimated to be abusing opiates 
within the region, accounting for almost one fifth of the 
global population of people abusing opiates (17.4 mil-
lion). Considered as the primary drug of concern in 
Malaysia, Myanmar and Viet Nam, opiates were found to 
be abused by a large number of people in China, 
Indonesia, the Lao People’s Democratic Republic and 
Thailand. About 1.5 million people who abuse heroin 
were registered in 2015 in China, slightly more than the 
year before, but they represent a smaller share among the 
total number of registered drug users in the country. That 
decrease suggests the diminishing popularity of heroin, 
while the opposite trend has been observed for registered 
users of amphetamine-type stimulants. 
611. With an estimated 3.15 million people who inject 
drugs, East and South-East Asia continues to be the 
region with the largest number of people who inject drugs 
and accounts for about a quarter of the global total. The 
public health risk of a higher prevalence rate of HIV 
among people who inject drugs has been seen in some 
of the region’s countries. Relevant interventions and treat-
ment therefore should be expanded and made accessible 
to target groups, particularly in Cambodia, Indonesia, 
Myanmar and the Philippines, where the HIV prevalence 
rate among persons who abuse drugs by injection was 
estimated at more than twice the regional average 
(10.5 per cent) in 2015.
612. The Government of China has devoted consider-
able resources to the provision of community-based drug 
treatment and rehabilitation services to drug-dependent 
persons. In 2015, authorities selected 37 national model 
units and 51 national model sites for community-based 
drug treatment and rehabilitation. Close to 230,000 peo-
ple were receiving community-based drug treatment ser-
vices and a further 91,000 were enrolled in drug 
rehabilitation programmes. 
South Asia
1. Major developments
613. In 2015, South Asia continued to be particularly 
vulnerable to trafficking in opiates and heroin. Trafficking 
in cannabis, synthetic drugs and new psychoactive sub-
stances also persisted in the region. In addition, the 
region continued to witness increases in the manufactur-
ing of and trafficking in methamphetamine, the diversion 
of controlled substances from licit to illicit channels and 
the abuse of pharmaceutical preparations containing nar-
cotic drugs and psychotropic substances. Bhutan started 
using buprenorphine for the treatment of opioid depend-
ence in 2015.
2. Regional cooperation
614. Sixty-fifth anniversary celebrations for the Colombo 
Plan for Cooperative Economic and Social Development 
in Asia and the Pacific were held in Colombo on 1 July 
2016. The Colombo Plan has provided several services 
and programmes in the countries of the region since its 
establishment. The Drug Advisory Programme of the 
Plan, in particular, addresses the growing drug problem 
in the region and promotes regional cooperation that is 
aimed at building capacity in the areas of drug abuse and 
drug control, drug demand reduction, precursor chemi-
cal control, border protection, abuse of pharmaceutical 
preparations and trafficking, and forensic drug analysis. 
615. Between February and December 2016, India was 
the Chair of the BRICS countries Anti-Drug Working 
Group, whose membership also comprises Brazil, China, 
the Russian Federation and South Africa. The Working 
Group discusses various issues related to drug trafficking, 
including the diversion of precursor chemicals, new psy-
choactive substances, maritime drug trafficking, narco-
terrorism and the laundering of the proceeds of drug 
trafficking, with the aim of enhancing cooperation among 
the participating countries to deal with such problems.
616. The Narcotics Control Bureau of India and the 
Central Narcotics Bureau of Singapore signed a memo-
randum of understanding on 24 November 2015 to facili-
tate and enhance cooperation in order to combat 
trafficking in narcotic drugs, psychotropic substances and 
their precursors.
617. The Colombo Plan International Centre for 
Certification and Education of Addiction Professionals, 
together with the Drug Advisory Programme of the 
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Colombo Plan, held several training events in the region 
for national trainers on the universal treatment curricu-
lum for substance use disorders. In November 2015 and 
February 2016, treatment practitioners from the region 
received training on the child substance use disorder 
treatment programme.
618. With the aim of facilitating the collection, analysis 
and sharing of information related to drug trafficking and 
other forms of transnational organized crime between 
Bangladesh, Bhutan, India, Maldives, Nepal and Sri Lanka 
and to improve inter-agency regional cooperation between 
law enforcement agencies in the region, UNODC contin-
ued to assist in the creation of a South Asian regional 
intelligence and coordination centre on transnational 
organized crime. Two expert group meetings were held 
with key government counterparts from the region to 
 discuss the proposed options for creating the centre. 
3. National legislation, policy and 
action
619. Bhutan introduced computer-based training in 
order to upgrade the capacity of drug law enforcement 
officials and financial institutions to combat drug-related 
crime and money-laundering. Twenty-two law enforce-
ment officers from Bhutan participated in the first 
 e-learning training course, organized by UNODC and 
held in Faridabad, India, in November 2015.
620. Following Commission on Narcotic Drugs deci-
sion 58/3, to include AH-7921 in Schedule I of the 1961 
Convention as amended, in June 2016, the Government 
of India, through the Narcotic Drugs and Psychotropic 
Substances (Amendment) Rules, 2016, also brought 
AH-7921 under national control, under the Narcotic 
Drugs and Psychotropic Substances Act, 1985.
621. In 2016, the Central Bureau of Narcotics of India 
established an online registration system for controlled 
substances and made registration in the system manda-
tory for all those involved in the manufacture, sale, dis-
tribution, possession, or consumption of narcotic drugs, 
psychotropic substances and chemical precursors 
 commonly used in the manufacture of narcotic drugs and 
psychotropic substances.
622. The revised national drug law of Bhutan, entitled 
Narcotic Drugs, Psychotropic Substances and Substance 
Abuse Act of Bhutan 2015, was enacted in 2015. The Act 
repeals the 2005 law and addresses the health dimension 
of drug abuse, while emphasizing both supply and 
demand reduction. The Act also establishes a clear 
difference between drug users and traffickers by setting 
out a threshold for the quantities that can be considered 
for personal use.
623. To improve security and prevent the illegal use of 
airports in transnational organized criminal activities, 
including drug and precursor trafficking, Maldives, Nepal 
and Sri Lanka joined the Air Cargo Programme of 
UNODC (part of the Container Control Programme).
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
624. The Narcotics Control Bureau of India reported the 
following number of cases in which drugs were seized in 
2015: cannabis (8,130), heroin (3,931) and cannabis resin 
(2,295). The number of cannabis seizures increased by 
47  per cent, but the total quantity of cannabis seized 
decreased. Illicit cultivation of cannabis plant was reported 
to be just over 313 ha in 2015. Eradication operations 
were undertaken by law enforcement authorities in all 
identified areas of cultivation. Cannabis is one of the most 
widely abused substances in India. Trafficking of  cannabis 
from Nepal to India continued to be a major concern. 
625. Bangladesh is exposed to drug trafficking across 
the borders it shares with India and Myanmar. Bangladesh 
also has a history of illicit cannabis production and con-
sumption; cannabis remains the main substance of abuse 
in the country. The total amount seized increased from 
35 tons in 2014 to 41 tons in 2015.
626. Illicit cultivation and the wild growth of canna-
bis were reported in the highlands of the western and 
central parts of Nepal. Although the Government carries 
out cannabis eradication campaigns on a yearly basis, 
illicit cultivation continued in the reporting period. 
Cannabis was trafficked to India across the shared bor-
der. Nepal reported seizures of over 6.6 tons of cannabis 
in 2015, slightly lower than the 6.9 tons seized in 2014.
627. Bhutan reported eradication of cannabis plants in 
various parts of the country. In some areas, assistance in 
growing cash crops was given to farmers to provide them 
with an alternative to cultivating cannabis plants.
628. Cannabis and heroin are the major drugs of abuse 
in Sri Lanka. Cannabis plant is illicitly cultivated in the 
country and abuse of cannabis has become a significant 
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problem. About 99 kg of cannabis were seized in the first 
half of 2016, which was comparable to the amount seized 
during the same period in 2015, as well as 3 kg of 
 cannabis  resin. 
629. In India, cannabis resin seizures in 2015 increased 
by 46.8 per cent compared with the previous year 
(3.3  tons, up from 2.28 tons seized in 2014). In addition 
to being produced domestically, cannabis resin is also 
trafficked into India from Nepal. In 2015, cannabis resin 
of Nepalese origin represented 21.9 per cent of the total 
amount of the substance seized in India.
630. The quantity of heroin seized in India increased 
slightly, to just under 1.42 tons in 2015, from 1.37 tons 
reported in 2014. The State of Punjab, which shares a bor-
der with Pakistan, accounted for most of the South-West 
Asian heroin seized in India. Trafficking of heroin from 
South-West Asia to India and then to Sri Lanka, Maldives 
and countries in Western Europe was identified by the 
Narcotics Control Bureau of India as a major trafficking 
trend.
631. The amount of heroin trafficked into Sri Lanka 
continued to increase in 2016. Seizure data for the first 
half of 2016 indicated a sharp increase over the same 
period of the previous year. The Police Narcotics Bureau 
reported that 134 kg of heroin had been seized between 
January and June 2016, compared with 18 kg during the 
same period in 2015. 
632. Similar increases in heroin trafficking have also 
been observed in other countries in the region. In 
Bangladesh, seizures of heroin increased by 29.5 per cent, 
from 84.3 kg in 2014 to 108.7 kg in 2015. In Nepal, 3.8 kg 
of heroin were seized in 2014 and 6.4 kg in 2015.
633. The Narcotics Control Bureau of India indicated 
that the quantity of opium seized decreased from 1.77 tons 
in 2014 to 1.69 tons in 2015, although the number of 
reported seizures increased. The highest quantity of 
opium seizures (420 kg) were reported in the State of 
Punjab. In 2015, 61 kg of morphine were seized, com-
pared with 25 kg in 2014. About 1,401 ha of illicitly cul-
tivated opium poppy were identified and destroyed by the 
Narcotics Control Bureau in 2015.
634. There was an increase in the amount of codeine-
based preparations seized in Bangladesh. In 2015, 860,429 
bottles of codeine-based preparations were seized in the 
country, an increase of 15 per cent over the 748,730 bot-
tles seized in 2014. Synthetic opiates such as buprenor-
phine and pethidine (chemical name meperidine) in 
injectable form continued to be trafficked into Bangladesh. 
Seizures of drugs in injectable form sharply decreased to 
86,172 ampoules in 2015, slightly less than half the 
178,889 ampoules seized in 2014.
635. Even though trafficking in cocaine in South Asia 
has historically been very limited, there has been a rise 
in annual seizures in India over the past few years. The 
quantity of cocaine seized in India increased from about 
15 kg in 2014 to 113 kg in 2015. During the first half of 
2016, 1.7 kg of cocaine were seized in Sri Lanka. The sei-
zure of 5.7 kg of cocaine in Bangladesh in 2015 was the 
first reported seizure of cocaine in that country since 
2009. In Nepal, 5.5 kg of cocaine were seized in 2014 and 
11 kg were seized in 2015. 
636. Nepal is becoming a transit stage for international 
trafficking through its airspace and land routes to the 
world illicit drug market. In 2015, authorities in Nepal 
arrested 2,636 individuals for drug trafficking offences, 
compared with 2,918 in 2014. According to the Narcotics 
Control Bureau of Nepal, 9.8 kg of opium were seized in 
2015 and 34 kg in 2014.
637. In Bhutan, there was a drop in the number of 
cases for possession of and trafficking in controlled sub-
stances, from 370 cases in 2014 to 296 in 2015. The 
Bhutan Narcotics Control Agency has attributed the drop 
to intensified inspections and awareness-raising pro-
grammes, as well as the deterrent effect of more severe 
sanctions. 
(b) Psychotropic substances
638. The manufacture and abuse of amphetamine-type 
stimulants are continuing challenges in the region. 
According to reports by the Narcotics Control Bureau of 
India, several attempts have been made to set up clandes-
tine facilities for manufacturing amphetamine-type stimu-
lants, especially in the States of Maharashtra and Gujarat. 
However, those attempts were successfully prevented by 
the Bureau. A total of 166 kg of amphetamine-type stimu-
lants were seized in India in 2015, slightly less than the 
amount seized in 2014 (196 kg). In 2015, the Narcotics 
Control Bureau reported the dismantling of one illicit 
manufacturing facility, from which about 14 kg of meth-
amphetamine were seized. Additionally, one illicit Internet 
pharmacy was dismantled by the enforcement agencies in 
India, and 14,310 tablets containing psychotropic sub-
stances weighing about 277 kg were seized in 2015.
639. Seizures of methaqualone in India increased from 
54 kg in 2014 to 89 kg in 2015. After placing mephed-
rone under national control in 2015, India seized about 
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1.27 tons of mephedrone in that year. In November 2016, 
the Directorate of Revenue Intelligence seized 23.5 tons 
of methaqualone in a clandestine factory in the State of 
Rajasthan. It was one of the largest seizures of methaqua-
lone not only in India but also in the world.
640. Smuggling of “yaba” (methamphetamine) tablets 
from Myanmar across the south-eastern border to 
Bangladesh has continued; the quantities seized by law 
enforcement agencies in Bangladesh have been rapidly 
increasing. In January 2016, Bangladesh police seized 
2.8 million methamphetamine tablets, worth an estimated 
$10.5 million, in the country’s biggest ever single seizure 
of the drug. In 2015, “yaba” tablet seizures more than tri-
pled (20 million) compared with 2014 (6.5 million). 
641. According to the Narcotics Control Bureau of 
Nepal, the trafficking in and abuse of psychotropic sub-
stances continue to escalate. In 2015, 25,056 ampoules of 
diazepam and 18,950 ampoules of buprenorphine were 
seized in Nepal.
(c) Precursors
642. Since 2013 there has been a continuous decrease 
in the amounts of ephedrine and pseudoephedrine seized 
in India. However, combating the diversion of those sub-
stances from legal manufacture to illicit channels remains 
a major challenge for law enforcement agencies in the 
country. In 2015, a large number of tablets containing 
pseudoephedrine or ephedrine were seized along the 
India-Myanmar border, which were possibly being smug-
gled into Myanmar for extraction of the substances in 
order to manufacture amphetamine-type stimulants.
643. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in South Asia can be found 
in the report of the Board for 2016 on the implementa-
tion of article 12 of the 1988 Convention. 
(d) Substances not under international 
control
644. India continues to be a source country for ketamine 
trafficked to South-East Asia. Additionally, instances of using 
courier parcel services to traffic ketamine from India to South 
Africa and the United Kingdom have been observed. In 2015, 
India seized approximately 211.6 kg of ketamine, a substan-
tial increase over the amount seized in the previous year, 
which amounted to approximately 20.4  kg.
645. Considering the seizures of new psychoactive sub-
stances identified as originating in this region, the Board 
encourages Governments in the region to take part in the 
INCB Project Ion and IONICS, which facilitate the shar-
ing of information on incidents involving new psycho-
active substances.
5. Abuse and treatment
646. In July 2016, the Ministry of Social Justice and 
Empowerment of India, in collaboration with the National 
Drug Dependence Treatment Centre of the All India 
Institute of Medical Sciences, began conducting a survey 
to compile national and state-level estimates of the num-
bers of persons abusing drugs. The two-year-long survey 
will map the presence of treatment and rehabilitation ser-
vices for drug-dependent individuals and identify the 
gaps in service delivery. The last such survey was con-
ducted in 2001 and the data were published in 2004. An 
opioid dependence survey carried out in Punjab in 2015 
found that of the state’s population of 28 million, 230,000 
persons were opioid dependent and 860,000 were opioid 
users. Most of them were male.
647. On 12 April 2016, the Government of Maldives 
invited interested parties (both local and international) to 
submit proposals to operate the Drug Rehabilitation and 
Treatment Centre at Kaafu Hinmafushi. The Centre is the 
only drug rehabilitation centre in the country. 
Approximately 250 clients are accommodated and treated 
annually at the Centre, which takes a therapeutic, 
 community-based treatment approach.
648. The National Dangerous Drugs Control Board of 
Sri Lanka reported that a total of 1,482 drug users had 
received services in treatment facilities in 2015. Cannabis 
and heroin continued to be the two drugs most com-
monly abused in Sri Lanka. People in treatment for alco-
hol and tobacco abuse were also counted in the statistics. 
In 2015, the number of treated drug users decreased by 
10 per cent compared with 2014. Among those reported 
as drug users, 58 per cent were receiving treatment in 
government facilities, 21 per cent were in the prison 
 service drug treatment and rehabilitation programme, 
and 14 per cent were receiving assistance from non- 
governmental organizations. Almost all clients (99 per 
cent) in the treatment centres were men.
649. In 2015, a total of 9,987 patients (all male) were 
treated in private treatment centres in Bangladesh, down 
from 10,364 patients in 2014. Most of them (32 per cent) 
reported cannabis as their primary drug of abuse, fol-
lowed by “yaba” (methamphetamine) (20.6 per cent and 
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increasing) and heroin (20.1 per cent and decreasing). 
The abuse of “yaba” and of codeine-based preparations 
continue to be widespread in Bangladesh, and are still 
increasing. Buprenorphine is one of the most popular 
drugs of abuse among those who inject drugs. Many 
 heroin users have switched to it because it is cheap and 
accessible. 
650. Codeine-based cough syrups, buprenorphine, 
diazepam, nitrazepam and morphine were the pharma-
ceutical preparations containing controlled substances 
that are most commonly abused in Nepal.
651. The National Dangerous Drugs Control Board of 
Sri Lanka called for research proposals for conducting a 
national prevalence survey during the period 2016-2017 
to estimate the number of drug users in the country. In 
May 2016, the National Dangerous Drugs Control Board 
organized, in cooperation with UNODC, an expert group 
meeting on assessing the abuse of pharmaceutical drugs 
containing narcotic drugs and psychotropic substances in 
Sri Lanka.
652. Bhutan reports that the majority of drug users in 
the country are young people and that they are mainly 
dependent on cannabis and pharmaceutical products 
such as dextropropoxyphene, nitrazepam, diazepam and 
codeine-based cough syrups. In 2015, Bhutan introduced 
pharmacological treatment with buprenorphine for  opioid 
drug users. UNODC also facilitated capacity-building and 
the training of nurses and doctors to ensure the smooth 
implementation of the treatment. In addition, guidelines 
for the certification of treatment centres in Bhutan were 
introduced.
West Asia
1. Major developments
653. The drug control situation in West Asia continues 
to be heavily influenced by developments in the opiate 
market in Afghanistan, particularly with regard to the 
steady supply of opiates from opium poppy illicitly culti-
vated in Afghanistan transiting the region to markets 
around the world. As all three major transregional opiate 
trade routes originating in Afghanistan run through West 
Asia (the northern route, through Central Asian coun-
tries towards the Russian Federation; the Balkan route, 
through Iran (Islamic Republic of) and Turkey towards 
Europe; and the southern route, through Pakistan towards 
all regions of the world, except Latin America), the effec-
tiveness of drug control efforts in the region continues to 
have considerable implications for illicit opiate markets 
globally. 
654. Drug control challenges associated with the loca-
tion of West Asian countries along major global drug traf-
ficking routes remain complex and multifaceted. Progress 
remains tied to the region’s ability to respond to broader 
and interrelated developmental and criminal justice chal-
lenges, such as corruption, terrorism and continued polit-
ical instability, which have culminated, in parts of the 
region, in ineffective governmental control over signifi-
cant areas. The situation is further exacerbated by pro-
tracted armed conflicts in Iraq, the Syrian Arab Republic 
and Yemen, massive migration flows with ever-growing 
refugee populations settling in shelters and camps located 
in Jordan, Lebanon and Turkey, and the vulnerability of 
affected populations, presenting further drug control 
challenges for authorities in the region.
655. A further issue of concern for the region has been 
the continuing widespread availability and use of coun-
terfeit tablets marketed as “captagon”.64 Both media and 
anecdotal reports suggest that “captagon” pills are widely 
used by terrorists and combatants engaged in the armed 
conflicts ravaging across West Asia, in order to achieve a 
state of lowered inhibition to engage in violence and pro-
long their ability to remain alert for combat without need-
ing rest. However, to date, there is little reliable information 
available to confirm the source of the chemicals and the 
synthesizing processes used in the manufacture of those 
amphetamine-based compounds, including the location 
of the laboratories chemically synthesizing them.
656. A new phenomenon observed in the region, 
which has started to develop over the past few years and, 
based on information available to INCB, is becoming 
more common, is the discovery of multiple methamphet-
amine production sites in Afghanistan, in particular since 
the beginning of 2016. Recent raids on illicit laboratories 
revealed the presence of equipment and precursor chemi-
cals used in the illicit manufacture of methamphetamine, 
whereas in previous years, methamphetamine had gener-
ally entered the country as an end product. In addition 
to accounting for the second highest illicit production of 
64 “Captagon” was originally the official trade name for a pharmaceu-
tical preparation containing the substance fenethylline, a synthetic stimu-
lant. The substance currently known as “captagon”, as encountered in 
seizures across West Asia today and referred to in the present report, is a 
counterfeit drug compressed into pills or tablets that are similar in 
 appearance but distinct from the original “Captagon”. The active 
 ingredient in counterfeit “captagon” is amphetamine, which is typically 
cut with multiple adulterants, such as caffeine and other substances.
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cannabis resin and the largest illicit production of opium 
in the world, Afghanistan now appears to be facing an 
additional drug control challenge related to illicit meth-
amphetamine manufacture. The scope and magnitude of 
the new development and its significance for regional 
methamphetamine markets have yet to be seen.
657. The Board notes with concern the rapidly deteri-
orating safety and security situation in Afghanistan and 
its impact on the authorities’ ability to monitor and con-
trol the illicit supply of drugs originating in the country. 
At the same time, the Board observed that the willing-
ness of the international community to continue provid-
ing support to Afghanistan appeared to be declining, in 
particular in the area of drug control. The Board acknowl-
edges that any possible improvement in the drug control 
situation in Afghanistan is intrinsically linked to broader 
developmental and criminal justice challenges being ade-
quately addressed but cautions that action against drugs, 
money-laundering and corruption cannot be removed 
from the equation if sustainable development is to be 
achieved. In that context, the Board calls upon partner 
Governments and the international community to sus-
tain their support for the counter-narcotics efforts of 
Afghanistan, in the spirit of their common and shared 
responsibility to respond to the world drug problem and 
in order to ensure that the potential vacuum left by the 
withdrawal of international support from the country is 
not filled by criminal or terrorist elements. 
2. Regional cooperation
658. Cooperation at the regional level has continued in 
West Asia on the basis of both existing and new bilateral 
and multilateral agreements (some of which were con-
cluded during the reporting period). In addition, multi-
ple regional cooperation initiatives and processes exist, 
based on subregional affiliations among the countries of 
Central Asia and the Caucasus, the Gulf and the Middle 
East. Others are centred around issues of common con-
cern for clusters of neighbouring countries, as is the case 
with many initiatives built around the need to address 
threats emanating from the drug market in Afghanistan, 
which also have global dimensions. 
659. The Central Asian Regional Information and 
Coordination Centre (CARICC), a standing intergovern-
mental body that combats trafficking in narcotic drugs, 
psychotropic substances and their precursors, continues 
to serve as a regional platform for exchanging informa-
tion and good practices in countering drug trafficking 
and promoting law enforcement cooperation. Activities 
in the past year were centred around the coordination of 
several joint operations among CARICC participating 
States (Azerbaijan, Kazakhstan, Kyrgyzstan, the Russian 
Federation, Tajikistan, Turkmenistan and Uzbekistan), 
and countries including Australia and China when tar-
geting specific trafficking routes. One concrete result, in 
November 2015, was a controlled delivery conducted 
between the competent national authorities of Kazakhstan 
and Tajikistan, under the auspices of CARICC, which led 
to the seizure in Kazakhstan of close to 40 kg of  cannabis, 
allegedly originating in Afghanistan.
660. On 30 May 2016, the members of the Afghanistan, 
Kyrgyzstan and Tajikistan (AKT) Initiative adopted a 
ministerial declaration at the fourth tripartite ministerial-
level meeting, held in Issyk-Kul, Kyrgyzstan. In the dec-
laration, the importance of regional cooperation and 
capacity-building in drug control matters, particularly 
with regard to customs and border control, was empha-
sized. Participating countries agreed to support the estab-
lishment of border liaison offices, to develop standard 
operating procedures for such offices between Afghanistan 
and Tajikistan, and to draft a memorandum of under-
standing to form the basis of operational information-
sharing across borders and for future coordinated 
operations.
661. At the annual summit of the Shanghai Cooperation 
Organization, held in Tashkent in June 2016, India and 
Pakistan formalized their bids for membership of the 
organization, currently comprising China, Kazakhstan, 
Kyrgyzstan, the Russian Federation, Tajikistan and 
Uzbekistan, through the signing of “memoranda of com-
mitment”. The instruments are considered to be the last 
step before full-fledged membership, which is expected 
to be granted in 2017. Since 2006, the Shanghai 
Cooperation Organization has taken up drug trafficking 
as one of the priority areas for closer cooperation among 
its member States.
662. The Government of Afghanistan and the European 
Union co-hosted the Brussels Conference on Afghanistan, 
held on 5 October 2016. The conference was part of a 
series of ministerial-level meetings convened with the aim 
of supporting progress on the development agenda in 
Afghanistan throughout the so-called “Transformation 
Decade” (2015-2024). The Brussels Conference adopted a 
communiqué entitled “Partnership for Prosperity and 
Peace”, reaffirming the commitment of participating 
countries and international organizations to strengthen-
ing cooperation towards achieving the self-reliance of 
Afghanistan. International partners further pledged to 
provide $15.2 billion in support of Afghanistan’s develop-
ment priorities for the period 2017-2020, based on the 
Afghanistan National Peace and Development Framework, 
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presented by the Government at the Conference, and the 
“Self-reliance through Mutual Accountability Framework”. 
Under the heading “Peace, security and regional cooper-
ation”, the Conference further underlined the need for 
renewed efforts and a sustained and integrated approach 
in reducing the illicit production and trafficking of nar-
cotics and precursors, as well as treating and rehabilitat-
ing persons with substance abuse disorders, including 
through the implementation of the Afghan National Drug 
Action Plan.
3. National legislation, policy and 
action
663. In October 2015, the Government of Afghanistan 
adopted a new National Drug Action Plan, for the period 
2015-2019, which was presented to the international 
community at a high-level meeting convened in Vienna 
in December 2015. The main objectives of the Plan are 
to decrease the cultivation of opium poppy and the pro-
duction and trafficking of opiates, reduce the illicit 
demand for drugs and increase the provision of treatment 
for users. Also in 2015, the Ministry of Counter Narcotics 
launched the Afghanistan Drug Reporting System, which 
is an interactive online system for narcotics-related data 
collection. The System consolidates all drug-related 
data  on Afghanistan from officially verified sources and 
is the first comprehensive nationwide data repository of 
its kind. 
664. The Government of Armenia supplemented its 
2014 National Strategy for Combating Drug Addiction 
and Illicit Traffic in Narcotic Drugs with a programme 
for 2016, setting out actions towards achieving the objec-
tives of the three substantive components of the Strategy, 
namely: (a) primary prevention of drug addiction; 
(b)  prevention of illicit traffic in narcotic drugs, psycho-
tropic substances and their precursors; and (c) provision 
of medical, social and psychological care services to per-
sons using narcotic drugs or psychotropic substances. 
Those actions are complemented by chapters dedicated to 
expected outputs and financing, as well as monitoring and 
evaluation of the implementation of the Strategy.
665. Jordan placed six synthetic cannabinoids from the 
JWH group under national control during the reporting 
period, including JWH-018 and five substances not cur-
rently under international control. Israel placed nine new 
psychoactive substances not currently under international 
control under national control in 2015. 
666. Georgia reported having reduced, in 2015, crimi-
nal penalties for the possession of drugs, which had 
previously carried the same sanction as the distribution 
of drugs. In practice, Georgian courts had reportedly 
already started employing alternatives to incarceration in 
cases of simple drug possession. A national drug moni-
toring centre was also established to collect and analyse 
data on the drug situation, laying the foundation for 
 evidence-based approaches to drug policy formulation in 
the country.
667. Lebanon introduced significant amendments to 
its criminal code during the reporting period to improve 
its response to financial crimes. Those amendments are 
expected to have an impact on the country’s ability to 
tackle drug-related crime through more effective action 
against illicit financial flows. The amendments introduce, 
inter alia, the concept of money-laundering as a stand-
alone offence not requiring a conviction for the related 
predicate offence; fines amounting to double the amount 
of the value of laundered assets; an expansion of the con-
cept of what can be considered as proceeds of crime; an 
extension of the scope of application of the law with 
regard to the commission of related offences outside the 
national territory; and a broader mandate for the special 
investigative commission, whose tasks were defined 
 further in the amendments. 
668. The National Strategy for Combating Drugs of 
Oman for the period 2016-2020 was updated to include 
additional stakeholders, in line with its aim to reflect a 
multisectoral and multidisciplinary approach, including 
legislative and operational measures in the sphere of law 
enforcement, as well as a strong prevention component 
focusing on awareness-raising among the general 
population. 
669. In the State of Palestine, a presidential decree 
adopted in 2015 further defined the mandate of the Anti-
Narcotics Department of the Palestinian Police to include 
the development of a crime prevention plan concerning 
drug trafficking, cultivation and manufacture; information- 
gathering and exchange of information on drug traffick-
ing cases through increased international and regional 
cooperation; and the maintenance of registers and mon-
itoring of drug manufacturers, traffickers and trafficking 
suspects, as well as users. 
670. In addition to the recent expansion of the defini-
tion of new psychoactive substances to include generic 
(as opposed to substance-specific) definitions, Turkey 
amended its Penal Code to add synthetic cannabinoids 
and their derivatives to the list of substances for which 
higher penalties may be applied. An additional 29 sub-
stances were placed under national control during the 
reporting period. Article 191 of the Penal Code was also 
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amended to consider the sale of any type of drug or 
stimu lant in schools, dormitories, hospitals, barracks or 
places of worship as an aggravating circumstance in sen-
tencing. Turkey also upgraded its national counter- 
narcotics infrastructure by according the former 
counter-narcotics branch within the Turkish National 
Police the status of a fully-fledged department. 
671. Uzbekistan amended its law No. 293, on the import, 
export and transit of narcotic drugs, psychotropic sub-
stances and precursor chemicals, through Council of 
Ministers decree No. 330, in November 2015. Changes 
introduced through the amendment include a simplifica-
tion of procedures for the acceptance of import and 
export authorizations concerning narcotic drugs and psy-
chotropic substances, and the inclusion of some 80 sub-
stances, mainly new psychoactive substances, into the 
national list of prohibited substances.
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
672. West Asia, in particular Afghanistan, continues to 
be a major source of illicitly produced opiates. As a 
region, West Asia also saw the largest share of opiate sei-
zures in the world during the reporting period. The 
Balkan route, which runs through Iran (Islamic Republic 
of) and Turkey to reach mainly European markets, 
remains the most prominent among the three established 
opiate trafficking routes. However, recent reports indicate 
that other routes are gaining in importance. Turkey 
observed the gradual emergence of a second Balkan route, 
encompassing Iraq and the Syrian Arab Republic in addi-
tion to the countries traditionally lying on the Balkan 
route. At the same time, the southern route, using Iran 
(Islamic Republic of) and Pakistan as distribution hubs 
to supply markets in virtually all regions of the world, 
except Latin America, is growing in importance. Even the 
traditionally least frequented northern route, reaching the 
Russian Federation and other countries of the 
Commonwealth of Independent States via Central Asian 
countries that border Afghanistan, has recently shown 
signs of increased use after a decline during the period 
2008-2012. 
673. Afghanistan has, for more than a decade, 
accounted for the world’s largest illicit production of 
opium, despite the significant decline in opium poppy 
cultivation and estimated production reported in the 
Afghanistan Opium Survey 2015. Figures for 2016 
confirm that there is little cause for optimism, as practi-
cally all surveyed indicators of opium production in the 
country show increases in production, suggesting that the 
developments observed in 2015 have effectively been 
reversed.
674. According to the executive summary of the 
Afghanistan Opium Survey 2016, the estimated total area 
under illicit opium poppy cultivation in Afghanistan has 
increased by 10 per cent compared with 2015, reaching 
201,000 ha in 2016; that is the third highest level since 
estimations began in 1994. Increases in the estimated area 
under illicit opium poppy cultivation were noted in all 
regions of the country except the southern region, where 
the level of cultivation continues to be by far the highest 
but is considered to have remained stable compared with 
2015 levels. In other words, no decrease in cultivation 
was reported in any part of the country in 2016.
675. Helmand remained Afghanistan’s main province 
of illicit opium poppy cultivation in 2016. The area under 
illicit opium poppy cultivation in Badghis Province 
increased by 184 per cent between 2015 and 2016, and 
the number of poppy-free provinces declined from 14 in 
2015 to 13 of the 34 provinces of Afghanistan in 2016.
676. The estimates for both potential opium production 
(4,800 tons in 2016, compared with 3,300 tons in 2015) 
and for average opium yield (23.8 kg per hectare in 2016, 
compared with 18.3 kg per hectare in 2015) rose signifi-
cantly in 2016, namely by 43 per cent and 30 per cent, 
respectively. The higher rate of potential opium produc-
tion in 2016 is mostly attributed to the increase in yield, 
which, in contrast to 2015, was not affected by lack of 
water, crop diseases or similar unfavourable conditions. At 
the same time, the estimated figures are likely to be under-
estimates, as some of the main cultivating provinces were 
excluded from the yield survey for security reasons. The 
increases in potential production affected all regions of 
Afghanistan without exception, most strikingly the esti-
mated 286 per cent increase in the northern region, where 
the security situation deteriorated significantly in 2016.
677. A decline of 91 per cent in verified governor-led 
eradication of illicit opium poppy country-wide meant an 
almost complete halt in eradication in 2016 compared 
with 2015. A total of 355 ha of opium poppy were report-
edly eradicated in Afghanistan in 2016, a negligible 
amount compared to the estimated total area under illicit 
opium poppy cultivation.
678. While the socioeconomic analysis attached to the 
Afghanistan Opium Survey 2016 was not available at the 
time of drafting the present report, data published in 
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March 2016 relating to the results of the 2015 Survey fur-
ther explain the factors that may have contributed to the 
decrease in the illicit cultivation of opium poppy and the 
production of opium in 2015. Sharp decreases in 2015 in 
the farm-gate value of opium (33 per cent decrease com-
pared with 2014 and the lowest level since 2009) and the 
gross income from opium per hectare (18 per cent 
decrease compared with 2014 and the lowest level since 
2002), coupled with the consistently moderate to poor 
yields of opium poppy observed over the previous four 
years, had a severe impact on the extent of illicit opium 
poppy cultivation and opium production in the country. 
In addition to unfavourable climatic conditions that 
directly reduced yield per hectare, the decline in the value 
of and income from opium led many farmers to abandon 
cultivation of opium poppy in 2015 because of its low 
profitability. Notably, 12 per cent of farmers, who discon-
tinued the cultivation of opium poppy in 2015, reported 
having replaced the crop with cannabis. However, find-
ings also suggest that farmers’ general lack of access to 
markets to sell alternative products — including wheat, 
which was the main substitute crop grown in 2015 — 
may be a more significant factor in their dependence on 
illicit crop cultivation than the level of profit attainable 
from such crops. 
679. In 2015, opium poppy cultivation was also reported 
in Lebanon and Uzbekistan, with areas of cultivation in 
Lebanon being concentrated around the Beqaa Valley 
where, according to government sources, illicit cultivation 
of cannabis is also taking place. In the same year, some 
eradication efforts (of opium poppy and cannabis plants) 
were reported by Uzbekistan, whereas none were reported 
by Lebanon. Tajikistan reported seizures of more than 
4.5 tons of narcotic drugs in the course of 2015, of which 
more than 1.5 tons consisted of heroin and other opiates. 
Saudi Arabia observed that heroin was still being smug-
gled into the country by individuals carrying the sub-
stance across the border in their clothes or intestines in 
pure form, and that a variety of cutting agents were being 
added later, thus confirming that significant adulteration 
of the drug happens inside the country. 
680. Cannabis is the most widely produced, trafficked 
and consumed drug in the world, and cannabis plant con-
tinues to be widely cultivated in West Asia. Of the five 
countries in the world where the most cannabis resin is 
produced, three are located in West Asia, namely 
Afghanistan, Lebanon and Pakistan. Those three countries 
mainly supply markets in the Near and Middle East, where 
25 per cent of global cannabis resin seizures in 2014 took 
place (mainly in Afghanistan, Iran (Islamic Republic of) 
and Pakistan). Saudi Arabia reported large seizures, total-
ling close to 3 tons of cannabis over 2015.
681. Cocaine seizures in Asia, although still compara-
tively small in absolute terms, have tripled in the last dec-
ade, according to the latest estimates by UNODC, with 
almost 50 per cent of seizures in Asia carried out in the 
Middle East subregion. Entering from Latin America, the 
most frequently mentioned final destination for cocaine 
trafficked into West Asia was Israel. No data were avail-
able with regard to seizures of cocaine in Central Asia 
and the Caucasus, except for Armenia, where 26 kg of 
cocaine were reported to have been seized.
682. Several cross-border operations were conducted 
in countries of the region during the reporting period. 
For example, Tajikistan reported having conducted 25 
joint operations in 2015 with Afghanistan and neighbour-
ing countries in Central Asia, as well as the Russian 
Federation, resulting in the seizure of more than 950 kg 
of narcotic drugs and psychotropic substances.
(b) Psychotropic substances
683. West Asian countries, in particular in the Middle 
East and Gulf subregions, continue to be used mainly as 
points of transit for methamphetamine trafficking. In 
contrast, for amphetamine, they are both points of tran-
sit and source and destination countries, mirroring the 
largely intraregional pattern of the current amphetamine 
trafficking. 
684. A considerable challenge with regard to psycho-
tropic substances in the region remains the supply of 
counterfeit “captagon” tablets, which continue to be seized 
in large quantities, especially in countries in the Gulf and 
Middle East subregions. In 2015, authorities in Lebanon 
and Turkey reported seizures of more than 15 million 
“captagon” tablets each. In 2016, “captagon” seizures con-
tinued to make headlines in the media across the region, 
for example in Jordan, where two seizures, one of more 
than 4.5 million tablets and the other of more than 3.5 
million tablets, were made within 10 days of each other 
in April 2016, and the biggest seizure of “captagon” tab-
lets on record in the country, of more than 13 million 
tablets, took place in September 2016. Authorities in 
Lebanon have also detected an increased number of traf-
ficking cases involving “captagon” and an increase in the 
number of clandestine laboratories manufacturing the 
tablets in the country, possibly as a result of the destruc-
tion of production facilities associated with the ongoing 
conflict in the neighbouring Syrian Arab Republic. Other 
countries that reported large “captagon” seizures include 
Saudi Arabia, where foodstuffs or construction materials 
were reportedly being used to conceal the tablets smug-
gled in trucks and passengers’ vehicles. 
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685. According to information provided to the Board, 
government authorities in Oman registered more than 
3,000 drug-related seizures in 2015, none of which, 
 however, involved “captagon”. 
686. Few countries in the region reported seizures 
involving psychotropic substances other than “captagon”, 
such as diazepam or lorazepam (reported, for instance, 
by Armenia). However, Turkey reported a significant 
amount of seizures involving MDMA or “ecstasy”-type 
substances, namely more than five and a half million 
 tablets in 2015, as well as seizures of LSD. 
(c) Precursors
687. Given the significant illicit production of a 
 number  of narcotic drugs and psychotropic substances 
in  the region, West Asia continues to be a target 
 destination  for precursor chemicals diverted from licit 
trade, such as  acetic anhydride (for heroin manufacture), 
 ephedrine,  pseudoephedrine, 1-phenyl-2-propanone 
(P-2-P),  phenylacetic acid (for the manufacture of 
amphetamine-type stimulants) and others.
688. With regard to seizures of acetic anhydride, the 
declining trend seen in recent years has continued in 
Afghanistan, dropping by nearly half every year since 
2011. The substance reportedly continues to enter the 
country from neighbouring Iran (Islamic Republic of) 
and Pakistan, where occasional large-scale seizures con-
tinued to be carried out in the course of 2015 and 2016. 
Overall, however, the number and volume of acetic anhy-
dride seizures in the region are continually going down, 
possibly because of increased domestic diversion, or 
because traffickers may have started to resort to using 
non-scheduled substances instead of acetic anhydride as 
a key ingredient in illicit heroin manufacture. 
689. There is insufficient information to date about the 
synthesizing processes, locations and sources of precur-
sor chemicals used in the manufacture of “captagon”, 
which has been reported to originate in Lebanon and the 
Syrian Arab Republic. However, Lebanon reported sei-
zures of some 16 tons of phenylacetic acid in 2015, which 
authorities suspect may have been intended for use in the 
manufacture of “captagon”. 
690. Against that backdrop, a time-bound operation of 
the Board’s Project Prism entitled “Missing Links” was 
launched in October 2016, with the aim of filling infor-
mation gaps with regard to the types and sources of 
scheduled and non-scheduled chemicals used in the illicit 
manufacture of “captagon” tablets, how they are getting 
into clandestine laboratory environments, the trafficking 
organizations involved and any links between them. 
Results of the operation will be reported by the Board in 
its annual report for 2017.
691. Another recent development of concern is the 
increased detection by authorities in Afghanistan of 
methamphetamine precursors in illicit laboratories in the 
country, suggesting that Afghanistan may be emerging as 
a site of production rather than merely a destination 
country for methamphetamine. Further detailed informa-
tion on the precursors control situation in West Asia can 
be found in the 2016 report of the Board on the imple-
mentation of article 12 of the 1988 Convention.65
692. INCB urges all relevant stakeholders in the region to 
increase the exchange of drug-related intelligence among 
their competent national law enforcement authorities, 
including by using electronic tools developed by the Board 
for that purpose, such as PICS, and through relevant regional 
intelligence centres, such as CARICC, the Joint Planning 
Cell of Afghanistan, Iran (Islamic Republic of) and Pakistan, 
and the Criminal Information Centre to Combat Drugs of 
the Cooperation Council for the Arab States of the Gulf. 
(d) Substances not under international 
control
693. Plant-based psychoactive substances such as khat 
(Catha edulis) are still widely used in parts of West Asia, 
for example in Oman, Saudi Arabia and Turkey. However, 
despite the continually increasing number of synthetic 
new psychoactive substances emerging every year at the 
global level, relatively few of such substances were iden-
tified in countries in West Asia between 2008 and 2015. 
In 2015, Kyrgyzstan reported the emergence of new psy-
choactive substances in its territory for the first time, 
while data for large parts of South-West Asia (compris-
ing Afghanistan, Iran (Islamic Republic of) and Pakistan) 
are not available to date. Turkey was one of the few coun-
tries reporting large seizures of synthetic cannabinoids 
(more than 500 kg) in 2015.
694. There continue to be indications of large-scale 
prescription drug abuse in the region. One substance of 
concern to several countries in West Asia is tramadol, a 
synthetic opioid, which is considered a substance of abuse 
in Armenia, Jordan, Lebanon (imported from Egypt), 
Oman (where it is reportedly imported from China and 
Egypt), Qatar, Saudi Arabia, Turkey and Turkmenistan. 
One sizeable seizure, of 142,000 ampoules of tramadol, 
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was reported to have been carried out by authorities in 
Jordan in 2015. It was one of a series of seizures of coun-
terfeit and trafficked goods that Jordan had undertaken 
since it joined the World Customs Organization (WCO)-
UNODC Container Control Programme in September 
2015. In March 2016, according to information available 
to the Board, 1 million tramadol pills originating in India 
were seized by customs authorities at Imam Khomeini 
International Airport, Tehran. The pills had been falsely 
declared as “advertising and exhibition substances”. 
695. In Saudi Arabia, pregabalin, a medicine with anti-
convulsant properties used widely to treat epilepsy, neuro-
pathic pain and anxiety, has recently been placed under 
national control as a result of its abuse by school students. 
Saudi Arabia, the Syrian Arab Republic and Turkey also 
reported significant seizures of unspecified diverted 
 prescription drugs.
5. Abuse and treatment
696. Efforts to improve systematic data collection on 
drug abuse and treatment measures are under way in sev-
eral countries of the region, yet a realistic assessment of 
the availability of treatment services compared with the 
need for such services remains difficult. A comprehensive 
situation assessment regarding the extent and patterns of 
drug use in the State of Palestine was envisaged to be com-
pleted by the end of 2016 and could provide a valuable 
update against baseline data last collected there in 2006.
697. Based on available data, cannabis, opioids and 
amphetamine-type stimulants are among the most fre-
quently used substances in West Asia. Drug abuse in 
Afghanistan has continued to rise and, according to the 
latest estimates, now affects some 12.6 per cent of the 
adult population (or one in three households). That fig-
ure is more than double the global drug abuse rate, which 
is estimated at just over 5 per cent. Opioids remain the 
most commonly used drug in Afghanistan, with abuse 
rates estimated at 4.9 per cent among the general 
 population and 8.5 per cent among adults.
698. In 2015, Saudi Arabia reported a new trend in 
drug use, namely methamphetamine being injected 
(rather than smoked) by young people. That observation 
was based on information provided by emergency and 
outpatient treatment facilities at a hospital in Jeddah 
(situ ated in the west of the country). At the same time, 
data from treatment and other registers of drug users in 
the country’s eastern provinces show that more than 1,000 
problem drug users (defined in Saudi Arabia as persons 
who inject drugs and people using drugs on a daily basis) 
take amphetamine-type stimulants, which is more than 
double the number of problem drug users reported to be 
taking opioids (some 450). Persons in treatment for the 
use of amphetamine-type stimulants also represent the 
highest number (more than half) of people receiving drug 
abuse-related treatment in the country. In the same geo-
graphical area in 2015, more than 5,200 non-fatal, drug-
related emergency-room visits were recorded, with 
drug-related deaths remaining stable and associated 
exclusively with the use of opioids. 
699. With regard to overdose deaths, the data availa-
ble for West Asia mirror the global trend, with drug-
related mortality mostly being attributed to the abuse of 
opioids. Most countries in the region that reported on 
drug-related death cases for 2015 (including Saudi Arabia, 
the Syrian Arab Republic and the United Arab Emirates) 
named opioids (predominantly heroin) as the cause of 
drug-related deaths. In an effort to reduce drug-related 
mortality, Georgia has removed a significant obstacle for 
drug users seeking medical assistance, as it no longer 
requires medical personnel to inform law enforcement 
authorities of overdose cases.
700. More than 200,000 persons are estimated to be in 
need of treatment for drug abuse in Turkey. In 2015, Turkey 
reported an increase in the residential treatment of meth-
amphetamine addicts, while inpatient treatment of users of 
synthetic cannabinoids remained stable. While no general 
prevalence data for drug abuse were reported, Turkey 
observed a slight decrease in the overall number of persons 
who inject drugs (mainly related to heroin), with some 
increase in the use of amphetamine-type stimulants, tran-
quillizers and stimulants, as well as pharmaceutical products 
containing opioids. The most prevalent disease among per-
sons who inject drugs was hepatitis C (affecting close to 40 
per cent of those who received inpatient treatment in Turkey 
in 2015). Of all cases of drug-related mortality caused by 
overdose deaths in Turkey, more than half involved poly-
drug use, with just as many deaths associated with the use 
of opioids; close to one third of all cases involved 
 amphetamine-type stimulants and/or cannabis use.
D. Europe
1. Major developments
701. Illicit drug markets remain one of the main threats 
to the security of European countries. According to esti-
mates by the European Monitoring Centre for Drugs and 
Drugs Addiction (EMCDDA), around one fifth of global 
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crime proceeds are generated by the illicit drug trade. 
European Union citizens alone spend between 21 to 31 bil-
lion euros every year on illicit drugs. Accelerated changes 
in illicit drug markets observed in past years can be attrib-
uted, in part, to globalization and technological develop-
ments. Current markets are characterized by increasing 
organizational and technical complexity, interconnected-
ness and specialization of the criminal groups involved. 
Those illicit drug markets not only relate to other crimi-
nal activities, but also create a strain on government insti-
tutions and have a negative impact on legitimate business 
and on society. Cannabis is the most widely used illicit 
drug in Europe: it is estimated that about 27 million adults 
in Europe have used cannabis in the past year. 
702. The annual prevalence of cocaine use in Europe in 
2014 was estimated at about 0.7 per cent of the popu-
lation aged 15-64, approximately just over 4 million peo-
ple. However, that masks significant variance between 
countries and subregions: in 2014, the annual prevalence 
rate for Eastern and South-Eastern Europe was about 
0.2  per cent for the same population group (approxi-
mately half a million people) and 1.1 per cent for Western 
and Central Europe (about 3.5 million people). 
703. Opiates abused in Europe are produced mainly in 
Afghanistan and trafficked into Europe by two major 
routes, the Balkan route and the northern route. The 
Balkan route, through Iran (Islamic Republic of) and 
Turkey, followed by countries in South-Eastern and 
Central Europe, continues to be the main trafficking 
route, particularly for heroin. Opiate trafficking along the 
northern route, from Afghanistan to States in Central 
Asia and then to the Russian Federation, has been 
reported to be increasing over the last few years. 
704. An estimated 2.4 million people have used 
amphetamine or methamphetamine in the whole of 
Europe in the past year. In countries of the European 
Union, abuse of the main synthetic stimulants (amphet-
amine, methamphetamine and MDMA), together, is 
slightly higher than that of cocaine. There is concern in 
States members of the European Union about the availa-
bility of high-potency “ecstasy” products and the grow-
ing use of methamphetamine. New synthetic opioids are 
also increasingly being misused in the European Union.
705. By May 2016, the European Union early warning 
system had identified over 560 new psychoactive sub-
stances; 100 new psychoactive substances were reported 
for the first time in 2015. European authorities are con-
cerned that, with the increased availability of those sub-
stances, associated health risks and dependency problems 
will also increase.
706. In August 2016, the European Commission pro-
posed an amendment to the founding regulation of 
EMCDDA to allow for swifter and more effective action 
in dealing with new psychoactive substances in the 
European Union. The proposal aims, in particular, to 
 further strengthen the European Union early warning 
system and risk assessment for new psychoactive sub-
stances by speeding up data collection and assessment 
procedures. The proposal is part of the agreement between 
the European Parliament and the Council of the European 
Union reached in September 2013, which aimed at 
 facilitating the negotiations on proposed legislative 
amendments for tackling new psychoactive substances.
2. Regional cooperation
707. The European Union continued intensive cooper-
ation among its member States and with third countries 
and other regions. The Horizontal Working Party on Drugs, 
a working group of the Council of the European Union, 
has led the Council’s work on legislative and general pol-
icy work on drug supply reduction and drug demand 
reduction areas. The work focused on cross-cutting 
themes, namely coordination, international cooperation, 
and research, monitoring and evaluation. The working 
party cooperated with European Union agencies such as 
EMCDDA and Europol, as well as with international 
organizations and with countries not members of the 
European Union.
708. In 2016, Monaco became the thirty-eighth mem-
ber State of the Cooperation Group to Combat Drug 
Abuse and Illicit Trafficking in Drugs (Pompidou Group) 
of the Council of Europe. The Board noted that the 
Pompidou Group supported the publication of the 2015 
report of the European School Survey Project on Alcohol 
and Other Drugs, which was prepared on the basis of 
information provided by almost 100,000 students from 
35 European countries, 24 of which were States members 
of the European Union. In June 2016, experts from 36 
countries and 11 international organizations participated 
in the annual meeting of the Airports Group organized 
by the Pompidou Group and discussed practical solutions 
to challenges in airports, including aviation-related fraud, 
risk analysis and controlled deliveries. 
709. In February 2016, the European Commission pre-
sented the outcomes of “Operation Cocair 5”, an inter-
national operation to combat drug trafficking that was 
supported by about 30 countries from Africa, Latin 
America and the Caribbean. The operation, which 
resulted in seizures of sizeable amounts of illicit drugs, in 
particular cocaine, as well as ammunition and currency, 
90  INCB REPORT 2016
was conducted under the Airport Communication Project 
(AIRCOP), co-funded under the “Instrument contribut-
ing to Stability and Peace”, one of the main tools of the 
European Commission to address the threat of organized 
crime in partner countries. 
710. Japan and the Russian Federation, in cooperation 
with UNODC, continued their partnership to provide 
specialized training courses to counter-narcotic officers 
from Afghanistan. The trilateral initiative, which marked 
its fifth anniversary in 2016, has expanded to include pro-
vision of training to Central Asian countries, contribut-
ing to the strengthening of regional cooperation between 
Afghanistan and neighbouring countries. 
711. In 2016, the Governments of countries in South-
Eastern Europe continued implementing drug control 
activities, in line with the regional programme for South-
Eastern Europe 2016-2019, developed by Governments of 
the subregion with UNODC assistance. 
3. National legislation, policy and 
action
712. In November 2015, the European Commission 
presented to the European Parliament and the Council of 
the European Union a report on progress in implement-
ing the European Union Drugs Strategy and 2013-2016 
Action Plan on Drugs. The report, among other things, 
showcased some best practices in European Union mem-
ber States, including quick access to drug treatment in 
England, where 98 per cent of people commenced treat-
ment within three weeks of referral; the establishment, 
within the Federal Criminal Police Office in Germany, of 
a dedicated working group to address the problems of 
increased drug trafficking over the Internet; and the rep-
resentation of non-governmental organizations in the 
Government Council for Drug Policy of Slovakia, the 
main coordination body on drug policy in the country.
713. In 2015-2016, several European countries, includ-
ing Czechia, Finland, Hungary, Lithuania, the Netherlands, 
Norway, Sweden and the United Kingdom, developed 
new drug control strategies, policies and/or drug action 
plans. For example, in November 2015, the Government 
of the Netherlands formulated a new policy on drug pre-
vention that, among other things, was aimed at changing 
the prevailing tolerant views of young adults on the use 
of drugs in nightlife settings. 
714. In December 2015, Law No. 318/2015 was 
adopted by the Parliament of Romania. The law estab-
lishes the National Agency for the Management of Seized 
Assets, which will report to the Ministry of Justice. The 
Agency is tasked with facilitating the tracing and identi-
fication of assets resulting from the commission of crimi-
nal offences that may be subject to a criminal seizure or 
criminal confiscation, and coordinating, evaluating and 
monitoring, at the national level, the implementation of 
criminal asset recovery policies.
715. In the United Kingdom, the Psychoactive 
Substances Act became law in 2016, criminalizing the 
production, supply or possession with intent to supply of 
any psychoactive substance knowing that it is to be used 
for its psychoactive effects. While simple possession of 
such substances does not constitute an offence, the 
 possession within a custodial institution does.
716. In the Russian Federation, presidential decree 
No.  156 was issued on 5 April 2016 with the aim of 
improving public administration in the sphere of control 
of trafficking in narcotic drugs, psychotropic substances 
and their precursors. According to the decree, the Federal 
Service of the Russian Federation for Drug Control 
became part of the country’s Ministry of Internal Affairs. 
The presidential decree establishes that the Ministry of 
Internal Affairs remains the only federal executive author-
ity responsible for the development and implementation 
of State policy and normative legal regulation in the 
sphere of internal affairs, as well as in the control of traf-
ficking in narcotic drugs, psychotropic substances and 
their precursors. A draft law containing the necessary 
legal amendments following the transfer of powers to the 
Ministry of Interior was submitted to the State Duma of 
the Russian Federation and is expected to be adopted by 
the end of 2016. 
717. On 1 July 2016, the Government of the Russian 
Federation approved order No. 1403-r, on improving the 
availability of narcotic drugs and psychotropic substances 
for medical use. Among the main provisions of the order’s 
action plan are: enhancement of the range of narcotic prep-
arations used for pain relief, including for children’s treat-
ment; optimization of the process for preparing estimates 
of the needs for preparations containing narcotic drugs and 
psychotropic substances; improvement in the availability 
and quality of pain relief, including through a simplified 
procedure for prescribing medical preparations; and har-
monization of laws and regulations with regard to traffick-
ing in narcotic drugs and psychotropic substances. 
718. Supervised “drug consumption facilities”, where 
drugs can be used for non-medical purposes under the 
supervision of medically trained staff, have been operat-
ing in Western Europe for the last three decades. The pri-
mary aim of the facilities is to reduce the acute risks of 
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disease transmission through unhygienic injecting, pre-
vent drug-related overdose deaths and connect high-risk 
drug users with addiction treatment and other health and 
social services. By February 2016, there were a total of 74 
official “drug consumption facilities” operating in 
Denmark, Germany, Luxembourg, the Netherlands, 
Norway, Spain and Switzerland. 
719. In March 2016, the Government of France issued 
decree 0072, which approved, on a trial basis, the estab-
lishment of “drug injection rooms” in the country, for a 
maximum period of six years. The decree was adopted 
following a decision by the French Constitutional Council 
in January 2016 that the proposed establishment of the 
“drug consumption rooms”, based on the aim of reduc-
ing the risks associated with drug use and leading drug 
users to cease their use of drugs, with limited criminal 
immunity for drug users and the professional practition-
ers inside the facility, was in conformity with the 
Constitution of France. 
720. With respect to “drug consumption rooms”, the 
Board wishes to reiterate its frequently expressed 
 concern that, in order for the operation of such  facilities 
to be consistent with the international drug  conventions, 
certain conditions must be fulfilled. Chief among those 
conditions is that the ultimate objective of these 
 measures is to reduce the adverse consequences of drug 
abuse through treatment, rehabilitation and  reintegration 
measures, without condoning or increasing drug abuse 
or encouraging drug trafficking. “Drug consumption 
rooms” must be operated within a framework that offers 
treatment and rehabilitation services as well as social 
reintegration measures, either directly or by active 
 referral for access, and must not be a substitute for 
demand reduction programmes, in particular  prevention 
and treatment activities. 
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs 
721. Trafficking in cannabis, both resin and herb, con-
tinues at significant levels in Eastern and South-Eastern 
Europe. Most of the herbal cannabis produced in those 
subregions originates in Albania, Montenegro, the 
Republic of Moldova, Serbia, the former Yugoslav 
Republic of Macedonia and Ukraine. According to 
UNODC, in 2014, Albania was an important source 
country for cannabis herb available in countries in 
Western and Central Europe. 
722. Over the last 10 years, countries in Europe have 
seen an increase in domestic cultivation of cannabis plant, 
ranging from small-scale cultivation for personal use to 
major commercial plantations. In many countries, as a 
result of that increase, locally produced herbal cannabis 
has been partially displacing imported cannabis resin. 
Nonetheless, cannabis resin smuggled from other regions 
worldwide, in particular the resin produced from the 
high-potency, high-yield hybrid strains of the plant cul-
tivated in Morocco, continues to be a major source of 
cannabis resin in Europe.
723. In 2015, illicit indoor cannabis cultivation was 
reported by a number of European countries, including 
Belgium, Bosnia and Herzegovina, Bulgaria, Czechia, 
France, Greece, Latvia, Lithuania, Poland, Romania, the 
Russian Federation and Ukraine.
724. Although the reported average potency of canna-
bis, in terms of THC content, has significantly increased 
over the past decade, according to EMCDDA, the reported 
retail prices for both cannabis herb and cannabis resin 
have increased only slightly in the European Union over 
that period. In several European Union countries, the 
retail (street) prices of cannabis herb and cannabis resin 
do not differ significantly: for example, in Spain, the retail 
price of cannabis herb is about 4.6 euros per gram, and 
the price of cannabis resin 5.6 euros per gram.
725. In 2014, seizures of cannabis resin and cannabis 
herb in European Union member States amounted to 
574  tons and 139 tons, respectively. Spain, a main entry 
point for cannabis resin originating in Morocco, recently 
also reported increased amounts of cannabis herb seized: 
15.2 tons in 2014 and 15.9 tons in 2015. That increase, 
according to EMCDDA, could indicate a growth in 
domestic or regional cannabis production. Some recent 
interceptions of large consignments of cannabis resin 
moving eastwards along the North African coast may 
suggest the emergence of new trafficking routes through 
countries in Southern Europe and the western Balkans. 
726. In 2015, the countries that reported seizing more 
than 1 ton of cannabis resin were Spain (380.4 tons), 
France (60.8 tons), the United Kingdom (7.5 tons), 
Belgium (7 tons), Denmark (3.6 tons), Norway (2 tons) 
and Sweden (1.1 tons). The bulk of the cannabis resin 
seized in Spain in 2015 originated in Morocco. 
727. Almost all heroin available on the illicit drug mar-
kets in Europe originates in Afghanistan. Owing to its 
geographical location, Turkey continues to be a main cor-
ridor for heroin trafficking towards Europe, serving as a 
starting point on the Balkan route. In 2014, seizures of 
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heroin and morphine along the Balkan route amounted 
to 48 tons, an increase compared with the quantity seized 
in previous years. 
728. Despite the diversification of heroin trafficking 
routes, the Balkan route (from Turkey to Bulgaria and 
through countries in the western Balkans to Western and 
Central Europe, or from Bulgaria through Romania and 
Hungary to Western and Central Europe) remains the 
main corridor for trafficking bulk quantities of heroin to 
the main heroin markets in Europe. Reasonably recent 
variations to the Balkan route involve trafficking through 
the Islamic Republic of Iran and the Caucasus countries 
and then across the Black Sea to Romania to follow the 
traditional Balkan route, or through the Islamic Republic 
of Iran to Iraq and the Syrian Arab Republic and then to 
Turkey. There are also increasing concerns about the 
southern route, along which heroin is trafficked by sea 
from Iran (Islamic Republic of) and Pakistan, initially to 
the Arabian Peninsula and East Africa, and then onwards 
to other parts of Africa or directly to Europe. The con-
tainer ports of Rotterdam (Netherlands) and Antwerp 
(Belgium) appear to be major hubs for heroin and cocaine 
smuggled into the European Union.
729. Until 2013, countries in the European Union had 
witnessed a long-term decrease in both the number of 
heroin seizures and the quantity of the drug seized. Since 
that time, seizures of amounts of heroin larger than 100 
kg have been reported more regularly. In 2015, sizeable 
amounts of heroin were seized in the following countries: 
the United Kingdom (1,114 kg), France (818 kg), Greece 
(567 kg), Romania (334 kg), Bulgaria (265 kg), Spain 
(256  kg), Germany (210 kg) and Belgium (121 kg). The 
increased availability and purity of heroin on the illicit 
markets may have also contributed to an increasing num-
ber of overdose deaths reported in some countries in 
2015, for example in Lithuania, Slovenia and the United 
Kingdom. Those latest developments raise concerns about 
a potential resurgence of heroin use in the European 
Union, following more than a decade-long decrease in 
demand for the drug.
730. In 2015 in Romania, there was a significant increase 
(about 55 per cent) in the total quantity of drugs seized 
compared with 2014. The situation was mainly deter-
mined by the increase in seizures of heroin (from 25.7 kg 
to more than 334 kg), which represented about 28 per 
cent of the total amount of drugs seized in the country. 
The quantity of substances seized in 2015 indicates a 
decrease in the seizures of “ecstasy”, amphetamine-type 
stimulants, opioids, LSD, piperazines, cathinones, syn-
thetic cannabinoids, tryptamines, cannabis plants, canna-
bis resin and buprenorphine. During 2015, 64 drug 
trafficking groups were dismantled in Romania, a 16.4 per 
cent increase compared with the previous year, when 55 
such groups were dismantled. The total number of  persons 
involved in those groups decreased in 2015 (from 517 
persons in 2014 to 425 persons in 2015). 
731. The cocaine market in the European Union has 
been fairly stable over recent years, although there are 
indications of increasing availability of the drug. In 2014, 
countries in the European Union reported seizures of 
cocaine totalling 61.6 tons, about the same amount as in 
2013 (62.6 tons). In 2015, seizures of cocaine, in quanti-
ties of more than 1 ton, occurred in Spain (21.6 tons), 
Belgium (17.5 tons), France (10.9 tons), the United 
Kingdom (3.5 tons) and Germany (3.1 tons). Austria, 
Czechia, Cyprus, Denmark, Greece, Lithuania, Poland 
and Sweden reported seizures of cocaine larger than 
100  kg. Seizure data for the Netherlands were not avail-
able at the time of publication of the present report.
732. According to the European countries that seized 
the largest amounts of cocaine in 2015, Colombia, 
Ecuador and Venezuela (Bolivarian Republic of) were 
among the main countries of departure for the drug traf-
ficked by sea and air to Europe. The Caribbean and West 
Africa continue to be used by traffickers as important 
transit areas, and the increasingly important role of 
Central America as a transit point has also been noted. 
733. The concealment methods used by traffickers for 
smuggling cocaine to Europe continue to evolve. The traf-
ficking in cocaine in maritime containers through major 
European ports appears to be increasing. In 2013, seizures 
of cocaine concealed in sea containers accounted for 
about three quarters of maritime seizures. There are con-
cerns about the continued trafficking in cocaine by melt-
ing it into “carrier materials” such as plastics, which 
requires chemical extraction of cocaine in so-called sec-
ondary extraction laboratories that are linked to criminal 
organizations. The swallowing of latex packages contain-
ing liquid cocaine, instead of capsules containing cocaine 
in powder form, by air couriers (so-called “mules”) has 
been detected in some airports.
(b) Psychotropic substances 
734. For a number of years, the European Union has 
been a manufacturing region for synthetic drugs: 
 amphetamine and “ecstasy” have been illicitly 
 manufactured in Belgium and the Netherlands, and meth-
amphetamine in countries in Central Europe, mostly in 
Czechia. Recent evidence suggests a significant manu-
facturing  capacity of methamphetamine also emerging in 
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the Netherland  and  some small-scale manufacturing in 
 countries bordering Czechia. 
735. In 2015, Belgium and Poland reported the destruc-
tion of eight and five clandestine amphetamine laborato-
ries, respectively. One or two amphetamine laboratories 
were dismantled in the following countries: Austria, 
Germany, Latvia, Spain and Sweden. The largest number 
of dismantled methamphetamine laboratories in the 
European Union, 263, was reported by Czechia. Those 
laboratories used pseudoephedrine as a primary precur-
sor for the manufacture of methamphetamine. The dis-
mantling of fewer than 10 methamphetamine laboratories 
were reported by each of the following countries: Austria, 
Germany, Lithuania and Poland. Three laboratories 
 manufacturing “ecstasy” were dismantled in Belgium.
736. The regional manufacture of synthetic drugs results 
not only in significant intra-European trafficking, but also 
trafficking to other regions, including the Americas and 
Oceania, particularly Australia. Moreover, the territory of 
the European Union has been used as a transit corridor 
for methamphetamine manufactured in the Islamic 
Republic of Iran and in West Africa that is destined for 
markets in East Asia. The organized criminal groups 
involved in the trafficking of synthetic drugs also often 
smuggle other substances: for example, criminal groups 
supplying amphetamine and “ecstasy” originating in 
Belgium and the Netherlands also supply drug markets 
with cannabis and cocaine. In Czechia, some organized 
criminal groups have expanded from cannabis plant 
 cultivation to methamphetamine manufacture.
737. Amphetamine is far more commonly mentioned 
in seizure reports than methamphetamine. In 2014, the 
States members of the European Union reported seizures 
of 7.1 tons of amphetamine and 0.5 tons of methamphet-
amine. Wastewater analysis conducted by laboratories 
across European cities during the period 2011-2014 as 
part of the Sewage Analysis CORe Group (supported by 
the European Union) also confirmed that the use of 
amphetamine is far more common than the use of meth-
amphetamine in Europe. Out of 59 cities where analysis 
was done, 47 cities (80 per cent) showed higher residues 
of amphetamine than of methamphetamine in their 
wastewater.
738. In 2015, seizures of amphetamine larger than 
100  kg were reported by Germany (1.4 tons), Poland 
(0.7  tons), the United Kingdom (0.6 tons), Sweden 
(0.5  tons), Norway (0.5 tons), France (0.4 tons) and 
Finland (0.3 tons). Seizures of methamphetamine larger 
than 100 kg were carried out in Czechia, France and 
Norway (in descending) order. Seizures of large amounts 
of “ecstasy” in 2015 were reported by France (1.3 million 
units), the United Kingdom (1.1 million units) and 
Germany (1.0 million units).
(c) Precursors 
739. Challenges in precursor control in the European 
Union member States mainly relate to the substances 
listed in Table I of the 1988 Convention; non-scheduled 
chemicals, in particular those used in the illicit manu-
facture of amphetamine-type stimulants; and, more 
recently, the precursors of new psychoactive substances. 
In particular, seizures of large amounts of non-scheduled 
chemicals raise concerns about the continued manufac-
ture of synthetic drugs, in particular amphetamines and 
“ecstasy”. 
740. The Netherlands is one of the main countries 
worldwide communicating seizures of diverse chemical 
substances through PICS, which is aimed at facilitating 
and promoting regional operational cooperation. Those 
seizures included scheduled and non-scheduled sub-
stances used in the illicit manufacture of “ecstasy”, such 
as 3,4-methylenedioxyphenyl-2-propanone (3,4-MDP-
2-P) and its internationally non-controlled glycidic acid 
derivatives, and those used in the illicit manufacture of 
amphetamines, such as salts of 1-phenyl-2-propanone 
(P-2-P), methyl glycidic acid and reagents such as meth-
ylamine and formic acid. Other countries reporting size-
able seizures of those substances included Belgium and 
France. 
741. Seizures of APAAN, a substitute chemical that 
can be used in laboratories illicitly manufacturing amphet-
amine and methamphetamine, have significantly decreased 
in the European Union since 2014, when the substance 
was brought under international control. During the 
period 2015-2016, seizures of the substance were reported 
by Germany, the Netherlands and Spain. 
742. Through PICS, Czechia continued communicat-
ing seizures of pharmaceutical preparations containing 
pseudoephedrine. France, Luxembourg and the 
Netherlands also used PICS to report seizures of precur-
sors of new psychoactive substances, mainly precursors 
of synthetic cathinones.
743. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the report of the Board for 2016 on the implementa-
tion of article 12 of the 1988 Convention. 
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(d) Substances not under international 
control 
744. There is no indication of a slowdown in the devel-
opment of new psychoactive substances. Manufacturers 
of such substances are making continued efforts to cir-
cumvent legal and regulatory controls imposed by 
Governments worldwide. The continued growth of the 
European Union market for new psychoactive substances, 
which are often sold openly through conventional stores 
and online shops as “legal” replacements for illicit drugs, 
is also corroborated by the amounts of the substances 
seized. 
745. In 2014, States members of the European Union, 
as well as Norway and Turkey, reported almost 50,000 
seizures of new psychoactive substances, amounting to 
almost 4 tons. Seizures of synthetic cannabinoids, often 
advertised as legal replacements for cannabis, and syn-
thetic cathinones that have been consumed as an alter-
native to amphetamine, cocaine and “ecstasy”, together 
accounted for over three quarters of the total number of 
seizures of new psychoactive substances during 2014.
746. According to EMCDDA, many new psychoactive 
substances found in Europe have been manufactured by 
legitimate companies in China, and to a lesser extent in 
India. Those companies use their websites and online 
marketplaces to advertise their capacity to supply new 
psychoactive substances in amounts ranging from a few 
milligrams to hundreds of kilograms. From the manufac-
turing countries, large consignments of the substances are 
shipped to Europe as sea or air cargo; smaller amounts 
are delivered directly to buyers by express mail and 
 delivery companies.
747. Given the scheduling of 116 new psychoactive 
substances by the Chinese Food and Drug Administration 
in October 2015, the manufacture of new psychoactive 
substances may in future gradually shift to other coun-
tries and, as a result, the importance of China as the main 
source of new psychoactive substances may also decline. 
In fact, the emergence of clandestine laboratories in 
Europe may suggest traffickers’ increasing interest in 
manufacturing a range of new psychoactive substances in 
Europe. That has been corroborated, for example, by 
 seizures from two mephedrone laboratories in Poland 
in 2015. 
748. During 2015, 14 new psychoactive substances 
were identified as part of 77 seizure cases in Bulgaria. The 
total weight of seized new psychoactive substances 
amounted to 4,074 grams; synthetic cannabinoids 
amounted to 4,072 grams of the total seized, and 
accounted for 71 out of the 77 seizure cases of new psy-
choactive substances. Use of new psychoactive substances 
was highest among those aged under 35.
749. In Romania, no drug-producing clandestine labo-
ratories were identified in 2015; however, three laborato-
ries used for mixing and packaging new psychoactive 
substances, mainly synthetic cannabinoids, were detected 
and dismantled.
750. In Latvia, according to data from the national 
early warning system, the number of seizures of new psy-
choactive substances decreased from 1,387 seizures in 
2014 to 735 seizures in 2015. The most seized group of 
new psychoactive substances remains synthetic cannabi-
noids (n=402); however, there was a sharp increase in the 
seizures of so-called “other drugs” (n=228). Those  seizures 
comprised 116 carfentanil seizures (or carfentanil in a 
mixture with heroin), 92 tramadol seizures and 20  fentanyl 
and 3-methylfentanyl seizures. In general, there was a 
reported increase in the seizures of synthetic opioids.
5. Abuse and treatment 
751. In the European Union,66 it is estimated that over 
a quarter of those aged 15 to 64 have consumed illicit 
drugs at least once in their lives. In comparison with the 
past, drug consumption now encompasses a much wider 
choice of psychoactive substances. Individual patterns of 
drug use range from experimental to habitual and 
dependent use; polydrug use is also common.
752. According to the EMCDDA report on Comorbidity 
of Substance Use and Mental Disorders in Europe,67 pub-
lished in 2015, depression is among the most common 
psychiatric comorbidity associated with problematic drug 
use in Europe. Comorbid major depression is more fre-
quent in women with substance use disorders than in 
men with such disorders. Among that group of women, 
the prevalence of major depression is two times higher 
than among women in the general population.
753. The twenty-third European Cities against Drugs 
Mayors’ Conference was held in Stavanger, Norway, on 9 
and 10 May 2016. The goal of the Conference was to 
66 Data on drug abuse and treatment in the European Union are 
based on information published in EMCDDA, European Drug Report 
2016: Trends and Developments (Publications Office of the European 
 Union, Luxembourg, 2016), unless otherwise specified. The report 
 encompasses information provided by the European Union member 
States, the candidate country Turkey, and Norway.
67 Luxembourg, Publications Office of the European Union.
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identify ways to build healthy and safe cities through pre-
vention and treatment. INCB delivered a keynote presen-
tation entitled “Proactivity beats reactivity: examining the 
evidence for sound drug prevention in our cities”. 
754. The prevalence of cannabis use in countries of the 
European Union varies from country to country. It is esti-
mated that 51.5 million adult males and 32.4 million adult 
females consume cannabis at least once in their lives 
(24.8  per cent lifetime prevalence), making cannabis the 
most commonly used drug in the European Union. In 
the European Union about 1 per cent of those aged 15 
to 64 use cannabis on a daily or almost daily basis. 
755. Cannabis is the drug most frequently reported as 
the principal reason for first entry into drug treatment 
and the second most frequently mentioned substance 
among all drug treatment clients. The overall number of 
first-time treatment admissions for cannabis abuse in the 
European Union increased from 45,000 in 2006 to 69,000 
in 2014, an increase of more than 50 per cent.
756. About 1.1 per cent of the general population aged 
15-64 in the European Union (3.6 million people) have 
used cocaine in the past year. Of those, two thirds (about 
2.4 million) are aged 15 to 34, for whom the prevalence 
rate of last year use was almost double (1.9 per cent). 
Almost half of the States members of the European Union 
that provided information on the prevalence of cocaine 
use in 2015, including Austria, Bulgaria, France, Latvia, 
Lithuania, Spain and the United Kingdom, reported sta-
ble prevalence. In 2015, the prevalence of cocaine use 
largely decreased in Belgium, but significantly increased 
in Romania. 
757. The most commonly used illicit opioid in the 
European Union is heroin. In addition to heroin, a range 
of synthetic opioids such as methadone, buprenorphine 
and fentanyl have also been misused. About three quar-
ters of the 1.3 million high-risk adult users in the 
European Union were reported to be in France, Germany, 
Italy, Spain and the United Kingdom. In 2014, more 
than  600,000 opioid users in the European Union were 
receiving substitution treatment.
758. High-risk opioid users in the European Union also 
misuse benzodiazepines, substances that are often associ-
ated with morbidity and mortality in that group of users. 
In several European countries, small groups of high-risk 
drug users who previously injected heroin and ampheta-
mines, including those that were on opioid substitution 
treatment, started experimenting with injecting new psy-
choactive substances, such as synthetic cathinones. There 
are also concerns that opioids, such as methadone and 
buprenorphine, which are primarily prescribed for the 
treatment of opioid dependence, are likely to be misused 
in some European Union member States. 
759. The consumer market for opiates in Eastern 
European countries continued to expand. In 2016, 
UNODC reported that opioid use remained a major cause 
of concern, in particular in Eastern and Southern Europe, 
with more than 70 per cent of all drug treatment patients 
receiving treatment for opiate use disorders. UNODC 
estimates that, in  2014, the total number of people in 
treatment for  opioid use in those subregions ranged 
between 80,000 and 90,000.
760. National general population surveys on drug use 
in Latvia have been conducted every four years since 
2003, and the most recent data are available for 2015, dur-
ing which 9.9 per cent of respondents (compared with 
12.5 per cent in 2011 and 12.1 per cent in 2007) reported 
having used cannabis at least once during their lifetime. 
The lifetime prevalence rate was 2.5 per cent for “ecstasy” 
(compared with 2.7 per cent in 2011 and 4.7 per cent in 
2007) and 2.0 per cent for amphetamines (compared with 
2.2 per cent in 2011 and 3.3 per cent in 2007). In  general, 
the use of illicit substances has declined and returned to 
the levels of 2003. 
761. Data on substance use among 15- to 16-year-old 
schoolchildren are available from the regular European 
School Survey Project on Alcohol and Other Drugs, 
which has been carried out in Latvia since 1999. According 
to the data from the 2015 survey, cannabis is the most 
popular drug among students aged 15-16. Lifetime preva-
lence of cannabis use was reported by 16.3 per cent of 
students (compared with 24 per cent in 2011 and 18 per 
cent in 2007). The lifetime prevalence rate was 3.7 per 
cent for LSD, 2.9 per cent for amphetamines/metham-
phetamines and 2.6 per cent for “ecstasy”. In 2015, some 
9.5 per cent of 15- to 16-year-old schoolchildren indi-
cated that they had tried new psychoactive substances, 
such as “Spice” or similar mixtures (compared with 11 per 
cent in 2011).
762. In Ukraine, according to a report published in 
2015 by the Medical Statistics Centre of the Ministry of 
Health, the number of people in need of treatment for 
drug abuse was estimated at 60,187.
763. The patterns and prevalence of use of the main 
synthetic stimulants abused in the European Union, 
namely amphetamine, “ecstasy” and, to a lesser extent, 
methamphetamine, differ considerably among States 
members of the European Union. Notwithstanding their 
preferred drug of abuse, consumers of those synthetic 
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stimulants readily switch to other psychoactive sub-
stances, subject to their availability, price and perceived 
quality. EMCDDA, for example, reported links between 
the cocaine market and the new psychoactive substances 
market, in particular that of synthetic cathinones. 
764. Consumption of amphetamines (amphetamine 
and methamphetamine) has been stable in most European 
Union countries since about 2000. In the European 
Union, it is estimated that 1 per cent of those aged 15-34 
(1.3 million people) consumed amphetamines during the 
past year. Significant consumption of methamphetamine 
has been reported in Czechia and Slovakia, where the use 
of the drug has been long established. There are, how-
ever, indications that use of methamphetamine has spread 
further to several other European countries, including 
Austria, Germany and Poland.
765. Until recently, the prevalence of “ecstasy” abuse 
had been declining in many European Union member 
States, from peak levels reached in the early to mid-
2000s. Recent data indicate that, after a period of rela-
tive shortage, the drug is once again more widely 
available. Moreover, the potency of “ecstasy” products 
(tablets, powders and crystals) has increased since 2010, 
now reaching an all-time high, while prices appear to 
have remained relatively stable. The availability of 
 high-dose “ecstasy” products on the illicit markets 
 constitutes an emerging threat and a challenge for  public 
health and safety. 
766. Surveys conducted in the European Union between 
2013 and 2015 further corroborate the suspected 
 overall   increase in “ecstasy” use in the subregion. It is 
estimated that 1.7 per cent of those aged 15-34 (2.1 mil-
lion  people) used “ecstasy” in the past year, with national 
estimates ranging from 0.3 to 5.5 per cent. Demand for 
treatment for “ecstasy” abuse is, however, very low in 
the  subregion.
767. Throughout the two-decade-long history of abuse 
of gamma-hydroxybutyric acid (GHB) (including its 
 precursor GBL) and ketamine, national estimates of the 
preva lence of GHB and ketamine abuse in both adult and 
school populations, where they existed, remained low in 
the European Union. Likewise, the prevalence of use of 
LSD and hallucinogenic mushrooms has also been 
 generally low and stable in the subregion for a number 
of years.
768. In spite of the considerable significance given by 
Governments to the problem of new psychoactive sub-
stances, estimating the prevalence of abuse of that group 
of substances continues to be a challenge. The Board 
notes that an increasing number of countries now include 
new psychoactive substances in their drug abuse surveys, 
although differences in survey methods and questions 
may limit the comparability of their results. According to 
EMCDDA, since 2011, 11 European Union member 
States have reported their national estimates of prevalence 
of use of those substances. 
769. There is a permanent risk that new psychoactive 
substances with unpredictable toxicological profiles and 
a potentially unknown detrimental impact on human 
health, may enter the market. It is therefore essential to 
regularly update data about the patterns of their con-
sumption and the needs of their users. According to an 
EMCDDA report on health responses to new psycho-
active substances that was published in 2016, in view of 
the rapid emergence of the group of substances and the 
complexity of their markets, it is essential to develop and 
implement effective public health responses to their use. 
770. Although progress has been made in recent years, 
drug use resulting in overdoses or drug-related morbid-
ity, accidents, violence and suicide remain among the 
major causes of avoidable mortality among young people 
in the European Union. The European Union estimates 
that in 2013 alone, at least 5,800 people died from drug 
overdoses. According to data available to EMCDDA, HIV 
infections among injecting drug users have decreased, 
although the infection rates for hepatitis C were still high 
in many countries in the European Union. Among all 
HIV cases reported in Europe where the route of trans-
mission is known, the percentage attributable to inject-
ing drug use has remained low and stable for the last 
decade (less than 8 per cent). Higher rates, however, were 
reported for Lithuania (32 per cent), Latvia (31 per cent), 
Estonia (28 per cent) and Romania (25 per cent). 
771. The Minister for Health of the Russian Federation 
outlined the Government’s strategy for combating HIV/
AIDS during the three-day United Nations high-level 
meeting on ending AIDS that was held at United Nations 
Headquarters from 8 to 10 June 2016. Among the meas-
ures proposed were encouraging drug users to abstain 
from the use of narcotic drugs and providing access to 
modern rehabilitation centres. Free HIV screening had 
been made available in the Russian Federation for more 
than 30 million people, anonymously, if desired. Activities 
to combat HIV in the Russian Federation were financed 
from the federal budget, freeing those who had been 
infected from financial burden.
772. According to UNODC, Eastern and South-Eastern 
Europe are the subregions with the highest preva lence of 
injecting drug use, estimated at about 1.27 per cent of the 
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population in the 15-64 age group. The total number 
reported from those subregions is estimated to account 
for 24 per cent of the total number of people who inject 
drugs worldwide, with the majority of them registered in 
the Russian Federation and Ukraine. Among people who 
inject drugs in Eastern and South-Eastern Europe, HIV 
prevalence is particularly high, estimated at more than 
22 per cent.
E. Oceania
1. Major developments
773. The illicit market for amphetamine-type stimulants 
in Oceania, particularly in Australia and New Zealand, is 
dominated by methamphetamine, with evidence suggest-
ing a growing prevalence of abuse and an increase in 
purity and in the affordability and availability of the sub-
stance. The high volume of seizures in both countries 
reflects the situation, with record levels of methamphet-
amine seized in New Zealand. Methamphetamine sei-
zures in other countries of the region, such as Fiji, indicate 
that they are used as trafficking transit points but may 
also indicate local abuse of the substance.
774. The Drug Harm Index has been developed in New 
Zealand to estimate the social costs to community and 
individuals arising from drug abuse, taking also into 
account the cost of health, education and law enforce-
ment interventions. The second edition of the New 
Zealand Drug Harm Index 2016 was published under the 
auspices of the Ministry of Health in July 2016. It was 
estimated that cannabinoids, followed by amphetamine-
type stimulants, then opioids and sedatives, were respon-
sible for the greatest proportion of social costs (including 
intervention costs) associated with drug abuse.
2. Regional cooperation
775. At its eighteenth annual conference, held in Tuvalu 
in June 2016, the Oceania Customs Organization adopted 
the Regional Information and Intelligence Sharing 
Framework and the Regional High-Level Understanding 
on Information and Intelligence Sharing. The conference 
endorsed the concept of a joint Pacific law enforcement 
conference, to be explored with the Pacific Islands Chiefs 
of Police, the Pacific Islands Forum secretariat and the 
Pacific Immigration Directors’ Conference. Among other 
things, members of the Organization noted the 
importance of potential threats to border security posed 
by transnational crime and “e-crime”, and welcomed 
 further discussions on the regional efforts to develop a 
common data model to enhance an integrated 
border approach.
776. The Forum Regional Security Committee of the 
Pacific Islands Forum met in Suva in June 2016 to  discuss 
human security, threats resulting from natural disasters, 
and transnational organized crime. In May 2016, the 
Pacific Islands Forum secretariat, in partnership with the 
Government of New Zealand and UNODC, held a work-
shop with policy, law enforcement and legislative draft-
ing experts from the countries of the region to revise the 
Forum’s Model Provisions on Counter-Terrorism and 
Transnational Organized Crime from 2002. The outcome 
of the workshop was to be presented to the Forum’s 
Working Group on Counter-Terrorism and Transnational 
Organized Crime at its meeting held in June 2016.
777. The Pacific Police Dog Programme, which facili-
tates in-country training of dog handlers from the Cook 
Islands, Samoa and Tonga, was expanded to include the 
detector dog project in Fiji, which became operational in 
2016. The project is aimed at stemming the flow of 
drugs  trafficked into Fiji and is a joint venture between 
the Fiji Revenue and Customs Authority, the Fiji Police 
Force, the New Zealand Customs Service and the 
New  Zealand Police. 
778. Cooperation between Australia, Fiji and New 
Zealand in addressing drug trafficking continues to be 
strengthened. A joint operation between the Fiji Revenue 
and Customs Authority, the Fiji Police Force, the New 
Zealand Customs Service and the Australian Federal 
Police in July 2015 resulted in a seizure of 80 kg of meth-
amphetamine. In June 2016, the authorities of the three 
countries participated in the INTERPOL Operation 
Pangea IX, which targeted the online sale of counterfeit 
medicines.
3. National legislation, policy and 
action
779. Oceania remains the region of the world with the 
highest level of non-adherence to the international drug 
control treaties. Kiribati and Tuvalu have not adhered to 
any of the three international drug control conventions, 
while the Cook Islands, Nauru, Niue, Samoa and Vanuatu 
are not parties to the 1961 Convention or the 1971 
Convention. Solomon Islands is not a party to the 1971 
Convention or the 1988 Convention, and Palau and 
Papua New Guinea are also not yet party to the 
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1988  Convention. Given the emerging role of countries 
in Oceania, particularly the Pacific island States, as tran-
sit points for drug trafficking, and the role of some of 
those States as offshore financial centres that may be vul-
nerable to the laundering of proceeds of drug-related 
crime, the lack of adherence to and implementation of 
the conventions renders the countries particularly vulner-
able to drug trafficking and its consequences. The 
International Narcotics Control Board urges the countries 
of the region to set in place the necessary processes to 
accede to the conventions and offers its support in that 
regard. The Board also calls upon the international com-
munity to support those countries in efforts to fully 
adhere to and implement the treaties. 
780. In October 2016, the Narcotic Drugs Amendment 
Act 2016 entered into force in Australia, providing a 
 legislative framework that enables cannabis cultivation, 
permits access to cannabis for medical purposes and 
ensures that the cultivation of cannabis and the manu-
facture of cannabis products for medical purposes are in 
compliance with the 1961 Convention. The Amendment 
Act establishes a licensing scheme for the cultivation of 
cannabis for medical and related scientific purposes and 
includes measures to ensure security and prevent over-
production. Under the legislation, a system of licences 
and permits along the chain from patient to manufac-
turer to cultivator will control the amounts that can be 
cultivated and manufactured. Medicinal cannabis prod-
ucts are to be supplied under medical prescription; pre-
scribing doctors will require authorization from the 
Government. 
781. Owing to the high levels of abuse and trafficking 
of methamphetamine in Australia and its consequences, 
the National Ice68 Taskforce, comprising health and law 
enforcement experts, was established in April 2015 to 
coordinate local, state and federal action. The National 
Ice Action Strategy, adopted in December 2015, outlines 
measures on support for families and communities, tar-
geted prevention, investment in treatment, focused law 
enforcement and better research and data. In addition, 
the National Organised Crime Response Plan 2015-2018 
outlines initiatives to address the illicit supply of meth-
amphetamine, while the National Law Enforcement 
Methylamphetamine Strategy facilitates a nationally coor-
dinated operational response to the drug by defining roles 
and aligning responsibility for enforcement, intelligence 
collection and awareness. In response to a recommenda-
tion of the National Ice Taskforce, a new ministerial drug 
and alcohol forum will be established to oversee the 
development, implementation and monitoring of the 
68 “Ice” is a colloquial term for methamphetamine.
national drug policy framework, including the National 
Ice Action Strategy. That Strategy forms a key component 
of the Australian National Drug Strategy 2016-2025.
782. The Australian Federal Police recommitted to close 
working relationships with Cambodia, China and Viet 
Nam to address the shared threat of transnational organ-
ized crime and to improve understanding of concealment 
methods, trafficking routes and criminal networks facili-
tating the trafficking of drugs into Australia. For exam-
ple, Taskforce Blaze was established by the authorities of 
Australia and China in November 2015 to address the 
international illicit market for methamphetamine. Two 
separate operations involving the Taskforce led to seizures 
totalling 720 litres of liquid methamphetamine and more 
than 300 kg of crystalline methamphetamine in Australia 
between February and July 2016. In March 2016, the 
Australian Federal Police and the Central Narcotics 
Bureau of Singapore agreed to enter into a memorandum 
of understanding on combating transnational crime and 
developing police cooperation. 
783. In 2016, the customs authorities of Fiji and Vanuatu 
adopted the World Customs Organization National 
Customs Enforcement Network, becoming the only two 
customs administrations in the Pacific region, among 
only 20 other countries worldwide, to have implemented 
the system.
784. The Government of Samoa is establishing an 
 alcohol and other drugs court, with a view to facilitating 
the rehabilitation of people who reoffend in connection 
with their dependency on alcohol and drugs. Expert 
advice on the establishment of the court is being provided 
by New Zealand.
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
785. Cannabis remains the most widely trafficked and 
abused drug throughout Oceania. Although the number 
of cannabis seizures in Australia, both at the border and 
within the country, reached a record high during the 
period 2014-2015, the weight of cannabis seized within 
the country decreased from over 7 tons during the period 
2013-2014 to around 6 tons during the period 2014-2015, 
and the weight of cannabis seized at the border decreased 
from 158 kg to 60 kg over the same period. The amount 
of cannabis herb seized in New Zealand increased from 
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518 kg in 2014 to 692 kg in 2015. The six-month National 
Cannabis and Crime Operation, held in New Zealand 
during the 2015-2016 growing season, resulted in the 
eradication of more than 130,000 cannabis plants and 
almost 80 kg of cannabis herb, the second highest amount 
seized in the past nine years. In Fiji, law enforcement 
Operation Cavuraka had, by June 2016, eradicated more 
than 38,000 cannabis plants found on 15 farms in the 
Navosa highlands.
786. The amount of heroin seized at the Australian bor-
der increased by 168 per cent, from 118.9 kg during the 
period 2013-2014 to 318.7 kg during the period 2014-
2015, with the predominance of South-East Asia as the 
source of the heroin seized increasing to 98.1 per cent in 
the first half of 2015. The amount of heroin seized within 
Australia also increased, from 158 kg during the period 
2013-2014 to 477 kg during the period 2014-2015, the 
second highest level in the past decade. In 2015 in New 
Zealand, a small amount of heroin (38.4 g) was seized, 
significantly less than the 16 kg seized in 2014, but a 
 similar level to that seized in 2013.
787. Australia, which accounted for 99 per cent of total 
cocaine seizures in Oceania between 1988 and 2014, saw 
an increase in the frequency and amount of cocaine seized, 
with seizures at the border increasing from 245.6 kg dur-
ing the period 2013-2014 to 368.9 kg during the period 
2014-2015. Seizures within the country also increased, 
from 317.4 kg during the period 2013-2014 to 514.4 kg 
during the period 2014-2015, still around half the one ton 
seized in 2012-2013. While cocaine seized at the Australian 
border in 2013 had predominantly come from Peru, the 
prominence of Colombia as a source country has 
 re-emerged, with 69.4 per cent of cocaine seized at the 
border in the first half of 2015 originating in Colombia, 
compared with 21.1 per cent originating in Peru. 
788. Following a decrease in the amount of cocaine 
seized in New Zealand, from 10.2 kg in 2014 to 129 g in 
2015, a record seizure of the drug was made in May 2016: 
a shipment of 35 kg from Mexico. Other significant sei-
zures of cocaine in the Pacific, such as 50 kg in Fiji in 
2015 and 680 kg from a yacht in French Polynesia in 
February 2016, suggest the existence of various traffick-
ing routes through the region, likely destined for Australia 
or New Zealand.
(b) Psychotropic substances
789. A record 12.6 tons of amphetamine-type stimu-
lants, comprising 49 per cent amphetamines and 48.3 per 
cent MDMA, were seized in Australia during the period 
2014-2015, having more than tripled from 4.1 tons  during 
the period 2013-2014, and representing just over half 
(53.6 per cent) of the weight of drugs seized in the  country. 
The amount of amphetamine-type stimulants (excluding 
“ecstasy”) detected at the Australian border almost dou-
bled, from 1.8 tons during the period  2013-2014 to a 
record 3.4 tons during the period  2014-2015; crystalline 
methamphetamine accounted for 76.4 per cent of the 
weight of amphetamine-type  stimulants seized at the 
 border during the period 2014-2015. 
790. In New Zealand, the quantity of methampheta-
mine seized more than tripled, from 98.8 kg in 2014 to 
a record amount of 334.3 kg in 2015; however, one large 
shipment of 79.3 kg of methamphetamine seized by cus-
toms authorities was suspected to be destined for 
Australia. That trend appears to be continuing, with a 
record seizure of 494 kg methamphetamine made in 
New Zealand in June 2016. Seizures of methampheta-
mine reported elsewhere in the region, for example Fiji, 
suggest the use of those countries as transit points for 
the trafficking of methamphetamine to Australia and 
New Zealand, but also indicate, given some seizures of 
small quantities, abuse of the substance in those 
countries.
791. The amount of “ecstasy” seized at the Australian 
border increased to 2 tons during the period 2014-2015, 
the second-highest reported level in the previous decade, 
compared with 94.8 kg during the period 2013-2014. A 
single seizure of 1.92 tons of “ecstasy” that had been con-
cealed in sea cargo accounted for 95.8 per cent of the 
“ecstasy” seized at the border during the period 2014-
2015. The amount of the substance seized within the coun-
try also increased, to 6.1 tons during the period 2014-2015. 
In New Zealand, the trend in seizures of “ecstasy”-type 
substances has fluctuated, decreasing in 2014 after a record 
in 2013, and increasing to 5.17 kg in 2015.
(c) Precursors 
792. The majority of methamphetamine seized in 
Australia was primarily manufactured from ephedrine 
and pseudoephedrine, with the proportion of samples 
manufactured from 1-phenyl-2-propanone (P-2-P) 
decreasing. The weight of amphetamine-type stimulant 
(excluding “ecstasy”) precursors seized at the Australian 
border decreased from 1.5 tons during the period 2013-
2014 to 0.5 tons during the period 2014-2015. It remains 
to be seen whether that trend will continue: a signifi-
cant seizure, of 340 kg of ephedrine, was made in Sydney 
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in January 2016. In contrast, the weight of “ecstasy” pre-
cursors seized at the border increased from 1.24 kg in 
the period 2013-2014 to 288 kg in the period 
2014-2015.
793. The number of clandestine laboratories detected in 
Australia has decreased since 2011, and during the period 
2014-2015 it reached the lowest level (667 laboratories) 
since 2008-2009. The proportion of smaller, “user-based” 
clandestine laboratories detected increased during the 
period 2014-2015, to 60.9 per cent. While the majority 
of the facilities were being used to illicitly manufacture 
amphetamines, the number of laboratories manufactur-
ing “ecstasy” increased from 3 during the period 2013-
2014 to 18 during the period 2014-2015.
794. In New Zealand, the trend seen in 2014 towards 
ephedrine, rather than pseudoephedrine, becoming the 
main precursor used in the illicit manufacture of meth-
amphetamine continued in 2015 and into 2016, account-
ing for 92 per cent of the 966.6 kg of methamphetamine 
precursors seized in 2015. Record seizures of ephedrine 
were made in New Zealand in October 2015 and April 
2016 (95 kg and 200 kg, respectively). The number of 
clandestine laboratories dismantled in New Zealand 
decreased from 82 in 2014 to 69 in 2015.
795. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the report of the Board for 2016 on the implementa-
tion of article 12 of the 1988 Convention. 
(d) Substances not under international 
control
796. New psychoactive substances were increasingly 
detected at the Australian border, with a record number 
of seizures made during the period 2014-2015 (551 com-
pared with 92 during the period 2013-2014). However, 
the total weight of new psychoactive substances seized 
decreased, from 543 kg during the period 2013-2014 to 
52.7 kg during the period 2014-2015, the second-lowest 
amount on record. The majority (by weight) of samples 
analysed were cathinone analogues (71.1 per cent), fol-
lowed by synthetic cannabinoids (22.8 per cent). The 
number of ketamine detections at the border increased 
from 155 during the period 2013-2014 to a record 218 
during the period 2014-2015, with the international mail 
stream accounting for 97.2 per cent of ketamine 
detections.
797. Increased illegal importation of new psychoactive 
substances has been reported in New Zealand. 
5. Abuse and treatment
798. Of the internationally controlled substances, can-
nabis remains the most widely abused substance in 
Oceania, with estimated annual prevalence at about 
10 per cent, well above the global estimate of 3.8 per cent. 
In recent years, the abuse of cannabis has been reported 
to be relatively stable, albeit at a high level, in Australia 
and New Zealand, the countries for which recent data are 
available.
799. Although prevalence of abuse of amphetamines 
(i.e., amphetamine and methamphetamine) appears to 
have remained somewhat constant over recent years in 
both Australia and New Zealand, with annual prevalence 
among adults in those countries estimated at 2.1 per cent 
and 0.9 per cent, respectively, methamphetamine consum-
ption has strongly increased in Australia. The number of 
people in Australia who used methamphetamine in the 
previous year is, according to household survey data, 
reported to have doubled, from an estimated 100,000 in 
2007 to 200,000 in 2013, representing 1.1 per cent of the 
adult population. The proportion of detainees testing pos-
itive for methamphetamine more than doubled between 
the periods 2009-2010 and 2014-2015 in Australia. 
Between the periods 2009-2010 and 2013-2014, the num-
ber of hospitalizations related to methamphetamine 
increased fivefold and the number of specialized drug 
treatment cases concerning amphetamines tripled.
800. An Australian study utilizing indirect prevalence 
estimates based on treatment and hospitalization data, 
which was designed to include “more hidden and stigma-
tized” groups of drug users, indicated that the level of 
methamphetamine use was at its highest level, with the 
monthly prevalence among adults increasing from 1.03 
per cent during the period 2002-2003 to 2.09 per cent 
during the period 2013-2014, and with methampheta-
mine addiction increasing from 0.66 per cent during the 
period 2002-2003 to 1.24 per cent during the period 
2013-2014. Furthermore, the study estimated dependent 
use at 1.14 per cent and 1.50 per cent among those aged 
15 to 24 years and 25 to 34 years, respectively. 
801. Wastewater analysis in Australia suggested three-
fold to fivefold increases between 2009 and 2015 in per 
capita methamphetamine consumption in two population 
groups in Queensland. Such analysis also indicated that 
abuse of amphetamines has exceeded that of “ecstasy” and 
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cocaine since 2010 in large parts of Queensland and 
South Australia, and indicated a decline in levels of 
“ecstasy” use in a number of population groups between 
2014 and 2015. 
802. The level of abuse of cocaine is reported to be rela-
tively stable, albeit at a high level, in Australia and New 
Zealand, with annual prevalence among adults of 2.1 per 
cent and 0.6 per cent, respectively. Annual prevalence of 
“ecstasy” abuse among adults in both Australia and New 
Zealand was reported to have declined to 2.5 per cent 
and 2 per cent, respectively, by 2013.
803. In New Zealand, the prevalence of abuse of 
amphetamines was found to be higher among the Maori 
population than among the non-Maori population. 
Similarly, in Australia, annual prevalence of abuse of 
amphetamines in indigenous communities was estimated 
at 5 per cent, higher than the national average. Reported 
levels of annual prevalence of drug abuse among 
Aboriginal and Torres Strait Islander people in Australia 
have been consistently higher than among non- indigenous 
people. Such data should be taken into account in the 
design and implementation of prevention and treatment 
programmes.
804. The rate of accidental overdose deaths due to 
 opioids among those aged 15 to 54 in Australia decreased 
from 49.5 per million in 2011 to 44.7 per million in 2012; 
70 per cent of the accidental opioid deaths in Australia 
among those aged 15 to 54 in 2012 were due to pharma-
ceutical opioids, with the remainder of such deaths due 
to heroin, which was relatively stable with respect to the 
previous year. Annual prevalence of heroin abuse declined 
in Australia from 0.2 per cent in 2010 to 0.1 per cent in 
2013. 
805. Noting the lack of recent data on drug abuse and 
treatment in the other countries of Oceania, the Board 
reiterates its call to the Governments of those countries 
to step up their efforts to increase the collection of data 
on drug abuse and treatment. The Board invites the inter-
national community and regional and bilateral partners 
to provide support to those countries to that end.
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Chapter IV.
Recommendations to Governments, 
the United Nations and other relevant 
international and national organizations
806. The present chapter contains the Board’s most 
important observations contained in the present report 
and the related recommendations. As always, the Board 
would appreciate receiving feedback from Governments 
and international organizations alike regarding their 
experiences, including difficulties encountered, in imple-
menting the provisions of the international drug control 
conventions and the recommendations contained in the 
Board’s annual reports. 
Women and drugs
807. At the special session of the General Assembly on 
the world drug problem held in 2016, the importance of 
incorporating gender perspectives into drug-related poli-
cies and programmes was highlighted. Focusing on drug 
abuse among women in its four main aspects (epidemi-
ology, consequences, special populations and treatment), 
INCB has highlighted a number of gender-specific prob-
lems. For example, while overall drug abuse among 
women remains low by comparison with such abuse 
among men, women are more likely to misuse prescrip-
tion drugs. In addition, the proportion of women involved 
in drug offences is increasing, and special populations, 
such as female prisoners and sex workers, experience 
acute problems. Often, stigma prevents women from 
seeking and/or accessing treatment and rehabilitation 
services. 
Recommendation 1: The Board urges Governments to 
better design, fund and coordinate prevention, treatment 
and rehabilitation activities related to drug abuse among 
women. As a first step, Governments are encouraged to 
collect gender-disaggregated data on drug abuse and 
treatment participation, in order to allow for, for  example, 
the efficient allocation of resources. 
Recommendation 2: Governments should give priority to 
providing easily accessible health care for drug-dependent 
women, keeping in mind that targeted and evidence-
based interventions are particularly effective. Drug treat-
ment programmes must be able to guarantee personal 
safety and confidentiality with women-only spaces or 
times, particularly for women engaged in sex work or 
women who have experienced violence. Special groups, 
such as drug-dependent women who are pregnant, 
need  the enhanced services of specially trained multi-
disciplinary teams.
Recommendation 3: Treatment, education, aftercare, 
post-prison rehabilitation and/or social reintegration ser-
vices should be offered to drug-dependent women who 
have committed criminal offences, in order to provide 
more humane, effective and proportionate alternatives to 
conviction, taking into account the seriousness of offence 
committed, within the flexibility afforded by the conven-
tions. The use of non-custodial options (such as those 
foreseen in the United Nations Rules for the Treatment 
of Women Prisoners and Non-custodial Measures for 
Women Offenders (the Bangkok Rules)) requires 
increased collaboration between public health and justice 
authorities. Preventing the harm that women and their 
children experience from incarceration requires special 
strategies, as well as measures designed to reduce the like-
lihood of reoffending. Providing basic health services in 
prisons is essential, and substandard and unhealthy liv-
ing conditions, as well as any source of psychological, sex-
ual or physical violence, must be eliminated. 
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Special session of the General 
Assembly on the world drug problem 
held in 2016
808. INCB welcomes the adoption by the General 
Assembly of the outcome document of the special session 
of the Assembly on the world drug problem held in 2016, 
in which Member States reaffirmed their commitment to 
the international drug control conventions and which 
contains a practical plan of action for Member States to 
deal with the world drug problem.
Recommendation 4: INCB strongly encourages strength-
ened international cooperation towards addressing the 
world drug problem on the basis of shared responsibil-
ity, as emphasized in chapter I of the Board’s annual 
report for 2012.69 The Board looks forward to continuing 
its cooperation with Governments and civil society with 
a view to improving the drug control situation worldwide 
in the context of the 2030 Agenda for Sustainable 
Development. States are encouraged to move further 
towards the 2019 target date for review of the implemen-
tation of the Political Declaration and Plan of Action on 
International Cooperation towards an Integrated and 
Balanced Strategy to Counter the World Drug Problem.
Proportionality
809. Disproportionate responses to drug-related offences 
undermine the aims of the conventions and can also have 
a negative impact on the application of and compliance 
with the rule of law. The treaties allow States to focus the 
most severe penalties on more serious forms of crime, 
such as trafficking and money-laundering, giving States a 
certain discretion in the legislative and policy choices 
they make in implementing their obligations under the 
three conventions when addressing drug-related offences. 
Recommendation 5: The principle of proportionality, as 
discussed in chapter I of the Board’s annual report for 
2007,70 must continue to act as a guiding principle in 
drug-related matters. Although the determination of 
sanctions applicable to drug-related crime remains the 
prerogative of States parties to the conventions, INCB 
reiterates its position on the issue of capital punishment 
for drug-related offences and encourages States that 
retain capital punishment for drug-related offences to 
consider the abolition of the death penalty for that cat-
egory of offence. 
69 E/INCB/2012/1.
70 E/INCB/2007/1.
810. The recently reported extrajudicial targeting of per-
sons suspected of illicit drug-related activity is not only 
a breach of the three conventions, which require a crimi-
nal justice response to drug-related offences and also 
require the parties to take all practicable measures for the 
prevention of drug abuse and for the early identification, 
treatment, education, aftercare, rehabilitation and social 
reintegration of the persons affected, also constitutes a 
serious breach of human rights standards, including the 
right to due process.
Recommendation 6: The Board urges all Governments 
concerned to put an immediate stop to extrajudicial acts 
of violence or reprisal against persons suspected of illicit 
drug-related activity and to investigate and sanction, as 
warranted, the aiding and abetting, encouragement, 
 counselling or incitement to commit these acts, in full 
observance of due legal process and the rule of law.
Availability
811. The outcome document of the special session of 
the General Assembly on the world drug problem held 
in 2016 includes operational recommendations on ensur-
ing the availability of and access to controlled substances 
for medical and scientific purposes, while preventing 
their diversion. INCB stands ready to continue to sup-
port Governments in their efforts to ensure the availabil-
ity of narcotic drugs and psychotropic substances for 
medical and scientific purposes, in coordination with 
other relevant international, regional and national 
organizations.
Recommendation 7: INCB urges all Governments to fully 
implement the operational recommendations on ensur-
ing the availability of and access to controlled substances 
for medical and scientific purposes, while preventing 
their diversion, contained in the outcome document of 
the special session of the General Assembly on the world 
drug problem held in 2016, and the recommendations 
contained in the supplement to the Board’s annual report 
for 2015.71 Furthermore, INCB invites Governments to 
support and participate in concrete initiatives for the 
implementation of the operational recommendations 
contained in the above-mentioned outcome document, 
including the project named INCB Learning (see also 
paras. 154-157, above). 
812. Some Governments are not in a position to imple-
ment the above-mentioned recommendations on their 
71 Availability of Internationally Controlled Drugs: Ensuring Adequate 
Access for Medical and Scientific Purposes (E/INCB/2015/1/Supp.1).
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own. They need advice, training and resources to address 
the limitations of their systems.
Recommendation 8: The Board again calls upon the 
international community to improve cooperation among 
Governments, international organizations (WHO, 
UNODC, UNAIDS and the United Nations Development 
Programme, among others), the donor community and 
civil society organizations to ensure the sharing of 
 expertise and the coordinated delivery of resources and 
technical support to countries in need of assistance.
Consumption of psychotropic 
substances
813. The Board is concerned that fewer than 60 coun-
tries submit data on consumption of psychotropic sub-
stances. These data are essential to enable the Board to 
analyse the levels of consumption and promote the 
 adequate availability and rational use of such substances. 
Recommendation 9: The Board appreciates the coopera-
tion of the Governments concerned and calls upon all 
Governments to report on the consumption of psycho-
tropic substances on an annual basis, pursuant to 
Commission on Narcotic Drugs resolution 54/6, as such 
data are essential for an improved evaluation of the 
 availability of psychotropic substances for medical and 
scientific purposes.
National control measures for 
psychotropic substances
814. While most countries and territories have already 
introduced an import and export authorization require-
ment for psychotropic substances listed in Schedules III 
and IV of the 1971 Convention, in accordance with 
Economic and Social Council resolutions 1985/15, 
1987/30 and 1993/38, a limited number of States have not 
yet done so, despite reminders, and have not aligned their 
national control measures with those stipulated in the 
aforementioned resolutions. 
Recommendation 10: The Board urges the Governments 
of the few remaining States in which national legislation 
does not yet require import and export authorizations for 
all psychotropic substances to extend the system of import 
and export authorizations provided for in article 12, para-
graph 1, of the 1971 Convention to cover international 
trade in substances listed in Schedules III and IV as soon 
as possible and to inform the Board accordingly.
Cannabis
815. Some States have introduced or are considering the 
introduction of measures that would allow the use, dis-
tribution and sale of cannabis for non-medical 
purposes. 
Recommendation 11: INCB reiterates that such measures 
are not in line with the international drug control con-
ventions and reminds all parties of their legal obliga-
tion to take legislative and administrative measures to 
limit exclusively to medical and scientific purposes the 
cultivation, production, manufacture, export, import, 
distribution of, trade in and use and possession of nar-
cotic drugs, including cannabis, and psychotropic sub-
stances throughout their entire territories.
816. Some States have attempted to justify the legaliza-
tion of the use of cannabis for non-medical purposes by 
the need to address the disproportionate representation 
in the criminal justice and prison systems of drug users 
belonging to minority groups. However, the conventions 
do not require the imposition of imprisonment for drug 
users and provide alternatives to incarceration. 
Recommendation 12: The Board encourages States with 
high rates of arrest and incarceration of drug users for 
minor drug-related offences to consider availing them-
selves of the possibility provided for in the international 
drug control conventions to adopt non-punitive 
responses to such circumstances.
817. The 1961 Convention allows States parties to use 
cannabis for medical purposes. Reflecting concerns about 
abuse and diversion, the Convention establishes an addi-
tional set of control measures that should be imple-
mented in order for programmes for the use of cannabis 
for medical purposes to be in compliance with the 
Convention.
Recommendation 13: All Governments that have estab-
lished programmes for the use of cannabis for medical 
purposes, or that are considering such initiatives, are 
reminded of their reporting and licensing obligations 
under the international drug control treaties. Such pro-
grammes must ensure that the prescription of cannabis 
for medical purposes is performed with competent medi-
cal knowledge and supervision and that such prescrip-
tion is based on sound medical practice. States parties to 
the 1961 Convention in which research on the use of can-
nabis for medical purposes is ongoing are invited to share 
their findings and any other data on the medical useful-
ness or otherwise of cannabis with INCB and with WHO 
and other relevant international organizations.
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Complete, accurate and timely reporting
818. One of the central areas in ensuring the balance 
between the availability of internationally controlled nar-
cotic drugs and psychotropic substances for medical and 
scientific purposes and preventing their diversion and 
abuse is the role of the Board in collecting national esti-
mates and assessments for the licit requirements of those 
substances. These are essential elements of the inter-
national drug control system and enable exporting and 
importing countries to prevent diversion from inter-
national trade. Competent national authorities play a key 
role in consolidating the data received from pharmaceu-
tical companies, importers and exporters and other 
authorized agents within their jurisdictions to ensure that 
complete and reliable data are provided in a timely man-
ner to the Board. However, some Governments still fail 
to provide the Board with timely and adequate estimates 
and assessments, and reliable statistical returns, including 
quarterly and annual statistics on international trade.
Recommendation 14: Governments should provide to 
the Board, in an accurate and timely manner, the infor-
mation requested pursuant to the treaties and relevant 
resolutions of the Commission on Narcotic Drugs and 
the Economic and Social Council. In addition, govern-
ment authorities are urged to provide for the training 
of staff to enable them to fulfil their reporting obliga-
tions under the international drug control conventions 
and to take the necessary steps to maintain the knowl-
edge base of their employees at times of staff turnover.
Precursors
819. The Board considers precursor control as a form 
of preventing serious illicit activity. To that end, INCB 
provides tools such as PEN Online and PICS, which 
should be actively used by Governments for the exchange 
of information in order to enhance international control 
over precursors. The increasing use of non-scheduled pre-
cursors in the illicit manufacture of drugs is another issue 
that demands flexible approaches and effective coopera-
tion at the international level. 
Recommendation 15: The Board calls upon Governments 
to continue to monitor international trade in precursors 
by actively using PEN Online. Competent national 
authorities are encouraged to request the assistance of 
the Board, as needed, in ascertaining whether a suspi-
cious individual transaction is legitimate or not. 
Recommendation 16: INCB encourages all Governments 
to make use of the Board’s guidelines for the 
establishment of partnerships with the private sector for 
the control of precursors and for addressing the emer-
gence of so-called “designer precursors”.
820. In recent years, the Board has observed a shift in 
the diversion of precursors from international to domes-
tic trade. While that shift may be an indicator of the suc-
cessful functioning of the precursor control system at the 
international level, it exposes potential weaknesses in the 
design of domestic control systems, which the 1988 
Convention leaves to the discretion of States parties. 
Recommendation 17: Increased attention must be paid 
to establishing and implementing comprehensive pre-
cursor monitoring systems at the national level, focus-
ing on domestic trade. Article 12, paragraph 8, of the 
1988 Convention provides some guidance on possible 
basic features of such a system. Several initiatives of the 
Board, including Project Prism and Project Cohesion, 
also offer a platform for the exchange of information on 
best  practices in precursor control.
New psychoactive substances
821. With an increase in the prevalence of abuse and 
an increase in reported health consequences and fatali-
ties, new psychoactive substances continue to pose a 
 serious problem to public health. 
Recommendation 18: The Board encourages all 
Governments to take practical measures to prevent the 
abuse and related consequences for individuals and 
society of new psychoactive substances, to share exist-
ing knowledge, experiences and good practices, and to 
pursue and enhance collaboration and the utilization of 
various initiatives on the issue. In particular, the Board 
encourages all Governments to make full use of the 
global focal point network of Project Ion and its inci-
dent  communication tool (IONICS).
Use of modern technology 
822. As with most online electronic systems established 
to respond to practical challenges, the effectiveness of the 
INCB online tools (namely I2ES, PEN Online, PICS and 
IONICS) depends on the number of participating 
Governments, the extent of utilization, the quality, time-
liness and volume of the data shared and the availability 
of sustained support, including financial support, to 
 operate and maintain the systems.
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Recommendation 19: The Board expresses its apprecia-
tion to all Governments that have provided financial sup-
port and technical input for the development of all INCB 
electronic tools. Further use of those electronic tools by 
Governments and further political and financial support 
are required to ensure the further success of their imple-
mentation and to enable INCB to administer them in line 
with its mandate and to provide reliable, responsive and 
tailored user support to competent national authorities. 
The Board therefore invites all Governments to fully uti-
lize the available tools, which are available to them at no 
cost, and to provide further ongoing support, including 
financial support, to sustain the range of electronic tools 
made available by INCB, so that it can improve and 
 further develop such tools as the need arises.
Application of the international drug 
control treaties in specific countries and 
regions
823. The deteriorating drug control situation in 
Afghanistan remains a matter of the gravest concern. That 
situation not only negatively affects the people of 
Afghanistan, but has ramifications for the drug control 
and security situation worldwide. INCB has continued 
close consultations with the Government of Afghanistan 
under article 14 of the 1961 Convention, which it invoked 
in 2000 in view of the serious situation in the country.
Recommendation 20: The Board calls upon the 
Government of Afghanistan, with the assistance of the 
Governments of its development partners and in cooper-
ation with relevant international and regional organiza-
tions, to further and urgently address the drug control 
situation in the country. In that context, the Board urges 
the Government of Afghanistan to translate its commit-
ment into specific actions in order to ensure that substan-
tial, sustainable and demonstrable progress is achieved in 
addressing the illicit cultivation and production of nar-
cotic drugs, and related trafficking and money-launder-
ing, as well as in promoting effective alternative 
development and livelihood programmes and reducing 
drug demand by expanding drug abuse prevention initi-
atives and programmes to provide treatment, rehabilita-
tion and recovery services to those affected by drug abuse. 
824. Although Africa is perceived mainly as a transit 
region for drug trafficking, it is increasingly becoming a 
consumer market for all types of drugs of abuse. While 
illicit production of, trafficking in and abuse of cannabis 
have remained major challenges throughout many parts 
of Africa, heroin abuse is also reportedly growing. 
Recommendation 21: The Board appeals to the 
Governments of countries in Africa, as well as to inter-
national partners, to allocate necessary resources with 
a view to preventing a deterioration of the drug abuse 
and trafficking situation in the region. Preventing drug-
related problems remains an important element of 
wider efforts towards improving the security and soci-
oeconomic  situation throughout Africa. 
825. Owing to a paucity of detailed and reliable infor-
mation related to abuse and treatment in Africa and 
Oceania, assessing the extent of drug abuse and accurately 
estimating the number of people in treatment in those 
regions remain challenging. Such data are a prerequisite 
for the design and implementation of appropriate 
 prevention and treatment strategies.
Recommendation 22: INCB calls on the Governments of 
countries in Africa and Oceania to step up their efforts 
to increase the collection of data on drug abuse and 
treatment. 
826. Trafficking in and abuse of “captagon” tablets, con-
taining amphetamine, continues to be on the rise in West 
Asia, accompanied by increased numbers of seizures. 
Recommendation 23: The Board urges Governments to 
take an active part in INCB initiatives under Project Prism, 
which provides for cooperation among national authori-
ties and relevant international organizations, to identify 
the way in which precursors used for the manufacture of 
“captagon” tablets, namely precursors needed for the illicit 
manufacture of amphetamine, are obtained and trafficked, 
and to address the problem of abuse of the substance. 
(Signed)
Werner Sipp 
President
(Signed)
Sri Suryawati 
Rapporteur
(Signed)
Andrés Finguerut
Secretary
Vienna, 18 November 2016
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Annex I.
Regional and subregional groupings used in the 
report of the International Narcotics Control 
Board for 2016
The regional and subregional groupings used in the report of the International Narcotics Control Board for 2016, 
together with the States in each of those groupings, are listed below.
Africa
Algeria Libya
Angola Madagascar
Benin Malawi
Botswana Mali
Burkina Faso Mauritania
Burundi Mauritius
Cameroon Morocco
Cabo Verde Mozambique
Central African Republic Namibia
Chad Niger
Comoros Nigeria
Congo Rwanda
Côte d’Ivoire Sao Tome and Principe
Democratic Republic of the Congo Senegal
Djibouti Seychelles
Egypt Sierra Leone
Equatorial Guinea Somalia
Eritrea South Africa
Ethiopia South Sudan
Gabon Sudan
Gambia Swaziland
Ghana Togo
Guinea Tunisia
Guinea-Bissau Uganda
Kenya United Republic of Tanzania
Lesotho Zambia
Liberia Zimbabwe
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Central America and the Caribbean
Antigua and Barbuda Guatemala
Bahamas Haiti
Barbados Honduras
Belize Jamaica
Costa Rica Nicaragua
Cuba Panama
Dominica Saint Kitts and Nevis
Dominican Republic Saint Lucia
El Salvador Saint Vincent and the Grenadines
Grenada Trinidad and Tobago
North America
Canada United States of America
Mexico
South America
Argentina Guyana
Bolivia (Plurinational State of) Paraguay
Brazil Peru
Chile Suriname
Colombia Uruguay
Ecuador Venezuela (Bolivarian Republic of)
East and South-East Asia
Brunei Darussalam Mongolia
Cambodia Myanmar
China Philippines
Democratic People’s Republic of Korea Republic of Korea
Indonesia Singapore
Japan Thailand
Lao People’s Democratic Republic Timor-Leste
Malaysia Viet Nam
South Asia
Bangladesh Maldives
Bhutan Nepal
India Sri Lanka
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West Asia
Afghanistan Oman
Armenia Pakistan
Azerbaijan Qatar
Bahrain Saudi Arabia
Georgia State of Palestine
Iran (Islamic Republic of) Syrian Arab Republic
Iraq Tajikistan
Israel Turkey
Jordan Turkmenistan
Kazakhstan United Arab Emirates
Kuwait Uzbekistan
Kyrgyzstan Yemen
Lebanon
Europe
Eastern Europe
Belarus Russian Federation
Republic of Moldova Ukraine
South-Eastern Europe
Albania Montenegro
Bosnia and Herzegovina Romania
Bulgaria Serbia
Croatia The former Yugoslav Republic of Macedonia
Western and Central Europe
Andorra Liechtenstein
Austria Lithuania
Belgium Luxembourg
Cyprus Malta
Czechiaa Monaco
Denmark Netherlands
Estonia Norway
Finland Poland
France Portugal
Germany San Marino
Greece Slovakia
Holy See Slovenia
Hungary Spain
Iceland Sweden
Ireland Switzerland
Italy United Kingdom of Great Britain and Northern Ireland
Latvia
a Since 17 May 2016, “Czechia” has replaced “Czech Republic” as the short name used in the United Nations.
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Oceania
Australia Niue
Cook Islands Palau
Fiji Papua New Guinea
Kiribati Samoa
Marshall Islands Solomon Islands
Micronesia (Federated States of) Tonga
Nauru Tuvalu
New Zealand Vanuatu
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Annex II.
Current membership of the International 
Narcotics Control Board
Wei Hao 
Born in 1957. National of China. Professor of Psychiatry 
and Deputy Director of the Mental Health Institute, 
Central South University, Changsha, China. Director of 
the World Health Organization (WHO) Collaborating 
Centre for Psychosocial Factors, Substance Abuse and 
Health. Currently serving as Chair, Education Committee 
of the Asian-Pacific Society for Alcohol and Addiction 
Research, and as President, Chinese Association of Drug 
Abuse Prevention and Treatment and Chinese Association 
of Addiction Medicine.
Bachelor of Medicine, Anhui Medical University; Master’s 
and Doctorate degrees of Psychiatry, Hunan Medical 
University.
Previously held positions as Scientist, Substance Abuse 
Department, WHO, Geneva (1999-2000); Medical Officer, 
Department of Mental Health and Substance Abuse, WHO, 
Western Pacific Region, and President, Chinese Psychiatrist 
Association (2008-2011). Membership in the Scientific 
Advisory Committee on Tobacco Product Regulation, 
WHO (2000-2004). Currently holding membership of the 
Expert Advisory Panel on Drug Dependence and Alcohol 
Problems, WHO (2006-present); and member of the 
Working Group on the Classification of Substance Abuse 
for the eleventh revision of the International Classification 
of Diseases (ICD-11), WHO (2011-present).
Recipient of research support from various bodies at the 
national level (Ministry of Health, Ministry of Science 
and Technology, National Natural Science Foundation) 
and at the international level (WHO and the National 
Institute on Drug Abuse and the National Institute on 
Alcohol Abuse and Alcoholism of the United States). 
Coordinator of a series of WHO/China workshops on 
addictive behaviour. Member of the Expert Committee of 
the national project on mental health services in commu-
nities in China. Consultant for the development, imple-
mentation and evaluation of China’s mental health law, 
and for the development of the anti-drug law and 
 regulations in China.
Published over 400 academic articles and 50 books on 
alcohol and drug dependence. Selected recent publica-
tions in peer-reviewed journals include the following: 
“Longitudinal surveys of prevalence rates and use pat-
terns of illicit drugs at selected high-prevalence areas in 
China from 1993 to 2000”, Addiction (2004); “Drug pol-
icy in China: progress and challenges”, Lancet (2014); 
“Alcohol and the sustainable development goals”, Lancet 
(2016); “Transition of China’s drug policy: problems in 
practice” Addiction (2015); “Improving drug addiction 
treatment in China”, Addiction (2007); “Stigmatization of 
people with drug dependence in China: a community-
based study in Hunan province”, Drug Alcohol Dependence 
(2013); and “Drinking and drinking patterns and health 
status in the general population of five areas of China”, 
Alcohol & Alcoholism (2004).
Member of the International Narcotics Control Board 
(since 2015). Member of the Committee on Finance and 
Administration (2015). Member of the Standing 
Committee on Estimates (since 2015). Vice-Chair of the 
Standing Committee on Estimates (2016).
David T. Johnson
Born in 1954. National of the United States. Vice-
President, Janus Global Operations; retired diplomat. 
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Bachelor’s degree in economics from Emory University; 
graduate of the National Defence College of Canada.
United States Foreign Service officer (1977-2011). 
Assistant Secretary for the Bureau of International 
Narcotics and Law Enforcement Affairs, United States 
Department of State (2007-2011). Deputy Chief of 
Mission (2005-2007) and Chargé d’affaires, a.d. (2003-
2005), United States Embassy, London. Afghan 
Coordinator for the United States (2002-2003). United 
States Ambassador to the Organization for Security and 
Cooperation in Europe (1998-2001). Deputy Press 
Secretary at the White House and Spokesman for the 
National Security Council (1995-1997). Deputy Spokesman 
at the State Department (1995) and Director of the State 
Department Press Office (1993-1995). United States 
Consul General, Vancouver (1990-1993). Assistant 
National Trust Examiner, Office of the Comptroller of the 
Currency, United States Treasury (1976-1977).
Member of the International Narcotics Control Board 
(since 2012). Member of the Committee on Finance and 
Administration (since 2012). Chair of the Committee on 
Finance and Administration (2014).
Bernard Leroy 
Born in 1948. National of France. Honorary Deputy 
Prosecutor General and Director of the International 
Institute of Research against Counterfeit Medicines.
Degrees in Law from the University of Caen, Institute of 
European Studies of Saarbrucken, Germany, and 
University Paris X. Graduate of the French National 
School for the Judiciary (1979).
Previously held positions of Deputy General Prosecutor, 
Versailles Court of Appeal, 2010-2013. Senior Legal 
Adviser, United Nations Office on Drugs and Crime 
(UNODC) (1990-2010). Adviser in charge of inter-
national, legislative and legal affairs in the French National 
Drug Coordination (1988-1990). Investigating judge 
 specializing in drug cases, Evry High Court (1979-1988). 
Head of the Legal Assistance Programme, UNODC, and 
Coordinator of the decentralized team of legal experts, 
Bogota, Tashkent and Bangkok (1990-2010). Leader of 
the legal assistance team assisting the Government of 
Afghanistan in the drafting process of the new drug con-
trol law, 2004. Co-author of the preparatory study for the 
law introducing community service sentencing as an 
alternative to imprisonment in France (1981). Co-founder 
of “Essonne Accueil”, a non-governmental organization 
providing treatment services for drug addicts (1982). 
Member of the French delegation for the final negotia-
tions of the United Nations Convention against Illicit 
Traffic in Narcotic Drugs and Psychotropic Substances, 
1988. Chair of the study group on cocaine trafficking in 
Europe, Council of Europe (1989). Author of the report 
resulting in the first European political coordinating com-
mittee to combat drugs (1989). Chair of the World Bank 
and UNODC joint team (the Stolen Asset Recovery 
(StAR) Initiative) which organized the freezing and sub-
sequent recovery in Switzerland of the assets stolen by 
the former dictator Jean-Claude Duvalier in Haiti (2008).
Organizer of the lifelong learning programme on com-
bating drug trafficking and addiction for members of the 
French judiciary, French National School for the Judiciary 
(1984-1994). Lecturer for medical graduates in psychia-
try in the field of forensic expertise and responsibility, 
Faculty of Medicine, Paris-Sud University (1983-1990). 
Lecturer in the field of social work, University of Paris 
13 (1984-1988). Lecturer for second year Master’s courses 
in Security and Public International Law, Jean Moulin 
Lyon 3 University (2005-2013).
Member of the Executive Board of the international sec-
tion of the National Association of Drug Court Professionals 
(2006). External member of the Management Board of the 
French Monitoring Centre for Drugs and Drug Addiction 
(2013). Member of the committee of the Reynaud report 
(2013). Honours: chevalier of the Legion of Honour.
Selected publications include “Le travail au profit de la 
communauté, substitut aux courtes peines 
d’emprisonnement”, Revue de science criminelle et de droit 
comparé, No. 1 (Sirey, 1983); Drogues et drogués, École 
nationale de la magistrature, studies and research (1983); 
Étude comparative des législations et des pratiques judici-
aires européennes face à la drogue (Commission of the 
European Communities, 1991); Ecstasy, Inserm Collective 
Expertise series (Editions Inserm, 1997); The International 
Drug Control System, in cooperation with Cherif Bassiouni 
and J.F. Thony, in International Criminal Law: Sources, 
Subjects and Contents (Martinus Nijhoff Publishers, 2007); 
Routledge Handbook of Transnational Criminal Law, Neil 
Boister and Robert Curie, eds. (Routledge, 2014).
Member of the International Narcotics Control Board 
(since 2015). Rapporteur (2015). Member of the Standing 
Committee on Estimates (2016).
Richard P. Mattick 
Born in 1955. National of Australia. Professor of Drug 
and Alcohol Studies at the National Drug and Alcohol 
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Research Centre, Faculty of Medicine, University of New 
South Wales; Professor of Brain Sciences, University of 
New South Wales; Principal Research Fellow, Australian 
Government National Health and Medical Research 
Council (2013-2017), and Registered Clinical Psychologist.
Bachelor of Science (Psychology), Honours, Class 1, 
University of New South Wales, 1982; Master of 
Psychology (Clinical), University of New South Wales, 
1989; Doctor of Philosophy, University of New South 
Wales, 1988; and Certificate in Neuroanatomy, Anatomy, 
University of New South Wales, 1992.
Director of Research, Australian National Drug and 
Alcohol Research Centre (1995-2001), and Executive 
Director, Australian National Drug and Alcohol Research 
Centre, Faculty of Medicine, University of New South 
Wales (2001-2009). Member, Australian National Expert 
Advisory Committee on Illicit Drugs (2002-2004), 
Australian National Expert Advisory Group on Sustained 
Release Naltrexone (2002-2004), Monitoring Committee 
of the Medically Supervised Injecting Centre for the New 
South Wales Government Cabinet Office (2003-2004), 
Australian Ministerial Council on Drug Strategy Working 
Party on Performance and Image Enhancing Drugs (2003-
2005), Australian Government Department of Health and 
Ageing Expert Advisory Committee on Cannabis and 
Health (2005-2006), New South Wales Expert Advisory 
Group on Drugs and Alcohol for the New South Wales 
Minister of Health (2004-2013), Australian National 
Council on Drugs advising the Prime Minister (2004-
2010), WHO/UNODC Technical Guidelines Development 
Group on Pharmacotherapy of Opioid Dependence 
(2004-2008), Australian Research Alliance for Children 
and Youth (2005-2015).
Served on the editorial and executive boards of Drug and 
Alcohol Review (1994-2005), and as Deputy Editor (1995-
2000) and Executive Editor (2000-2005). Assistant Editor 
of the international peer-reviewed journal Addiction 
(1995-2005). Editor, Cochrane Review Group on Drugs 
and Alcohol (1998-2003). Authored over 280 books, 
chapters in edited volumes on substance abuse, addiction 
and treatment, and peer-reviewed academic journal arti-
cles on those subjects. Recent articles include 
“Buprenorphine maintenance versus placebo or metha-
done maintenance for opioid dependence”, “Young adult 
sequelae of adolescent cannabis use” and “The Pain and 
Opioids IN Treatment study: characteristics of a cohort 
using opioids to manage chronic non-cancer pain”. 
Recipient of academic and research support from the 
Australian Government Department of Health; the New 
South Wales Government Department of Health; the 
Australian National Drug Law Enforcement Research 
Fund; the Alcohol Education and Rehabilitation 
Foundation; UNODC; the National Institute on Drug 
Abuse of the United States; the Australian Research 
Council; and the Australian Government National Health 
and Medical Research Council.
Member of the International Narcotics Control Board 
(since 2015). Member of the Standing Committee on 
Estimates (since 2015).
Alejandro Mohar Betancourt 
Born in 1956. National of Mexico. Director General of 
the National Cancer Research Institute of Mexico (2003-
2013) and member of the National System of Researchers 
of Mexico, the National Academy of Medicine, the 
Mexican Academy of Sciences and the American Society 
of Clinical Oncology.
Doctor of Medicine, National Autonomous University of 
Mexico (UNAM) (1980); Postgraduate studies in anatom-
ical pathology, National Institute of Nutrition (1985), 
Master of Sciences (1986) and Doctor of Sciences in 
Epidemiology (1990), Harvard School of Public Health. 
Recipient of academic and research support from the 
National Council on Science and Technology (CONACYT) 
and the Mexican Foundation of Health. Head of the 
Department of Epidemiology (1988-1989), Deputy 
Director of Clinical Research (1993-1999) and Director 
of Research (1999-2003), National Cancer Research 
Institute of Mexico. Lecturer and Research Associate, 
Harvard School of Public Health (1988-1990). Lecturer 
and Director of master’s and doctoral dissertations at the 
Faculty of Medicine, UNAM (since 1991). Coordinator of 
the Unit for Biomedical Research on Cancer, Biomedical 
Research Institute, UNAM (1998). Author of more than 
110 scientific and popular works, 70 of which appear in 
indexed journals, including “Intratypic changes of the E1 
gene and the long control region affect ori function of 
human papillomavirus type 18 variants”, “Screening breast 
cancer: a commitment to Mexico (preliminary report)”, 
“Impact of diabetes and hyperglycemia on survival in 
advanced breast cancer patients”, “Ovarian cancer: the 
new challenge in gynaecologic oncology?” and “Validation 
of the Mexican-Spanish version of the EORTC QLQ-C15-
PAL questionnaire for the evaluation of health-related 
quality of life in patients on palliative care”. 
Awarded various recognitions including the following: 
Miguel Otero Award for clinical research, General Health 
Council (2012); third place for best pharmacoeconomics 
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work, Mexican College for Pharmacoeconomics and 
International Society for Pharmacoeconomics and 
Outcomes Research, Mexico chapter (2010); member of 
the Group of the 300 Most Influential Leaders of Mexico; 
recognition for participation in the meeting of the Global 
Health Strategic Operations Advisory Group of the 
American Cancer Society (2009); member of the Board 
of Governors of the National Autonomous University of 
Mexico (2008); Distinction of Edward Larocque Tinker 
Visiting Professor, Stanford University (2000); member of 
the External Advisory Group for the Mexico Report on 
Social Determinants of Health (2010); member of the jury 
for the Aaron Sáenz Annual Prize for Paediatric Research, 
Federico Gómez Children’s Hospital of Mexico and the 
“General y Lic. Aarón Sáenz Garza, A.C.” Association 
(2010); member of the Global Health Strategic Operations 
Advisory Group of the American Cancer Society (2010); 
Certificate of Achievement for dedication and commit-
ment to establishing a national cancer plan for Mexico, 
American Cancer Society (2006); member of the Scientific 
Committee of the Mexican Association of Pathologists 
(1993-1995).
Member of the International Narcotics Control Board 
(2013-2016).b Member of the Standing Committee on 
Estimates (since 2014). Vice-Chair of the Standing 
Committee on Estimates (2015). Member of the 
Committee on Finance and Administration (2016).
Jagjit Pavadia 
Born in 1954. National of India. Graduate in English 
Honours (1974), Dhaka University, LL.B from Delhi 
University (1988), Master’s Diploma in Public 
Administration, Indian Institute of Public Administration 
(1996). Completed dissertation “Forfeiture of Property 
under the Narcotics Drugs and Psychotropic Substances 
Act, 1985” towards completion of Master’s Diploma. 
Held several senior positions in the Indian Revenue 
Service for 35 years in the Government of India, includ-
ing Narcotics Commissioner of India, Central Bureau of 
Narcotics (2006-2012); Commissioner, Legal Affairs 
(2001-2005); Chief Vigilance Officer, Power Finance 
Corporation (1996-2001); Customs Training Adviser 
Maldives, deputed by the Commonwealth Secretariat 
(1994-1995); Deputy Director, Narcotics Control Bureau 
(1990-1994); and retired as Chief Commissioner, Customs, 
Central Excise and Service Tax, Nagpur, in 2014.
b Resigned, effective 10 August 2016.
Recipient of Presidential Appreciation Certificate for 
Specially Distinguished Record of Service on the occa-
sion of Republic Day (2005), published in the Gazette of 
India Extraordinary.
Member of the Indian delegation to the Commission on 
Narcotics Drugs, Vienna (2007-2012); introduced resolu-
tions 51/15 (2008) and 53/12 (2010), adopted by the 
Commission on Narcotic Drugs, and organized a side 
event on the margins of the Commission’s 2011 session, 
presenting issues involved in the illegal movement of 
poppy seeds to producing, importing and exporting 
countries. As representative of the competent national 
authority, attended Project Prism and Project Cohesion 
task force meetings (2006-2012), and coordinated and 
organized the Project Prism and Project Cohesion meet-
ing in New Delhi (2008). Participated in the Meeting of 
Heads of National Drug Law Enforcement Agencies 
(HONLEA), Asia and the Pacific, held in Bangkok (2006), 
and organized the Meeting of HONLEA, Asia and the 
Pacific, held in Agra, India (2011). Member of the INCB 
advisory expert group on the scheduling of substances 
(2006), and member of the advisory group finalizing the 
INCB Guidelines for a Voluntary Code of Practice for the 
Chemical Industry (2008). Rapporteur of the forty-first 
session of the Subcommission on Illicit Drug Traffic and 
Related Matters in the Near and Middle East, held in 
Amman (2006); Chairperson of the forty-second session 
of the Subcommission, held in Accra, India (2007); organ-
ized the meeting of the Paris Pact Initiative Expert 
Working Group on Precursors, held in New Delhi (2011), 
and participated in the International Drug Enforcement 
Conferences hosted by the United States Drug Enforcement 
Agency, held in Istanbul (2008) and Cancún, Mexico 
(2011).
Member of the International Narcotics Control Board 
(since 2015). Second Vice-President and Chair of the 
Standing Committee on Estimates (2015). Member of the 
Committee on Finance and Administration (2016). First 
Vice-President of the Board (2016).
Ahmed Kamal Eldin Samak
Born in 1950. National of Egypt. Graduated with a Law 
and Police Licence in 1971. Worked in the field of anti-
narcotics for more than 35 years, until becoming the 
Minister Assistant of Police and Head of the Anti-Narcotics 
General Administration of Egypt, which is considered the 
first organization of anti-narcotics in the world and was 
founded in 1929. Independent adviser in the field of anti-
narcotics and crime. First-rank badge of honour on the 
occasion of the police festival (1992). Contributed to 
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several missions, such as to Jordan, for anti-narcotics train-
ing (1988); India, for the signing of an agreement between 
India and Egypt to strengthen anti-narcotics and security 
cooperation to combat crime and terrorism (1995); France, 
for cooperation between Egypt and the International 
Criminal Police Organization (INTERPOL) relating to 
drugs and money-laundering (1996); Palestine,c to partic-
ipate in a regional anti-narcotics workshop (1999); Saudi 
Arabia, to participate in a training programme related to 
drug cases (2001); United Arab Emirates, to represent the 
Ministry of the Interior at the thirty-sixth session of the 
committee concerned with illegal trade in drugs (2001); 
Libyan Arab Jamahiriya,d to participate in the celebration 
of the International Day against Drug Abuse and Illicit 
Trafficking (2002); Kenya, to participate in the twelfth and 
seventeenth conferences of African national anti-narcotics 
department leaders (2002 and 2007); Mauritius, for the sec-
ond ministerial anti-narcotics meeting (2004); Lebanon, to 
participate in the conference “Drugs are a social epidemic”, 
organized by Lebanese organizations for human rights 
(2004); Tunisia, to participate in the seventeenth to twenty-
first Arab conferences of anti-narcotics department leaders 
(2003-2007); United States (2004); Austria, to represent the 
Ministry at the forty-fifth, forty-sixth and forty-eighth to 
fiftieth sessions of the Commission on Narcotic Drugs 
(2002-2007); Saudi Arabia, as a member of a scientific 
organization to prepare an article about arrest and inves-
tigation procedures (2007); United Arab Emirates, for the 
Regional Seminar for Strategic and Cooperative Planning 
in the Field of Anti-Narcotics (2007). Member of the 
National General Trust Fund for Anti-Narcotics and 
Addiction; and the Committee of National Strategy 
Planning on Anti-Narcotics.
Member of the International Narcotics Control Board 
(since 2012). Member of the Standing Committee on 
Estimates (2012 and 2014-2016). 
Werner Sipp
Born in 1943. National of Germany. Lawyer (Universities 
of Heidelberg, Germany, and Lausanne, Switzerland; 
University Institute of European Studies, Turin, Italy).
Assistant lecturer in Public Law, University of Regensburg 
(1971-1977). Senior administrative posts in several  federal 
ministries (1977-2008). Head of the Division for Narcotic 
c Pursuant to General Assembly resolution 67/19 of 29 November 
2012, Palestine has been accorded the status of a non-member observer 
State. The name “State of Palestine” is now used in all United Nations 
documents.
d Since 16 September 2011, “Libya” has replaced “Libyan Arab Jama-
hiriya” as the short name used in the United Nations.
Law and International Narcotic Drugs Affairs in the 
Federal Ministry of Health (2001-2008); Permanent 
Correspondent of Germany in the Pompidou Group of 
the Council of Europe (2001-2008); Legal Correspondent 
of Germany in the European Legal Database on Drugs, 
Lisbon (2002-2008); Chairman of the Horizontal Working 
Party on Drugs of the Council of the European Union 
(2007); Coordinator of the German delegation to the 
Commission on Narcotic Drugs (2001-2009). 
Expert Consultant to the German Federal Ministry of 
Health and Drug Commissioner of the Federal 
Government in international drug matters (2008-2009); 
Expert Consultant on drug issues to the Deutsche 
Gesellschaft für Internationale Zusammenarbeit (2008-
2011); Expert on several European Union drug projects 
such as “Implementing the national strategy to fight drug 
abuse in Serbia” and the Central Asia Drug Action 
Programme.
Member of the International Narcotics Control Board 
(since 2012). Member of the Standing Committee on 
Estimates (2012-2014). Rapporteur (2013). First Vice-
President of the Board (2014). President of the Board 
(2015 and 2016).
Viroj Sumyai
Born in 1953. National of Thailand. Retired Assistant 
Secretary-General of the Food and Drug Administration, 
Ministry of Public Health of Thailand, and clinical phar-
macologist specializing in drug epidemiology. Professor, 
Mahidol University (since 2001).
Bachelor of Science degree in chemistry (1976), Chiang 
Mai University. Bachelor’s degree in pharmacy (1979), 
Manila Central University. Master’s degree in clinical 
pharmacology (1983), Chulalongkorn University. 
Apprenticeship in narcotic drugs epidemiology at St. 
George’s University of London (1989). Doctor of 
Philosophy, Health Policy and Administration (2009), 
National Institute of Administration. Member of the 
Pharmaceutical Association of Thailand. Member of the 
Pharmacological and Therapeutic Society of Thailand. 
Member of the Thai Society of Toxicology. Author of nine 
books in the field of drug prevention and control, includ-
ing Drugging Drinks: Handbook for Predatory Drugs 
Prevention and Déjà vu: A Complete Handbook for 
Clandestine Chemistry, Pharmacology and Epidemiology of 
LSD. Columnist, Food and Drug Administration Journal. 
Recipient, Prime Minister’s Award for Drug Education 
and Prevention (2005). 
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Member of the International Narcotics Control Board 
(since 2010). Member (since 2010) and Chair (2012, 2014 
and 2016) of the Standing Committee on Estimates. Chair 
of the Committee on Finance and Administration (2011 
and 2013). Second Vice-President of the Board (2012, 
2014 and 2016). 
Sri Suryawati
Born in 1955. National of Indonesia. Professor and Head, 
Division of Medicine Policy and Management, Faculty of 
Medicine, Gadjah Mada University, Yogyakarta. 
Educational background includes pharmacy (1979), spe-
cialist in pharmacology (1985); doctoral degree in clini-
cal pharmacokinetics (1994), certificate in medicine 
policy (1997). Lecturer in pharmacology/clinical pharma-
cology (since 1980); supervisor for more than 150 mas-
ter’s and doctoral theses in the areas of medicine policy, 
essential medicines, clinical pharmacology, pharmaco-
economics and pharmaceutical management.
Member of the WHO Expert Advisory Panel for Medicine 
Policy and Management (since 1999). Member of the 
Executive Board of the International Network for the 
Rational Use of Drugs (INRUD). Member of the WHO 
Expert Committee on the Selection and Use of Essential 
Medicines (2002, 2003, 2005 and 2007). Member of the 
WHO Expert Committee on Drug Dependence (2002 
and 2006). Member of the United Nations Millennium 
Project Task Force on HIV/AIDS, Malaria and Tuberculosis 
and Access to Essential Medicines (Task Force 5) (2001-
2005). Consultant in essential medicine programmes and 
promoting rational use of medicines in Bangladesh (2006-
2007), Cambodia (2001-2008), China (2006-2008), Fiji 
(2009), the Lao People’s Democratic Republic (2001-
2003), Mongolia (2006-2008) and the Philippines (2006-
2007). Consultant in medicine policy and drug evaluation 
in Cambodia (2003, 2005 and 2007), China (2003), 
Indonesia (2005-2006) and Viet Nam (2003). Facilitator 
of various international training courses in medicine pol-
icy and promoting the rational use of medicines, includ-
ing WHO and INRUD courses on promoting the rational 
use of medicines (1994-2007), training courses on hospi-
tal drugs and therapeutics committees (2001-2007) and 
international courses on medicine policy (2002-2003).
Member of the International Narcotics Control Board 
(2007-2012 and since 2013). Member (2008-2011 and since 
2013), Vice-Chair (2009) and Chair (2010 and 2013) of the 
Standing Committee on Estimates. Second Vice-President 
of the Board (2010 and 2013). First Vice-President of the 
Board (2015). Rapporteur (2011, 2014 and 2016).
Francisco E. Thoumi
Born in 1943. National of Colombia and the United 
States. Bachelor of Arts and Doctor of Philosophy in 
Economics. Senior member of the Colombian Academy 
of Economic Sciences and Corresponding Member of the 
Royal Academy of Moral and Political Sciences (Spain).
Professor at the University of Texas, Rosario University 
(Bogota) and California State University, Chico. Worked 
for 15 years in the research departments of the World 
Bank and the Inter-American Development Bank. 
Founder and Director, Research and Monitoring Center 
on Drugs and Crime, Rosario University (August 
2004-December 2007); Research Coordinator, Global 
Programme against Money-Laundering, Proceeds of 
Crime and the Financing of Terrorism; Coordinator for 
the World Drug Report, UNODC (August 1999-September 
2000); Researcher, Comparative Study of Illegal Drugs in 
Six Countries, United Nations Research Institute for 
Social Development, Geneva (June 1991-December 1992); 
Fellow, Woodrow Wilson International Center for 
Scholars (August 1996-July 1997); Research Coordinator, 
Research Programme on the Economic Impact of Illegal 
Drugs in the Andean Countries, United Nations 
Development Programme, Bogota (November 
1993-January 1996).
Author of two books and co-author of one book on ille-
gal drugs in Colombia and the Andean region. Editor of 
three volumes and author of over 60 academic journal 
articles and book chapters on those subjects.
Member of the Friedrich Ebert Foundation Observatory 
of Organized Crime in Latin America and the Caribbean 
(since 2008) and the World Economic Forum’s Global 
Agenda Council on Organized Crime (2012-2014). 
Member of the International Narcotics Control Board 
(since 2012). Rapporteur (2012). Member of the 
Committee on Finance and Administration (2014 and 
2015). Member of the Standing Committee on Estimates 
(2013 and 2016).
Jallal Toufiq 
Born in 1963. National of Morocco. Head of the National 
Centre for Drug Abuse Prevention and Research; Director 
of the Moroccan National Observatory on Drugs and 
Addictions; Director of the Ar-razi University Psychiatric 
Hospital and Professor of Psychiatry at the Rabat Faculty 
of Medicine.
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Medical Doctor, Rabat Faculty of Medicine (1989); 
Diploma of Specialization in Psychiatry (1994); and 
 lecturer at the Rabat Faculty of Medicine (since 1995). 
Undertook specialized training in Paris at the Sainte-
Anne Psychiatric Hospital and Marmottan Centre (1990-
1991); and at Johns Hopkins University as a National 
Institute on Drug Abuse research fellow and Clinical 
Observer (1994-1995). Conducted research at the 
University of Pittsburgh (1995); and gained Clinical Drug 
Research certificates at the Vienna School of Clinical 
Research (2001 and 2002).
Currently holding positions in Morocco as Head of the 
Harm Reduction Programme, National Centre for 
Drug Abuse Prevention and Research; teaching and 
residency training coordinator, Ar-razi Hospital; 
Director of the National Diploma Programme on 
Treatment and Prevention of Drug Abuse, Rabat 
Faculty of Medicine; Director of the National Diploma 
Programme on Child Psychiatry, Rabat Faculty of 
Medicine and Member of the Ministry of Health 
Commission on Drug Abuse.
At the international level, Representative of the 
Mediterranean Network (MedNET) for Morocco 
(MedNET/Pompidou Group/Council of Europe); former 
permanent correspondent of the Pompidou Group for 
Morocco (Council of Europe) on drug abuse prevention 
and research and former member of the Reference Group 
to the United Nations on HIV and Injecting Drug Use. 
Founding member and steering committee member, 
Middle East and North Africa Harm Reduction 
Association (MENAHRA); Director of Knowledge Hub 
Ar-razi for North Africa, MENAHRA; Member, Mentor 
International Scientific Advisory Network (drug abuse 
prevention in youth); former focal point/expert on pre-
vention, United Nations Office on Drug Control and 
Crime Prevention (local network for North Africa); 
founding member, MedNET (advisory group on AIDS 
and drug abuse policies) of the Council of Europe, and 
member of the Reference Group to the United Nations 
on HIV and Injecting Drug Use.
Held consultancy roles with the WHO Regional Office 
for the Eastern Mediterranean, UNODC and other inter-
national institutions, research fellowships and the 
National Institute on Drug Abuse of the United States. 
Published widely in the field of psychiatry, alcohol and 
drug abuse. 
Member of the International Narcotics Control Board 
(since 2015). Member of the Standing Committee on 
Estimates (2015). Member of the Committee on Finance 
and Administration (2016).
Raymond Yans
Born in 1948. National of Belgium. Graduate in Germanic 
philology and in philosophy (1972). 
Belgian Foreign Service: Attaché, Jakarta (1978-1981); 
Deputy-Mayor of Liège (1982-1989); Consul, Tokyo 
(1989-1994); Consul, Chargé d’affaires, Luxembourg 
(1999-2003); Head of the Drug Unit, Ministry of Foreign 
Affairs (1995-1999 and 2003-2007); Chairman of the 
Dublin Group (2002-2006); Chairman of the European 
Union Drug Policy Cooperation Working Group during 
the Belgian Presidency of the European Union; charged 
with the national coordination of the ratification and 
implementation process of the Convention on Psychotropic 
Substances of 1971 and the United Nations Convention 
against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988 (1995-1998); liaison between the 
Ministry of Foreign Affairs and the National Police for 
drug liaison officers in Belgian embassies (2003-2005); 
participation in the launching by the European Union 
Joint Action on New Synthetic Drugs of an early warn-
ing system to alert Governments to the appearance of 
new synthetic drugs (1999); active in the creation of the 
Cooperation Mechanism on Drugs between the European 
Union, Latin America and the Caribbean (1997-1999). 
Author of numerous articles and speeches, including: 
“The future of the Dublin Group” (2004) and “Is there 
anything such as a European Union Common Drug 
Policy?” (2005). Member of the Belgian delegation to the 
Commission on Narcotic Drugs (1995-2007); all the pre-
paratory sessions (on amphetamine-type stimulants, pre-
cursors, judicial cooperation, money-laundering, drug 
demand reduction and alternative development) for the 
twentieth special session of the General Assembly; 
European Union Seminar on Best Practices in Drug 
Enforcement by Law Enforcement Authorities, Helsinki 
(1999); Joint European Union/Southern African 
Development Community Conferences on Drug Control 
Cooperation, Mmabatho, South Africa (1995) and 
Gabarone (1998); UNODC/Paris Pact round tables, 
Brussels (2003), Tehran and Istanbul (2005); meetings of 
the High-level Dialogue on Drugs between the Andean 
Community and the European Union, Lima (2005) and 
Vienna (2006).
Member of the International Narcotics Control Board 
(since 2007). Member of the Standing Committee on 
Estimates (2007-2010). Rapporteur (2010). First Vice-
President of the Board (2011). President of the Board 
(2012 and 2013). Member (2007-2009) and Chair (2015 
and 2016) of the Committee on Finance and 
Administration.
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About the International Narcotics Control Board
The International Narcotics Control Board (INCB) is an 
independent and quasi-judicial control organ, established 
by treaty, for monitoring the implementation of the inter-
national drug control treaties. It had predecessors under 
the former drug control treaties as far back as the time 
of the League of Nations.
Composition
INCB consists of 13 members who are elected by the 
Economic and Social Council and who serve in their per-
sonal capacity, not as government representatives. Three 
members with medical, pharmacological or pharmaceu-
tical experience are elected from a list of persons nomi-
nated by the World Health Organization (WHO) and 10 
members are elected from a list of persons nominated by 
Governments. Members of the Board are persons who, 
by their competence, impartiality and disinterestedness, 
command general confidence. The Council, in consulta-
tion with INCB, makes all arrangements necessary to 
ensure the full technical independence of the Board in 
carrying out its functions. INCB has a secretariat that 
assists it in the exercise of its treaty-related functions. The 
INCB secretariat is an administrative entity of the United 
Nations Office on Drugs and Crime, but it reports solely 
to the Board on matters of substance. INCB closely col-
laborates with the Office in the framework of arrange-
ments approved by the Council in its resolution 1991/48. 
INCB also cooperates with other international bodies 
concerned with drug control, including not only the 
Council and its Commission on Narcotic Drugs, but also 
the relevant specialized agencies of the United Nations, 
particularly WHO. It also cooperates with bodies outside 
the United Nations system, especially the International 
Criminal Police Organization (INTERPOL) and the 
World Customs Organization.
Functions
The functions of INCB are laid down in the following 
treaties: Single Convention on Narcotic Drugs of 1961 as 
amended by the 1972 Protocol; Convention on 
Psychotropic Substances of 1971; and United Nations 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988. Broadly speaking, INCB 
deals with the following:
  (a) As regards the licit manufacture of, trade in 
and use of drugs, INCB endeavours, in cooperation with 
Governments, to ensure that adequate supplies of drugs 
are available for medical and scientific uses and that the 
diversion of drugs from licit sources to illicit channels 
does not occur. INCB also monitors Governments’ con-
trol over chemicals used in the illicit manufacture of 
drugs and assists them in preventing the diversion of 
those chemicals into the illicit traffic;
  (b) As regards the illicit manufacture of, traffick-
ing in and use of drugs, INCB identifies weaknesses in 
national and international control systems and contrib-
utes to correcting such situations. INCB is also responsi-
ble for assessing chemicals used in the illicit manufacture 
of drugs, in order to determine whether they should be 
placed under international control.
In the discharge of its responsibilities, INCB:
  (a) Administers a system of estimates for narcotic 
drugs and a voluntary assessment system for psychotropic 
substances and monitors licit activities involving drugs 
through a statistical returns system, with a view to assist-
ing Governments in achieving, inter alia, a balance 
between supply and demand;
  (b) Monitors and promotes measures taken by 
Governments to prevent the diversion of substances fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances and assesses such substances 
to determine whether there is a need for changes in the 
scope of control of Tables I and II of the 1988 Convention;
  (c) Analyses information provided by Governments, 
United Nations bodies, specialized agencies or other com-
petent international organizations, with a view to ensur-
ing that the provisions of the international drug control 
treaties are adequately carried out by Governments, and 
recommends remedial measures;
  (d) Maintains a permanent dialogue with 
Governments to assist them in complying with their obli-
gations under the international drug control treaties and, 
to that end, recommends, where appropriate, technical or 
financial assistance to be provided.
INCB is called upon to ask for explanations in the event 
of apparent violations of the treaties, to propose appropri-
ate remedial measures to Governments that are not fully 
applying the provisions of the treaties or are encountering 
difficulties in applying them and, where necessary, to assist 
Governments in overcoming such difficulties. If, however, 
INCB notes that the measures necessary to remedy a seri-
ous situation have not been taken, it may call the matter 
to the attention of the parties concerned, the Commission 
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on Narcotic Drugs and the Economic and Social Council. 
As a last resort, the treaties empower INCB to recommend 
to parties that they stop importing drugs from a default-
ing country, exporting drugs to it or both. In all cases, 
INCB acts in close cooperation with Governments.
INCB assists national administrations in meeting their 
obligations under the conventions. To that end, it pro-
poses and participates in regional training seminars and 
programmes for drug control administrators.
Reports
The international drug control treaties require INCB to 
prepare an annual report on its work. The annual report 
contains an analysis of the drug control situation world-
wide so that Governments are kept aware of existing and 
potential situations that may endanger the objectives of 
the international drug control treaties. INCB draws the 
attention of Governments to gaps and weaknesses in 
national control and in treaty compliance; it also makes 
suggestions and recommendations for improvements at 
both the national and international levels. The annual 
report is based on information provided by Governments 
to INCB, United Nations entities and other organizations. 
It also uses information provided through other inter-
national organizations, such as INTERPOL and the World 
Customs Organization, as well as regional 
organizations.
The annual report of INCB is supplemented by detailed 
technical reports. They contain data on the licit move-
ment of narcotic drugs and psychotropic substances 
required for medical and scientific purposes, together 
with an analysis of those data by INCB. Those data are 
required for the proper functioning of the system of con-
trol over the licit movement of narcotic drugs and psy-
chotropic substances, including preventing their diversion 
to illicit channels. Moreover, under the provisions of arti-
cle 12 of the 1988 Convention, INCB reports annually to 
the Commission on Narcotic Drugs on the implementa-
tion of that article. That report, which gives an account 
of the results of the monitoring of precursors and of the 
chemicals frequently used in the illicit manufacture of 
narcotic drugs and psychotropic substances, is also 
 published as a supplement to the annual report.
Since 1992, the first chapter of the annual report has been 
devoted to a specific drug control issue on which INCB 
presents its conclusions and recommendations in order 
to contribute to policy-related discussions and decisions 
in national, regional and international drug control. The 
following topics were covered in past annual reports:
1992:  Legalization of the non-medical use of drugs
1993:  The importance of demand reduction
1994:  Evaluation of the effectiveness of the inter-
national drug control treaties
1995:  Giving more priority to combating 
money-laundering
1996:  Drug abuse and the criminal justice system
1997:  Preventing drug abuse in an environment of 
illicit drug promotion
1998:  International control of drugs: past, present 
and future
1999:  Freedom from pain and suffering
2000:  Overconsumption of internationally controlled 
drugs
2001: Globalization and new technologies: challenges 
to drug law enforcement in the twenty-first century
2002:  Illicit drugs and economic development
2003:  Drugs, crime and violence: the microlevel 
impact
2004:  Integration of supply and demand reduction 
strategies: moving beyond a balanced approach
2005: Alternative development and legitimate 
livelihoods
2006: Internationally controlled drugs and the 
unregulated market
2007: The principle of proportionality and drug-
related offences
2008: The international drug control conventions: 
history, achievements and challenges
2009: Primary prevention of drug abuse
2010: Drugs and corruption
2011: Social cohesion, social disorganization and 
illegal drugs
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2012: Shared responsibility in international drug 
control
2013: Economic consequences of drug abuse
2014: Implementation of a comprehensive, integrated 
and balanced approach to addressing the world drug 
problem
2015: The health and welfare of mankind: challenges 
and opportunities for the international control of 
drugs
Chapter I of the report of the International Narcotics 
Control Board for 2016 is entitled “Women and drugs”.
Chapter II presents an analysis of the operation of the 
international drug control system based primarily on 
information that Governments are required to submit 
directly to INCB in accordance with the international 
drug control treaties. Its focus is on the worldwide 
control  of all licit activities related to narcotic drugs and 
psychotropic substances, as well as chemicals used in 
the  illicit manufacture of such drugs.
Chapter III presents some of the major developments in 
drug abuse and trafficking and measures by Governments 
to implement the international drug control treaties by 
addressing those problems.
Chapter IV presents the main recommendations addressed 
by INCB to Governments, UNODC, WHO and other 
 relevant international and regional organizations.
 United Nations system and drug control organs and their secretariat
General Assembly
Economic and Social 
Council
INCB Commission onNarcotic Drugs
UNODCa/INCB secretariatb
Key:
Direct connection (administrative or constitutional)
Reporting, cooperating and advising relationship 
a United Nations Office on Drugs and Crime.
b The INCB secretariat reports on substantive matters to INCB only.
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INTERNATIONAL NARCOTICS CONTROL BOARD
The International Narcotics Control Board (INCB) is the independent monitoring body for the 
implementation of United Nations international drug control conventions. It was established in 
1968 in accordance with the Single Convention on Narcotic Drugs, 1961. It had predecessors 
under the former drug control treaties as far back as the time of the League of Nations.
Based on its activities, INCB publishes an annual report that is submitted to the United Nations 
Economic and Social Council through the Commission on Narcotic Drugs. The report provides a 
comprehensive survey of the drug control situation in various parts of the world. As an impartial 
body, INCB tries to identify and predict dangerous trends and suggests necessary measures to 
be taken.
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